6. パーキンソン病 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
(11C)PE2I
Weill Medical College of Cornell University
2018 Phase 1/Phase 2 NCT03675282 United States;
(2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide)
Juha Rinne / PET Centre
2018 Phase 2 EUCTR2018-000405-23-FI Finland;
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
AbbVie Inc
2011 Phase 3 EUCTR2008-001329-33-GB Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
2010 Phase 3 EUCTR2008-001329-33-CZ Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
2009 - EUCTR2008-001329-33-PT Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
Abbott Healthcare Products B.V.
2009 - EUCTR2006-005186-18-CZ Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
2008 Phase 3 EUCTR2006-005186-18-GB Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
2008 - EUCTR2006-005186-18-PT Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2006-005186-18-DE Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
Abbott Laboratories
2009 - EUCTR2006-000578-53-DE Germany;New Zealand;United States;
Solvay Pharmaceuticals B.V.
2009 - EUCTR2006-005186-18-NL Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2006-005186-18-ES Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2007 - EUCTR2006-005186-18-FI Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
(2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylprop acid
AbbVie Inc
2011 Phase 3 EUCTR2008-001329-33-GB Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
2010 Phase 3 EUCTR2008-001329-33-CZ Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
2009 - EUCTR2008-001329-33-PT Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
(2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylpropanoic acid
Abbott Healthcare Products B.V.
2009 - EUCTR2006-005186-18-CZ Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
2008 Phase 3 EUCTR2006-005186-18-GB Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
2008 - EUCTR2006-005186-18-PT Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2006-005186-18-DE Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
Abbott Laboratories
2009 - EUCTR2006-000578-53-DE Germany;New Zealand;United States;
Solvay Pharmaceuticals B.V.
2009 - EUCTR2006-005186-18-NL Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2006-005186-18-ES Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2007 - EUCTR2006-005186-18-FI Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
(3beta, 5beta, 25R)-spirostan-3-ol
Phytopharm plc
2011 - EUCTR2010-018534-44-HU Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
2011 - EUCTR2010-018534-44-DE Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
2011 - EUCTR2010-018534-44-CZ Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
2010 Phase 2 EUCTR2010-018534-44-GB Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
(3ß, 5ß, 25R)-spirostan-3-ol
Phytopharm plc
2011 - EUCTR2010-018534-44-HU Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
2011 - EUCTR2010-018534-44-DE Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
2011 - EUCTR2010-018534-44-CZ Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
2010 Phase 2 EUCTR2010-018534-44-GB Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
(6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol
Schwarz BioSciences Inc.
2008 - EUCTR2004-000148-26-HU Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2008 - EUCTR2004-000148-26-AT Austria;Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 Phase 3 EUCTR2004-000148-26-ES Austria;Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 - EUCTR2004-000148-26-SE Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 - EUCTR2004-000148-26-FI Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 - EUCTR2004-000148-26-CZ Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
(R)-troloxamide quinone
BioElectron Technology Corporation (formerly Edison Pharmaceuticals Inc.)
2016 Phase 2 EUCTR2015-001786-10-GB Germany;United Kingdom;United States;
2016 Phase 2 EUCTR2015-001786-10-DE Germany;United Kingdom;United States;
(S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-DE Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-CZ Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
(S)-(+)-2-(4-(3-fluorobenzyl)oxybenzyl)aminopropanamide methanesulfonate
Merck Serono S.A. - Geneva
2011 - EUCTR2009-017174-20-AT Austria;Canada;France;Germany;South Africa;
2010 - EUCTR2009-017174-20-DE Austria;Canada;France;Germany;South Africa;
(minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
2007 - EUCTR2006-000577-29-DE Germany;United States;
00000
Genzyme Corporation
2017 Phase 2 EUCTR2016-000657-12-IT Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
000000
Genzyme Corporation
2017 Phase 2 EUCTR2016-000657-12-IT Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
009-0
Alexza Pharmaceuticals, Inc.
2018 Phase 1 NCT03822364 Netherlands;
009-1
Alexza Pharmaceuticals, Inc.
2018 Phase 1 NCT03822364 Netherlands;
009-2
Alexza Pharmaceuticals, Inc.
2018 Phase 1 NCT03822364 Netherlands;
009-3
Alexza Pharmaceuticals, Inc.
2018 Phase 1 NCT03822364 Netherlands;
009-4
Alexza Pharmaceuticals, Inc.
2018 Phase 1 NCT03822364 Netherlands;
009-5
Alexza Pharmaceuticals, Inc.
2018 Phase 1 NCT03822364 Netherlands;
009-A0
Alexza Pharmaceuticals, Inc.
2019 Phase 1 NCT04157933 Netherlands;
009-A1
Alexza Pharmaceuticals, Inc.
2019 Phase 1 NCT04157933 Netherlands;
009-A2
Alexza Pharmaceuticals, Inc.
2019 Phase 1 NCT04157933 Netherlands;
009-A3
Alexza Pharmaceuticals, Inc.
2019 Phase 1 NCT04157933 Netherlands;
023145028
BIAL-Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-002754-24-IT Germany;Italy;Portugal;Spain;United Kingdom;
043906039
OSPEDALE SANTA MARIA DELLA MISERICORDIA
2021 Phase 3 EUCTR2018-004892-11-IT Italy;
1. Tesofensine (NS 2330)
Boehringer Ingelheim
2003 Phase 2 NCT00148512 Austria;El Salvador;France;Germany;Netherlands;Spain;United Kingdom;
100
Orion Corporation
2011 - EUCTR2010-022200-46-LV Finland;Germany;Latvia;Lithuania;
2011 - EUCTR2010-022200-46-LT Finland;Germany;Latvia;Lithuania;
2011 - EUCTR2010-022200-46-FI Finland;Germany;Latvia;Lithuania;
- - EUCTR2010-022200-46-DE Finland;Germany;Latvia;Lithuania;
11C-PBR28
William Charles Kreisl
2015 Phase 2 NCT02702102 United States;
11C-PiB
Oriental Neurosurgery Evidence-Based-Study Team
2017 Phase 2 NCT03555292 China;
11C-Raclopride
Orion Corporation Orion Pharma
2007 - EUCTR2007-002496-14-FI Finland;
11C]PBR28
AstraZeneca AB
2012 - EUCTR2011-004803-19-SE Finland;Sweden;
2012 - EUCTR2011-004803-19-FI Finland;Sweden;
11C]SMW139
Juha Rinne / PET Centre
2018 Phase 2 EUCTR2018-000405-23-FI Finland;
125
Orion Corporation
2011 - EUCTR2010-022200-46-LV Finland;Germany;Latvia;Lithuania;
2011 - EUCTR2010-022200-46-LT Finland;Germany;Latvia;Lithuania;
2011 - EUCTR2010-022200-46-FI Finland;Germany;Latvia;Lithuania;
- - EUCTR2010-022200-46-DE Finland;Germany;Latvia;Lithuania;
15O H2O
Umeå University Hospital
2015 Phase 2 EUCTR2015-003045-26-SE Sweden;
15O]H2O
Umeå University Hospital
2015 Phase 2 EUCTR2015-003045-26-SE Sweden;
18-FDTBZ
Chang Gung Memorial Hospital
2015 Phase 2 NCT02599753 Taiwan;
18F florbetaben
Institute for Neurodegenerative Disorders
2016 Phase 2 EUCTR2015-004129-15-ES Spain;
18F- DTBZ
Chang Gung Memorial Hospital
2012 Phase 2 NCT02039024 Taiwan;
18F-AV-133
Avid Radiopharmaceuticals
2012 Phase 2/Phase 3 NCT01550484 Australia;United States;
2010 Phase 1/Phase 2 NCT01503944 United States;
Renji Hospital (South Court), School of Medicine, Shanghai Jiao Tong University
2020 Phase 0 ChiCTR2000036137 China;
18F-AV-45
Avid Radiopharmaceuticals
2010 Phase 1/Phase 2 NCT01503944 United States;
18F-DOPA
University of Alberta
2021 Phase 3 NCT04706910 Canada;
2017 Phase 3 NCT03042416 Canada;
18F-DOPA PET
National Taiwan University Hospital
2017 - NCT03973502 Taiwan;
18F-DTBZ
Chang Gung Memorial Hospital
2013 Phase 2 NCT02059733 Taiwan;
2011 Phase 2 NCT01759888 Taiwan;
2010 Phase 2 NCT01283347 Taiwan;
18F-DTBZ AV-133
Chang Gung Memorial Hospital
2011 Phase 2 NCT01556100 -
18F-FDG
Chang Gung Memorial Hospital
2010 Phase 2 NCT01824056 Taiwan;
Huashan Hospital Affiliated to Fudan University
2020 Phase 0 ChiCTR2000037856 China;
Nagoya City Rehabilitation Agency
2019 - JPRN-UMIN000036908 Japan;
Renji Hospital (South Court), School of Medicine, Shanghai Jiao Tong University
2020 Phase 0 ChiCTR2000036137 China;
18F] LBT-999
ZIONEXA
2021 Phase 3 EUCTR2019-000247-27-FR France;
18F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane
Umeå University Hospital
2015 Phase 2 EUCTR2015-003045-26-SE Sweden;
18F]FE-PE2I
AstraZeneca AB
2012 - EUCTR2011-004803-19-SE Finland;Sweden;
2012 - EUCTR2011-004803-19-FI Finland;Sweden;
Umeå University Hospital
2015 Phase 2 EUCTR2015-003045-26-SE Sweden;
18F]MC225
University Medical Center Groningen
2022 Phase 2 EUCTR2021-005024-37-NL Netherlands;
1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]-
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-DE Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-CZ Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]-
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-DE Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-CZ Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
2,5-Dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide
BIAL Portela & Cª, S.A.
2011 Phase 3 EUCTR2010-022366-27-GB Argentina;Australia;Belgium;Chile;Czech Republic;Estonia;India;Israel;Korea, Republic of;Russian Federation;South Africa;United Kingdom;
2011 Phase 3 EUCTR2010-022366-27-BE Belgium;Czech Republic;Estonia;United Kingdom;
2011 - EUCTR2010-022366-27-CZ Argentina;Australia;Belgium;Chile;Czech Republic;Estonia;India;Israel;Korea, Republic of;Russian Federation;South Africa;United Kingdom;
2010 - EUCTR2010-022366-27-EE Belgium;Czech Republic;Estonia;United Kingdom;
2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE
Alkahest, Inc.
2020 Phase 2 EUCTR2019-001657-42-SK Estonia;Germany;Hungary;Poland;Slovakia;United States;
2019 Phase 2 EUCTR2019-001657-42-DE Estonia;Germany;Hungary;Poland;Slovakia;United States;
207-3120
Aston University
2018 Phase 2 EUCTR2017-004297-34-GB United Kingdom;
25330
Regional Dementia Research Centre, Dept of Neurology
2018 Phase 4 EUCTR2017-002707-10-DK Denmark;
3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-DE Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-CZ Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
3-(3,4-Dihydroxyphenyl)-L-alanine
Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
2007 - EUCTR2006-000577-29-DE Germany;United States;
6036937.00.01
BIAL-Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-002754-24-IT Germany;Italy;Portugal;Spain;United Kingdom;
6abeta - apomorphine-10,11-diol hydrochloride hemihydrate
Britannia Pharmaceuticals Limited
2006 Phase 3 EUCTR2006-000391-32-GB Germany;Netherlands;United Kingdom;
2006 - EUCTR2006-000391-32-NL Germany;Netherlands;United Kingdom;
2006 - EUCTR2006-000391-32-DE Germany;Netherlands;United Kingdom;
6aß - apomorphine-10,11-diol hydrochloride hemihydrate
Britannia Pharmaceuticals Limited
2006 Phase 3 EUCTR2006-000391-32-GB Germany;Netherlands;United Kingdom;
2006 - EUCTR2006-000391-32-NL Germany;Netherlands;United Kingdom;
2006 - EUCTR2006-000391-32-DE Germany;Netherlands;United Kingdom;
75
Orion Corporation
2011 - EUCTR2010-022200-46-LV Finland;Germany;Latvia;Lithuania;
2011 - EUCTR2010-022200-46-LT Finland;Germany;Latvia;Lithuania;
2011 - EUCTR2010-022200-46-FI Finland;Germany;Latvia;Lithuania;
- - EUCTR2010-022200-46-DE Finland;Germany;Latvia;Lithuania;
8-OHdG
Nagoya University Graduate School of Medicine
2015 - JPRN-UMIN000019082 Japan;
A-dopamine
InBrain Pharma SAS
2020 Phase 1;Phase 2 EUCTR2020-000155-12-FR France;
University Hospital, Lille
2020 Phase 1/Phase 2 NCT04332276 France;
AAV2-GDNF
Brain Neurotherapy Bio, Inc.
2020 Phase 1 NCT04167540 United States;
AB1010
AB Science
2015 Phase 2 EUCTR2010-024424-26-SK Bulgaria;Czech Republic;France;Germany;Hungary;Romania;Slovakia;South Africa;Spain;United States;
ABBV-0805
AbbVie
2020 Phase 1 NCT04127695 Puerto Rico;United States;
ABBV-951
ABBVIE DEUTSCHLAND GMBH & CO. KG
2020 Phase 3 EUCTR2019-004235-23-IT Australia;Canada;Italy;Japan;Netherlands;Russian Federation;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-IT Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
AbbVie
2022 Phase 1 NCT05094050 United States;
2021 Phase 3 NCT04750226 Australia;United States;
2020 Phase 3 NCT04380142 Australia;United States;
2020 Phase 3 NCT04379050 Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 NCT03781167 Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
2018 Phase 1 NCT03374917 United States;
2017 Phase 1 NCT03033498 United States;
AbbVie Deutschland
2020 Phase 3 EUCTR2018-002144-85-DE Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-NL Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-GB Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-ES Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-DK Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-BE Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
Abbvie Deutschland GmbH & Co. KG
2021 Phase 3 EUCTR2019-004235-23-SE Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004235-23-DE Australia;Canada;Germany;Italy;Japan;Netherlands;Russian Federation;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-NL Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-GB Australia;Canada;Japan;Russian Federation;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-DK Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
ABT-SLV187
AbbVie
2015 Phase 3 NCT02549092 Australia;Canada;Germany;Greece;Italy;Korea, Republic of;Spain;Sweden;United States;
2014 Phase 3 NCT02082249 Japan;Korea, Republic of;Taiwan;
AbbVie (prior sponsor, Abbott)
2011 Phase 2 NCT01479127 Japan;
Abbott Japan Co., Ltd.
- Phase 2 JPRN-JapicCTI-111699 -
ACP-103
ACADIA PHARMACEUTICALS INC.
2009 - EUCTR2007-003035-22-IT Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
ACADIA Pharmaceuticals Inc.
2004 Phase 2 NCT00087542 United States;
Acadia Pharmaceuticals Inc
2009 Phase 2;Phase 3 EUCTR2007-003035-22-AT Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
2008 Phase 2;Phase 3 EUCTR2007-003035-22-FR Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
2008 - EUCTR2007-003051-36-SE Austria;Portugal;Spain;Sweden;
2008 - EUCTR2007-003051-36-PT Austria;Portugal;Spain;Sweden;
2008 - EUCTR2007-003051-36-ES Austria;Portugal;Spain;Sweden;
2008 - EUCTR2007-003051-36-BE Austria;Belgium;Portugal;Spain;Sweden;
2008 - EUCTR2007-003051-36-AT Austria;Portugal;Spain;Sweden;
2008 - EUCTR2007-002906-23-BG Bulgaria;France;United Kingdom;
2007 - EUCTR2007-002906-23-GB Bulgaria;France;United Kingdom;
2007 - EUCTR2007-002906-23-FR Bulgaria;France;United Kingdom;
National Institute of Neurological Disorders and Stroke (NINDS)
2004 Phase 2 NCT00086294 United States;
ACR325
NeuroSearch A/S
2009 Phase 1 NCT01023282 Germany;
AD-810N (zonisamide)
Dainippon Sumitomo Pharma Co., Ltd.
- Phase 3 JPRN-JapicCTI-070377 -
- - JPRN-JapicCTI-050099 -
ADS-5102
Adamas Pharmaceuticals, Inc.
2015 Phase 3 EUCTR2014-003739-20-FR Austria;France;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003739-20-ES Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003739-20-DE Austria;France;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003739-20-AT Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003738-24-ES Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003738-24-DE Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003738-24-AT Austria;Germany;Spain;United States;
2014 Phase 3 NCT02274766 Austria;France;Germany;Spain;United States;
2014 Phase 3 NCT02202551 Austria;Canada;France;Germany;Spain;United States;
2014 Phase 3 NCT02136914 Canada;United States;
ADS-5102 (extended release amantadine HCl)
Adamas Pharmaceuticals, Inc.
2011 Phase 2/Phase 3 NCT01397422 United States;
ADX48621
Addex Pharma S.A.
2011 Phase 2 NCT01336088 Austria;France;Germany;United States;
Addex Pharma SA
2011 Phase 2 EUCTR2010-022517-25-DE Austria;France;Germany;United States;
2011 - EUCTR2010-022517-25-AT Austria;France;Germany;United States;
AFFITOPE® PD01A
Affiris AG
2016 Phase 1 NCT02618941 Austria;
2014 Phase 1 NCT02216188 Austria;
2012 Phase 1 NCT01568099 Austria;
AFFITOPE® PD01A + Adjuvant
Affiris AG
2015 Phase 1 NCT02758730 Germany;
AFQ056
NOVARTIS FARMA
2012 - EUCTR2011-004378-27-IT Austria;Canada;Germany;Hungary;Italy;Spain;United States;
2012 - EUCTR2011-002074-23-IT Austria;Canada;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
2011 - EUCTR2011-002073-30-IT Canada;European Union;Germany;Italy;Spain;Switzerland;United States;
2009 - EUCTR2008-008712-98-IT Finland;France;Germany;Italy;Spain;
Novartis
2009 Phase 2 NCT00986414 Australia;Canada;Finland;France;Germany;Italy;Japan;Spain;
2009 Phase 2 NCT00888004 Germany;
2007 Phase 2 NCT00582673 Germany;
Novartis Farmacéutica, S.A.
2012 - EUCTR2011-002074-23-ES Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
Novartis Pharma AG
2010 - EUCTR2010-019418-25-FR Finland;France;Germany;Italy;
2010 - EUCTR2010-019418-25-FI Finland;France;Germany;Italy;
2009 - EUCTR2008-008712-98-FR Finland;France;Germany;Italy;Spain;
2009 - EUCTR2008-008712-98-FI Finland;France;Germany;Italy;Spain;
2009 - EUCTR2008-008712-98-DE Finland;France;Germany;Italy;Spain;
Novartis Pharma Services AG
2012 - EUCTR2011-004378-27-SK Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
2012 - EUCTR2011-004378-27-HU Austria;Canada;France;Germany;Hungary;Italy;Spain;United States;
2012 - EUCTR2011-004378-27-DE Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
2012 - EUCTR2011-004378-27-AT Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
2012 - EUCTR2011-002074-23-SK Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
2012 - EUCTR2011-002074-23-HU Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
2012 - EUCTR2011-002074-23-DE Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
2012 - EUCTR2011-002074-23-AT Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
2007 - EUCTR2007-002900-16-DE Germany;
- - EUCTR2011-002073-30-DE Canada;France;Germany;Hungary;Italy;Spain;United States;
Novartis Pharma Sevices AG
2010 - EUCTR2010-019418-25-DE Australia;Canada;Finland;France;Germany;Italy;Japan;
Novartis Pharmaceuticals
2012 Phase 2 NCT01491932 Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
2012 Phase 2 NCT01491529 Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
2011 Phase 2 NCT01385592 Canada;France;Germany;Hungary;Italy;Spain;United States;
2010 Phase 2 NCT01173731 Australia;Canada;Finland;France;Germany;Italy;Spain;United States;
AFQ056 with L-dopa
Novartis
2010 Phase 2 NCT01092065 United States;
AFQ065
Novartis Pharma AG
2010 - EUCTR2010-019418-25-FI Finland;France;Germany;Italy;
Novartis Pharma Sevices AG
2010 - EUCTR2010-019418-25-DE Australia;Canada;Finland;France;Germany;Italy;Japan;
AHA Exergame System
Campus Neurológico Sénior
2018 - NCT03891069 Portugal;
AKST4290
Alkahest, Inc.
2020 Phase 2 NCT04369430 Estonia;Germany;Hungary;Poland;Slovakia;United States;
2020 Phase 2 EUCTR2019-001657-42-SK Estonia;Germany;Hungary;Poland;Slovakia;United States;
2019 Phase 2 EUCTR2019-001657-42-DE Estonia;Germany;Hungary;Poland;Slovakia;United States;
ALTROPANE®
Molecular NeuroImaging
2006 Phase 2 NCT00397228 United States;
AMANTADINE HYDROCHLORIDE
CHU de Toulouse
2010 - EUCTR2009-016143-19-AT Austria;France;
AMBROSAN 60mg Tablets
Joint Research Office
2016 Phase 2 EUCTR2015-002571-24-GB United Kingdom;
ANAVEX2-73
Anavex Life Sciences Corp.
2019 Phase 2 NCT04575259 Australia;Spain;
2018 Phase 2 EUCTR2017-004335-36-ES Spain;
ANHYDROUS CARBIDOPA
BIAL-Portela & Ca, SA
2009 - EUCTR2009-012897-12-RO Romania;
Impax Laboratories, LLC
2020 Phase 3 EUCTR2018-002234-21-GB Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2018-002233-37-PL Canada;Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002234-21-ES Czech Republic;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002234-21-DE Czech Republic;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002234-21-CZ Czech Republic;Czechia;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-IT Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-GB Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-DE Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-CZ Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
AP-CD/LD
Intec Pharma Ltd.
2012 Phase 2 NCT00947037 Israel;
AP09004
Intec Pharma Ltd.
2009 Phase 2 NCT00918177 Israel;
APL-130277
SUNOVION PHARMACEUTICALS
2016 Phase 2 EUCTR2016-001762-29-IT Italy;
SUNOVION PHARMACEUTICALS INC
2018 Phase 3 EUCTR2016-003456-70-IT Austria;France;Germany;Italy;Spain;United Kingdom;
2018 Phase 3 EUCTR2016-000637-43-IT Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States;
Sunovion
2018 Phase 3 NCT03391882 Austria;France;Germany;Italy;Spain;United Kingdom;
2017 Phase 2 NCT03292016 United States;
2017 Phase 2 NCT03187301 Italy;United States;
2015 Phase 3 NCT02542696 Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States;
2015 Phase 3 NCT02469090 Canada;United Kingdom;United States;
2014 Phase 2 NCT02228590 United States;
Sunovion Pharmaceuticals Inc.
2018 Phase 3 EUCTR2016-003456-70-ES Austria;Spain;United Kingdom;
2018 Phase 3 EUCTR2016-003456-70-DE Austria;France;Germany;Italy;Spain;United Kingdom;
2018 Phase 3 EUCTR2016-003456-70-AT Austria;France;Germany;Italy;Spain;United Kingdom;
2018 Phase 3 EUCTR2016-000637-43-ES Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2016-000637-43-AT Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003456-70-GB Austria;France;Germany;Italy;Spain;United Kingdom;
2016 Phase 3 EUCTR2016-000637-43-GB Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States;
Sunuvion Pharmaceuticals Inc
2016 Phase 3 EUCTR2016-000636-18-GB Canada;United Kingdom;United States;
APO-go
SUNOVION PHARMACEUTICALS INC
2018 Phase 3 EUCTR2016-003456-70-IT Austria;France;Germany;Italy;Spain;United Kingdom;
Sunovion
2017 Phase 2 NCT03292016 United States;
Sunovion Pharmaceuticals Inc.
2018 Phase 3 EUCTR2016-003456-70-ES Austria;Spain;United Kingdom;
2018 Phase 3 EUCTR2016-003456-70-DE Austria;France;Germany;Italy;Spain;United Kingdom;
2018 Phase 3 EUCTR2016-003456-70-AT Austria;France;Germany;Italy;Spain;United Kingdom;
2017 Phase 3 EUCTR2016-003456-70-GB Austria;France;Germany;Italy;Spain;United Kingdom;
University Medical Center Groningen
2016 Phase 2;Phase 3 EUCTR2016-000102-11-NL Netherlands;
2015 Phase 2 EUCTR2014-000657-36-NL Netherlands;
APO-go®
Criceto IKM B.V.
2020 Phase 1;Phase 2 EUCTR2019-003315-60-NL Netherlands;
APOKINON
CHU Rennes
2021 Phase 4 EUCTR2021-000826-89-FR France;
CHU Toulouse
2007 - EUCTR2006-005318-11-FR France;
CHU de Rennes
2016 Phase 3 EUCTR2016-002454-20-FR France;
CHU de Toulouse
2010 Phase 3 EUCTR2010-018650-12-FR France;
APOMORFINA CLORIDRATO
SUNOVION PHARMACEUTICALS INC
2018 Phase 3 EUCTR2016-003456-70-IT Austria;France;Germany;Italy;Spain;United Kingdom;
APOMORPHINE HYDROCHLORIDE HEMIHYDRATE
Criceto IKM B.V.
2020 Phase 1;Phase 2 EUCTR2019-003315-60-NL Netherlands;
APORON
Criceto IKM B.V.
2020 Phase 1;Phase 2 EUCTR2019-003315-60-NL Netherlands;
AQW051
NOVARTIS FARMA
2012 - EUCTR2011-001092-39-IT Germany;Italy;United States;
Novartis Pharma Services AG
2011 - EUCTR2011-001092-39-DE France;Germany;Italy;United States;
Novartis Pharmaceuticals
2011 Phase 2 NCT01474421 France;Germany;Italy;United States;
ARICEPT
Eisai Limited
2002 Phase 3 NCT00165815 Germany;Ireland;
AS2
University College London
2015 Phase 2 EUCTR2014-002697-37-GB United Kingdom;
ASyn Mab
F. HOFFMANN - LA ROCHE LTD.
2021 Phase 2 EUCTR2020-004997-23-IT Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
F. Hoffmann-La Roche Ltd
2021 Phase 2 EUCTR2020-004997-23-FR Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004997-23-AT Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000087-15-FR Austria;France;Germany;Spain;United States;
2017 Phase 2 EUCTR2017-000087-15-ES Austria;France;Germany;Spain;United States;
2017 Phase 2 EUCTR2017-000087-15-DE Austria;France;Germany;Spain;United States;
2017 Phase 2 EUCTR2017-000087-15-AT Austria;France;Germany;Spain;United States;
Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
2021 Phase 2 EUCTR2020-004997-23-ES Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
ATH-1017
Athira Pharma
2022 Phase 2 NCT04831281 United States;
ATM FOG in PD
Medical University of South Carolina
2013 Phase 3 NCT03651856 United States;
AV-101
VistaGen Therapeutics, Inc.
2022 Phase 2 NCT04147949 -
AVALOX - 400
SUNOVION PHARMACEUTICALS
2016 Phase 2 EUCTR2016-001762-29-IT Italy;
AVE8112
Michael J. Fox Foundation for Parkinson's Research
2013 Phase 1 NCT01803945 United States;
AVP-923
Avanir Pharmaceuticals
2003 Phase 3 NCT00056524 United States;
AVP-923-45
Avanir Pharmaceuticals
2013 Phase 2 NCT01767129 Canada;United States;
AZD0328
King's College London
2021 Phase 2 NCT04810104 Norway;
AZD3241 300 mg BID
AstraZeneca
2012 Phase 2 NCT01603069 United States;
AZD3241 600 mg BID
AstraZeneca
2012 Phase 2 NCT01603069 United States;
AZD3241 Alternative titration scheme with formulation 1 or 2
AstraZeneca
2011 Phase 1 NCT01457807 United Kingdom;
AZD3241 ER formulation 1
AstraZeneca
2011 Phase 1 NCT01457807 United Kingdom;
AZD3241 Extended release tablets
AstraZeneca AB
2012 - EUCTR2011-004803-19-SE Finland;Sweden;
2012 - EUCTR2011-004803-19-FI Finland;Sweden;
AZILECT 1 mg comprimidos
Teva Pharmaceutical Industries Ltd
2009 Phase 4 EUCTR2009-011541-24-ES France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
AZILECT®
University Hospital, Clermont-Ferrand
2013 Phase 4 NCT01765257 France;
Aadipose-Derived Mesenchymal Stem Cells
Taiwan Mitochondrion Applied Technology Co., Ltd.
2022 Phase 1 NCT05094011 -
Abdominal compression
Vanderbilt University Medical Center
2020 Early Phase 1 NCT04620382 United States;
Acamprosate
Baylor College of Medicine
2006 - NCT00640952 United States;
Accordion Pill Carbidopa/Levodopa
Intec Pharma Ltd.
2018 Phase 2 NCT03576638 -
Accordion Pill ¿ Carbidopa/Levodopa 50/
INTEC PHARMA LTD
2016 Phase 3 EUCTR2015-003513-24-IT Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-IT Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Accordion Pill? Carbidopa/Levodopa 50/
Intec Pharma, Ltd.
2016 Phase 3 EUCTR2015-003513-24-ES Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-ES Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Accordion Pill¿ Carbidopa/levodopa
INTEC PHARMA LTD
2018 Phase 2 EUCTR2018-001209-95-IT Italy;Spain;
Accordion Pill™ Carbidopa/Levodopa
Intec Pharma Ltd.
2016 Phase 3 NCT02615873 Bulgaria;Germany;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 NCT02605434 Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
Accordion Pill™ Carbidopa/Levodopa 50/
Intec Pharma, Ltd.
2017 Phase 3 EUCTR2015-003513-24-SK Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003513-24-HU Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003513-24-GB Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003513-24-DE Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003513-24-BG Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-SK Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-PL Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-HU Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-GB Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
ActiMyo recording
Institut de Myologie, France
2016 - NCT02785978 France;
Active Investigational Treatment ENT-01
Enterin Inc.
2020 Phase 2 NCT04483479 United States;
2019 Phase 1 NCT03938922 United States;
2018 Phase 2 NCT03781791 United States;
Active comparator
Alexza Pharmaceuticals, Inc.
2018 Phase 1 NCT03822364 Netherlands;
Active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.
Biogen Idec
2003 Phase 2 NCT00451815 -
Active drug: pimavanserin 17mg (2 strength tablets)
University Hospital, Strasbourg, France
2020 Phase 2 NCT03947216 France;
Active tDCS
National Cheng-Kung University Hospital
2015 Phase 1/Phase 2 NCT02917122 -
Active tPCS
Western University, Canada
2019 - NCT04054960 Canada;
Adaptor: Hakko Adaptor
AbbVie (prior sponsor, Abbott)
2011 Phase 2 NCT01479127 Japan;
Adjuvant without active component
Affiris AG
2015 Phase 1 NCT02758730 Germany;
2014 Phase 1 NCT02267434 Austria;
Administration of stable isotope-labelled leucine-
University Hospital, Montpellier
2013 - NCT02263235 France;
Agomelatine or PIacebo
Second Affiliated Hospital of Soochow University
2019 Phase 4 NCT03977441 -
AlloRx
The Foundation for Orthopaedics and Regenerative Medicine
2022 Phase 1 NCT05152394 Antigua and Barbuda;
Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)
The University of Texas Health Science Center, Houston
2017 Phase 1 NCT02611167 United States;
Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)
The University of Texas Health Science Center, Houston
2017 Phase 1 NCT02611167 United States;
Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)
The University of Texas Health Science Center, Houston
2017 Phase 1 NCT02611167 United States;
Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)
The University of Texas Health Science Center, Houston
2017 Phase 1 NCT02611167 United States;
Allopurinol
Kamatani Naoyuki
2019 Phase 1 JPRN-jRCTs031190115 Japan;
Alternating, 10 sec High-Frequency, 10 sec Low-Frequency Stimulation
The Cleveland Clinic
2021 Phase 1 NCT05022147 United States;
Alternating, 10 sec High-Frequency, 50 sec Low-Frequency Stimulation
The Cleveland Clinic
2021 Phase 1 NCT05022147 United States;
Alternating, 50 sec High-Frequency, 10 sec Low-Frequency Stimulation
The Cleveland Clinic
2021 Phase 1 NCT05022147 United States;
Alternating, 50 sec High-Frequency, 50 sec Low-Frequency Stimulation
The Cleveland Clinic
2021 Phase 1 NCT05022147 United States;
Amantadin-ratiopharm
CHU de Toulouse
2010 - EUCTR2009-016143-19-AT Austria;France;
Amantadine
CHU de Toulouse
2012 Phase 2 EUCTR2011-005201-75-FR France;
Comprehensive clinical study group concerning diagnosis, treatment, and prevention of the neurological disorders
2007 - JPRN-UMIN000000780 Japan;
Department of Neurology, Juntendo University School of Medicine
2013 - JPRN-UMIN000010596 Japan;
Northwestern University
2011 Phase 3 NCT01652534 United States;
Oregon Health and Science University
2009 - NCT00794313 United States;
Rabin Medical Center
2010 - NCT01190553 -
2008 Phase 2 NCT00600093 Israel;
Rush University Medical Center
2013 Phase 2 NCT01789047 United States;
2010 Phase 4 NCT01071395 Austria;Canada;France;United States;
University Hospital, Toulouse
2012 Phase 2 NCT01538329 France;
Amantadine HCl ER
Adamas Pharmaceuticals, Inc.
2014 Phase 3 NCT02153632 Canada;France;Germany;Spain;United States;
Amantadine HCl ER tablets
Adamas Pharmaceuticals, Inc.
2014 Phase 3 NCT02153645 Canada;France;Germany;Spain;United States;
Amantadine HCl Extended Release
Osmotica Pharmaceutical Corp.
2014 Phase 3 EUCTR2014-001132-10-ES Canada;France;Germany;Spain;United States;
2014 Phase 3 EUCTR2014-001131-36-ES Canada;France;Germany;Spain;United States;
2014 - EUCTR2014-001132-10-FR Canada;France;Germany;Spain;United States;
Amantadine HCl Extended Release Capsule
Adamas Pharmaceuticals, Inc.
2015 Phase 3 EUCTR2014-003739-20-FR Austria;France;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003739-20-ES Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003739-20-DE Austria;France;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003739-20-AT Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003738-24-ES Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003738-24-DE Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003738-24-AT Austria;Germany;Spain;United States;
Amantadine hydrochloride (HCl)
Adamas Pharmaceuticals, Inc.
2015 Phase 3 EUCTR2014-003739-20-FR Austria;France;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003739-20-ES Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003739-20-DE Austria;France;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003739-20-AT Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003738-24-ES Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003738-24-DE Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003738-24-AT Austria;Germany;Spain;United States;
Amantadine sulfate
Jee-Young Lee
2011 Phase 4 NCT01313845 Korea, Republic of;
Ambroxol
Lawson Health Research Institute
2015 Phase 2 NCT02914366 Canada;
University College, London
2016 Phase 2 NCT02941822 United Kingdom;
Ambroxol Hydrochloride
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
2022 Phase 2 NCT05287503 Italy;
Ambroxol hydrochloride
Joint Research Office
2016 Phase 2 EUCTR2015-002571-24-GB United Kingdom;
Ampreloxetine
THERAVANCE BIOPHARMA ANTIBIOTICS, INC.
2019 Phase 3 EUCTR2018-003289-15-IT Austria;Bulgaria;Canada;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Theravance Biopharma
2019 Phase 3 NCT03829657 Argentina;Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Theravance Biopharma Ireland Limited
2020 Phase 3 EUCTR2018-003289-15-DE Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-HU Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-ES Austria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Ampreloxetine chydrochloride
Theravance Biopharma Ireland Limited
2019 Phase 3 EUCTR2018-003289-15-PL Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Ampreloxetine hydrochloride
Theravance Biopharma Ireland Limited
2020 Phase 3 EUCTR2018-003941-41-PT Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-003941-41-AT Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-003289-15-PT Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-PL Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-IT Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-HU Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-GB Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-ES Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-EE Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-BG Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-GB Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-EE Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-DK Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-BG Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-AT Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Ampyra first,
University of Miami
2012 Phase 1/Phase 2 NCT01491022 United States;
Anle138b
MODAG GmbH
2020 Phase 1 NCT04685265 United Kingdom;
Anti-Parkinson medication
Beth Israel Deaconess Medical Center
2016 - NCT02994719 United States;
Anti-Parkinsonian Drugs
Second Affiliated Hospital, School of Medicine, Zhejiang University
2014 - NCT04928079 -
Antiparkinsonian Agent(s)
Sage Therapeutics
2016 Phase 2 NCT03000569 United States;
Aplindore
Ligand Pharmaceuticals
2008 Phase 2 NCT00623324 United States;
Aplindore MR tablets
Neurogen Corporation
2008 Phase 2 NCT00809302 United States;
Apo-go®
Britannia Pharmaceuticals Limited
2014 Phase 3 EUCTR2013-000980-10-NL Austria;Denmark;France;Germany;Netherlands;Spain;
2014 Phase 3 EUCTR2013-000980-10-DK Austria;Denmark;France;Germany;Netherlands;Spain;
2013 Phase 3 EUCTR2013-000980-10-AT Austria;Denmark;France;Germany;Netherlands;Spain;
STADA Arzneimittel AG
2014 Phase 3 EUCTR2013-000980-10-FR Austria;Denmark;France;Germany;Netherlands;Spain;
2014 Phase 3 EUCTR2013-000980-10-ES Austria;Denmark;France;Germany;Netherlands;Spain;
Apokinon
CHU de Rennes
2009 Phase 3 EUCTR2008-006045-10-FR France;
Apokyn
Sunovion
2017 Phase 2 NCT03292016 United States;
Apomor
Sunovion Pharmaceuticals Inc.
2018 Phase 3 EUCTR2016-003456-70-DE Austria;France;Germany;Italy;Spain;United Kingdom;
2018 Phase 3 EUCTR2016-003456-70-AT Austria;France;Germany;Italy;Spain;United Kingdom;
Apomorp
Sunovion Pharmaceuticals Inc.
2017 Phase 3 EUCTR2016-003456-70-GB Austria;France;Germany;Italy;Spain;United Kingdom;
Apomorphine
CHU de Toulouse
2010 Phase 3 EUCTR2010-018650-12-FR France;
Clinique Beau Soleil
2018 Phase 4 NCT02940912 France;
Fondation Ophtalmologique Adolphe de Rothschild
2016 Phase 4 NCT02688465 France;
Oregon Health and Science University
2009 Phase 2 NCT00758368 United States;
2005 Phase 2 NCT00472355 United States;
Rennes University Hospital
2021 Phase 4 NCT04887467 France;
2017 Phase 3 NCT02864004 France;
University Hospital, Toulouse
2007 - NCT00524914 France;
University Medical Center Groningen
2017 Phase 2 NCT02702076 Netherlands;
2016 Phase 2;Phase 3 EUCTR2016-000102-11-NL Netherlands;
2015 Phase 2 EUCTR2014-000657-36-NL Netherlands;
Apomorphine (2.5mg/ml)
University Medical Center Groningen
2015 Phase 2 NCT02230930 Netherlands;
Apomorphine HCl injection
Mylan Bertek Pharmaceuticals
2001 Phase 3 NCT00200525 -
2001 Phase 3 NCT00145171 -
1999 Phase 3 NCT00142545 United States;
1999 Phase 2/Phase 3 NCT00200512 United Kingdom;
Apomorphine Hydrocloride Hemihydrate
SUNOVION PHARMACEUTICALS
2016 Phase 2 EUCTR2016-001762-29-IT Italy;
Apomorphine Injectable Solution
University of Calgary
2021 Phase 2/Phase 3 NCT04879134 Canada;
Apomorphine Nasal Powder
Britannia Pharmaceuticals Limited
2006 Phase 3 EUCTR2006-000391-32-GB Germany;Netherlands;United Kingdom;
2006 - EUCTR2006-000391-32-NL Germany;Netherlands;United Kingdom;
2006 - EUCTR2006-000391-32-DE Germany;Netherlands;United Kingdom;
Britannia Pharmaceuticals Ltd.
2006 Phase 2/Phase 3 NCT00346827 -
Apomorphine hydrochloride
Britannia Pharmaceuticals Limited
2014 Phase 3 EUCTR2013-000980-10-NL Austria;Denmark;France;Germany;Netherlands;Spain;
2014 Phase 3 EUCTR2013-000980-10-DK Austria;Denmark;France;Germany;Netherlands;Spain;
2013 Phase 3 EUCTR2013-000980-10-AT Austria;Denmark;France;Germany;Netherlands;Spain;
Britannia Pharmaceuticals Ltd.
2014 Phase 3 NCT02006121 Austria;Denmark;France;Germany;Netherlands;Spain;United Kingdom;
Kyowa Kirin Co., Ltd.
2007 Phase 2 NCT00610103 Japan;
STADA Arzneimittel AG
2014 Phase 3 EUCTR2013-000980-10-FR Austria;Denmark;France;Germany;Netherlands;Spain;
2014 Phase 3 EUCTR2013-000980-10-ES Austria;Denmark;France;Germany;Netherlands;Spain;
SUNOVION PHARMACEUTICALS INC
2018 Phase 3 EUCTR2016-000637-43-IT Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States;
Vectura Group plc
2006 Phase 2 EUCTR2006-005509-79-GB United Kingdom;
2006 Phase 2 EUCTR2006-004582-33-GB United Kingdom;
2005 Phase 2 EUCTR2005-005120-13-GB United Kingdom;
Apomorphine hydrochloride 1.8mg inhalation powder, pre-dispensed
Vectura Limited
2009 - EUCTR2008-004447-11-GB Germany;Italy;United Kingdom;
- - EUCTR2008-004447-11-DE Germany;Italy;United Kingdom;
Apomorphine hydrochloride 2.8mg inhalation powder, pre-dispensed
Vectura Limited
2009 - EUCTR2008-004447-11-GB Germany;Italy;United Kingdom;
- - EUCTR2008-004447-11-DE Germany;Italy;United Kingdom;
Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed
Vectura Limited
2009 - EUCTR2008-004447-11-GB Germany;Italy;United Kingdom;
- - EUCTR2008-004447-11-DE Germany;Italy;United Kingdom;
Apomorphine hydrochloride 5.8 mg inhalation powder, pre-dispensed
Vectura Limited
2009 - EUCTR2008-004447-11-GB Germany;Italy;United Kingdom;
- - EUCTR2008-004447-11-DE Germany;Italy;United Kingdom;
Apomorphine infusion
US WorldMeds LLC
2015 Phase 3 NCT02339064 United States;
Aricept 5 mg-Filmtabletten
Eisai Limited
2004 - EUCTR2004-003355-39-AT Austria;
Aricept 5mg-Filmtabletten
Eisai Limited
2004 - EUCTR2004-003355-39-AT Austria;
Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc.
2003 Phase 4 NCT00095810 United States;
Armodafinil
NYU Langone Health
2011 - NCT01256905 United States;
Artane
First Affiliated Hospital of Xinjiang Medical University
2007 - ChiCTR-TRC-07000027 China;
Atomoxetine
Hubert Fernandez
2016 Early Phase 1 NCT02879136 United States;
Johns Hopkins University
2005 - NCT00286949 United States;
Medical University of South Carolina
2012 Phase 2 NCT01738191 United States;
University of Pennsylvania
2004 Phase 4 NCT00304161 United States;
Atypical Antipsychotics
Pontifical Catholic University of Argentina
2015 - NCT02409823 -
Autologous mesenchymal stem cells
Belarusian Medical Academy of Post-Graduate Education
2017 Phase 2/Phase 3 NCT04146519 Belarus;
Azathioprine
Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
2019 Phase 2 EUCTR2018-003089-14-GB United Kingdom;
Azilect
Dresden University of Technology
2011 - EUCTR2010-023756-82-DE Germany;
Institut de Recerca de l'Hospital de la santa Creu i Sant Pau
2007 - EUCTR2007-004400-12-ES Spain;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
2011 - EUCTR2009-015161-31-DE Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
2011 Phase 3 EUCTR2009-013552-72-GB Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015162-57-PT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015161-31-PT Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2011 Phase 3 EUCTR2009-015162-57-GB Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-BG Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015161-31-GB Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015161-31-BG Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-013552-72-BG Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
- - EUCTR2009-013552-72-DE Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Merck Sharp & Dohme corp.
2011 Phase 3 EUCTR2009-015162-57-NL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Schering Corporation, división Schering-Plough Research
2010 Phase 3 EUCTR2009-013552-72-ES Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
Schering-Plough Research Institute, a division of Schering Corporation
2011 Phase 3 EUCTR2009-015162-57-LV Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-LT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-FI Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-ES Austria;Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2011 Phase 3 EUCTR2009-015162-57-CZ Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-013552-72-CZ Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015162-57-SE Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-PL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-AT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015161-31-PL Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015161-31-CZ Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-013552-72-PL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 Phase 3 EUCTR2009-015161-31-IT Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2009-015161-31-FR Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2009-013552-72-HU Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2009-013552-72-FI Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-SE Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-NL Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-FI Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-AT Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-013552-72-SE Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-013552-72-IT Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
Schering-Plough Research Institute, division of Schering Corporation
2011 - EUCTR2009-015162-57-IT Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
Technische Universität Dresden
2009 Phase 4 NCT00902941 Germany;
2009 - EUCTR2008-005085-30-DE Germany;
Teva Pharmaceuticals Industries LtD
2005 Phase 3 EUCTR2005-001416-42-GB Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
University of British Columbia
2013 - NCT02207387 Canada;
Azilect®
H. Lundbeck A/S
2011 Phase 3 NCT01479530 China;
2011 Phase 3 NCT01268891 Korea, Republic of;
Teva Pharma GmbH
2014 - NCT02384512 Germany;
B-CIT and SPECT imaging
Institute for Neurodegenerative Disorders
2006 Phase 2 NCT00404170 United States;
B-STN DBS
Vanderbilt University Medical Center
2006 - NCT00282152 United States;
B6, B12, L-methylfolate
North Shore Long Island Jewish Health System
2006 - NCT00853879 United States;
BAVISANT HYDROCHLORIDE MONOHYDRATE
BenevolentAI Bio
2017 Phase 2 EUCTR2017-000877-35-GB Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000877-35-ES Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000877-35-DE Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000877-35-CZ Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
BEFIRADOL
Neurolixis SAS
2021 Phase 2 EUCTR2020-006053-22-SE Sweden;
BEN-2001
BenevolentAI Bio
2017 Phase 2 NCT03194217 United States;
BENSERAZIDE HYDROCHLORIDE
BIAL-Portela & Ca, SA
2009 - EUCTR2009-012897-12-RO Romania;
Bial - Portela & Ca, S.A.
2022 Phase 4 EUCTR2020-002754-24-DE Germany;Italy;Portugal;Spain;United Kingdom;
2021 Phase 4 EUCTR2020-002754-24-ES Germany;Italy;Portugal;Spain;United Kingdom;
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2011 - EUCTR2010-022363-35-DE Germany;
BF 2.649
Bioprojet
2007 Phase 2 NCT00642928 France;
2007 - EUCTR2007-003512-57-FR France;
BF2.649
BIOPROJET
2010 - EUCTR2009-013886-24-SE Czech Republic;Germany;Sweden;
2010 - EUCTR2009-013886-24-DE Czech Republic;Germany;Sweden;
2009 - EUCTR2009-013886-24-CZ Czech Republic;Germany;Sweden;
2009 - EUCTR2009-013885-14-FR France;Spain;
2009 - EUCTR2009-013885-14-ES France;Spain;
BF2.649 (Pitolisant)
Bioprojet
2010 Phase 3 NCT01066442 Germany;
BF2.649 (pitolisant)
Bioprojet
2009 Phase 3 NCT01036139 France;
BI-Sifrol®
Boehringer Ingelheim
2004 Phase 4 NCT02231905 -
BIA 3-202
BIAL - Portela & Cª, SA
2006 - EUCTR2006-001793-24-PT Austria;Portugal;
2006 - EUCTR2006-001793-24-AT Austria;Portugal;
Bial - Portela C S.A.
2005 Phase 2 NCT02834507 -
2005 Phase 1 NCT02778594 Portugal;
2005 Phase 1 NCT02774564 Portugal;
2001 Phase 1 NCT02763852 Portugal;
2001 Phase 1 NCT02763839 Portugal;
2000 Phase 1 NCT02763800 United Kingdom;
2000 Phase 1 NCT02763787 United Kingdom;
BIA 3-202 (200 mg)
Bial - Portela C S.A.
2006 Phase 1 NCT02772614 Switzerland;
BIA 6-512
Bial - Portela C S.A.
2006 Phase 1 NCT03097211 Portugal;
2006 Phase 1 NCT03095105 Germany;
2006 Phase 1 NCT03094156 Portugal;
2005 Phase 1 NCT03095092 Portugal;
2005 Phase 1 NCT03093389 Portugal;
2004 Phase 1 NCT03091868 Portugal;
BIA 6-512 100 mg dose
Bial - Portela C S.A.
2004 Phase 1 NCT03091543 Portugal;
BIA 6-512 200 mg dose
Bial - Portela C S.A.
2004 Phase 1 NCT03091543 Portugal;
BIA 6-512 25 mg dose
Bial - Portela C S.A.
2004 Phase 1 NCT03091543 Portugal;
BIA 6-512 50 mg dose
Bial - Portela C S.A.
2004 Phase 1 NCT03091543 Portugal;
BIA 9 1067
Bial - Portela C S.A.
2018 Phase 1 NCT04265027 United Kingdom;
BIA 9-1067
BIAL - PORTELA & Cª, S.A.
2011 - EUCTR2010-021860-13-IT Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Russian Federation;Slovakia;Spain;
BIAL - Portela & Ca, S.A.
2011 Phase 3 EUCTR2010-021860-13-RO Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-SK Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-ES Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
2011 - EUCTR2010-021860-13-DE Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-CZ Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-BG Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-AT Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2010 - EUCTR2010-021860-13-PT Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2010 - EUCTR2010-021860-13-LV Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
2010 - EUCTR2010-021860-13-LT Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2010 - EUCTR2010-021860-13-HU Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
BIAL Portela & Cª, S.A.
2011 Phase 3 EUCTR2010-022366-27-GB Argentina;Australia;Belgium;Chile;Czech Republic;Estonia;India;Israel;Korea, Republic of;Russian Federation;South Africa;United Kingdom;
2011 Phase 3 EUCTR2010-022366-27-BE Belgium;Czech Republic;Estonia;United Kingdom;
2011 - EUCTR2010-022366-27-CZ Argentina;Australia;Belgium;Chile;Czech Republic;Estonia;India;Israel;Korea, Republic of;Russian Federation;South Africa;United Kingdom;
2010 - EUCTR2010-022366-27-EE Belgium;Czech Republic;Estonia;United Kingdom;
BIAL – Portela & Cª, S.A.
2021 Phase 3 EUCTR2020-005011-52-PT Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
2021 Phase 3 EUCTR2020-005011-52-FR Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
2021 Phase 3 EUCTR2020-005011-52-CZ Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
2021 Phase 3 EUCTR2020-005011-52-BG Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
2021 Phase 3 EUCTR2020-005011-52-BE Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
BIAL-Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-002754-24-IT Germany;Italy;Portugal;Spain;United Kingdom;
2021 Phase 3 EUCTR2020-005011-52-IT Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
2020 Phase 4 EUCTR2020-001175-32-IT Germany;Italy;Portugal;Spain;United Kingdom;
BIAL-Portela & Ca, SA
2009 - EUCTR2009-012897-12-RO Romania;
Bial - Portela & Cª, S.A.
2008 - EUCTR2008-003869-72-PT Portugal;
Bial - Portela C S.A.
2016 Phase 4 NCT02847442 Germany;
2014 Phase 1 NCT02305030 -
2014 Phase 1 NCT02305017 -
2011 Phase 3 NCT01568073 Austria;Portugal;
2011 Phase 3 NCT01227655 Portugal;
2011 Phase 1 NCT02170376 France;
2011 Phase 1 NCT01520987 United States;
2010 Phase 2 NCT01568047 Romania;Ukraine;
2010 Phase 1 NCT02169414 France;
2010 Phase 1 NCT02101190 France;Russian Federation;
2010 Phase 1 NCT01532115 France;
2009 Phase 2 NCT01568034 Portugal;Romania;Ukraine;
2009 Phase 1 NCT02169466 Portugal;
2009 Phase 1 NCT02169440 Portugal;
2009 Phase 1 NCT01536366 Portugal;
2009 Phase 1 NCT01533116 Canada;
2009 Phase 1 NCT01533077 Canada;
2009 Phase 1 NCT01532141 France;
2009 Phase 1 NCT01532128 France;
2009 Phase 1 NCT01519284 Portugal;
2009 Phase 1 NCT01515891 Switzerland;
2008 Phase 1 NCT02169895 Canada;
2008 Phase 1 NCT02169479 Canada;
2008 Phase 1 NCT02169453 Canada;
2008 Phase 1 NCT02092168 France;
2008 Phase 1 NCT02071810 France;
2007 Phase 1 NCT01520727 France;
BIA 9-1067 (test)
Bial - Portela C S.A.
2019 Phase 1 NCT03820037 United Kingdom;
BIA 9-1067 micronized
Bial - Portela C S.A.
2014 Phase 1 NCT02305316 -
BIA 9-1067 non-micronized
Bial - Portela C S.A.
2014 Phase 1 NCT02305316 -
BIA9 1067
Bial - Portela C S.A.
2018 Phase 1 NCT04265027 United Kingdom;
BIIB014
BIOGEN IDEC LTD
2006 Phase 2 EUCTR2006-003490-27-GB United Kingdom;
Biogen Idec
2007 Phase 2 NCT00442780 Former Serbia and Montenegro;Israel;Poland;Serbia;
2007 Phase 2 NCT00438607 India;Israel;United Kingdom;
BIIB054
BIOGEN IDEC RESEARCH LIMITED
2018 Phase 2 EUCTR2016-004610-95-IT Australia;Austria;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;United States;
Biogen
2019 Phase 1 NCT03716570 Japan;
2018 Phase 2 NCT03318523 Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom;United States;
2015 Phase 1 NCT02459886 United States;
Biogen Idec Research Limited
2018 Phase 2 EUCTR2016-004610-95-GB Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom;United States;
2018 Phase 2 EUCTR2016-004610-95-FR Austria;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2016-004610-95-ES Austria;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2016-004610-95-DE Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom;United States;
2018 Phase 2 EUCTR2016-004610-95-AT Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom;United States;
BIIB094
Biogen
2019 Phase 1 NCT03976349 Canada;Israel;Norway;Spain;United Kingdom;United States;
BT
University of Valencia
2020 - NCT04353947 Spain;
BTRX-246040
BlackThorn Therapeutics, Inc.
2018 Phase 2 NCT03608371 United States;
BTX-A
Shanghai Tongji Hospital, Tongji University
2017 - ChiCTR-INR-17012013 China;
Balance
Affiliated Lianyungang Hospital of Xuzhou Medical University
2017 - ChiCTR-IPR-17011875 China;
Ankara Yildirim Beyazit University
2019 - NCT04420910 Turkey;
Boston University Charles River Campus
2011 - NCT02302144 United States;
Domen Kazuhisa
2018 - JPRN-jRCTs052180158 Japan;
Gansu Provincial Hospital
2020 Phase 0 ChiCTR2000035872 China;
Gazi University
2018 - NCT03587168 Turkey;
Hyogo College of Medicine
2018 - JPRN-UMIN000033454 Japan;
Istanbul Kültür University
2018 - NCT03827746 Turkey;
Juntendo University
2015 - JPRN-UMIN000016591 Japan;
Karolinska Institutet
2010 - NCT01417598 Sweden;
National Taiwan University Hospital
2007 Phase 1 NCT01301651 Taiwan;
Rehabilitation Institute of Chicago
2010 - NCT01228851 United States;
Sage Bionetworks
2015 - NCT02696603 United States;
Shanghai Tongji Hospital
2014 - ChiCTR-TRC-14004707 China;
Shanghai University of Sport
2020 - ChiCTR2000038852 china;
The Hong Kong Polytechnic University
2021 - NCT04665869 Hong Kong;
2018 - NCT04048291 Hong Kong;
Tianjin Huanhu Hospital
2019 - ChiCTR1900022715 China;
Tsinghua University Yuquan Hospital
2019 Phase 0 ChiCTR1900027210 China;
University Hospital, Basel, Switzerland
2016 - NCT02935842 Switzerland;
University of California, San Francisco
2010 Phase 2 NCT01162226 United States;
University of Houston
2019 - NCT04146454 United States;
University of Kiel
2011 - NCT02253563 -
University of Manitoba
2017 - NCT03232996 Canada;
University of Nevada, Las Vegas
2014 Phase 2 NCT02230267 United States;
University of Pavia
2014 - NCT03314597 -
University of Sao Paulo General Hospital
2015 - NCT02488265 Brazil;
University of Valencia
2021 - NCT04963894 Spain;
University of Vigo
2018 - NCT03882398 Spain;
Xianhui Feng
2020 Phase 0 ChiCTR2000034323 China;
Yeditepe University
2021 - NCT04694872 Turkey;
Balance Training
Bezmialem Vakif University
2018 - NCT04228887 Turkey;
Balance Training with Nintendo Wii Fit
Sao Camilo University Center
2009 - NCT01580787 -
Bavisant dihydrochloride monohydrate
BENEVOLENTAI BIO
2017 Phase 2 EUCTR2017-000877-35-IT Czech Republic;Czechia;Germany;Italy;Poland;Spain;United Kingdom;United States;
BenevolentAI Bio
2017 Phase 2 EUCTR2017-000877-35-GB Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000877-35-ES Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000877-35-DE Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000877-35-CZ Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
Beam
University Medical Center Groningen
2018 - NCT03532984 Brazil;Germany;Hungary;Japan;Netherlands;
Bee venom
Assistance Publique - Hôpitaux de Paris
2011 Phase 2 NCT01341431 France;
Benserazide
Bial - Portela C S.A.
2011 Phase 3 NCT01568073 Austria;Portugal;
2011 Phase 3 NCT01227655 Portugal;
First Affiliated Hospital of Xinjiang Medical University
2007 - ChiCTR-TRC-07000027 China;
The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital)
2020 Phase 4 ChiCTR2000039201 China;
Berachin
CuraSen Therapeutics, Inc.
2020 Phase 2 EUCTR2020-003796-17-GB United Kingdom;
Best Medical Treatment
German Parkinson Study Group (GPS)
2006 Phase 4 NCT00354133 France;Germany;
Best médical treatment
Poitiers University Hospital
2011 Phase 2 NCT01291537 France;
Betaquik MCT supplement
Université de Sherbrooke
2021 - NCT04322461 -
Better
University of California, San Francisco
2020 - NCT04428112 United States;
Biofluid samplings
Michael J. Fox Foundation for Parkinson's Research
2015 - NCT02572713 Canada;United States;
Biological/Vaccine: Allogeneic HB-adMSCs
Hope Biosciences Stem Cell Research Foundation
2021 Phase 2 NCT04995081 United States;
Bisphosphonates
FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE
2010 - EUCTR2010-018904-94-IT Italy;
Blood analysis
University Hospital, Strasbourg, France
2020 Phase 2 NCT03947216 France;
Blood draw
Howard Gendelman, MD
2013 Phase 1 NCT01882010 United States;
BoNT-A
Western University, Canada
2011 Phase 2 NCT02427646 -
Bone marrow derived mesenchymal stem cells
Guangzhou General Hospital of Guangzhou Military Command
2011 Phase 1/Phase 2 NCT01446614 China;
Botulinum Toxin
University Health Network, Toronto
2014 Phase 4 NCT02472210 -
Botulinum Toxin Type B (Myobloc)
Solstice Neurosciences
2007 Phase 2 NCT00515437 United States;
Botulinum Toxin: Xeomin
University Hospital, Clermont-Ferrand
2009 Phase 3 NCT00909883 France;
Botulinum toxin
AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
2011 - EUCTR2009-017412-32-IT Italy;
Rabin Medical Center
2009 Phase 1 NCT00767546 -
Botulinum toxin type A
University of Calgary
2020 Phase 2/Phase 3 NCT04277247 Canada;
Bromocriptine
Boehringer Ingelheim
2003 Phase 3 NCT00240409 China;
1999 Phase 3 NCT02172573 -
Sandoz
2012 Phase 4 NCT01673724 Korea, Republic of;
Bromocriptine and other dopamine agonists
Boehringer Ingelheim
1998 Phase 4 NCT02233023 -
Bumetanide white, oblong, scored tablet
B&A Therapeutics
2019 Phase 2 NCT03899324 France;
Bupleurum+Ginkgo
Xuanwu Hospital, Beijing
2008 Phase 2 NCT01416818 China;
Buspirone
Oregon Health and Science University
2016 Phase 1 NCT02589340 United States;
University of Rochester
2016 Phase 2 NCT02803749 United States;
Buspirone Hydrochloride
Imperial College London-Imperial College Healthcare NHS Trust
2015 Phase 4 EUCTR2014-005422-35-GB United Kingdom;
Buspirone hydrochloride
Contera Pharma
2020 Phase 2 EUCTR2017-003415-19-IT France;Germany;Italy;Spain;
2018 Phase 2 EUCTR2017-003415-19-ES France;Germany;Spain;
Butylphthalide
The Second Affiliated Hospital of Soochow University
2016 - ChiCTR-IPR-16009395 China;
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2018 Phase 4 ChiCTR1800017084 China;
Zhujiang Hospital of Southern Medical University
2019 Phase 0 ChiCTR1900023725 China;
Bydureon
University College London
2014 Phase 2 EUCTR2013-003363-64-GB United Kingdom;
University College London Comprehensive Clinical Trial Unit
2019 Phase 3 EUCTR2018-003028-35-GB United Kingdom;
Bydureon 2 mg powder and solvent for prolonged-release suspension
Stockholm Health Care Services
2019 Phase 2 EUCTR2019-000732-26-SE Sweden;
Byetta 5 micrograms
University College London
2010 Phase 2 EUCTR2009-018137-37-GB United Kingdom;
CADD-Legacy ambulatory infusion pump
AbbVie
2017 Phase 3 NCT02799381 Finland;Greece;Hungary;Italy;Slovakia;Spain;United States;
CADD-Legacy® 1400 ambulatory infusion pump
AbbVie
2013 Phase 3 NCT01960842 Japan;Korea, Republic of;Taiwan;
2009 Phase 3 NCT00660673 Australia;Canada;Czech Republic;Czechia;Israel;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;United States;
AbbVie (prior sponsor, Abbott)
2009 Phase 3 NCT00660387 New Zealand;United States;
2009 Phase 3 NCT00360568 Germany;New Zealand;United States;
2009 Phase 3 NCT00357994 Germany;United States;
2008 Phase 3 NCT00335153 Australia;Canada;Czech Republic;Finland;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
2006 Phase 4 NCT00141518 Norway;Sweden;
CAPTURE
Westfälische Wilhelms-Universität Münster
2019 - NCT03638479 Germany;
CARBIDOPA (CD)
NEURODERM LTD.
2016 Phase 2 EUCTR2015-005814-31-IT Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
CARBIDOPA (FU)
NOVARTIS FARMA
2004 - EUCTR2004-000185-12-IT Finland;Italy;Sweden;United Kingdom;
CARBIDOPA ANIDRA
NOVARTIS FARMA
2005 - EUCTR2005-001032-72-IT Czech Republic;Italy;Portugal;
CARBIDOPA FU
VERNALIS DEVELOPMENT LIMITED
2006 - EUCTR2006-004112-51-IT Italy;
CARBIDOPA INN
NOVARTIS FARMA
2005 - EUCTR2005-001032-72-IT Czech Republic;Italy;Portugal;
CARBIDOPA LEVODOPA
IMPAX LABORATORIES, INC.
2010 - EUCTR2009-017238-39-IT France;Germany;Italy;
CARBIDOPA MONOHYDRATE
ABBVIE DEUTSCHLAND GMBH & CO. KG
2016 Phase 3 EUCTR2016-001403-23-IT European Union;Finland;Greece;Hungary;Italy;Slovakia;Spain;United States;
AbbVie Deutschland GmbH & Co. KG
2018 Phase 3 EUCTR2016-001403-23-HU European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
2017 Phase 3 EUCTR2016-001403-23-GR European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
2017 Phase 3 EUCTR2016-001403-23-FI European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
2017 Phase 3 EUCTR2014-004865-26-GR Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;United States;
2016 Phase 3 EUCTR2016-001403-23-SK European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
2016 Phase 3 EUCTR2016-001403-23-ES European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
2015 Phase 3 EUCTR2014-004865-26-SE Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;United States;
2015 Phase 3 EUCTR2014-004865-26-ES Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;
2015 Phase 3 EUCTR2014-004865-26-DE Australia;Canada;European Union;Germany;Italy;Spain;Sweden;
2015 - EUCTR2014-004865-26-IT Australia;Canada;European Union;Germany;Italy;Spain;Sweden;
Centre for Human Drug Research
2020 Phase 2 EUCTR2020-000686-16-NL Netherlands;
Civitas Therapeutics, Inc.
2012 - EUCTR2012-000181-37-GB Israel;Serbia;United Kingdom;
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2010 - EUCTR2009-017416-33-DE Germany;
Novartis Pharma Services AG
2008 - EUCTR2007-003134-42-DE Germany;
CARBODOPA LEVADOPA
Institute for Neurodegenerative Disorders
2005 - EUCTR2004-001485-41-ES Spain;United Kingdom;
CD
Yagi Michio
2021 Phase 1 JPRN-jRCT2051200104 Japan;
CD-LD CR
Impax Laboratories, LLC
2006 Phase 2 NCT00279825 United States;
CD-LD IR
Impax Laboratories, LLC
2015 Phase 2 NCT02271503 United States;
2006 Phase 2 NCT00279825 United States;
2005 Phase 2 NCT00253084 United States;
CDNF
Herantis Pharma Plc
2018 Phase 1;Phase 2 EUCTR2018-000346-19-SE Finland;Sweden;
2018 Phase 1;Phase 2 EUCTR2018-000346-19-FI Finland;Sweden;
2017 Phase 1;Phase 2 EUCTR2015-004175-73-FI Finland;
Renishaw Neuro Solutions Ltd.
2019 Phase 1;Phase 2 EUCTR2017-005170-19-FI Finland;Sweden;
2018 Phase 1;Phase 2 EUCTR2017-005170-19-SE Finland;Sweden;
CEP-1347
Cephalon
2002 Phase 2/Phase 3 NCT00040404 Canada;Puerto Rico;United States;
CEP1347
Cephalon
2002 Phase 2/Phase 3 NCT00040404 Canada;Puerto Rico;United States;
CERE-120
Ceregene Inc.
2008 - EUCTR2007-006721-27-GB United Kingdom;
2008 - EUCTR2007-006721-27-AT Austria;United Kingdom;
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])
Ceregene
2006 Phase 2 NCT00400634 United States;
CERE-120: Adeno-Associated Virus Delivery of Neurturin
Sangamo Therapeutics
2009 Phase 1/Phase 2 NCT00985517 United States;
CERETEC (TM) Estabilizado
IDIBAPS
2016 Phase 2 EUCTR2015-004238-85-ES Spain;
CITICOLIN*1G/4ML IM IV 5 F
PIAM FARMACEUTICI S.P.A.
2016 Phase 4 EUCTR2014-005562-30-IT Italy;
CITICOLINA SODICA
PIAM FARMACEUTICI S.P.A.
2016 Phase 4 EUCTR2014-005562-30-IT Italy;
CJH1 (CLR4001)
Alexandra Marine and General Hospital
2012 Phase 1/Phase 2 NCT01684475 Canada;
CLE
Impax Laboratories, LLC
2010 Phase 3 NCT01130493 France;Germany;Italy;United States;
CLENBUTEROL HYDROCHLORIDE
CuraSen Therapeutics, Inc.
2020 Phase 2 EUCTR2020-003796-17-GB United Kingdom;
CO
University of Manitoba
2014 - NCT02007785 Canada;
COMTAN
AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
2010 - EUCTR2010-019396-29-IT Italy;
IMPAX LABORATORIES, INC.
2010 - EUCTR2009-017238-39-IT France;Germany;Italy;
COMTAN 200* 60 CPR
KYOWA HAKKO UK LTD
2005 - EUCTR2004-000817-20-IT Italy;Latvia;Lithuania;Spain;
COMTAN®
BIAL - Portela & Cª, SA
2006 - EUCTR2006-001793-24-PT Austria;Portugal;
CP
Nagai Masahiro
2016 Phase 2 JPRN-jRCTs061180060 Japan;
CPL500036
Celon Pharma S.A.
2021 Phase 2 EUCTR2020-006004-16-PL Poland;
CST-103
CuraSen Therapeutics, Inc.
2020 Phase 2 EUCTR2020-003796-17-GB United Kingdom;
- Phase 2 EUCTR2020-006067-28-BE Australia;Belgium;New Zealand;United Kingdom;
CST-107
CuraSen Therapeutics, Inc.
- Phase 2 EUCTR2020-006067-28-BE Australia;Belgium;New Zealand;United Kingdom;
CST-139
CuraSen Therapeutics, Inc.
2020 Phase 2 EUCTR2020-003796-17-GB United Kingdom;
CVD00118-E
PREXTON THERAPEUTICS B.V.
2017 Phase 2 EUCTR2017-000135-14-IT Austria;France;Germany;Italy;Spain;United Kingdom;
Prexton Therapeutics B.V.
2017 Phase 2 EUCTR2017-000135-14-GB Austria;Germany;Spain;United Kingdom;
2017 Phase 2 EUCTR2017-000135-14-ES Austria;Germany;Italy;Spain;United Kingdom;
2017 Phase 2 EUCTR2017-000135-14-DE Austria;Germany;Italy;Spain;United Kingdom;
2017 Phase 2 EUCTR2017-000135-14-AT Austria;Germany;Spain;United Kingdom;
CVL-751
Cerevel Therapeutics LLC
2021 Phase 3 EUCTR2019-002952-17-IT Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002951-40-IT Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002950-22-IT Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002949-38-IT Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
Cerevel Therapeutics, LLC
2021 Phase 3 EUCTR2019-002952-17-DE Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2021 Phase 3 EUCTR2019-002952-17-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2021 Phase 3 EUCTR2019-002951-40-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2021 Phase 3 EUCTR2019-002949-38-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002952-17-HU Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002952-17-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002951-40-HU Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002951-40-ES Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002951-40-DE Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002951-40-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002950-22-HU Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002949-38-PL Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002949-38-HU Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002949-38-ES Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002949-38-DE Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002949-38-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States;
2020 Phase 1 NCT04295642 United States;
CVN424 High Dose
Cerevance Beta, Inc.
2019 Phase 2 NCT04191577 United States;
CVN424 Low Dose
Cerevance Beta, Inc.
2019 Phase 2 NCT04191577 United States;
CVT-301
Acorda Therapeutics
2019 Phase 1 NCT03887884 United States;
2015 Phase 3 NCT02352363 Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 NCT02242487 Canada;Czech Republic;Czechia;Poland;Spain;United States;
2013 Phase 2 NCT01777555 Italy;Serbia;United Kingdom;United States;
2012 Phase 2 NCT01617135 Israel;Serbia;United Kingdom;
Civitas Therapeutics, Inc.
2016 Phase 3 EUCTR2015-005626-19-CZ Canada;Czech Republic;Poland;Spain;United States;
2016 Phase 3 EUCTR2015-005067-17-CZ Canada;Czech Republic;Poland;Spain;United States;
2015 Phase 3 EUCTR2014-003799-22-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;
2015 Phase 3 EUCTR2014-003799-22-GB Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003799-22-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;
2015 Phase 3 EUCTR2014-003799-22-DE Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003799-22-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003799-22-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003799-22-AT Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2013 - EUCTR2012-005822-31-IT Italy;Serbia;United Kingdom;United States;
2013 - EUCTR2012-005822-31-GB Italy;Serbia;United Kingdom;United States;
2012 - EUCTR2012-000181-37-GB Israel;Serbia;United Kingdom;
Civitas Therapeutics, a wholly owned subsidiary of Acorda
2016 Phase 3 EUCTR2015-005626-19-ES Canada;Czech Republic;Poland;Spain;United States;
Civitas Therapeutics, a wholly owned subsidiary of Acorda Therapeutics, Inc.
2016 Phase 3 EUCTR2015-005067-17-ES Canada;Czech Republic;Poland;Spain;United States;
CVT-301 (Dose Level 1)
Acorda Therapeutics
2016 Phase 1 NCT02812394 United States;
CVT-301 (Dose Level 2)
Acorda Therapeutics
2016 Phase 1 NCT02812394 United States;
CVT-301 High Dose
Acorda Therapeutics
2014 Phase 3 NCT02240030 Canada;Czech Republic;Czechia;Poland;Spain;United States;
CVT-301 Low Dose
Acorda Therapeutics
2014 Phase 3 NCT02240030 Canada;Czech Republic;Czechia;Poland;Spain;United States;
CVT-301, LIP
Acorda Therapeutics
2016 Phase 1 NCT02807675 United States;
CVXL-0107
CleveXel Pharma
2016 Phase 2 NCT02641054 France;
CX-8998
Jazz Pharmaceuticals
2019 Phase 2 NCT03436953 United States;
CYMBALTA
CHU de Toulouse
2010 Phase 3 EUCTR2010-018650-12-FR France;
Cabaser
Institute for Neurodegenerative Disorders
2005 - EUCTR2004-001485-41-GB Spain;United Kingdom;
Cabaseril
Institute for Neurodegenerative Disorders
2005 - EUCTR2004-001485-41-GB Spain;United Kingdom;
2005 - EUCTR2004-001485-41-AT Austria;Spain;United Kingdom;
Cabaseril, 1,0 mg Tablette
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
Cabaseril, 2,0 mg Tablette
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
Cabergoline
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-DE Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-CZ Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
Institute for Neurodegenerative Disorders
2005 - NCT00129181 Austria;Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2004-001485-41-GB Spain;United Kingdom;
2005 - EUCTR2004-001485-41-ES Spain;United Kingdom;
2005 - EUCTR2004-001485-41-AT Austria;Spain;United Kingdom;
Pfizer
2004 Phase 4 NCT00174239 Australia;Italy;Spain;United Kingdom;
Technische Universität Dresden
2005 Phase 4 NCT00153972 Germany;
Caffeine
Department of Neurology, Juntendo University
2016 - JPRN-UMIN000022187 Japan;
Kyowa Kirin Co., Ltd.
2019 Phase 1 NCT03970798 Japan;
McGill University Health Center
2014 Phase 3 NCT01738178 Brazil;Canada;
Caffeine 100-200 mg BID
Ron Postuma
2007 Phase 2/Phase 3 NCT00459420 Canada;
Caffeine alkaloid
Ron Postuma
2010 Phase 2 NCT01190735 Canada;
Calcium
VA Office of Research and Development
2011 Phase 2 NCT01119131 United States;
Cannabidiol
University of Colorado, Denver
2018 Phase 2 NCT03582137 United States;
2016 Phase 2 NCT02818777 United States;
Cannabidiol (CBD)
King's College London
2020 Phase 2 EUCTR2019-003623-37-GB United Kingdom;
Cannabis Oil
University Health Network, Toronto
2018 Phase 2 NCT03639064 -
Cannabis, Medical
OMNI Medical Services, LLC
2018 Phase 2 NCT03944447 United States;
Capsaicin
University of Florida
2017 - NCT03321019 United States;
2014 Phase 1/Phase 2 NCT02183519 United States;
Capsaicin vapor
University of Florida
2015 Phase 1 NCT02390089 United States;
Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)
Novartis
2005 Phase 3 NCT00134966 Canada;Czech Republic;Czechia;Israel;Italy;Poland;Portugal;Turkey;United States;
Carbidopa
BIAL-Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-002754-24-IT Germany;Italy;Portugal;Spain;United Kingdom;
Bial - Portela C S.A.
2011 Phase 3 NCT01568073 Austria;Portugal;
2011 Phase 3 NCT01227655 Portugal;
Department of Neuroscience, neurology
2007 - EUCTR2007-004985-41-SE Sweden;
Dept of Neuroscience, Uppsala University
2008 - EUCTR2008-003581-26-SE Sweden;
Fujita Health University School of MedicineDepartment of Gastroenterology
2020 Phase 4 JPRN-UMIN000040889 Japan;
Juntendo University School of Medicine
2017 - JPRN-UMIN000025645 Japan;
Kansai Medical University
2012 - JPRN-UMIN000007896 Japan;
Kyoto University
2017 Phase 1,2 JPRN-UMIN000030084 Japan;
Merck Sharp & Dohme Corp.
2009 Phase 1 NCT00845000 United States;
National Institute of Neurological Disorders and Stroke (NINDS)
2007 Phase 1/Phase 2 NCT00547911 United States;
NeuroDerm Ltd.
2011 Phase 1/Phase 2 NCT01229332 Israel;
Oregon Health and Science University
2009 Phase 2 NCT01399905 United States;
Orion Corporation Orion Pharma
2007 - EUCTR2007-002496-14-FI Finland;
2006 Phase 4 EUCTR2006-001755-36-GB Germany;Sweden;United Kingdom;
- - EUCTR2006-001755-36-DE Germany;Sweden;United Kingdom;
Orion Corporation Orion Pharma, FI-02200 Espoo, Finland
2006 - EUCTR2006-001755-36-SE Germany;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA
2005 - EUCTR2004-005234-39-FI Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-FI Finland;Italy;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA, Finland
2005 Phase 4 EUCTR2004-005234-39-GB Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA, 02200 Espoo, Finland
2008 - EUCTR2004-005234-39-DE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2007 Phase 3 EUCTR2004-000185-12-GB Austria;Finland;Italy;Sweden;United Kingdom;
2006 - EUCTR2004-005234-39-LV Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2006 - EUCTR2004-005234-39-LT Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 Phase 4 EUCTR2004-005234-39-IE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-005234-39-SE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-005234-39-DK Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-SE Finland;Italy;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-AT Austria;Finland;Italy;Sweden;United Kingdom;
Orion Corporation, Orion Pharma
2011 Phase 2 NCT01296464 Finland;Sweden;
Solvay Pharmaceuticals BV.
2008 - EUCTR2006-005186-18-IT Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
Solvay Pharmaceuticals GmbH
2006 - EUCTR2005-002654-21-NO Norway;Sweden;
2005 - EUCTR2005-002654-21-SE Sweden;
The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital)
2020 Phase 4 ChiCTR2000039201 China;
Vanderbilt University Medical Center
2017 Phase 4 NCT03115827 United States;
Yagi Michio
2021 Phase 1 JPRN-jRCT2051200104 Japan;
Carbidopa 200mg oral dose
Daniel Claassen
2020 Phase 1 NCT04246437 United States;
Carbidopa 65 mg capsule
Orion Corporation
2017 Phase 2 EUCTR2015-004507-23-HU Finland;Germany;Hungary;Latvia;
2017 Phase 2 EUCTR2015-004507-23-FI Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-LV Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-DE Finland;Germany;Hungary;Latvia;
Carbidopa Levodopa
Neurocrine Biosciences
2018 Phase 1 NCT03496870 United States;
Carbidopa Monohydrate
Abbott Healthcare Products B.V.
2009 - EUCTR2006-005186-18-CZ Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
2008 Phase 3 EUCTR2006-005186-18-GB Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
2008 - EUCTR2006-005186-18-PT Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2006-005186-18-DE Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
Abbott Laboratories
2009 - EUCTR2006-000578-53-DE Germany;New Zealand;United States;
Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
2007 - EUCTR2006-000577-29-DE Germany;United States;
Solvay Pharmaceuticals B.V.
2009 - EUCTR2006-005186-18-NL Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2006-005186-18-ES Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2007 - EUCTR2006-005186-18-FI Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
Carbidopa Pill
XenoPort, Inc.
2009 Phase 1/Phase 2 NCT00914602 United States;
Carbidopa and Levodopa 25mg/
NeuroDerm Ltd.
2019 Phase 3 NCT04006210 Austria;Belgium;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
Carbidopa and Levodopa Controlled Release Tablets
Second Affiliated Hospital, School of Medicine, Zhejiang University
2022 Phase 4 NCT04952194 -
Carbidopa and Levodopa Tablets, USP
Impax Laboratories, LLC
2020 Phase 3 EUCTR2018-002233-37-PL Canada;Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-IT Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-GB Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-DE Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-CZ Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
Carbidopa and Levodopa tablets, USP
NEURODERM LTD.
2020 Phase 3 EUCTR2018-004156-37-IT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
NeuroDerm Ltd.
2020 Phase 3 EUCTR2018-004156-37-SK Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-SE Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-PT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-NL Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-GB Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-ES Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-BE Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-AT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004156-37-HU Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004156-37-CZ Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
Carbidopa monohydrate
AbbVie Inc
2011 Phase 3 EUCTR2008-001329-33-GB Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
2010 Phase 3 EUCTR2008-001329-33-CZ Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
2009 - EUCTR2008-001329-33-PT Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
Carbidopa, levodopa, entacapone
Novartis
2005 Phase 4 NCT00143026 Australia;Philippines;Taiwan;Thailand;
Carbidopa- Levodopa
Oregon Health and Science University
2008 Phase 2 NCT00745277 United States;
Carbidopa-4'-Monophosphate
ABBVIE DEUTSCHLAND GMBH & CO. KG
2019 Phase 3 EUCTR2018-002144-85-IT Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
AbbVie Deutschland
2020 Phase 3 EUCTR2018-002144-85-DE Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-NL Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-GB Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-ES Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-DK Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-BE Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
Abbvie Deutschland GmbH & Co. KG
2021 Phase 3 EUCTR2019-004235-23-SE Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004235-23-DE Australia;Canada;Germany;Italy;Japan;Netherlands;Russian Federation;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-NL Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-GB Australia;Canada;Japan;Russian Federation;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-DK Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
Carbidopa-Levodopa
Northwestern University
2011 - NCT01528592 United States;
Oregon Health and Science University
2008 Phase 2 NCT00745277 United States;
Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet
Western University, Canada
2021 - NCT04590612 -
Carbidopa-levodopa
Baylor College of Medicine
2006 Phase 4 NCT00590122 United States;
Carbidopa/Levodopa, immediate release
Intec Pharma Ltd.
2009 Phase 2 NCT00918177 Israel;
Carbidopa/Levodopa/Entacapone
Novartis Pharmaceuticals
2008 Phase 4 NCT00601978 United States;
Carbidopa/l-dopa/entacapone
Molecular NeuroImaging
2004 Phase 2 NCT00200447 -
Carbidopa/levodopa
Institute for Neurodegenerative Disorders
2005 - NCT00129181 Austria;Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2004-001485-41-GB Spain;United Kingdom;
2005 - EUCTR2004-001485-41-AT Austria;Spain;United Kingdom;
Carbidopa/levodopa, as prescribed by treating physician
University of Michigan
2020 - NCT04821830 United States;
Carbidopa/levodopa/entacapone
Novartis
2008 Phase 4 NCT00642356 United States;
Novartis Pharmaceuticals
2005 Phase 4 NCT00219284 Puerto Rico;United States;
2004 Phase 3 NCT00099268 Austria;Belgium;Canada;Finland;France;Germany;Greece;Italy;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Carbidopamonohydraat
Centre for Human Drug Research
2020 Phase 2 EUCTR2020-000686-16-NL Netherlands;
Carbodopa/levadopa
Institute for Neurodegenerative Disorders
2005 - EUCTR2004-001485-41-ES Spain;United Kingdom;
Carbon Fiber Ankle Foot Orthosis (AFO)
University of Texas Southwestern Medical Center
2016 - NCT03192046 United States;
Carbon-14 BIA 28-6156
Bial R&D Investments, S.A.
2021 Phase 1 NCT05220072 United Kingdom;
Cardiac monitoring
University Hospital, Strasbourg, France
2020 Phase 2 NCT03947216 France;
Carnosine supplementation
Slovak Academy of Sciences
2017 - NCT03330470 Slovakia;Taiwan;
Carvedilol
Cedars-Sinai Medical Center
2019 Phase 2 NCT04218968 United States;
Michele Tagliati, MD
2019 Phase 2 NCT03775096 United States;
Catapres ampoules
Summit (Cambridge) Ltd.
2007 - EUCTR2007-004654-81-GB United Kingdom;
Ceftriaxone
BrainX Corporation
2019 Phase 2 NCT03413384 Taiwan;
Cerebral Dopamine Neurotrophic Factor
Herantis Pharma Plc.
2018 Phase 1/Phase 2 NCT03775538 Finland;Sweden;
2017 Phase 1/Phase 2 NCT03295786 Finland;Sweden;
Champix
VU University Medical Center
2012 Phase 3 EUCTR2012-001530-34-NL Netherlands;
Chinese herbal medicine treatment
Hong Kong Baptist University
2021 Phase 2/Phase 3 NCT05001217 -
Chocolate
Technische Universität Dresden
2009 - NCT00906763 Germany;
Circadin®
University College London
2015 Phase 2 EUCTR2014-002697-37-GB United Kingdom;
Citalopram
University of Michigan
2021 Phase 2 NCT04497168 United States;
Western University, Canada
2021 - NCT04590612 -
Citicolina 1000 mg/die
PIAM FARMACEUTICI S.P.A.
2016 Phase 4 EUCTR2014-005562-30-IT Italy;
Clarithromycin
Kyowa Kirin Co., Ltd.
2019 Phase 1 NCT04070495 Japan;
Clarithromycin (Not used as of 4/2020)
Nicolaas Bohnen, MD, PhD
2018 Phase 1/Phase 2 NCT03440112 United States;
Clarium 50 mg Retardtabletten
Desitin Arzneimittel GmbH
2009 - EUCTR2009-012419-16-DE Germany;
Clartihromycin, amoxicillin, and omeprazole
University of California, Los Angeles
2008 Phase 3 NCT00664209 United States;
Clenbuterol HCl
CuraSen Therapeutics, Inc.
2020 Phase 2 EUCTR2020-003796-17-GB United Kingdom;
Clenbuterol Hydrochloride
CuraSen Therapeutics, Inc.
- Phase 2 EUCTR2020-006067-28-BE Australia;Belgium;New Zealand;United Kingdom;
Clonazepam
Seoul National University Hospital
2016 Phase 2 NCT02789592 Korea, Republic of;
Clonidine
Hospices Civils de Lyon
2019 Phase 2 NCT03552068 France;
Clonidine (Catapressan)
Hospices Civils de Lyon
2012 - NCT01796483 France;
Clonidine hydrochloride
Summit (Cambridge) Ltd.
2007 - EUCTR2007-004654-81-GB United Kingdom;
Clozapine
Memorial Hospital of Rhode Island
1993 - NCT00004826 -
CoQ10
University of Rochester
2004 Phase 2 NCT00076492 United States;
Coarse wheat bran
University of Florida
2021 - NCT04829760 United States;
Cocoa
Oxford Brookes University
2017 - NCT03288155 Italy;
Coenzyme Q10
National Institute of Neurological Disorders and Stroke (NINDS)
1998 Phase 2 NCT00004731 United States;
Coenzyme Q10 Nanodispersion (Nanoquinone)
Technische Universität Dresden
2003 Phase 3 NCT00180037 Germany;
Coenzyme Q10 with vitamin E
Weill Medical College of Cornell University
2008 Phase 3 NCT00740714 Canada;United States;
Cogane™ (PYM50028)
Phytopharm
2009 Phase 1 NCT00875316 United Kingdom;
Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)
Northwestern University
2017 Phase 2 NCT03205488 United States;
Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)
Northwestern University
2017 Phase 2 NCT03205488 United States;
Combination Product: L-dopa 70mg/carbidopa
Impel NeuroPharma Inc.
2018 Phase 2 NCT03541356 Australia;
Combination Product: ND0612 Solution for SC infusion
NeuroDerm Ltd.
2019 Phase 3 NCT04006210 Austria;Belgium;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
Combination Product: Sanacoach Parkinson (SCP)
Zuyderland Medisch Centrum
2021 - NCT05164783 Netherlands;
Combination Product: continuous oral delivery of levodopa/carbidopa
SynAgile Corporation
2021 Phase 2 NCT04778176 Italy;Luxembourg;
Combination injection of EPO and G-CSF
Yonsei University
2013 Phase 1/Phase 2 NCT02018406 Korea, Republic of;
Comparator: carbidopa
Merck Sharp & Dohme Corp.
2007 Phase 1 NCT00505843 United States;
Comparator: levodopa
Merck Sharp & Dohme Corp.
2007 Phase 1 NCT00505843 United States;
Comtan
Kyowa Hakko U.K. Limited
2004 - EUCTR2004-000817-20-ES Italy;Latvia;Lithuania;Spain;
Comtan®
BIAL - Portela & Ca, S.A.
2011 Phase 3 EUCTR2010-021860-13-RO Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-SK Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-ES Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
2011 - EUCTR2010-021860-13-DE Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-CZ Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-BG Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-AT Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2010 - EUCTR2010-021860-13-PT Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2010 - EUCTR2010-021860-13-LV Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
2010 - EUCTR2010-021860-13-LT Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2010 - EUCTR2010-021860-13-HU Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
Bial - Portela C S.A.
2006 Phase 2 NCT03103399 -
2006 Phase 1 NCT03094156 Portugal;
2005 Phase 2 NCT02834507 -
2004 Phase 1 NCT03091868 Portugal;
Comtan®
BIAL - PORTELA & Cª, S.A.
2011 - EUCTR2010-021860-13-IT Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Russian Federation;Slovakia;Spain;
Comtess
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2010 - EUCTR2009-017416-33-DE Germany;
Dept of Neuroscience, Uppsala University
2008 - EUCTR2008-003581-26-SE Sweden;
Eisai Limited
2007 Phase 3 EUCTR2006-002937-20-FR Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2007 - EUCTR2006-002937-20-HU Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2007 - EUCTR2006-002937-20-ES Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-LV Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-LT Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-EE Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-CZ Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
Kyowa Hakko U.K. Limited
2005 - EUCTR2004-000817-20-AT Austria;Italy;Latvia;Lithuania;Spain;
2004 Phase 3 EUCTR2004-000817-20-GB Austria;Italy;Latvia;Lithuania;Spain;United Kingdom;
2004 - EUCTR2004-000817-20-LV Italy;Latvia;Lithuania;Spain;
2004 - EUCTR2004-000817-20-LT Italy;Latvia;Lithuania;Spain;
2004 - EUCTR2004-000817-20-ES Italy;Latvia;Lithuania;Spain;
Comtess®
Orion Corporation, Orion Pharma
2002 Phase 4 NCT00247247 Germany;
Continuous Apomorphine infusion
Rennes University Hospital
2009 Phase 3 NCT01039090 France;
Continuous Release Dopamine Agonists
University of Toledo Health Science Campus
2007 Phase 3 NCT00465452 United States;
Continuous Subcutaneous Lisuride Infusion
Axxonis Pharma AG
2006 Phase 3 NCT00408915 Germany;
Continuous intrajejunal infusion of levodopa-carbidopa
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2014 Phase 4 NCT02480803 Netherlands;
Control
Johns Hopkins University
2018 Phase 1 NCT03069911 United States;
Controlled-release levodopa / carbidopa
Pfizer
2004 Phase 4 NCT00174239 Australia;Italy;Spain;United Kingdom;
Conventional medication
Hong Kong Baptist University
2021 Phase 2/Phase 3 NCT05001217 -
Creatine
University of Rochester
2007 Phase 3 NCT00449865 Canada;United States;
2003 Phase 2 NCT00063193 United States;
Cu(II)ATSM
Collaborative Medicinal Development Pty Limited
2017 Phase 1 NCT03204929 Australia;
CyberKnife
Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology
2015 Phase 2 NCT02406105 Poland;
Cystoscopic injection of Botox into the urinary bladder
Stanford University
2009 Phase 4 NCT01421719 United States;
D-serine (~2g/day)
Herzog Hospital
2003 Phase 4 NCT00215904 Israel;
DA-9701
Seoul National University Hospital
2016 Phase 4 NCT02775591 Korea, Republic of;
2013 Phase 4 NCT03022201 Korea, Republic of;
DA-9805
Dong-A ST Co., Ltd.
2018 Phase 2 NCT03189563 United States;
DAAOI-P
China Medical University Hospital
2016 Phase 2 NCT04470037 Taiwan;
DATscan and SPECT imaging
Institute for Neurodegenerative Disorders
2005 - NCT00129181 Austria;Germany;Italy;Spain;United Kingdom;
DC158AM
PIERRE FABRE MEDICAMENT
2008 Phase 3 EUCTR2007-002195-34-FR France;
DCI
Hamamatsu University School of Medicine
2015 - JPRN-UMIN000019524 Japan;
Ito Hidefumi
2016 Phase 2 JPRN-jRCTs051180098 Japan;
Osaka Redcross HospitalWakayama Prefectural Medical College
2016 Phase 2 JPRN-UMIN000022533 Japan;
Ouchi Yasuomi
2015 - JPRN-jRCTs041180070 Japan;
DCS
IRCCS National Neurological Institute C. Mondino Foundation
2019 - NCT04620863 Italy;
DEBRUMYL
PIERRE FABRE MEDICAMENT
2008 Phase 3 EUCTR2007-002195-34-FR France;
DM
Guangdong Provincial People's Hospital
2020 Phase 0 ChiCTR2000039475 China;
DM-1992
Depomed
2012 Phase 2 NCT01515410 United States;
DNL151
Denali Therapeutics Inc.
2019 Phase 1 NCT04056689 Belgium;Netherlands;United Kingdom;United States;
DNL201
Denali Therapeutics Inc.
2018 Phase 1 NCT03710707 United States;
DNS-7801 (high dose)
Dart NeuroScience, LLC
2017 Phase 2 NCT03306329 United States;
DNS-7801 (low-dose)
Dart NeuroScience, LLC
2017 Phase 2 NCT03306329 United States;
DPA
Assistance Publique - Hôpitaux de Paris
2012 - NCT02319382 France;
DPA-714-PET/MRI
University of Alabama at Birmingham
2018 Phase 1/Phase 2 NCT03457493 United States;
DUODOPA
CHU de Poitiers
2010 - EUCTR2010-020769-25-FR France;
DUODOPA®Intestinal Gel
Abbott Healthcare Products B.V.
2009 - EUCTR2006-005186-18-CZ Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
2008 Phase 3 EUCTR2006-005186-18-GB Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
2008 - EUCTR2006-005186-18-PT Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2006-005186-18-DE Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
2007 - EUCTR2006-000577-29-DE Germany;United States;
Solvay Pharmaceuticals B.V.
2009 - EUCTR2006-005186-18-NL Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2006-005186-18-ES Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2007 - EUCTR2006-005186-18-FI Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
DaTSCAN 74 MBq/ml solution for injection
ZIONEXA
2021 Phase 3 EUCTR2019-000247-27-FR France;
DaTSCAN™
Michael J. Fox Foundation for Parkinson's Research
2015 - NCT02572713 Canada;United States;
DaTSCAN™ Ioflupane (123I) Injection
GE Healthcare
2020 Phase 3 NCT04193527 China;
Dacepton 5 mg/ml infuusioneste, liuos
Eero Pekkonen
2016 Phase 4 EUCTR2016-001690-33-FI Finland;
Daily ingestion of Lactobacillus plantarum PS128
Professor Lu Neurological Clinic
2019 - NCT04389762 Taiwan;
Dark chocolate ( cocoa)
Technische Universität Dresden
2013 - NCT02275884 Germany;
Deanol pyroglutamate
PIERRE FABRE MEDICAMENT
2008 Phase 3 EUCTR2007-002195-34-FR France;
Deep Brain Stimulation
Beth Israel Deaconess Medical Center
2016 - NCT02994719 United States;
Deep brain stimulation
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2014 Phase 4 NCT02480803 Netherlands;
Second Affiliated Hospital, School of Medicine, Zhejiang University
2014 - NCT04928079 -
Deferiprone
ApoPharma
2016 Phase 2 NCT02728843 Canada;France;Germany;United Kingdom;
Imperial College London
2012 Phase 2 NCT01539837 United Kingdom;
University Hospital, Lille
2016 Phase 2 NCT02655315 Austria;Czech Republic;Czechia;France;Germany;Netherlands;Portugal;Spain;United Kingdom;
2011 - NCT02880033 France;
2009 Phase 2/Phase 3 NCT00943748 France;
Deferiprone (Ferriprox)
Imperial College London
2011 Phase 2 EUCTR2011-001148-31-GB United Kingdom;
Deferiprone 600 mg delayed release tablet
ApoPharma
2017 Phase 2 EUCTR2015-004344-19-DE Canada;France;Germany;United Kingdom;
2016 Phase 2 EUCTR2015-004344-19-GB Canada;France;Germany;United Kingdom;
ApoPharma Inc.
2016 Phase 2 EUCTR2015-004344-19-FR Canada;France;Germany;Italy;United Kingdom;United States;
Deferiprone DR
Centre Hospitalier Régional et Universitaire de Lille
2016 Phase 3 EUCTR2015-003679-31-ES Spain;
2016 Phase 2 EUCTR2015-003679-31-PT Austria;Czech Republic;Netherlands;Portugal;Spain;
2016 Phase 2 EUCTR2015-003679-31-NL Austria;Czech Republic;Netherlands;Portugal;Spain;
2016 Phase 2 EUCTR2015-003679-31-FR Austria;Czech Republic;France;Netherlands;Portugal;Spain;
2016 Phase 2 EUCTR2015-003679-31-CZ Austria;Czech Republic;Netherlands;Portugal;Spain;
2016 Phase 2 EUCTR2015-003679-31-AT Austria;Czech Republic;France;Germany;Netherlands;Portugal;Spain;United Kingdom;
Desmopressin Acetat
Universität Mainz, Klinik und Poliklinik für Neurologie
2008 - EUCTR2008-003966-25-DE Germany;
Desmotabs
Johannes Gutenberg University Mainz
2009 Phase 4 NCT00806468 Germany;
Desmotabs® 0,2 mg Tabletten
Universität Mainz, Klinik und Poliklinik für Neurologie
2008 - EUCTR2008-003966-25-DE Germany;
Desmotabs® 0,2mg Tabletten
Universität Mainz, Klinik und Poliklinik für Neurologie
2008 - EUCTR2008-003966-25-DE Germany;
Determination of drug effects through amantadine cessation
Seoul National University Hospital
2020 - NCT04260581 Korea, Republic of;
Dexdor
Clínica Universidad de Navarra/Universidad de Navarra
2016 Phase 4 EUCTR2016-002680-34-ES Spain;
2014 - EUCTR2014-000868-17-ES Spain;
Dexmedetomidine
Beijing Tiantan Hospital
2022 - NCT05197439 China;
Clinica Universidad de Navarra, Universidad de Navarra
2017 Phase 4 NCT02982512 Spain;
2014 Phase 4 NCT02256319 Spain;
Diskapi Teaching and Research Hospital
2013 Phase 4 NCT01789385 Turkey;
Shanghai Jing'an District Central Hospital
2016 Phase 0 ChiCTR2000037957 China;
The First Affiliated Hospital of University of Science and Technology of China (Southern District Phase 2)
2021 Phase 0 ChiCTR2100048680 China;
University of Wisconsin, Madison
2012 Phase 4 NCT01721460 United States;
West China Hospital, Sichuan University
2016 - ChiCTR-IOR-16010168 China;
Dexmedetomidine Hydrochloride Infusion
Vanderbilt University
2008 Phase 2/Phase 3 NCT00608231 United States;
Dextromethorphan
National Institute of Neurological Disorders and Stroke (NINDS)
1993 Phase 2 NCT00001365 United States;
Different diets
Sheba Medical Center
2014 - NCT02274324 -
Dihydroergotoxine Mesylate
Nanjing First Hospital Affiliated to Nanjing Medical University
2017 - ChiCTR-IPR-17011155 China;
Dipivefrin
katsuno Masahisa
2017 Phase 2 JPRN-jRCTs041180018 Japan;
Dipivefrine
Nagoya University
2017 - JPRN-UMIN000026128 Japan;
Dipraglurant
Addex Pharma S.A.
2021 Phase 2/Phase 3 NCT05116813 United States;
2021 Phase 2/Phase 3 NCT04857359 United States;
Addex Pharma SA
2011 Phase 2 EUCTR2010-022517-25-DE Austria;France;Germany;United States;
2011 - EUCTR2010-022517-25-AT Austria;France;Germany;United States;
Ditropan elixir
Summit (Cambridge) Ltd.
2007 - EUCTR2007-004654-81-GB United Kingdom;
Docosahexaenoic Acid (DHA)
VA Office of Research and Development
2012 Phase 1 NCT01563913 United States;
Domperidone
Canadian Network for Observational Drug Effect Studies, CNODES
2013 - NCT02500108 Canada;
Kansai Medical University
2012 - JPRN-UMIN000007896 Japan;
Royal Brisbane and Women's Hospital
2005 Phase 1 NCT00103597 Australia;
Seoul National University Hospital
2013 Phase 4 NCT03022201 Korea, Republic of;
Domperidone (drug)
University Health Network, Toronto
2006 Phase 2 NCT00305331 Canada;
Dompéridone
CHU de Toulouse
2010 Phase 3 EUCTR2010-018650-12-FR France;
Donepezil
Clinical Research Center, Utano National Hospital, National Hospital Organization
2010 - JPRN-UMIN000003080 Japan;
Designated Research, National Hospital Organization
2011 Phase 3 JPRN-UMIN000005403 Japan;
Inje University
2015 Phase 2 NCT02415062 Korea, Republic of;
Kansai Medical University
2013 - JPRN-UMIN000010752 Japan;
Kyung Hee University Hospital
2017 Phase 4 NCT03011476 Korea, Republic of;
National Hospital Organization, Sendai-Nishitaga Hospital
2013 - JPRN-UMIN000009958 Japan;
National Hospital of Utano
2013 - JPRN-UMIN000010778 Japan;
National Institute of Neurological Disorders and Stroke (NINDS)
2002 Phase 4 NCT00030979 United States;
Newcastle-upon-Tyne Hospitals NHS Trust
2013 Phase 3 NCT01014858 United Kingdom;
Oregon Health and Science University
2018 Early Phase 1 NCT03599726 United States;
2014 Phase 2 NCT02206620 United States;
2011 Phase 4 NCT01521117 United States;
2005 - NCT00912808 -
Per Borghammer
2013 - NCT02012595 Denmark;
2013 - NCT01877538 Denmark;
University of Chicago
2016 Phase 2 NCT02857244 United States;
Yonsei University
2015 Phase 2 NCT02450786 Korea, Republic of;
Zealand University Hospital
2020 Phase 4 NCT04117178 Denmark;
Donepezil Sandoz
Regional Dementia Research Centre, Dept of Neurology
2018 Phase 4 EUCTR2017-002707-10-DK Denmark;
DopaFuse Delivery System
SynAgile Corporation
2021 Phase 2 EUCTR2020-003372-41-IT Italy;Luxembourg;Spain;
2021 Phase 1;Phase 2 EUCTR2020-003372-41-ES Italy;Luxembourg;Spain;
Dopamine
Medical Corporation Abe Neurology Clinic
2016 - JPRN-UMIN000024859 Japan;
University Hospital, Clermont-Ferrand
2013 Phase 4 NCT01780467 France;
Dopamine Agent
I.R.C.C.S. Fondazione Santa Lucia
2014 Phase 4 NCT03151460 Italy;
Dopamine Agonists (pramipexole, ropirinole)
University of Toronto
2015 Phase 2 NCT02347059 Canada;
Dopaminergic Agonist + Apomorphine
Rennes University Hospital
2019 - NCT03693872 France;
Dopaminergic Agonists
Sandoz
2012 Phase 4 NCT01683253 Korea, Republic of;
Doxepin and Zopiclone
McGill University Health Center
2011 Phase 0 NCT01489982 Canada;
Droxidopa
Chelsea Therapeutics
2013 Phase 3 NCT01927055 United States;
2012 Phase 1/Phase 2 NCT01331122 Canada;United States;
2010 Phase 3 NCT01176240 United States;
Colorado Springs Neurological Associates
2016 - NCT03173781 United States;
Henry Ford Health System
2015 Phase 2 NCT02066571 United States;
Loma Linda University
2021 Phase 2 NCT03446807 United States;
National Institute of Neurological Disorders and Stroke (NINDS)
2007 Phase 1/Phase 2 NCT00547911 United States;
St. Joseph's Hospital and Medical Center, Phoenix
2018 Phase 2 NCT03567447 United States;
Vanderbilt University Medical Center
2017 Phase 4 NCT03115827 United States;
2016 Phase 1 NCT02897063 United States;
William Ondo, MD
2018 Phase 4 NCT03229174 United States;
Droxidopa 100 MG [Northera]
Alberto Espay, MD, MSc
2019 Phase 4 NCT04510922 United States;
Duloxetine
Ando Rina
2015 Phase 2 JPRN-jRCTs061180028 Japan;
CHU de Toulouse
2010 Phase 3 EUCTR2010-018650-12-FR France;
Department of Neurology, Juntendo University School of Medicine
2015 - JPRN-UMIN000016734 Japan;
Ehime University HospitalDept. of Clinical pharmacology and Neurology
2014 Phase 2 JPRN-UMIN000016893 Japan;
University Hospital, Toulouse
2011 Phase 3 NCT01504178 France;
University of Chicago
2016 Phase 2 NCT02857244 United States;
Duloxetine hydrochloride
Eli Lilly and Company
2007 Phase 4 NCT00437125 Italy;
Duodopa
ABBVIE DEUTSCHLAND GMBH & CO. KG
2016 Phase 3 EUCTR2016-001403-23-IT European Union;Finland;Greece;Hungary;Italy;Slovakia;Spain;United States;
AbbVie Deutschland GmbH & Co. KG
2018 Phase 3 EUCTR2016-001403-23-HU European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
2017 Phase 3 EUCTR2016-001403-23-GR European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
2017 Phase 3 EUCTR2016-001403-23-FI European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
2017 Phase 3 EUCTR2014-004865-26-GR Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;United States;
2016 Phase 3 EUCTR2016-001403-23-SK European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
2016 Phase 3 EUCTR2016-001403-23-ES European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
2015 Phase 3 EUCTR2014-004865-26-SE Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;United States;
2015 Phase 3 EUCTR2014-004865-26-ES Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;
2015 Phase 3 EUCTR2014-004865-26-DE Australia;Canada;European Union;Germany;Italy;Spain;Sweden;
2015 - EUCTR2014-004865-26-IT Australia;Canada;European Union;Germany;Italy;Spain;Sweden;
Department of Neuroscience, neurology
2007 - EUCTR2007-004985-41-SE Sweden;
Dept of Neuroscience, Uppsala University
2008 - EUCTR2008-003581-26-SE Sweden;
Institut de Recerca del Hospital de la Santa Creu i Sant Pau
2015 Phase 4 EUCTR2015-002631-17-ES Spain;
LobSor Pharmaceuticals AB
2015 Phase 1 NCT02448914 Sweden;
Organisation name was not entered
2008 - EUCTR2008-003225-16-FI Finland;
Poitiers University Hospital
2011 Phase 2 NCT01291537 France;
Duodopa LD/CD 20/5 mg/mL
NEURODERM LTD.
2018 Phase 3 EUCTR2017-002780-17-IT Austria;France;Italy;Netherlands;Spain;United States;
NeuroDerm Ltd.
2018 Phase 3 EUCTR2017-002780-17-FR Austria;France;Italy;Netherlands;Spain;United States;
2018 Phase 3 EUCTR2017-002780-17-ES Austria;France;Italy;Netherlands;Spain;United States;
Duodopa gel intestinale
Solvay Pharmaceuticals BV.
2008 - EUCTR2006-005186-18-IT Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
Duodopa intestinal gel
Solvay Pharmaceuticals GmbH
2005 - EUCTR2005-002654-21-SE Sweden;
Duodopa intestinalgel
Solvay Pharmaceuticals GmbH
2006 - EUCTR2005-002654-21-NO Norway;Sweden;
Duodopa, 20 mg/ml + 5 mg/ml, intestinal gel
AbbVie Inc
2011 Phase 3 EUCTR2008-001329-33-GB Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
2010 Phase 3 EUCTR2008-001329-33-CZ Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
2009 - EUCTR2008-001329-33-PT Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
Abbott Laboratories
2009 - EUCTR2006-000578-53-DE Germany;New Zealand;United States;
Duodopa, levodopa 20 mg/ml + carbidopa 5 mg/ml, intestinal gel
Academic Medical Center
2014 - EUCTR2014-004501-32-NL Netherlands;
Dynacirc CR (Isradipine)
Northwestern University
2008 Phase 2 NCT00753636 United States;
E2007
EISAI LTD UK
2007 Phase 3 EUCTR2007-000801-30-IT Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 - EUCTR2006-005714-12-IT Italy;
2006 Phase 3 EUCTR2006-002339-26-IT Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-IT Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2004 - EUCTR2004-000361-35-IT Czech Republic;Italy;
Eisai Inc.
2007 Phase 2 NCT00451633 Germany;Italy;
2007 Phase 2 NCT00427011 United States;
2006 Phase 3 NCT00360412 Germany;
2005 Phase 2 NCT00165789 United States;
Eisai Limited
2007 Phase 3 EUCTR2007-000801-30-PL Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 Phase 3 EUCTR2007-000801-30-FR Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 Phase 3 EUCTR2007-000801-30-ES Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 Phase 3 EUCTR2006-002937-20-FR Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2007 - EUCTR2007-000801-30-LV Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 - EUCTR2007-000801-30-LT Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 - EUCTR2007-000801-30-HU Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 - EUCTR2007-000801-30-EE Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 - EUCTR2007-000801-30-CZ Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 - EUCTR2006-002937-20-HU Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2007 - EUCTR2006-002937-20-ES Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2007 - EUCTR2006-002339-26-PT Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-002339-26-HU Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-002339-26-ES Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-002339-26-DE Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3 NCT00360308 France;
2006 Phase 3 NCT00286897 Austria;Belgium;Czech Republic;Estonia;Former Serbia and Montenegro;France;Germany;Hungary;Israel;Italy;Lithuania;Poland;Portugal;Serbia;South Africa;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-004314-33-GB Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-004314-33-ES Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002937-20-LV Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-LT Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-EE Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-CZ Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002339-26-SE Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-LT Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-GB Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-EE Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-CZ Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-BE Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-AT Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-SE Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-PT Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-LT Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-HU Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-EE Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-DE Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-CZ Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-BE Austria;Belgium;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-004314-33-AT Austria;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2004 Phase 2 NCT01172379 Czech Republic;France;Germany;Italy;Serbia;Spain;
2004 - EUCTR2004-000361-35-CZ Czech Republic;Italy;
E2027
Eisai Inc.
2021 Phase 2 NCT04764669 Canada;United States;
EBIXA®
Chru de Lille
2009 - EUCTR2008-008210-38-FR France;
ELC200
Novartis Pharma AG
2006 - EUCTR2005-001032-72-PT Czech Republic;Italy;Portugal;
2006 - EUCTR2005-001032-72-CZ Czech Republic;Italy;Portugal;
EMD 128130
MERCK KGaA
2004 Phase 3 EUCTR2004-001594-25-ES Austria;Finland;Spain;
MERCK S.P.A.
2004 - EUCTR2004-001593-10-IT Italy;United Kingdom;
National Institute of Neurological Disorders and Stroke (NINDS)
2001 Phase 2 NCT00009048 United States;
EMD128130
Merck KGaA
2005 Phase 3 EUCTR2005-000444-84-GB Austria;Finland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000444-84-ES Austria;Finland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-001593-10-GB Italy;United Kingdom;
2005 - EUCTR2005-000444-84-FI Finland;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000444-84-AT Austria;Finland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-001594-25-AT Austria;Finland;Spain;
2004 - EUCTR2004-001594-25-FI Finland;Spain;
EN
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2010 - EUCTR2009-017416-33-DE Germany;
ENA713
Research and Enterprise Department
2012 Phase 2 EUCTR2011-003053-25-GB United Kingdom;
ENA713B
NOVARTIS FARMA
2008 - EUCTR2007-000350-31-IT France;Italy;Spain;
ENT-01
Enterin Inc.
2017 Phase 1/Phase 2 NCT03047629 United States;
ENTACAPONE INN
NOVARTIS FARMA
2005 - EUCTR2005-001032-72-IT Czech Republic;Italy;Portugal;
EPI-589
BioElectron Technology Corporation (formerly Edison Pharmaceuticals Inc.)
2016 Phase 2 EUCTR2015-001786-10-GB Germany;United Kingdom;United States;
2016 Phase 2 EUCTR2015-001786-10-DE Germany;United Kingdom;United States;
PTC Therapeutics
2016 Phase 2 NCT02462603 Germany;United Kingdom;United States;
EPI-743
University of South Florida
2013 Phase 2 NCT01923584 United States;
ER CD-LD
Impax Laboratories, LLC
2016 Phase 2 NCT03007888 United States;
ER tablet 100 mg AZD3241
AstraZeneca
2012 Phase 2 NCT01527695 Sweden;
ER tablet 25 mg AZD3241
AstraZeneca
2012 Phase 2 NCT01527695 Sweden;
ETHNODYNE VISIO
University Hospital, Strasbourg, France
2016 - NCT02815800 France;
EXN-32 (CARBIDOPA E LEVODOPA)
DR. REDDY’S LABORATORIES LIMITED
2017 Phase 2 EUCTR2017-000262-30-IT Italy;
EXN-44(LEVODOPA)
DR. REDDY’S LABORATORIES LIMITED
2017 Phase 2 EUCTR2017-000262-30-IT Italy;
Ebixa
H. Lundbeck A/S
2007 Phase 3 EUCTR2005-002038-36-GR Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
2006 Phase 4 EUCTR2005-002038-36-GB Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
2006 Phase 3 EUCTR2005-002038-36-FR Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
2006 - EUCTR2005-002038-36-DE Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
2006 - EUCTR2005-002038-36-AT Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
Neurologisk afdeling F
2005 Phase 2 EUCTR2004-004139-74-DK Denmark;
Neuropsychiatric clinic
2006 - EUCTR2005-004109-27-SE Sweden;
Electroacupuncture
Nantes University Hospital
2014 - NCT02236260 France;
Eliprodil
National Institute of Neurological Disorders and Stroke (NINDS)
1999 Phase 2 NCT00001929 United States;
Elobixibat
Hatano Taku
2020 - JPRN-jRCTs031200172 Japan;
Eltoprazine HCl
Amarantus BioScience Holdings, Inc.
2015 Phase 2 NCT02439125 United States;
PsychoGenics Inc
2010 - EUCTR2009-015928-28-SE Sweden;
Eltoprazine Hydrochloride
Amarantus BioScience Holdings, Inc.
2015 - EUCTR2015-000373-13-DE France;Germany;Sweden;United States;
Embryonic dopamine cell implant surgery
University of Colorado, Denver
1995 Phase 3 NCT00038116 United States;
Entacapon
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2010 - EUCTR2009-017416-33-DE Germany;
Entacapone
AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
2010 - EUCTR2010-019396-29-IT Italy;
Assistance Publique - Hôpitaux de Paris
2006 Phase 4 NCT00373087 France;
BIAL - Portela & Cª, SA
2006 - EUCTR2006-001793-24-PT Austria;Portugal;
2006 - EUCTR2006-001793-24-AT Austria;Portugal;
Bial - Portela C S.A.
2011 Phase 3 NCT01568073 Austria;Portugal;
2011 Phase 1 NCT02170376 France;
2009 Phase 1 NCT01519284 Portugal;
Dept of Neuroscience, Uppsala University
2008 - EUCTR2008-003581-26-SE Sweden;
Eisai Limited
2007 Phase 3 EUCTR2006-002937-20-FR Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2007 - EUCTR2006-002937-20-HU Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2007 - EUCTR2006-002937-20-ES Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-LV Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-LT Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-EE Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-CZ Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
Geriatric Hospital of Hainan
2019 - ChiCTR1900022534 China;
IMPAX LABORATORIES, INC.
2010 - EUCTR2009-017238-39-IT France;Germany;Italy;
KYOWA HAKKO UK LTD
2005 - EUCTR2004-000817-20-IT Italy;Latvia;Lithuania;Spain;
Kansai Medical University
2010 - JPRN-UMIN000003601 Japan;
Kyowa Hakko U.K. Limited
2005 - EUCTR2004-000817-20-AT Austria;Italy;Latvia;Lithuania;Spain;
2004 Phase 3 EUCTR2004-000817-20-GB Austria;Italy;Latvia;Lithuania;Spain;United Kingdom;
2004 - EUCTR2004-000817-20-LV Italy;Latvia;Lithuania;Spain;
2004 - EUCTR2004-000817-20-LT Italy;Latvia;Lithuania;Spain;
2004 - EUCTR2004-000817-20-ES Italy;Latvia;Lithuania;Spain;
National Institute of Neurological Disorders and Stroke (NINDS)
2007 Phase 1/Phase 2 NCT00547911 United States;
Novartis
2003 Phase 2 NCT00237263 United States;
Orion Corporation Orion Pharma
2007 - EUCTR2007-002496-14-FI Finland;
2006 Phase 4 EUCTR2006-001755-36-GB Germany;Sweden;United Kingdom;
- - EUCTR2006-001755-36-DE Germany;Sweden;United Kingdom;
Orion Corporation Orion Pharma, FI-02200 Espoo, Finland
2006 - EUCTR2006-001755-36-SE Germany;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA
2005 - EUCTR2004-005234-39-FI Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-FI Finland;Italy;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA, Finland
2005 Phase 4 EUCTR2004-005234-39-GB Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA, 02200 Espoo, Finland
2008 - EUCTR2004-005234-39-DE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2007 Phase 3 EUCTR2004-000185-12-GB Austria;Finland;Italy;Sweden;United Kingdom;
2006 - EUCTR2004-005234-39-LV Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2006 - EUCTR2004-005234-39-LT Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 Phase 4 EUCTR2004-005234-39-IE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-005234-39-SE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-005234-39-DK Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-SE Finland;Italy;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-AT Austria;Finland;Italy;Sweden;United Kingdom;
Uppsala University
2008 Phase 4 NCT00906828 Sweden;
Yagi Michio
2021 Phase 1 JPRN-jRCT2051200104 Japan;
Entacapone 400mg oral dose
Daniel Claassen
2020 Phase 1 NCT04246437 United States;
Entacapone and carbidopa
Orion Corporation, Orion Pharma
2008 Phase 2 NCT00562198 Finland;
Entecapone
NOVARTIS FARMA
2004 - EUCTR2004-000185-12-IT Finland;Italy;Sweden;United Kingdom;
Equal
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
2006 - EUCTR2006-003717-41-IT Italy;
Equfina
Eisai Co., Ltd.
2020 - NCT04724109 Japan;
Eisai Korea Inc.
2021 - NCT05225324 Korea, Republic of;
Eradication of Helcobacter Pylori
National University of Malaysia
2012 - NCT02112812 Malaysia;
Eradication therapy for H.pylori infection
National University of Malaysia
2012 - NCT02112812 Malaysia;
Eradication therapy for Helicobacter pylori
National University of Malaysia
2012 - NCT02112812 Malaysia;
Erythromycin
Virginia Commonwealth University
2013 - NCT02005029 United States;
Erythropoietin human recombinant (EPOrh)
International Center for Neurological Restoration, Cuba
2008 Phase 1 NCT01010802 Cuba;
Escitalopram
LUNDBECK ITALIA
2008 - EUCTR2007-004009-93-IT Italy;
University College, London
2019 Phase 3 NCT03652870 -
Escitalopram oxalate
University College London Comprehensive Clinical Trials Unit
2019 Phase 3 EUCTR2018-002942-35-GB United Kingdom;
Eszopiclone
University of Medicine and Dentistry of New Jersey
2006 Phase 3 NCT00324896 United States;
Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below)
University of Bristol
2019 Phase 3 EUCTR2018-003219-23-GB United Kingdom;
Etomidate
Department of Anesthesiology, the First Affiliated Hospital of Sun Yat-Sen University
2020 Phase 4 ChiCTR2000039697 China;
Exelon
Oregon Health and Science University
2011 Phase 4 NCT01340885 United States;
Exelon 4.6 mg/24 h transdermal patch
Novartis Farmacéutica S.A
2008 Phase 3 EUCTR2007-000350-31-ES France;Italy;Spain;
Novartis Pharma AG
2008 - EUCTR2007-000350-31-FR France;Italy;Spain;
Exelon 9.5 mg/24 h transdermal patch
Novartis Farmacéutica S.A
2008 Phase 3 EUCTR2007-000350-31-ES France;Italy;Spain;
Novartis Pharma AG
2008 - EUCTR2007-000350-31-FR France;Italy;Spain;
Exelon Patch (rivastigmine transdermal system)
University of Pennsylvania
2011 Phase 4 NCT01519271 United States;
Exelon path transdermal
NOVARTIS FARMA
2008 - EUCTR2007-000350-31-IT France;Italy;Spain;
Exelon ®
Research and Enterprise Department
2012 Phase 2 EUCTR2011-003053-25-GB United Kingdom;
Exenatide
Center for Neurology, Stockholm
2020 Phase 2 NCT04305002 Sweden;
University College London
2014 Phase 2 EUCTR2013-003363-64-GB United Kingdom;
University College London Comprehensive Clinical Trial Unit
2019 Phase 3 EUCTR2018-003028-35-GB United Kingdom;
University College, London
2014 Phase 2 NCT01971242 United Kingdom;
2010 Phase 2 NCT01174810 United Kingdom;
University of Florida
2018 Phase 1 NCT03456687 United States;
Exenatide 10 micrograms
University College London
2010 Phase 2 EUCTR2009-018137-37-GB United Kingdom;
Exenatide 5 micrograms
University College London
2010 Phase 2 EUCTR2009-018137-37-GB United Kingdom;
Exenatide extended release 2mg (Bydureon)
University College, London
2020 Phase 3 NCT04232969 United Kingdom;
Exergame
University of Arizona
2014 - NCT02777060 United States;
F-18 FPCIT
Asan Medical Center
2006 Phase 3 NCT00468078 Korea, Republic of;
FB-101
1ST Biotherapeutics, Inc.
2019 Phase 1 NCT04165837 United States;
FLORBETABEN (18F)
Fundació Clínic per la Recerca Biomèdica
2016 Phase 4 EUCTR2014-001014-25-ES Spain;
Institute for Neurodegenerative Disorders
2016 Phase 2 EUCTR2015-004129-15-ES Spain;
FPF1100NW
FP Pharmaceutical Corp.
2012 Phase 2 JPRN-JapicCTI-122000 -
- Phase 3 JPRN-JapicCTI-121954 -
- Phase 2 JPRN-JapicCTI-101020 -
FPFS-1169
Fujimoto Pharmaceutical Corporation
2006 Phase 2 EUCTR2006-000361-11-GB United Kingdom;
Famotidine
University Health Network, Toronto
2011 Phase 2 NCT01937078 Canada;
Febuxostat
Kamatani Naoyuki
2019 Phase 1 JPRN-jRCTs031190115 Japan;
StaGen Co. Ltd.
2018 - JPRN-UMIN000030930 Japan;
Tsukuba International Clinical Pharmacology Clinic
2016 - JPRN-UMIN000024312 Japan;
Ferriprox
Centre Hospitalier Régional et Universitaire de Lille
2016 Phase 3 EUCTR2015-003679-31-ES Spain;
Ferrprox (Deferiprone)
Imperial College London
2011 Phase 2 EUCTR2011-001148-31-GB United Kingdom;
Fesoterodine
Sir Mortimer B. Davis - Jewish General Hospital
2016 Phase 4 NCT02385500 Canada;
Fetal porcine cells, Neurocell-PD
Genzyme, a Sanofi Company
1997 Phase 2 NCT00226460 United States;
Filgrastim
MinYoung Kim, M.D.
2014 - NCT02236065 Korea, Republic of;
Finamine tablets
Yiling Pharmaceutical Inc.
2017 Phase 1 NCT04162275 China;
Finasteride
AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI
2011 - EUCTR2011-000612-26-IT Italy;
Fipamezole
Juvantia Pharma Ltd
2008 Phase 2 NCT00758849 France;Portugal;
2007 Phase 2 NCT00559871 India;United States;
Fipamezole ODT
Valeant Pharmaceuticals International, Inc.
2010 - NCT01140841 United States;
Fipamezole ODT Cohort 2
Valeant Pharmaceuticals International, Inc.
2010 - NCT01149811 United States;
Fipamezole hydrochloride 30 mg oral disintegrating tablets
Juvantia Pharma Ltd
2008 - EUCTR2007-004890-24-PT France;Portugal;
2008 - EUCTR2007-004890-24-FR France;Portugal;
Fipamezole hydrochloride 60 mg oral disintegrating tablets
Juvantia Pharma Ltd
2008 - EUCTR2007-004890-24-PT France;Portugal;
2008 - EUCTR2007-004890-24-FR France;Portugal;
Fipamezole hydrochloride 90 mg oral disintegrating tablets
Juvantia Pharma Ltd
2008 - EUCTR2007-004890-24-PT France;Portugal;
2008 - EUCTR2007-004890-24-FR France;Portugal;
Flecainidum
Theranexus S.A.
2018 Phase 2 EUCTR2017-004475-31-HU Czech Republic;France;Germany;Hungary;United States;
2018 Phase 2 EUCTR2017-004475-31-CZ Czech Republic;France;Germany;Hungary;United States;
Florbetapir F 18
Avid Radiopharmaceuticals
2009 Phase 2 NCT00857532 United States;
Fludrocortisone
Christian Baumann
2012 Phase 2 NCT01993680 Switzerland;
Royal Brisbane and Women's Hospital
2005 Phase 1 NCT00103597 Australia;
Flumazenil
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
2013 - JPRN-UMIN000011111 Japan;
University of Michigan
2018 Phase 1/Phase 2 NCT03462641 United States;
Fluoroscopic swallow evaluation
University of Florida
2017 - NCT03321019 United States;
Flutemetamol
Itoh Yoshiaki
2019 - JPRN-jRCTs051180214 Japan;
Flutemetamol F18
Skane University Hospital
2017 - NCT03174938 Sweden;
Folic Acid, Vitamin B6, Vitamin B12
North Shore Long Island Jewish Health System
2006 - NCT00853879 United States;
Foliglurax
H. Lundbeck A/S
2019 Phase 1 NCT04175132 Sweden;
PREXTON THERAPEUTICS B.V.
2017 Phase 2 EUCTR2017-000135-14-IT Austria;France;Germany;Italy;Spain;United Kingdom;
Prexton Therapeutics B.V.
2017 Phase 2 EUCTR2017-000135-14-GB Austria;Germany;Spain;United Kingdom;
2017 Phase 2 EUCTR2017-000135-14-ES Austria;Germany;Italy;Spain;United Kingdom;
2017 Phase 2 EUCTR2017-000135-14-DE Austria;Germany;Italy;Spain;United Kingdom;
2017 Phase 2 EUCTR2017-000135-14-AT Austria;Germany;Spain;United Kingdom;
Foliglurax 10 mg (treatment A)
H. Lundbeck A/S
2020 Phase 1 NCT04322227 France;
Foliglurax 30 mg (treatment B)
H. Lundbeck A/S
2020 Phase 1 NCT04322227 France;
Foscarbidopa
ABBVIE DEUTSCHLAND GMBH & CO. KG
2019 Phase 3 EUCTR2018-002144-85-IT Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
AbbVie Deutschland
2020 Phase 3 EUCTR2018-002144-85-DE Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-NL Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-GB Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-ES Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-DK Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-BE Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
Foscarbidopa and Foslevodopa
ABBVIE DEUTSCHLAND GMBH & CO. KG
2020 Phase 3 EUCTR2019-004235-23-IT Australia;Canada;Italy;Japan;Netherlands;Russian Federation;United Kingdom;United States;
Abbvie Deutschland GmbH & Co. KG
2021 Phase 3 EUCTR2019-004235-23-SE Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004235-23-DE Australia;Canada;Germany;Italy;Japan;Netherlands;Russian Federation;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-NL Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-GB Australia;Canada;Japan;Russian Federation;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-DK Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
Foslevodopa
ABBVIE DEUTSCHLAND GMBH & CO. KG
2019 Phase 3 EUCTR2018-002144-85-IT Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
AbbVie Deutschland
2020 Phase 3 EUCTR2018-002144-85-DE Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-NL Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-GB Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-ES Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-DK Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-BE Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
Functional Magnetic Resonance Imaging
University of Florida
2016 Phase 2 NCT02789020 United States;
Furosemide Injection
University of Alberta
2021 Phase 3 NCT04706910 Canada;
G-CSF
Buddhist Tzu Chi General Hospital
2010 Phase 2 NCT01227681 Taiwan;
GABAPENTINA KERN PHARMA
ASOCIACIÓN INSTITUTO BIODONOSTIA
2012 Phase 2 EUCTR2011-005839-91-ES Spain;
GE180 PET Scan
Aaron Ritter, MD
2018 Phase 2 NCT03702816 United States;
GM1 ganglioside
Thomas Jefferson University
1999 Phase 2 NCT00037830 United States;
GM608
Genervon Biopharmaceuticals, LLC
2013 Phase 2 NCT01850381 United States;
GOCOVRI
Oregon Health and Science University
2020 Phase 4 NCT04387773 United States;
GPI 1485
Eisai Inc.
2002 Phase 2 NCT00209508 -
University of Rochester
2004 Phase 2 NCT00076492 United States;
GRF6021
Alkahest, Inc.
2018 Phase 2 NCT03713957 Australia;France;United States;
GSK962040
GlaxoSmithKline Research and Development Limited
2013 - EUCTR2011-004438-32-SE Australia;Germany;Sweden;United Kingdom;
2013 - EUCTR2011-004438-32-DE Australia;Germany;Sweden;United Kingdom;
2012 Phase 2 EUCTR2011-004438-32-GB Germany;Sweden;United Kingdom;
GSK962040 (25 mg tablet)
GlaxoSmithKline
2012 Phase 2 NCT01602549 Australia;Germany;Sweden;United Kingdom;
Galantamine
Memorial Hospital of Rhode Island
2004 - NCT00211588 United States;
Galantamine hydrobromide
Otto-von-Guericke University, Medical Faculty, Dpt. of Neurology
2009 - EUCTR2009-011093-15-DE Germany;
Ganoderma
Xuanwu Hospital, Beijing
2018 Phase 3 NCT03594656 China;
Genz-682452-AU
Genzyme Corporation
2019 Phase 2 EUCTR2016-000657-12-GR Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2016-000657-12-AT Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000657-12-PT Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000657-12-IT Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000657-12-DE Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000657-12-SE Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000657-12-ES Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
Ghrelin
Nagoya University Graduate School of Medicine
2015 - JPRN-UMIN000017036 Japan;
Glial Cell Line-Derived Neurotrophic Factor (GDNF)
North Bristol NHS Trust (NBT)
2013 Phase 2 EUCTR2013-001881-40-GB United Kingdom;
2012 Phase 2 EUCTR2011-003866-34-GB United Kingdom;
Glial cell line-derived neurotrophic factor
North Bristol NHS Trust
2012 Phase 2 NCT03652363 -
Glucose
National Institute of Mental Health (NIMH)
1998 - NCT00004451 United States;
Glutathione
University of South Florida
2003 Phase 2 NCT01177319 United States;
Glycopyrrolate
Ottawa Hospital Research Institute
2016 Phase 2 NCT02382198 Canada;
Gold
101th Hospital of PLA
2016 - ChiCTR-DOC-16008645 -
Department of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital
2014 - ChiCTR-DDD-17010794 China;
Guangdong General Hospital, Guangdong Academy of Medical Sciences
2015 - ChiCTR-DOD-15006097 China;
Huashan Hospital Affiliated to Fudan University
2020 Phase 0 ChiCTR2000037856 China;
Huashan Hospital, Fudan University
2020 Phase 0 ChiCTR2000038937 China;
Renji Hospital (South Court), School of Medicine, Shanghai Jiao Tong University
2020 Phase 0 ChiCTR2000036137 China;
Renji hospital, School of Medicine, Shanghai Jiao Tong University
2017 - ChiCTR-DDD-16009569 China;
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
2020 Phase 0 ChiCTR2000037239 China;
Shanghai Jiao Tong University School of Medicine affiliated Shanghai General Hospital
2020 Phase 0 ChiCTR2000032616 China;
The First Affiliated Hospital of Chengdu Medical College
2019 Phase 0 ChiCTR1900027306 China;
The First Affiliated Hospital, Sun Yat-sen University
2021 Phase 0 ChiCTR2100044662 China;
Tongji hospital, Tongji University
2019 - ChiCTR1800015757 China;
Xiangyang Hospital, Hubei University of Medicine
2016 - ChiCTR-DRD-16008778 China;
Zhongshan Hospital, Fudan University
2020 Phase 0 ChiCTR2000036006 China;
Gold Nanocrystals
Clene Nanomedicine
2019 Phase 2 NCT03815916 United States;
Grapefruit
Osaka University Graduate School of Medicine Department of Neurosurgery
2016 Phase 1 JPRN-UMIN000021236 Japan;
Green Tea Polyphenols (EGCG/ECG)
Xuanwu Hospital, Beijing
2006 Phase 2 NCT00461942 China;
Group AD Anti-PD + Antidepressant
Teva Pharmaceutical Industries
2009 - NCT00955604 United States;
Group R Rasagiline
Teva Pharmaceutical Industries
2009 - NCT00955604 United States;
Group R+AD Rasagiline + Antidepressant
Teva Pharmaceutical Industries
2009 - NCT00955604 United States;
HA 1A ANTICORPO MONOCLONALE UMANO CLASSE IGM
BIOGEN IDEC RESEARCH LIMITED
2018 Phase 2 EUCTR2016-004610-95-IT Australia;Austria;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;United States;
HB-adMSCs
Hope Biosciences
2019 - NCT04064983 United States;
Hope Biosciences Stem Cell Research Foundation
2021 Phase 2 NCT04928287 United States;
2021 - NCT04772378 United States;
HEC122505MsOH
Sunshine Lake Pharma Co., Ltd.
2021 Phase 1 NCT04625361 China;
HF0220
Hunter-Fleming Ltd
2007 - EUCTR2005-005791-32-SE Sweden;United Kingdom;
2006 Phase 2 EUCTR2005-005791-32-GB Sweden;United Kingdom;
HP-3000 (ropinirole hydrochloride patch)
Hisamitsu Pharmaceutical Co., Inc.
2011 Phase 2 JPRN-JapicCTI-111673 -
Hisamitsu Pharmaceutical Co.,Inc.
2015 Phase 3 JPRN-JapicCTI-152870 -
HP-3000 placebo
Hisamitsu Pharmaceutical Co.,Inc.
2015 Phase 3 JPRN-JapicCTI-152870 -
2012 Phase 2 JPRN-JapicCTI-121880 -
2012 Phase 2 JPRN-JapicCTI-121879 -
HP-3000(ropinirole hydrochloride patch)
Hisamitsu Pharmaceutical Co.,Inc.
2014 Phase 3 JPRN-JapicCTI-142748 -
2012 Phase 2 JPRN-JapicCTI-121880 -
2012 Phase 2 JPRN-JapicCTI-121879 -
Helicobacter pylori eradication therapy
University of Malaya
2013 - NCT02108704 Malaysia;
Heptaminol hydrochloride
PIERRE FABRE MEDICAMENT
2008 Phase 3 EUCTR2007-002195-34-FR France;
Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.)
Fudan University
2008 Phase 2/Phase 3 NCT00656253 China;
Hericium erinaceus mycelium
National Cheng-Kung University Hospital
2020 - NCT04428983 Taiwan;
High Protein. T-Diet plus Range
Vegenat, S.A.
2010 - NCT01192529 Spain;
High dose AFFITOPE® PD03A + Adjuvant
Affiris AG
2014 Phase 1 NCT02267434 Austria;
High dose ANAVEX2-73
Anavex Life Sciences Corp.
2018 Phase 2 NCT03774459 Australia;Spain;
High dose levodopa
Rush University Medical Center
2018 - NCT04956939 United States;
High-Frequency-Only Stimulation
The Cleveland Clinic
2021 Phase 1 NCT05022147 United States;
Home based balance training
University of Arizona
2014 - NCT02777060 United States;
Human Amniotic Epithelial Stem Cells
Shanghai East Hospital
2020 Early Phase 1 NCT04414813 -
Human Stem Cells
Celavie Bioscences, LLC
2014 Phase 1 NCT02780895 Mexico;
Human neural stem cell
Second Affiliated Hospital of Soochow University
2017 Phase 2/Phase 3 NCT03128450 China;
Hydrocortisone cream
University Medical Center Groningen
2015 Phase 2 NCT02230930 Netherlands;
Hydrocortisone cream 10mg/g FNA Fagron
University Medical Center Groningen
2015 Phase 2 EUCTR2014-000657-36-NL Netherlands;
Hydrogen
Department of Neurology, Juntendo University School of Medicine
2010 - JPRN-UMIN000007497 Japan;
Juntendo University Koshigaya Hospital
2019 - JPRN-UMIN000035602 Japan;
2015 - JPRN-UMIN000019090 Japan;
Juntendo University School of Medicine, Neurology
2013 - JPRN-UMIN000010014 Japan;
Nagoya University Graduate School of Medicine
2015 - JPRN-UMIN000019082 Japan;
Nagoya graduate school of medicine university
2015 - JPRN-UMIN000019654 Japan;
Stony Brook University
2019 Phase 2/Phase 3 NCT03971617 United States;
Hydrolyzed guar gum
IRCCS San Raffaele
2016 Phase 2 NCT04569656 Italy;
Hypoestoxide
University of Ibadan
2022 Phase 1/Phase 2 NCT04858074 Nigeria;
Hypoxic Gas Mixture
Radboud University Medical Center
2022 Phase 1/Phase 2 NCT05214287 Netherlands;
I-123-5-IA85380
National Institute of Neurological Disorders and Stroke (NINDS)
2003 - NCT00058721 United States;
I123
Tel-Aviv Sourasky Medical Center
2013 Phase 2 NCT01931488 Israel;
IBEROGAST
Nantes University Hospital
2016 Phase 2 NCT02719496 France;
INS-GSH
Gateway Institute for Brain Research
2022 Phase 2 NCT05266417 United States;
IODIO IOFLUPANO-123I
UCB Biopharma SRL
2021 Phase 2 EUCTR2020-003265-19-IT Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
IOFLUPANE (123I)
MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
2012 - EUCTR2010-019894-13-IT Italy;United States;
Umeå University Hospital
2015 Phase 2 EUCTR2015-003045-26-SE Sweden;
IPT803
Tools4Patient
2018 Phase 1/Phase 2 NCT03407378 Belgium;France;United States;
IPX054
Impax Laboratories, LLC
2006 Phase 2 NCT00279825 United States;
2005 Phase 2 NCT00253084 United States;
2005 Phase 1/Phase 2 NCT00239564 United States;
IPX066
Impax Laboratories, LLC
2011 Phase 3 NCT01411137 United States;
2010 Phase 3 NCT01130493 France;Germany;Italy;United States;
2010 Phase 3 NCT01096186 Canada;Estonia;Germany;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United States;
2009 Phase 3 NCT00974974 Canada;France;Germany;Poland;Romania;Spain;Ukraine;United States;
2008 Phase 2 NCT00869791 United States;
IPX066 145 mg LD
Impax Laboratories, LLC
2009 Phase 3 NCT00880620 Canada;Estonia;Latvia;Lithuania;Romania;Ukraine;United States;
IPX066 195 mg LD
Impax Laboratories, LLC
2009 Phase 3 NCT00880620 Canada;Estonia;Latvia;Lithuania;Romania;Ukraine;United States;
IPX066 245 mg LD
Impax Laboratories, LLC
2009 Phase 3 NCT00880620 Canada;Estonia;Latvia;Lithuania;Romania;Ukraine;United States;
IPX066 95 mg LD
Impax Laboratories, LLC
2009 Phase 3 NCT00880620 Canada;Estonia;Latvia;Lithuania;Romania;Ukraine;United States;
IPX066-145
IMPAX LABORATORIES, INC.
2010 - EUCTR2009-017238-39-IT France;Germany;Italy;
IMPAX Laboratories, Inc.
2009 - EUCTR2009-010193-38-LV Estonia;Latvia;Lithuania;
2009 - EUCTR2009-010193-38-EE Estonia;Latvia;Lithuania;
IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.
2009 - EUCTR2009-010193-38-LT Estonia;Latvia;Lithuania;
Impax Laboratories, Inc.
2010 - EUCTR2009-017182-38-PL Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-014688-37-PL France;Germany;Poland;Spain;
2009 Phase 3 EUCTR2009-014688-37-FR France;Germany;Poland;Spain;
2009 - EUCTR2009-014688-37-ES France;Germany;Poland;Spain;
2009 - EUCTR2009-014688-37-DE France;Germany;Poland;Spain;
Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)
2010 - EUCTR2009-017182-38-LV Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-LT Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-EE Estonia;Germany;Latvia;Lithuania;Poland;Spain;
Impax Laboratories, Inc. acting through its Impax Pharmaceuticals Division
2010 Phase 3 EUCTR2009-017182-38-ES Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-DE Estonia;Germany;Latvia;Lithuania;Poland;Spain;
Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
2010 Phase 3 EUCTR2009-017238-39-FR Belgium;France;Germany;Italy;
2010 Phase 3 EUCTR2009-017238-39-DE Belgium;France;Germany;Italy;
2010 Phase 3 EUCTR2009-017238-39-BE Belgium;France;Germany;Italy;
IPX066-195
IMPAX LABORATORIES, INC.
2010 - EUCTR2009-017238-39-IT France;Germany;Italy;
IMPAX Laboratories, Inc.
2009 - EUCTR2009-010193-38-LV Estonia;Latvia;Lithuania;
2009 - EUCTR2009-010193-38-EE Estonia;Latvia;Lithuania;
IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.
2009 - EUCTR2009-010193-38-LT Estonia;Latvia;Lithuania;
Impax Laboratories, Inc.
2010 - EUCTR2009-017182-38-PL Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-014688-37-PL France;Germany;Poland;Spain;
2009 Phase 3 EUCTR2009-014688-37-FR France;Germany;Poland;Spain;
2009 - EUCTR2009-014688-37-ES France;Germany;Poland;Spain;
2009 - EUCTR2009-014688-37-DE France;Germany;Poland;Spain;
Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)
2010 - EUCTR2009-017182-38-LV Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-LT Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-EE Estonia;Germany;Latvia;Lithuania;Poland;Spain;
Impax Laboratories, Inc. acting through its Impax Pharmaceuticals Division
2010 Phase 3 EUCTR2009-017182-38-ES Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-DE Estonia;Germany;Latvia;Lithuania;Poland;Spain;
Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
2010 Phase 3 EUCTR2009-017238-39-FR Belgium;France;Germany;Italy;
2010 Phase 3 EUCTR2009-017238-39-DE Belgium;France;Germany;Italy;
2010 Phase 3 EUCTR2009-017238-39-BE Belgium;France;Germany;Italy;
IPX066-245
IMPAX LABORATORIES, INC.
2010 - EUCTR2009-017238-39-IT France;Germany;Italy;
IMPAX Laboratories, Inc.
2009 - EUCTR2009-010193-38-LV Estonia;Latvia;Lithuania;
2009 - EUCTR2009-010193-38-EE Estonia;Latvia;Lithuania;
IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.
2009 - EUCTR2009-010193-38-LT Estonia;Latvia;Lithuania;
Impax Laboratories, Inc.
2010 - EUCTR2009-017182-38-PL Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-014688-37-PL France;Germany;Poland;Spain;
2009 - EUCTR2009-014688-37-ES France;Germany;Poland;Spain;
2009 - EUCTR2009-014688-37-DE France;Germany;Poland;Spain;
Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)
2010 - EUCTR2009-017182-38-LV Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-LT Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-EE Estonia;Germany;Latvia;Lithuania;Poland;Spain;
Impax Laboratories, Inc. acting through its Impax Pharmaceuticals Division
2010 Phase 3 EUCTR2009-017182-38-ES Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-DE Estonia;Germany;Latvia;Lithuania;Poland;Spain;
Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
2010 Phase 3 EUCTR2009-017238-39-FR Belgium;France;Germany;Italy;
2010 Phase 3 EUCTR2009-017238-39-DE Belgium;France;Germany;Italy;
2010 Phase 3 EUCTR2009-017238-39-BE Belgium;France;Germany;Italy;
IPX066-95
IMPAX LABORATORIES, INC.
2010 - EUCTR2009-017238-39-IT France;Germany;Italy;
IMPAX Laboratories, Inc.
2009 - EUCTR2009-010193-38-LV Estonia;Latvia;Lithuania;
2009 - EUCTR2009-010193-38-EE Estonia;Latvia;Lithuania;
IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.
2009 - EUCTR2009-010193-38-LT Estonia;Latvia;Lithuania;
Impax Laboratories, Inc.
2010 - EUCTR2009-017182-38-PL Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-014688-37-PL France;Germany;Poland;Spain;
2009 Phase 3 EUCTR2009-014688-37-FR France;Germany;Poland;Spain;
2009 - EUCTR2009-014688-37-ES France;Germany;Poland;Spain;
2009 - EUCTR2009-014688-37-DE France;Germany;Poland;Spain;
Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)
2010 - EUCTR2009-017182-38-LV Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-LT Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-EE Estonia;Germany;Latvia;Lithuania;Poland;Spain;
Impax Laboratories, Inc. acting through its Impax Pharmaceuticals Division
2010 Phase 3 EUCTR2009-017182-38-ES Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-DE Estonia;Germany;Latvia;Lithuania;Poland;Spain;
Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
2010 Phase 3 EUCTR2009-017238-39-FR Belgium;France;Germany;Italy;
2010 Phase 3 EUCTR2009-017238-39-DE Belgium;France;Germany;Italy;
2010 Phase 3 EUCTR2009-017238-39-BE Belgium;France;Germany;Italy;
IPX203
Impax Laboratories, LLC
2020 Phase 3 EUCTR2018-002234-21-GB Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2018-002233-37-PL Canada;Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 NCT03877510 Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002234-21-ES Czech Republic;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002234-21-DE Czech Republic;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002234-21-CZ Czech Republic;Czechia;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-IT Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-GB Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-DE Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-CZ Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2015 Phase 2 NCT02271503 United States;
IPX203 ER CD-LD
Impax Laboratories, LLC
2018 Phase 3 NCT03670953 Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
IR CD-LD
Impax Laboratories, Inc.
2010 - EUCTR2009-014688-37-PL France;Germany;Poland;Spain;
2009 Phase 3 EUCTR2009-014688-37-FR France;Germany;Poland;Spain;
2009 - EUCTR2009-014688-37-ES France;Germany;Poland;Spain;
2009 - EUCTR2009-014688-37-DE France;Germany;Poland;Spain;
Impax Laboratories, LLC
2018 Phase 3 NCT03670953 Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2016 Phase 2 NCT03007888 United States;
2009 Phase 3 NCT00974974 Canada;France;Germany;Poland;Romania;Spain;Ukraine;United States;
2008 Phase 2 NCT00869791 United States;
IR CD-LD (carbidopa-levodopa) tablets
Impax Laboratories, LLC
2020 Phase 3 EUCTR2018-002233-37-PL Canada;Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-IT Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-GB Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-DE Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-CZ Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
IR LD / CD
NEURODERM LTD.
2020 Phase 3 EUCTR2018-004156-37-IT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
NeuroDerm Ltd.
2020 Phase 3 EUCTR2018-004156-37-SK Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-SE Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-NL Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-BE Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-AT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004156-37-CZ Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
IR LD/CD
NeuroDerm Ltd.
2020 Phase 3 EUCTR2018-004156-37-PT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
IRL752
Integrative Research Laboratories AB
2017 Phase 2 EUCTR2017-001673-17-FI Finland;Sweden;
IRL790
Integrative Research Laboratories AB
2016 Phase 1/Phase 2 NCT03531060 -
Integrative Research Laboratories AB (IRLAB)
2019 Phase 2 EUCTR2017-003458-18-SE Sweden;
2017 Phase 2 EUCTR2017-003458-18-GB Sweden;United Kingdom;
Integrative Research Laboratories Sweden AB
2021 Phase 2 EUCTR2020-002010-41-IT France;Israel;Italy;Poland;Serbia;United States;
Integrative Research Laboratories Sweden AB (IRLAB)
2020 Phase 2 EUCTR2020-002010-41-FR France;Israel;Italy;Poland;Serbia;United States;
IRX4204
Io Therapeutics
2014 Phase 1 NCT02438215 United States;
ISC-hpNSC
Cyto Therapeutics Pty Limited
2016 Phase 1 NCT02452723 Australia;
ITI-214
Intra-Cellular Therapies, Inc.
2017 Phase 1/Phase 2 NCT03257046 United States;
IV Apomorphine
National Institute of Neurological Disorders and Stroke (NINDS)
2002 Phase 2 NCT00040209 United States;
IV Levodopa
National Institute of Neurological Disorders and Stroke (NINDS)
2005 Phase 2 NCT00108667 United States;
2002 Phase 2 NCT00040209 United States;
2001 Phase 2 NCT00013624 United States;
2001 Phase 2 NCT00009048 United States;
2000 Phase 2 NCT00006337 United States;
IZD174
Inflazome UK Ltd
2020 Phase 1 NCT04338997 -
Idebenone
Second Affiliated Hospital of Soochow University
2019 Phase 4 NCT03727295 -
Second Affiliated Hospital, School of Medicine, Zhejiang University
2020 Phase 2/Phase 3 NCT04152655 China;
IkT-148009
Inhibikase Therapeutics, Inc.
2021 Phase 1 NCT04350177 United States;
Immediate Release carbidopa/levodopa 10/
Intec Pharma, Ltd.
2016 Phase 3 EUCTR2015-003512-20-SK Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-HU Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-ES Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Immediate Release carbidopa/levodopa 25/
INTEC PHARMA LTD
2016 Phase 3 EUCTR2015-003512-20-IT Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Intec Pharma, Ltd.
2016 Phase 3 EUCTR2015-003512-20-SK Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-PL Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-HU Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-GB Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-ES Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Immediate release carbidopa/levodopa
Novartis
2008 Phase 4 NCT00642356 United States;
Novartis Pharmaceuticals
2004 Phase 3 NCT00099268 Austria;Belgium;Canada;Finland;France;Germany;Greece;Italy;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Impact
Oregon Research Institute
2008 Phase 2 NCT00611481 United States;
Inbrija
University of Texas Southwestern Medical Center
2022 - NCT04957095 United States;
Incobotulinum Toxin A
Beth Israel Deaconess Medical Center
2012 Phase 2 NCT01653132 United States;
2012 Phase 2 NCT01565395 United States;
IncobotulinumtoxinA
Yale University
2012 Phase 2 NCT02419313 United States;
IncobotulinumtoxinA (100 Units)
Merz Pharmaceuticals GmbH
2014 Phase 3 NCT02091739 Germany;Poland;United States;
IncobotulinumtoxinA (75 Units)
Merz Pharmaceuticals GmbH
2014 Phase 3 NCT02091739 Germany;Poland;United States;
Infudopa i.v.
Vastra Gotaland Region
2018 Phase 1 NCT03419806 Sweden;
Infudopa s.c.
Vastra Gotaland Region
2018 Phase 1 NCT03419806 Sweden;
Infusion Pump: CADD-Legacy® 1400 Pump
AbbVie (prior sponsor, Abbott)
2011 Phase 2 NCT01479127 Japan;
Infusions of young plasma
Stanford University
2016 Phase 1 NCT02968433 United States;
Inhaled VR040
South Glasgow University Hospitals NHS Trust
2006 Phase 2 NCT01683292 United Kingdom;
Injection of Umbilical cord derived MSCs
University of Jordan
2018 Phase 1/Phase 2 NCT03684122 Jordan;
Injection of apomorphine
University Hospital, Toulouse
2011 Phase 3 NCT01504178 France;
Injection of normal saline
Yonsei University
2013 Phase 1/Phase 2 NCT02018406 Korea, Republic of;
Inosine
Dept. of Clinical pharmacology and Neurology
2016 Phase 1 JPRN-UMIN000009062 Japan;
Ehime University Graduate School of Medicine
2016 Phase 2 JPRN-UMIN000020527 Japan;
Kamatani Naoyuki
2019 Phase 1 JPRN-jRCTs031190115 Japan;
Michael Alan Schwarzschild
2016 Phase 3 NCT02642393 Puerto Rico;United States;
Nagai Masahiro
2016 Phase 2 JPRN-jRCTs061180060 Japan;
StaGen Co. Ltd.
2018 - JPRN-UMIN000030930 Japan;
The Parkinson Study Group
2009 Phase 2 NCT00833690 United States;
Tsukuba International Clinical Pharmacology Clinic
2016 - JPRN-UMIN000024312 Japan;
Inspiratory Muscle Training
Bezmialem Vakif University
2018 - NCT04228887 Turkey;
Insulin
dr.dargahi
2020 Phase 2 NCT04687878 Iran, Islamic Republic of;
Intracerebral microinjections
NeuroGeneration
2021 Phase 1/Phase 2 NCT03309514 -
Intranasal Insulin
Peter Novak
2014 Phase 2 NCT02064166 United States;
Intranasal glutathione - (in)GSH
Bastyr University
2012 Phase 1 NCT01398748 United States;
Intravenous Infusion
VA Office of Research and Development
2019 - NCT04064294 United States;
Intravenous Levodopa
National Institute of Neurological Disorders and Stroke (NINDS)
2004 Phase 2 NCT00089622 United States;
2004 Phase 2 NCT00086294 United States;
2004 Phase 2 NCT00076674 United States;
Intravenous and Oral n-acetyl cysteine
Thomas Jefferson University
2014 - NCT02445651 United States;
Intravesical injection of Botulinum A toxin
University Of Perugia
2008 Phase 4 NCT00822913 -
Ioflupane
Weill Medical College of Cornell University
2018 Phase 1/Phase 2 NCT03675282 United States;
Ioflupane 123I (DATSCAN®)
University Hospital, Toulouse
2009 Phase 2 NCT00940914 France;
Ioflupane I 123
Julie Gurwell
2018 - NCT03531086 United States;
Ioflupane [123 I]
Institute for Neurodegenerative Disorders
2005 - EUCTR2004-001485-41-GB Spain;United Kingdom;
2005 - EUCTR2004-001485-41-AT Austria;Spain;United Kingdom;
Ioflupane [123I]
Institute for Neurodegenerative Disorders
2005 - EUCTR2004-001485-41-ES Spain;United Kingdom;
Ipratropium bromide (drug)
University Health Network, Toronto
2004 Phase 2 NCT00296946 Canada;
Ips-nsc cells
Allife Medical Science and Technology Co., Ltd.
2019 Early Phase 1 NCT03815071 -
Isicom
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2010 - EUCTR2009-017416-33-DE Germany;
Isoflurane
Columbia University
2003 - NCT00615472 United States;
Isradipine
University of Rochester
2014 Phase 3 NCT02168842 Canada;United States;
Isradipine CR
Northwestern University
2009 Phase 2 NCT00909545 Canada;United States;
Istradefylline
Fukuoka University
2016 - JPRN-UMIN000024536 Japan;
Hatano Taku
2019 - JPRN-jRCTs031180248 Japan;
Ichinomiya Nishi Hospital
2019 - JPRN-UMIN000037422 Japan;
2019 - JPRN-UMIN000037421 Japan;
Juntendo University Shizuoka Hospital
2016 - JPRN-UMIN000020288 Japan;
KYOWA HAKKO UK LTD
2005 - EUCTR2004-002844-93-IT Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-000817-20-IT Italy;Latvia;Lithuania;Spain;
Kyowa Hakko Kirin Company, Limited
2009 Phase 3 NCT00957203 Japan;
2009 Phase 3 NCT00955526 Japan;
2007 Phase 2 NCT00455507 Japan;
Kyowa Hakko Kirin Pharma, Inc.
2013 Phase 3 NCT01968031 Canada;Czech Republic;Czechia;Germany;Israel;Italy;Poland;Serbia;United States;
Kyowa Hakko U.K. Limited
2005 - EUCTR2004-002844-93-LV Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-002844-93-LT Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-002844-93-GB Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-002844-93-ES Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-002844-93-EE Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-002844-93-AT Austria;Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-000817-20-AT Austria;Italy;Latvia;Lithuania;Spain;
2004 Phase 3 EUCTR2004-000817-20-GB Austria;Italy;Latvia;Lithuania;Spain;United Kingdom;
2004 - EUCTR2004-000817-20-LV Italy;Latvia;Lithuania;Spain;
2004 - EUCTR2004-000817-20-LT Italy;Latvia;Lithuania;Spain;
2004 - EUCTR2004-000817-20-ES Italy;Latvia;Lithuania;Spain;
Kyowa Kirin Pharmaceutical Development, Inc.
2005 Phase 3 NCT00199381 United States;
2002 Phase 2/Phase 3 NCT00955045 United States;
Osaka Red Cross Hospital
2017 - JPRN-UMIN000026492 Japan;
Takahashi Makio
2017 - JPRN-jRCTs051180185 Japan;
Tsuboi Yoshio
2017 - JPRN-jRCTs071180014 Japan;N A;
University of Chicago
2005 Phase 3 NCT00203957 United States;
Istradefylline ( KW-6002)
Kyowa Kirin Pharmaceutical Development, Inc.
2004 Phase 3 NCT00199368 United States;
Istradefylline (KW-6002)
Kyowa Hakko Kirin Company, Limited
2005 Phase 2 NCT00250393 Japan;
2005 Phase 2 NCT00199355 Japan;
Kyowa Hakko Kirin UK, Ltd.
2004 Phase 3 NCT00199394 United Kingdom;
Kyowa Kirin Pharmaceutical Development, Inc.
2005 Phase 2 NCT00199433 United States;
2004 Phase 3 NCT00199420 United States;
2004 Phase 3 NCT00199407 United States;
2002 Phase 2 NCT00456794 United States;
Istradefylline 20 mg or
Kyowa Hakko Kirin Pharma, Inc.
2015 Phase 3 NCT02610231 Canada;Czech Republic;Czechia;Germany;Israel;Italy;Poland;Serbia;United States;
J-tube
AbbVie
2013 Phase 3 NCT01960842 Japan;Korea, Republic of;Taiwan;
AbbVie (prior sponsor, Abbott)
2009 Phase 3 NCT00660387 New Zealand;United States;
2009 Phase 3 NCT00360568 Germany;New Zealand;United States;
2009 Phase 3 NCT00357994 Germany;United States;
2008 Phase 3 NCT00335153 Australia;Canada;Czech Republic;Finland;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
JM-010
Bukwang Pharmaceutical
2015 Phase 2 NCT02439203 South Africa;
Contera Pharma
2020 Phase 2 EUCTR2017-003415-19-IT France;Germany;Italy;Spain;
2018 Phase 2 EUCTR2017-003415-19-ES France;Germany;Spain;
JM-010 group A
Contera Pharma
2019 Phase 2 NCT03956979 France;Germany;Italy;Spain;
JM-010 group B
Contera Pharma
2019 Phase 2 NCT03956979 France;Germany;Italy;Spain;
JNJ-31001074
BENEVOLENTAI BIO
2017 Phase 2 EUCTR2017-000877-35-IT Czech Republic;Czechia;Germany;Italy;Poland;Spain;United Kingdom;United States;
BenevolentAI Bio
2017 Phase 2 EUCTR2017-000877-35-GB Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000877-35-ES Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000877-35-DE Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000877-35-CZ Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
JNJ31-31001074
BENEVOLENTAI BIO
2017 Phase 2 EUCTR2017-000877-35-IT Czech Republic;Czechia;Germany;Italy;Poland;Spain;United Kingdom;United States;
JP 1730
National Institute of Neurological Disorders and Stroke (NINDS)
2002 Phase 2 NCT00040209 United States;
JP-1730/F01
Juvantia Pharma Ltd
2008 - EUCTR2007-004890-24-PT France;Portugal;
2008 - EUCTR2007-004890-24-FR France;Portugal;
JP-1730/F02
Juvantia Pharma Ltd
2008 - EUCTR2007-004890-24-PT France;Portugal;
2008 - EUCTR2007-004890-24-FR France;Portugal;
JP-1730/F03
Juvantia Pharma Ltd
2008 - EUCTR2007-004890-24-PT France;Portugal;
2008 - EUCTR2007-004890-24-FR France;Portugal;
JZP-110
Jazz Pharmaceuticals
2017 Phase 2 NCT03037203 United States;
Jejunal extension tube
AbbVie
2017 Phase 3 NCT02799381 Finland;Greece;Hungary;Italy;Slovakia;Spain;United States;
Jejunal extension tube (J-tube)
AbbVie (prior sponsor, Abbott)
2006 Phase 4 NCT00141518 Norway;Sweden;
Juvit D3
Medical University of Gdansk
2019 - NCT04768023 Poland;
K0706
Sun Pharma Advanced Research Company (SPARC) Limited
2019 Phase 2 EUCTR2018-003337-15-SK Hungary;India;Poland;Slovakia;Spain;United States;
2019 Phase 2 EUCTR2018-003337-15-HU Hungary;India;Poland;Slovakia;Spain;United States;
2019 Phase 2 EUCTR2018-003337-15-ES Czech Republic;Hungary;India;Poland;Slovakia;Spain;United States;
Sun Pharma Advanced Research Company Limited
2019 Phase 2 NCT03655236 Hungary;India;Poland;Slovakia;Spain;United States;
2017 Phase 1 NCT02970019 United States;
KDT-3594
Kissei Pharmaceutical Co., Ltd.
2021 Phase 2 NCT04867551 Japan;
2019 Phase 2 NCT03845387 Japan;
2017 Phase 1 NCT03068481 Japan;
KM-819
Kainos Medicine Inc.
2016 Phase 1 NCT03022799 Korea, Republic of;
KW-6002
KYOWA HAKKO UK LTD
2005 - EUCTR2004-002844-93-IT Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-000817-20-IT Italy;Latvia;Lithuania;Spain;
Kyowa Hakko U.K. Limited
2005 - EUCTR2004-002844-93-LV Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-002844-93-LT Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-002844-93-GB Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-002844-93-ES Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-002844-93-EE Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-002844-93-AT Austria;Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-000817-20-AT Austria;Italy;Latvia;Lithuania;Spain;
2004 Phase 3 EUCTR2004-000817-20-GB Austria;Italy;Latvia;Lithuania;Spain;United Kingdom;
2004 - EUCTR2004-000817-20-LV Italy;Latvia;Lithuania;Spain;
2004 - EUCTR2004-000817-20-LT Italy;Latvia;Lithuania;Spain;
2004 - EUCTR2004-000817-20-ES Italy;Latvia;Lithuania;Spain;
National Institute of Neurological Disorders and Stroke (NINDS)
2000 Phase 2 NCT00006337 United States;
KW-6002 (istradefylline)
KYOWA HAKKO KIRIN PHARMA, INC.
2016 Phase 3 EUCTR2015-003887-34-IT Canada;Czech Republic;Germany;Israel;Italy;Poland;Serbia;United States;
Kyowa Hakko Kirin Pharma, Inc.
2014 Phase 3 EUCTR2013-002254-70-IT Canada;Czech Republic;Germany;Israel;Italy;Poland;Serbia;United States;
Kyowa Kirin Pharmaceutical Development, Inc.
2016 Phase 3 EUCTR2015-003887-34-PL Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States;
2016 Phase 3 EUCTR2015-003887-34-DE Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States;
2016 Phase 3 EUCTR2015-003887-34-CZ Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States;
2014 Phase 3 EUCTR2013-002254-70-PL Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States;
2014 Phase 3 EUCTR2013-002254-70-DE Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States;
2014 Phase 3 EUCTR2013-002254-70-CZ Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States;
2002 Phase 2 NCT00456586 United States;
KW-6356
Kyowa Kirin Co., Ltd.
2020 Phase 1 NCT04342273 Japan;
2019 Phase 1 NCT04070495 Japan;
2019 Phase 1 NCT03970798 Japan;
2018 Phase 2 NCT03703570 Japan;
2016 Phase 2 NCT02939391 Japan;
KW-6356 High Dose
Kyowa Kirin Co., Ltd.
2019 Phase 1 NCT03830528 Japan;
KW-6356 Low Dose
Kyowa Kirin Co., Ltd.
2019 Phase 1 NCT03830528 Japan;
KW-6356 Middle Dose
Kyowa Kirin Co., Ltd.
2019 Phase 1 NCT03830528 Japan;
KW-6356 X Dose
Kyowa Kirin Co., Ltd.
2019 Phase 1 NCT03830528 Japan;
KW-6356 Y Dose
Kyowa Kirin Co., Ltd.
2019 Phase 1 NCT03830528 Japan;
KW-6500
Kyowa Hakko Kirin Co., Ltd
2010 Phase 3 NCT01063621 Japan;
2010 Phase 3 NCT01058291 Japan;
2009 Phase 3 NCT00955318 Japan;
Ketamine
PharmaTher Inc.
2021 Phase 2 NCT04912115 United States;
Ketamine Infusion
Yale University
2021 Phase 2 NCT04944017 United States;
Ketone Ester Elite endurance Nutrition Drink
University of Florida
2019 - NCT04477161 United States;
Ketone ester drink
University of Oxford
2011 - NCT01364545 United Kingdom;
Kinetra and Soletra (neurostimulator, Medtronic)
German Parkinson Study Group (GPS)
2006 Phase 4 NCT00354133 France;Germany;
Kinoquinone (proposed)
BioElectron Technology Corporation (formerly Edison Pharmaceuticals Inc.)
2016 Phase 2 EUCTR2015-001786-10-DE Germany;United Kingdom;United States;
L-123 Ioflupane
Wisconsin Institute for Neurologic and Sleep Disorders S.C.
2014 - NCT02138682 United States;
L-3-(3,4-Dihydroxyphenyl)alanine
Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
2007 - EUCTR2006-000577-29-DE Germany;United States;
L-DOPA
Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
2007 - EUCTR2006-000577-29-DE Germany;United States;
Ito Hidefumi
2016 Phase 2 JPRN-jRCTs051180098 Japan;
Osaka Redcross HospitalWakayama Prefectural Medical College
2016 Phase 2 JPRN-UMIN000022533 Japan;
Utano National Hospital, National Hospital Organization
2016 Phase 3 JPRN-UMIN000022529 Japan;
L-DOPA/DDCI
Bial - Portela C S.A.
2021 Phase 4 NCT04990284 -
L-DOPS
St. Joseph's Hospital and Medical Center, Phoenix
2016 Phase 2 NCT02812147 United States;
L-Dopa/ MODOPAR
Chru de Lille
2009 - EUCTR2008-008210-38-FR France;
L-tyrosine
New York Institute of Technology
2014 Phase 0 NCT02259049 United States;
LCIG
NeuroDerm Ltd.
2015 Phase 1 NCT02604914 United Kingdom;
LCIG (Duodopa)
Vastra Gotaland Region
2018 Phase 1 NCT03419806 Sweden;
LD / BE
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2011 - EUCTR2010-022363-35-DE Germany;
LD+DDCI
ASST Gaetano Pini-CTO
2016 Phase 2 NCT02680977 Bolivia;
LD-DDCI
ASST Gaetano Pini-CTO
2016 Phase 2 NCT02680977 Bolivia;
LD/CD
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2010 - EUCTR2009-017416-33-DE Germany;
LEVODOPA (DC.IT) (FU)
NOVARTIS FARMA
2004 - EUCTR2004-000185-12-IT Finland;Italy;Sweden;United Kingdom;
LEVODOPA (LD)
NEURODERM LTD.
2016 Phase 2 EUCTR2015-005814-31-IT Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
LEVODOPA / BENSERAZIDE 200 +
LEVODOPA DC.IT FU
VERNALIS DEVELOPMENT LIMITED
2006 - EUCTR2006-004112-51-IT Italy;
LEVODOPA INN
NOVARTIS FARMA
2005 - EUCTR2005-001032-72-IT Czech Republic;Italy;Portugal;
LEVODOPA/BENZERASIDE
CHU de Poitiers
2010 - EUCTR2010-020769-25-FR France;
LEVODOPA/CARBIDOPA
CHU de Poitiers
2010 - EUCTR2010-020769-25-FR France;
LODALÈS®
CHU de Bordeaux
2009 - EUCTR2009-011736-35-FR France;
LY03003
Luye Pharma Group Ltd.
2020 Phase 1 NCT04630860 China;
2018 Phase 1 NCT04629404 China;
2018 Phase 1 NCT03733561 United States;
2018 Phase 1 NCT03589066 United States;
2013 Phase 1 NCT04627155 -
2013 Phase 1 NCT02055274 United States;
LY03003 ( Rotigotine, extended-release microspheres)
Luye Pharma Group Ltd.
2017 Phase 1 NCT04045678 China;
LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)
Luye Pharma Group Ltd.
2020 Phase 1 NCT04384666 United States;
LY03003( the name of rotigotine)
Peking University Third Hospital
2018 Phase 3 NCT04455555 China;
LY03003(Rotigotine,extended-release microspheres)
Luye Pharma Group Ltd.
2020 Phase 3 NCT04571164 China;
LY03009 F1
Luye Pharma Group Ltd.
2021 Phase 1 NCT04593511 Australia;
LY03009 F2
Luye Pharma Group Ltd.
2021 Phase 1 NCT04593511 Australia;
LY03009 F3
Luye Pharma Group Ltd.
2021 Phase 1 NCT04593511 Australia;
LY03009 F4
Luye Pharma Group Ltd.
2021 Phase 1 NCT04593511 Australia;
LY300164
National Institute of Neurological Disorders and Stroke (NINDS)
2000 Phase 2 NCT00004576 United States;
LY3154207
Eli Lilly and Company
2017 Phase 2 NCT03305809 Canada;China;Puerto Rico;United States;
2015 Phase 1 NCT02562768 United States;
Lactobacillus casei DG (Enterolactis duo®)
University of Salerno
2019 - NCT04293159 Italy;
Lactobacillus plantarum PS128
Professor Lu Neurological Clinic
2018 - NCT03566589 Taiwan;
Lactose
Ehime University Graduate School of Medicine
2016 Phase 2 JPRN-UMIN000020527 Japan;
Kansai Medical University
2012 - JPRN-UMIN000007896 Japan;
Utano National Hospital, National Hospital Organization
2016 Phase 3 JPRN-UMIN000022529 Japan;
Leptin
Nagoya University Graduate School of Medicine
2015 - JPRN-UMIN000017036 Japan;
Levetiracetam
1st Hospital of Social Security Services
2006 Phase 2 NCT00291733 Greece;
Technische Universität Dresden
2006 Phase 4 NCT00307450 Germany;
The University of Queensland
2021 Phase 2 NCT04643327 Australia;
UCB Pharma
2003 Phase 2 NCT00160576 -
University of South Florida
2007 Phase 4 NCT00584025 United States;
Levodopa
AbbVie Inc
2011 Phase 3 EUCTR2008-001329-33-GB Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
2010 Phase 3 EUCTR2008-001329-33-CZ Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
2009 - EUCTR2008-001329-33-PT Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
Abbott Healthcare Products B.V.
2009 - EUCTR2006-005186-18-CZ Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
2008 Phase 3 EUCTR2006-005186-18-GB Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
2008 - EUCTR2006-005186-18-PT Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2006-005186-18-DE Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
Abbott Laboratories
2009 - EUCTR2006-000578-53-DE Germany;New Zealand;United States;
Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
2007 - EUCTR2006-000577-29-DE Germany;United States;
Bial - Portela C S.A.
2011 Phase 3 NCT01568073 Austria;Portugal;
2011 Phase 3 NCT01227655 Portugal;
CHU de Toulouse
2010 Phase 3 EUCTR2010-018650-12-FR France;
Chinese Academy of Sciences
2017 Phase 1/Phase 2 NCT03119636 China;
CleveXel Pharma
2016 Phase 2 NCT02641054 France;
Department of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital
2014 - ChiCTR-DDD-17010794 China;
Department of Neuroscience, neurology
2007 - EUCTR2007-004985-41-SE Sweden;
Dept of Neuroscience, Uppsala University
2008 - EUCTR2008-003581-26-SE Sweden;
First Affiliated Hospital of Xinjiang Medical University
2007 - ChiCTR-TRC-07000027 China;
Fujita Health University School of MedicineDepartment of Gastroenterology
2020 Phase 4 JPRN-UMIN000040889 Japan;
GlaxoSmithKline
2011 - NCT01545856 -
Hamamatsu University School of Medicine
2015 - JPRN-UMIN000019524 Japan;
Hatano Taku
2019 - JPRN-jRCTs031180248 Japan;
Institute for Neurodegenerative Disorders
2004 Phase 2 NCT00096720 United States;
Institute of Clinical Pharmacology, Central South University
2012 - ChiCTR-OCS-12002720 -
Institute of Psychology, Chinese Academy of Sciences
2018 - ChiCTR1800015331 China;
Juntendo University School of Medicine
2017 - JPRN-UMIN000025645 Japan;
Kansai Medical University
2012 - JPRN-UMIN000007896 Japan;
Kevin J. Black, MD
2017 Phase 1 NCT03205956 United States;
Merck Sharp & Dohme Corp.
2009 Phase 1 NCT00845000 United States;
National Institute of Neurological Disorders and Stroke (NINDS)
1998 Phase 3 NCT00004733 United States;
Oregon Health and Science University
2005 - NCT00692328 United States;
Orion Corporation Orion Pharma
2007 - EUCTR2007-002496-14-FI Finland;
2006 Phase 4 EUCTR2006-001755-36-GB Germany;Sweden;United Kingdom;
- - EUCTR2006-001755-36-DE Germany;Sweden;United Kingdom;
Orion Corporation Orion Pharma, FI-02200 Espoo, Finland
2006 - EUCTR2006-001755-36-SE Germany;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA
2005 - EUCTR2004-005234-39-FI Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-FI Finland;Italy;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA, Finland
2005 Phase 4 EUCTR2004-005234-39-GB Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA, 02200 Espoo, Finland
2008 - EUCTR2004-005234-39-DE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2007 Phase 3 EUCTR2004-000185-12-GB Austria;Finland;Italy;Sweden;United Kingdom;
2006 - EUCTR2004-005234-39-LV Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2006 - EUCTR2004-005234-39-LT Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 Phase 4 EUCTR2004-005234-39-IE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-005234-39-SE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-005234-39-DK Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-SE Finland;Italy;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-AT Austria;Finland;Italy;Sweden;United Kingdom;
Ouchi Yasuomi
2015 - JPRN-jRCTs041180070 Japan;
Rush University Medical Center
2011 Phase 2 NCT01351168 United States;
Sage Therapeutics
2016 Phase 2 NCT03000569 United States;
Solvay Pharmaceuticals B.V.
2009 - EUCTR2006-005186-18-NL Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2006-005186-18-ES Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2007 - EUCTR2006-005186-18-FI Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
Solvay Pharmaceuticals BV.
2008 - EUCTR2006-005186-18-IT Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
Solvay Pharmaceuticals GmbH
2006 - EUCTR2005-002654-21-NO Norway;Sweden;
2005 - EUCTR2005-002654-21-SE Sweden;
Technische Universität Dresden
2005 Phase 4 NCT00153972 Germany;
The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital)
2020 Phase 4 ChiCTR2000039201 China;
Tianjin Huanhu Hospital
2019 Phase 0 ChiCTR1900025372 China;
University Hospital, Toulouse
2016 Phase 2/Phase 3 NCT02601586 France;
2002 - NCT01044992 France;
Yagi Michio
2021 Phase 1 JPRN-jRCT2051200104 Japan;
Levodopa (L-DOPA) + Standard care
Bial - Portela C S.A.
2020 - NCT03959540 United Kingdom;
Levodopa (L-dopa)
Biotie Therapies Inc.
2011 Phase 2/Phase 3 NCT01283594 Argentina;Canada;Chile;Romania;Ukraine;United States;
Levodopa (delivered intravenously)
Oregon Health and Science University
2010 - NCT01003002 United States;
VA Office of Research and Development
2006 - NCT00467597 United States;
Levodopa (drug), intraduodenal administration
University Hospital, Akershus
2006 Phase 4 NCT00272688 Norway;
Levodopa / Benserazid
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2011 - EUCTR2010-022363-35-DE Germany;
Levodopa 100 mg / benserazide
Bial - Portela C S.A.
2005 Phase 1 NCT02778594 Portugal;
Levodopa 100 mg A CAP
Orion Corporation
2017 Phase 2 EUCTR2015-004507-23-HU Finland;Germany;Hungary;Latvia;
2017 Phase 2 EUCTR2015-004507-23-FI Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-LV Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-DE Finland;Germany;Hungary;Latvia;
Levodopa 125 mg A CAP
Orion Corporation
2017 Phase 2 EUCTR2015-004507-23-HU Finland;Germany;Hungary;Latvia;
2017 Phase 2 EUCTR2015-004507-23-FI Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-LV Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-DE Finland;Germany;Hungary;Latvia;
Levodopa 150 mg A CAP
Orion Corporation
2017 Phase 2 EUCTR2015-004507-23-HU Finland;Germany;Hungary;Latvia;
2017 Phase 2 EUCTR2015-004507-23-FI Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-LV Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-DE Finland;Germany;Hungary;Latvia;
Levodopa 25mg/
NeuroDerm Ltd.
2019 Phase 3 NCT04006210 Austria;Belgium;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
Levodopa 75 mg A CAP
Orion Corporation
2017 Phase 2 EUCTR2015-004507-23-HU Finland;Germany;Hungary;Latvia;
2017 Phase 2 EUCTR2015-004507-23-FI Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-LV Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-DE Finland;Germany;Hungary;Latvia;
Levodopa Benserazide Madopar
IRCCS San Raffaele
2014 Phase 4 NCT02741947 Italy;
Levodopa Benserazide Teva Italia
IRCCS San Raffaele
2014 Phase 4 NCT02741947 Italy;
Levodopa CR (controlled release)
Research and Development University Hospital of North Staffordshire
2014 - EUCTR2014-000335-17-GB United Kingdom;
Levodopa Cyclops
Pharmaceutical Technology and Biopharmacy, University of Groningen
2018 Phase 2 EUCTR2017-004006-18-NL Netherlands;
Levodopa MR
Orion Corporation, Orion Pharma
2016 Phase 2 NCT02764125 Finland;Germany;Hungary;Latvia;
Levodopa acute challenge
Institut de Myologie, France
2016 - NCT02785978 France;
Levodopa and Domperidone
National Institute of Neurological Disorders and Stroke (NINDS)
2000 Phase 2 NCT00006077 United States;
Levodopa and carbidopa
NeuroDerm Ltd.
2013 Phase 2 NCT01883505 Israel;
Levodopa and carbidopa SC solution
NeuroDerm Ltd.
2014 Phase 1/Phase 2 NCT02096601 Israel;United States;
Levodopa and carbidopa solution for SC administration
NeuroDerm Ltd.
2012 Phase 1/Phase 2 NCT01725802 Israel;
Levodopa and decarboxylase inhibitor
AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
2010 - EUCTR2010-019396-29-IT Italy;
IMPAX LABORATORIES, INC.
2010 - EUCTR2009-017238-39-IT France;Germany;Italy;
Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets
AbbVie (prior sponsor, Abbott)
2009 Phase 3 NCT00357994 Germany;United States;
Levodopa carbidopa intestinal gel (LCIG)
AbbVie (prior sponsor, Abbott)
2009 Phase 3 NCT00660387 New Zealand;United States;
2009 Phase 3 NCT00357994 Germany;United States;
Levodopa dispersible
Seoul National University Hospital
2015 Phase 4 NCT02769793 Korea, Republic of;
Levodopa infusion
Helsinki University
2009 Phase 4 NCT00914134 Finland;
Levodopa powder for inhalation
Pharmaceutical Technology and Biopharmacy, University of Groningen
2018 Phase 2 EUCTR2017-004006-18-NL Netherlands;
Levodopa tablet
Western University, Canada
2019 - NCT04054960 Canada;
Levodopa, carbidopa, ODM-104
Orion Corporation, Orion Pharma
2017 Phase 1 NCT03140956 Finland;
2015 Phase 1 NCT02554734 Finland;
2014 Phase 1 NCT02312232 Finland;
Levodopa, carbidopa, entacapone
Orion Corporation, Orion Pharma
2015 Phase 1 NCT02554734 Finland;
Levodopa, decarboxylase inhibitor and COMT inhibitor
AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
2010 - EUCTR2010-019396-29-IT Italy;
Levodopa-4'-Monophosphate
ABBVIE DEUTSCHLAND GMBH & CO. KG
2020 Phase 3 EUCTR2019-004235-23-IT Australia;Canada;Italy;Japan;Netherlands;Russian Federation;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-IT Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
AbbVie Deutschland
2020 Phase 3 EUCTR2018-002144-85-DE Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-NL Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-GB Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-ES Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-DK Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-BE Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
Abbvie Deutschland GmbH & Co. KG
2021 Phase 3 EUCTR2019-004235-23-SE Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004235-23-DE Australia;Canada;Germany;Italy;Japan;Netherlands;Russian Federation;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-NL Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-GB Australia;Canada;Japan;Russian Federation;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-DK Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
Levodopa-Carbidopa
AbbVie
2010 Phase 1 NCT01484990 Germany;Sweden;
Levodopa-Carbidopa Intestinal Gel
AbbVie (prior sponsor, Abbott)
2013 Phase 3 NCT01736176 United States;
Levodopa-Carbidopa Intestinal Gel (LCIG)
AbbVie
2017 Phase 3 NCT02799381 Finland;Greece;Hungary;Italy;Slovakia;Spain;United States;
Levodopa-Carbidopa Multilayer Extended Release Tablet
CombinatoRx, Inc
2008 - EUCTR2007-005033-11-DE Germany;
Levodopa-Carbidopa XL tablet (M)
CombinatoRx, Inc
2008 - EUCTR2007-005033-11-DE Germany;
Levodopa-carbidopa
EISAI LTD UK
2007 - EUCTR2006-005714-12-IT Italy;
Osmotica Pharmaceutical Corp.
2007 Phase 2 NCT00558337 Argentina;
Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets
AbbVie (prior sponsor, Abbott)
2009 Phase 3 NCT00660387 New Zealand;United States;
Levodopa-carbidopa Immediate Release (LC-IR) Tablets
AbbVie (prior sponsor, Abbott)
2013 Phase 3 NCT01736176 United States;
Levodopa-carbidopa intestinal gel
AbbVie
2013 Phase 3 NCT01960842 Japan;Korea, Republic of;Taiwan;
2009 Phase 3 NCT00660673 Australia;Canada;Czech Republic;Czechia;Israel;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;United States;
AbbVie (prior sponsor, Abbott)
2009 Phase 3 NCT00360568 Germany;New Zealand;United States;
2008 Phase 3 NCT00335153 Australia;Canada;Czech Republic;Finland;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
Levodopa-carbidopa intestinal gel (LCIG)
AbbVie (prior sponsor, Abbott)
2006 Phase 4 NCT00141518 Norway;Sweden;
Levodopa-carbidopa-entacapone
Institut de Recerca del Hospital de la Santa Creu i Sant Pau
2007 - EUCTR2006-002408-32-ES Spain;
Levodopa/Benzerazide
Bial - Portela C S.A.
2010 Phase 2 NCT01568047 Romania;Ukraine;
2009 Phase 2 NCT01568034 Portugal;Romania;Ukraine;
Levodopa/Carbidopa
Bial - Portela C S.A.
2010 Phase 2 NCT01568047 Romania;Ukraine;
2009 Phase 2 NCT01568034 Portugal;Romania;Ukraine;
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2010 - EUCTR2009-017416-33-DE Germany;
Institut de Recerca del Hospital de la Santa Creu i Sant Pau
2007 - EUCTR2006-002408-32-ES Spain;
Levodopa/Carbidopa (LD/CD)
AbbVie
2020 Phase 3 NCT04380142 Australia;United States;
Levodopa/Carbidopa (Sinemet)
NeuroDerm Ltd.
2015 Phase 1 NCT02486432 -
Levodopa/Carbidopa Solution
NeuroDerm Ltd.
2020 Phase 3 EUCTR2018-004156-37-SK Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
Levodopa/Carbidopa(200mg/50mg)
Sandoz
2012 Phase 4 NCT01683253 Korea, Republic of;
Levodopa/DDCI
Bial - Portela C S.A.
2006 Phase 2 NCT03103399 -
Levodopa/benserazide
Bial - Portela C S.A.
2009 Phase 1 NCT01533116 Canada;
Levodopa/benserazide 100/
Bial - Portela C S.A.
2010 Phase 1 NCT02169414 France;
Levodopa/carbidopa
Bial - Portela C S.A.
2011 Phase 1 NCT02170376 France;
2009 Phase 1 NCT01533116 Canada;
2009 Phase 1 NCT01519284 Portugal;
Uppsala University
2008 Phase 4 NCT00906828 Sweden;
2008 Phase 4 NCT00888186 Sweden;
Levodopa/carbidopa 100/25
Bial - Portela C S.A.
2010 Phase 1 NCT02169414 France;
Levodopa/carbidopa hydrate
ONO PHARMACEUTICAL CO.,LTD.
2014 Phase 1 JPRN-JapicCTI-142702 -
Levodopa/carbidopa solution
NEURODERM LTD.
2020 Phase 3 EUCTR2018-004156-37-IT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
NeuroDerm Ltd.
2020 Phase 3 EUCTR2018-004156-37-SE Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-PT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-NL Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-GB Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-ES Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-BE Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-AT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004156-37-HU Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004156-37-CZ Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-002033-30-NL Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002033-30-HU Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002033-30-GB Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2015-005814-31-PL Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
2017 Phase 2 EUCTR2015-005814-31-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States;
2017 Phase 2 EUCTR2015-005814-31-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States;
2017 Phase 2 EUCTR2015-005814-31-DE Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2015-005814-31-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
2017 Phase 2 EUCTR2015-005814-31-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States;
2016 Phase 3 EUCTR2016-002033-30-FR Belgium;Canada;Denmark;France;Hungary;Israel;Netherlands;Spain;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002033-30-ES Belgium;Canada;Denmark;France;Israel;Netherlands;Spain;Sweden;United States;
2016 Phase 3 EUCTR2016-002033-30-BE Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-005814-31-AT Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
2016 Phase 2 EUCTR2015-005078-39-DE Austria;Germany;Israel;Italy;United States;
2016 Phase 2 EUCTR2015-005078-39-AT Austria;Germany;Israel;Italy;United States;
Levodopa/carbidopa/entacapone
Novartis
2006 Phase 4 NCT00391898 Spain;
Novartis Pharma AG
2006 - EUCTR2005-001032-72-PT Czech Republic;Italy;Portugal;
Levodopa/dopa decarboxylase inhibitor
Bial - Portela C S.A.
2016 Phase 4 NCT02847442 Germany;
Liatermin
Amgen
2003 Phase 1/Phase 2 NCT00111982 United States;
North Bristol NHS Trust (NBT)
2013 Phase 2 EUCTR2013-001881-40-GB United Kingdom;
2012 Phase 2 EUCTR2011-003866-34-GB United Kingdom;
Liatermin (r-metHuGDNF)
Amgen
2003 Phase 1 NCT00115427 United States;
Lidocaine
Dept. of Clinical pharmacology and Neurology, Ehime University
2012 - JPRN-UMIN000007617 Japan;
Parkinson'
s disease and Movement Disorder Center
Light box ( Litebook company)
McGill University Health Center
2011 Phase 0 NCT01489982 Canada;
Light box (Litebook company)
McGill University Health Center
2011 Phase 0 NCT01489982 Canada;
Linaclotide
The 988th Hospitail of Joint Logistic Support Force
2021 Phase 4 ChiCTR2100043303 China;
Lingzhi (Ganoderma)
Xuanwu Hospital, Beijing
2005 Phase 2 NCT00224263 China;
Lipopolysaccharide
University of Exeter
2022 - NCT05205291 United Kingdom;
Liquigen MCT oil
National Institute of Neurological Disorders and Stroke (NINDS)
2021 Phase 1 NCT04584346 United States;
Liraglutide
Cedars-Sinai Medical Center
2017 Phase 2 NCT02953665 United States;
Lisparin
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-DE Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-CZ Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
Lisuride Hydrogenmaleate
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-DE Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-CZ Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
Lisuride TTS
NEUROBIOTEC GMBH
2007 - EUCTR2006-003732-30-IT Germany;Italy;Poland;
Lisuride TTS 10cm²
Axxonis Pharma AG
2007 - EUCTR2006-003732-30-DE Germany;Italy;Poland;
NeuroBiotec Pharma AG
2008 - EUCTR2006-003732-30-PL Germany;Italy;Poland;
Lisuride TTS 20cm²
Axxonis Pharma AG
2007 - EUCTR2006-003732-30-DE Germany;Italy;Poland;
NeuroBiotec Pharma AG
2008 - EUCTR2006-003732-30-PL Germany;Italy;Poland;
Lisuride Transdermal System
National Institute of Neurological Disorders and Stroke (NINDS)
2004 Phase 2 NCT00089622 United States;
Lithium
University at Buffalo
2019 Phase 1 NCT04273932 United States;
Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules
Beijing Friendship Hospital
2021 Phase 4 NCT04871464 China;
Lixisenatide
University Hospital, Toulouse
2018 Phase 2 NCT03439943 France;
Local Anesthesia (lidocaine hydrochloride)
Nantes University Hospital
2014 - NCT02236260 France;
Local Trade Name,
GlaxoSmithKline Research & Development Limited
2013 - EUCTR2011-002827-17-SK Estonia;Korea, Republic of;Russian Federation;Slovakia;United States;
Lovastatin
National Taiwan University Hospital
2017 Phase 2 NCT03242499 Taiwan;
Low dose AFFITOPE® PD03A + Adjuvant
Affiris AG
2014 Phase 1 NCT02267434 Austria;
Low dose levodopa
Rush University Medical Center
2018 - NCT04956939 United States;
Low-Frequency-Only Stimulation
The Cleveland Clinic
2021 Phase 1 NCT05022147 United States;
Lu 00-800
H. Lundbeck A/S
2006 Phase 4 EUCTR2005-002038-36-GB Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
Lu AE04621
H. Lundbeck A/S
2016 Phase 1 NCT02649608 United States;
Lu AF28996
H. Lundbeck A/S
2020 Phase 1 NCT04291859 Netherlands;United States;
Lu AF82422
H. Lundbeck A/S
2018 Phase 1 NCT03611569 United States;
Lubiprostone
Dokkyo Medical University
2016 - JPRN-UMIN000022023 Japan;
2016 - JPRN-UMIN000022022 Japan;
University of Arkansas
2009 - NCT00669461 United States;
Lumbar Puncture
National Institute of Neurological Disorders and Stroke (NINDS)
2017 Phase 1 NCT03104725 United States;
MANTADIX
CHU Toulouse
2007 - EUCTR2006-006684-22-FR France;
MARS
Eisai Limited
2007 Phase 3 EUCTR2007-000801-30-PL Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 Phase 3 EUCTR2007-000801-30-FR Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 Phase 3 EUCTR2007-000801-30-ES Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 Phase 3 EUCTR2006-002937-20-FR Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2007 - EUCTR2007-000801-30-LV Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 - EUCTR2007-000801-30-LT Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 - EUCTR2007-000801-30-HU Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 - EUCTR2007-000801-30-EE Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 - EUCTR2007-000801-30-CZ Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 - EUCTR2006-002937-20-HU Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2007 - EUCTR2006-002937-20-ES Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2007 - EUCTR2006-002339-26-PT Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-002339-26-HU Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-002339-26-ES Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-002339-26-DE Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-004314-33-GB Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-004314-33-ES Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002937-20-LV Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-LT Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-EE Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-CZ Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002339-26-SE Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-LT Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-GB Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-EE Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-CZ Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-BE Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-AT Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-SE Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-PT Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-LT Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-HU Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-EE Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-DE Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-CZ Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-BE Austria;Belgium;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-004314-33-AT Austria;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2004 - EUCTR2004-000361-35-CZ Czech Republic;Italy;
ME2125 (safinamide mesilate)
Meiji Seika Pharma Co., Ltd.
2015 Phase 3 JPRN-JapicCTI-153057 Japan;
2015 Phase 2-3 JPRN-JapicCTI-153056 Japan;
MEDI1341
AstraZeneca
2020 Phase 1 NCT04449484 United States;
2017 Phase 1 NCT03272165 United Kingdom;United States;
MEG
Howard Gendelman, MD
2013 Phase 1 NCT01882010 United States;
MEMANTINE HYDROCHLORIDE
H. Lundbeck A/S
2007 Phase 3 EUCTR2005-002038-36-GR Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
2006 Phase 3 EUCTR2005-002038-36-FR Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
2006 - EUCTR2005-002038-36-DE Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
2006 - EUCTR2005-002038-36-AT Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
METHYLPHENIDATE HYDROCHLORIDE
University Medical Center Groningen
2010 - EUCTR2009-012643-42-NL Netherlands;
MIRAPEXIN*30CPR 0,
CASA DI CURA PRIVATA S.RAFFAELE - PISANA
2009 - EUCTR2009-015833-66-IT Italy;
MK0657
Merck Sharp & Dohme Corp.
2007 Phase 1 NCT00505843 United States;
MODOPAR
CHU de Toulouse
2010 Phase 3 EUCTR2010-018650-12-FR France;
MS Band 2
IRCCS San Camillo, Venezia, Italy
2017 - NCT03425877 Italy;
MSC
The University of Texas Health Science Center, Houston
2020 Phase 2 NCT04506073 United States;
MSK-DA01 Cell Delivery Device
BlueRock Therapeutics
2021 Phase 1 NCT04802733 Canada;United States;
Madopar
Universitätsklinik für Neurologie Innsbruck
2010 - EUCTR2010-019354-40-AT Austria;
Madopar 125 mg T, tablets
BIAL-Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-002754-24-IT Germany;Italy;Portugal;Spain;United Kingdom;
Bial - Portela & Ca, S.A.
2022 Phase 4 EUCTR2020-002754-24-DE Germany;Italy;Portugal;Spain;United Kingdom;
2021 Phase 4 EUCTR2020-002754-24-ES Germany;Italy;Portugal;Spain;United Kingdom;
Madopar 125 mg, orodispersible tablet
Pharmaceutical Technology and Biopharmacy, University of Groningen
2018 Phase 2 EUCTR2017-004006-18-NL Netherlands;
Madopar 200+
Madopar LT
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2011 - EUCTR2010-022363-35-DE Germany;
Madopar Tab. 125 or Perkin Tab. 25-
SK Chemicals Co., Ltd.
2021 Phase 4 NCT04821687 Korea, Republic of;
Madopar monotherapy
Peking University Third Hospital
2018 Phase 4 NCT04968613 China;
Madopar® 125
Bial - Portela C S.A.
2001 Phase 1 NCT02763852 Portugal;
Madopar® 125 mg T Tablets Levodopa 100 mg Benserazide 25 mg (as benserazide hydrochloride)
BIAL-Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-002754-24-IT Germany;Italy;Portugal;Spain;United Kingdom;
Madopar® 250
Bial - Portela C S.A.
2006 Phase 1 NCT03097211 Portugal;
2006 Phase 1 NCT03094156 Portugal;
Madopar® HBS
Bial - Portela C S.A.
2009 Phase 1 NCT02169466 Portugal;
Madopar® HBS 125
Bial - Portela C S.A.
2004 Phase 1 NCT03091543 Portugal;
Magnesium oxide
Dokkyo Medical University
2016 - JPRN-UMIN000022023 Japan;
2016 - JPRN-UMIN000022022 Japan;
Maltodextrin
University of Florida
2021 - NCT04829760 United States;
Mannitol
Hadassah Medical Organization
2018 Phase 2 NCT03823638 Israel;
Mantadix
CHU de Toulouse
2012 Phase 2 EUCTR2011-005201-75-FR France;
University Hospital, Toulouse
2007 Phase 4 NCT00632762 France;
Masitinib mesylate
AB Science
2015 Phase 2 EUCTR2010-024424-26-SK Bulgaria;Czech Republic;France;Germany;Hungary;Romania;Slovakia;South Africa;Spain;United States;
Massage with a spiky ball
University Medical Center Groningen
2015 Phase 2 NCT02230930 Netherlands;
Mavoglurant
NOVARTIS FARMA
2012 - EUCTR2011-004378-27-IT Austria;Canada;Germany;Hungary;Italy;Spain;United States;
Novartis Pharma Services AG
2012 - EUCTR2011-004378-27-SK Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
2012 - EUCTR2011-004378-27-HU Austria;Canada;France;Germany;Hungary;Italy;Spain;United States;
2012 - EUCTR2011-004378-27-AT Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
Medical Cannabis
Sheba Medical Center
2021 - NCT05106504 Israel;
Melatonin
Instituto Mexicano del Seguro Social
2021 Phase 2/Phase 3 NCT04287543 Mexico;
University College London
2015 Phase 2 EUCTR2014-002697-37-GB United Kingdom;
University College, London
2015 Phase 2 NCT02359448 United Kingdom;
Melatonin PR
Seoul National University Hospital
2016 Phase 2 NCT02789592 Korea, Republic of;
Melatonin(Circadin®)
KIMJisun
2016 Phase 4 NCT03258294 -
Kuhnil Pharmaceutical Co., Ltd.
2016 Phase 4 NCT02768077 -
Melevodopa and decarboxylase inhibitor
VERNALIS DEVELOPMENT LIMITED
2006 - EUCTR2006-004112-51-IT Italy;
Melperon
OVATION PHARMACEUTICALS INC
2007 - EUCTR2007-002874-75-IT Italy;
2007 - EUCTR2007-000307-15-IT Italy;
Melperone HCl
Lundbeck LLC
2005 Phase 2 NCT00125138 India;Italy;United States;
Memantin Orion
Regional Dementia Research Centre, Dept of Neurology
2018 Phase 4 EUCTR2017-002707-10-DK Denmark;
Memantine
Baylor College of Medicine
2006 Phase 4 NCT00646204 United States;
Department of Neurology, Juntendo University School of Medicine
2013 - JPRN-UMIN000010596 Japan;
H. Lundbeck A/S
2007 Phase 4 NCT00855686 Germany;
Helse Stavanger HF
2006 Phase 2 NCT00630500 Norway;Sweden;United Kingdom;
Johns Hopkins University
2006 - NCT00294554 United States;
Neurologisk afdeling F
2005 Phase 2 EUCTR2004-004139-74-DK Denmark;
University Hospital, Lille
2009 Phase 4 NCT01108029 France;
Wayne State University
2019 Phase 3 NCT03858270 United States;
Zealand University Hospital
2020 Phase 4 NCT04117178 Denmark;
Memantine (drug)
University of Aarhus
2005 - NCT00375778 Denmark;
Mesdopetam
Integrative Research Laboratories AB
2020 Phase 2 NCT04435431 France;Israel;Italy;Poland;Serbia;United States;
Integrative Research Laboratories Sweden AB
2021 Phase 2 EUCTR2020-002010-41-IT France;Israel;Italy;Poland;Serbia;United States;
Integrative Research Laboratories Sweden AB (IRLAB)
2020 Phase 2 EUCTR2020-002010-41-FR France;Israel;Italy;Poland;Serbia;United States;
Mesdopetam (IRL790)
Integrative Research Laboratories AB
2018 Phase 2 NCT03368170 Sweden;United Kingdom;
Mesencephalic Neuronal Precursor Cells
Bundang CHA Hospital
2013 Phase 1/Phase 2 NCT01860794 Korea, Republic of;
Mesenchymal stem cells
Hebei Newtherapy BIo-Pharma technology Co., Ltd.
2018 Phase 1 NCT03550183 China;
Mestinon
Department of Neurology, Roskilde Hospital
2012 Phase 2 EUCTR2012-000122-21-DK Denmark;
Metabolic Cofactor Supplementation
Istanbul Medipol University Hospital
2019 Phase 2 NCT04044131 Turkey;
Metformin
Institute of Clinical Pharmacology, Central South University
2012 Phase 1 study ChiCTR-TTRCC-12002751 China;
Peking Union Medical College Hospital
2020 Phase 4 ChiCTR2000029465 China;
Methylphenidate
Department of Veterans Affairs
2006 - NCT00393562 United States;
Hubert Fernandez
2016 Early Phase 1 NCT02879136 United States;
Laval University
2010 Phase 4 NCT01244269 Canada;
Oregon Health and Science University
2004 Phase 2 NCT00359723 United States;
University Hospital, Lille
2009 Phase 4 NCT00914095 France;
Methylphenidate (MPD)
University of Cincinnati
2007 Phase 4 NCT00526630 United States;
Methylprednisolone
Prevail Therapeutics
2020 Phase 1/Phase 2 NCT04127578 Israel;United States;
Mid dose ANAVEX2-73
Anavex Life Sciences Corp.
2018 Phase 2 NCT03774459 Australia;Spain;
Midazolam
Kyowa Kirin Co., Ltd.
2019 Phase 1 NCT03970798 Japan;
PharmaTher Inc.
2021 Phase 2 NCT04912115 United States;
Midodrine
Philadelphia Veterans Affairs Medical Center
2014 - NCT02365012 United States;
Vanderbilt University Medical Center
2020 Early Phase 1 NCT04620382 United States;
2016 Phase 1 NCT02897063 United States;
Minocycline
University of Rochester
2003 Phase 2 NCT00063193 United States;
Minodronic acid
Department of Orthopaedic Surgery, Niigata University Medical and Dental Hospital
2018 - JPRN-UMIN000033285 Japan;
Mirabegron
Daniel Burdick, MD
2014 Phase 4 NCT02092181 United States;
HealthPartners Institute
2015 Phase 4 NCT02536976 United States;
Seoul National University Hospital
2017 Phase 4 NCT03412513 Korea, Republic of;
Mirapex
Abbott Healthcare Products B.V.
2009 - EUCTR2008-000400-81-DE Germany;Italy;Portugal;
Boehringer Ingelheim
2005 Phase 4 NCT00144300 United States;
Rajesh Pahwa, MD
2006 Phase 3 NCT00275275 United States;
SOLVAY PHARMACEUTICALS B.V.
2009 - EUCTR2008-000400-81-IT Germany;Italy;Portugal;
Solvay Pharmaceuticals B.V.
2008 Phase 2 EUCTR2008-004943-12-SK Slovakia;
Solvay Pharmaceuticals BV
2009 - EUCTR2008-000400-81-PT Germany;Italy;Portugal;
Mirapex (pramipexole)
Institute for Neurodegenerative Disorders
2004 Phase 2 NCT00096720 United States;
Mirapex ER
Seoul National University Hospital
2011 Phase 4 NCT01515774 Korea, Republic of;
Mirapex LA
Boehringer Ingelheim
2012 - NCT01525641 Japan;
Mirapexin
NEUROBIOTEC GMBH
2007 - EUCTR2006-003732-30-IT Germany;Italy;Poland;
Mirapexin / Sifrol
Boehringer Ingelheim España S.A.
2006 Phase 4 EUCTR2005-003788-22-ES Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Mirapexin extended release various strengths
University Hospital of North Staffordshire
2013 Phase 4 EUCTR2012-000801-64-GB United Kingdom;
Mirapexin/Sifrol
Boehringer Ingelheim España S.A.
2006 Phase 4 EUCTR2005-003788-22-ES Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
MitoQ
Antipodean Pharmaceuticals, Inc.
2006 Phase 2 NCT00329056 Australia;New Zealand;
Modafinil
Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine
2015 - JPRN-UMIN000019676 Japan;
Department of Veterans Affairs
2006 - NCT00393562 United States;
University of Arkansas
2017 Early Phase 1 NCT03083132 United States;
University of Chicago
2016 Phase 2 NCT02857244 United States;
Modal
Oregon Health and Science University
2021 - NCT04468919 United States;
Regis University
2017 - NCT04223245 United States;
The Cleveland Clinic
2020 Phase 2 NCT04634331 United States;
Modiodal
Theranexus S.A.
2018 Phase 2 EUCTR2017-004475-31-HU Czech Republic;France;Germany;Hungary;United States;
2018 Phase 2 EUCTR2017-004475-31-CZ Czech Republic;France;Germany;Hungary;United States;
Modopar 125
UHToulouse
2016 Phase 2;Phase 3 EUCTR2015-001523-24-FR France;
Modopar 62,5
UHToulouse
2016 Phase 2;Phase 3 EUCTR2015-001523-24-FR France;
Monoamine oxidase B inhibitors
NEWRON PHARMACEUTICALS
2007 - EUCTR2006-005861-21-IT Italy;
2004 - EUCTR2004-000833-12-IT Italy;Spain;
Montelukast Krka
Stockholm Health Care Services
2021 Phase 2 EUCTR2020-000148-76-SE Sweden;
Motion Analysis
Howard Gendelman, MD
2013 Phase 1 NCT01882010 United States;
Moxifloxacin
Bial - Portela C S.A.
2010 Phase 1 NCT01532115 France;
Kyowa Kirin Co., Ltd.
2020 Phase 1 NCT04342273 Japan;
Sunovion
2017 Phase 2 NCT03187301 Italy;United States;
Moxifloxacin infusion
UCB Pharma
2006 Phase 1 NCT00292227 South Africa;
Muscimol
National Institute of Neurological Disorders and Stroke (NINDS)
2009 Phase 1 NCT00921128 United States;
Mémantine
Chru de Lille
2009 - EUCTR2008-008210-38-FR France;
N acetyl cysteine
Thomas Jefferson University
2020 Phase 2 NCT04459052 United States;
N-0923
National Institute of Neurological Disorders and Stroke (NINDS)
1999 Phase 2 NCT00001931 United States;
N-Acetylcysteine
National Institute of Neurological Disorders and Stroke (NINDS)
2017 Phase 1 NCT03104725 United States;
N-acetylcysteine
University of Minnesota
2011 Phase 1 NCT01427517 United States;
Weill Medical College of Cornell University
2012 Phase 1/Phase 2 NCT01470027 United States;
N-acetylcysteine capsule
University of Minnesota
2014 Phase 2 NCT02212678 United States;
N.A.
INTEC PHARMA LTD
2018 Phase 2 EUCTR2018-001209-95-IT Italy;Spain;
N04BA
SynAgile Corporation
2021 Phase 2 EUCTR2020-003372-41-IT Italy;Luxembourg;Spain;
N04BC07
CHU Rennes
2021 Phase 4 EUCTR2021-000826-89-FR France;
N04BD02
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
2011 - EUCTR2009-015161-31-DE Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
2011 - EUCTR2009-015161-31-PT Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2011 Phase 3 EUCTR2009-015161-31-GB Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015161-31-BG Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Schering-Plough Research Institute, a division of Schering Corporation
2011 - EUCTR2009-015161-31-PL Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015161-31-CZ Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-SE Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-NL Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-FI Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-AT Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
NACOM 100
IMPAX LABORATORIES, INC.
2010 - EUCTR2009-017238-39-IT France;Germany;Italy;
NACOM levodopa+cardidopa
MERCK SERONO SA
2009 - EUCTR2008-002769-30-IT Italy;
NAL
Mundipharma Research GmbH & Co. KG
2012 - EUCTR2011-002901-31-DE Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-GB Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-HU Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-CZ Czech Republic;Germany;Hungary;Spain;United Kingdom;
NBTX-001
Nobilis Therapeutics Inc.
2019 Phase 1 NCT04097080 Russian Federation;
ND0611
NeuroDerm Ltd.
2010 Phase 1 NCT01103011 Israel;
ND0612
NEURODERM LTD.
2020 Phase 3 EUCTR2018-004156-37-IT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002780-17-IT Austria;France;Italy;Netherlands;Spain;United States;
2016 Phase 2 EUCTR2015-005814-31-IT Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
2016 Phase 2 EUCTR2015-005078-39-IT Austria;Germany;Israel;Italy;United States;
NeuroDerm Ltd.
2020 Phase 3 EUCTR2018-004156-37-SK Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-SE Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-PT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-NL Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-GB Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-ES Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-BE Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-AT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004156-37-HU Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004156-37-CZ Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002780-17-FR Austria;France;Italy;Netherlands;Spain;United States;
2018 Phase 3 EUCTR2017-002780-17-ES Austria;France;Italy;Netherlands;Spain;United States;
2018 Phase 3 EUCTR2016-002033-30-NL Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002033-30-HU Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002033-30-GB Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2015-005814-31-PL Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
2017 Phase 2 EUCTR2015-005814-31-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States;
2017 Phase 2 EUCTR2015-005814-31-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States;
2017 Phase 2 EUCTR2015-005814-31-DE Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2015-005814-31-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
2017 Phase 2 EUCTR2015-005814-31-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States;
2016 Phase 3 NCT02782481 Israel;
2016 Phase 3 EUCTR2016-002033-30-FR Belgium;Canada;Denmark;France;Hungary;Israel;Netherlands;Spain;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002033-30-ES Belgium;Canada;Denmark;France;Israel;Netherlands;Spain;Sweden;United States;
2016 Phase 3 EUCTR2016-002033-30-BE Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 2 NCT02726386 Austria;Czechia;France;Germany;Israel;Italy;Poland;Spain;United States;
2016 Phase 2 EUCTR2015-005814-31-AT Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
2016 Phase 2 EUCTR2015-005078-39-DE Austria;Germany;Israel;Italy;United States;
2016 Phase 2 EUCTR2015-005078-39-AT Austria;Germany;Israel;Italy;United States;
2015 Phase 1 NCT02604914 United Kingdom;
2012 Phase 1 NCT01486628 Israel;
ND0612 (Levodopa/Carbidopa solution)
NeuroDerm Ltd.
2015 Phase 2 NCT02577523 Austria;Israel;Italy;United States;
ND1421
Schwarz Biosciences GmbH
2006 Phase 2 EUCTR2005-004290-19-GB Austria;Germany;Spain;United Kingdom;
2006 - EUCTR2005-004290-19-DE Germany;Spain;United Kingdom;
2005 - EUCTR2005-004290-19-AT Austria;Germany;Spain;United Kingdom;
ND1587
Schwarz Biosciences GmbH
2008 - EUCTR2006-006752-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006907-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
- - EUCTR2006-006907-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006907-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
ND1589
Schwarz Biosciences GmbH
2008 - EUCTR2006-006752-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006907-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
- - EUCTR2006-006907-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006907-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
ND1590
Schwarz Biosciences GmbH
2008 - EUCTR2006-006752-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006907-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
- - EUCTR2006-006907-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006907-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
ND1702
Schwarz Biosciences GmbH
2008 - EUCTR2006-006752-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006907-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
- - EUCTR2006-006907-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006907-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
NE3107
BioVie Inc.
2021 Phase 1/Phase 2 NCT05083260 -
NERIXIA*IM EV 1F
FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE
2010 - EUCTR2010-018904-94-IT Italy;
NEUPRO 2 mg/24 h parche transdérmico
UCB Pharma SA
2011 Phase 4 EUCTR2010-021394-37-ES Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;
NEUPRO 4 mg/24 h parche transdérmico
UCB Pharma SA
2011 Phase 4 EUCTR2010-021394-37-ES Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;
NEUPRO 6 mg/24 h parche transdérmico
UCB Pharma SA
2011 Phase 4 EUCTR2010-021394-37-ES Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;
NEUPRO 8 mg/24 h parche transdérmico
UCB Pharma SA
2011 Phase 4 EUCTR2010-021394-37-ES Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;
NEUPRO*28CER 2MG/24H
FONDAZIONE SANTA LUCIA
2012 - EUCTR2012-001218-40-IT Italy;
NEUPRO*28CER 4MG/24H
FONDAZIONE SANTA LUCIA
2012 - EUCTR2012-001218-40-IT Italy;
NEUPRO*28CER 6MG/24H
FONDAZIONE SANTA LUCIA
2012 - EUCTR2012-001218-40-IT Italy;
NEUPRO*28CER 8MG/24H
FONDAZIONE SANTA LUCIA
2012 - EUCTR2012-001218-40-IT Italy;
NEUPRO*7CER 4MG/24H
FONDAZIONE SANTA LUCIA
2012 - EUCTR2012-001218-40-IT Italy;
NEUPRO*7CER 6MG/24H
FONDAZIONE SANTA LUCIA
2012 - EUCTR2012-001218-40-IT Italy;
NEUPRO*7CER 8MG/24H
FONDAZIONE SANTA LUCIA
2012 - EUCTR2012-001218-40-IT Italy;
NJ-Tube: Silicon ED Tube
AbbVie (prior sponsor, Abbott)
2011 Phase 2 NCT01479127 Japan;
NLX-112
Neurolixis SAS
2021 Phase 2 EUCTR2020-006053-22-SE Sweden;
NLY01
Neuraly, Inc.
2020 Phase 2 NCT04154072 Canada;United States;
NO
Department of Anesthesiology, Affiliated Hospital of Guizhou Medical University
2019 - ChiCTR1900024459 China;
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
2019 - ChiCTR1900026156 China;
NPC transplantation
Chinese Academy of Sciences
2017 Phase 1/Phase 2 NCT03119636 China;
NR2B NMDA Antagonist CP-101,606 (traxoprodil)
Pfizer
2005 Phase 2 NCT00163085 United States;
NS 2330
Boehringer Ingelheim
2003 Phase 2 NCT00148486 Canada;United States;
NS2330
National Institute of Neurological Disorders and Stroke (NINDS)
2000 Phase 2 NCT00006077 United States;
NT 101
Merz Pharmaceuticals GmbH
2014 Phase 3 EUCTR2012-005539-10-DE Germany;Poland;United States;
NTCELL Implantation
Living Cell Technologies
2016 Phase 2 NCT02683629 New Zealand;
NW-1015
MERCK SERONO SA
2010 - EUCTR2010-020109-34-IT Italy;Spain;
2009 Phase 3 EUCTR2008-005492-94-IT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
Merck Serono International S.A.
2008 Phase 3 EUCTR2007-002963-28-ES Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
2008 - EUCTR2007-002964-90-ES Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2007 - EUCTR2007-002964-90-NL Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2007 - EUCTR2007-002964-90-FI Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Merck Serono S.A - Geneva
2008 Phase 3 EUCTR2007-002964-90-GB Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom;
Merck Serono S.A-Geneva
2009 - EUCTR2007-002963-28-PT Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
Merck Serono S.A. - Geneva
2010 Phase 3 EUCTR2008-005492-94-BE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
2010 Phase 2 EUCTR2009-017174-20-FR Austria;France;Germany;
2010 - EUCTR2010-020109-34-ES Italy;Spain;
2010 - EUCTR2008-005492-94-NL Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
2010 - EUCTR2007-002964-90-CZ Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-005492-94-SK Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-005492-94-GB Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-005492-94-FR Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-005492-94-ES Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
2009 - EUCTR2008-005492-94-HU Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 - EUCTR2007-002964-90-FR Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-002964-90-DE Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2007 Phase 3 EUCTR2007-002964-90-SK Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom;
2007 Phase 3 EUCTR2007-002963-28-SK Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
Merck Serono S.A.-Geneva
2008 - EUCTR2007-002964-90-HU Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Merck Serono SA - Geneva
2009 Phase 3 EUCTR2008-004146-88-SK Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
2009 Phase 3 EUCTR2008-004146-88-ES Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
2009 Phase 3 EUCTR2008-001966-10-SK Austria;Estonia;Hungary;Slovakia;United Kingdom;
2009 - EUCTR2008-004146-88-PT Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
2009 - EUCTR2008-004146-88-PL Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
2009 - EUCTR2008-001966-10-HU Austria;Estonia;Hungary;United Kingdom;
2009 - EUCTR2008-001966-10-GB Austria;Estonia;Hungary;United Kingdom;
2009 - EUCTR2008-001966-10-EE Austria;Estonia;Hungary;United Kingdom;
2009 - EUCTR2008-001966-10-AT Austria;Estonia;Hungary;United Kingdom;
NEWRON PHARMACEUTICALS
2007 - EUCTR2006-005861-21-IT Italy;
2006 - EUCTR2006-005860-14-IT Italy;
2004 - EUCTR2004-000835-27-IT Italy;Spain;
2004 - EUCTR2004-000833-12-IT Italy;Spain;
Newron Pharmaceuticals
2011 - EUCTR2008-005492-94-PT Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2011 - EUCTR2008-005492-94-FI Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2011 - EUCTR2008-005492-94-CZ Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2011 - EUCTR2008-005492-94-BG Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2010 - EUCTR2008-004146-88-DE Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
2009 Phase 3 EUCTR2008-004146-88-BG Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
2009 - EUCTR2008-005492-94-EE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2009 - EUCTR2008-005492-94-AT Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2009 - EUCTR2008-004146-88-FI Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
2009 - EUCTR2008-004146-88-CZ Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
- - EUCTR2008-005492-94-DE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States;
Newron Pharmaceuticals S.P.A
2005 Phase 3 EUCTR2004-000835-27-ES Italy;Spain;
Newron Pharmaceuticals S.p.A.
2004 Phase 3 EUCTR2004-000833-12-ES Italy;Spain;
Newron Pharmaceuticals SpA
2011 Phase 3 EUCTR2007-002964-90-BE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Slovakia;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2010 - EUCTR2007-002963-28-DE Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States;
2009 - EUCTR2007-002964-90-AT Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2009 - EUCTR2007-002963-28-PL Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
2009 - EUCTR2007-002963-28-CZ Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States;
2009 - EUCTR2007-002963-28-BG Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States;
2008 - EUCTR2007-002964-90-EE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2007 - EUCTR2007-002963-28-FI Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Poland;Portugal;South Africa;Spain;United States;
NW-1015E, EMD 1195686, MSC2191632B
Merck Serono S.A. - Geneva
2011 - EUCTR2009-017174-20-AT Austria;Canada;France;Germany;South Africa;
2010 - EUCTR2009-017174-20-DE Austria;Canada;France;Germany;South Africa;
NYX-458
Aptinyx
2019 Phase 2 NCT04148391 United States;
Nabilone
Medical University Innsbruck
2018 Phase 3 NCT03773796 Austria;
2017 Phase 2 NCT03769896 Austria;
Nacom
Otto-von-Guericke University, Medical Faculty, Dpt. of Neurology
2009 - EUCTR2009-011093-15-DE Germany;
Nacom 100
Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
2010 Phase 3 EUCTR2009-017238-39-BE Belgium;France;Germany;Italy;
Novartis Pharma Services AG
2008 - EUCTR2007-003134-42-DE Germany;
Nadolol
CuraSen Therapeutics, Inc.
- Phase 2 EUCTR2020-006067-28-BE Australia;Belgium;New Zealand;United Kingdom;
Nalmefene
University Hospital, Clermont-Ferrand
2016 Phase 2 NCT02934919 France;
Naltrexone
University of Pennsylvania
2009 Phase 4 NCT01052831 United States;
Nardil
TEVA Pharmaceuticals Industries Ltd
2006 - EUCTR2006-005140-89-NL Netherlands;
Nebicapone
BIAL - Portela & Cª, SA
2006 - EUCTR2006-001793-24-PT Austria;Portugal;
2006 - EUCTR2006-001793-24-AT Austria;Portugal;
Bial - Portela C S.A.
2006 Phase 2 NCT03103399 -
2006 Phase 1 NCT03097211 Portugal;
2001 Phase 1 NCT02772627 Portugal;
Nebulizer
University of Florida
2015 Phase 1 NCT02390089 United States;
Nelotanserin
Axovant Sciences Ltd.
2016 Phase 2 NCT02871427 United States;
2016 Phase 2 NCT02708186 United States;
Neu-120
Neurim Pharmaceuticals Ltd.
2008 Phase 1/Phase 2 NCT00607451 Israel;
Neupro
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2011 - EUCTR2010-022363-35-DE Germany;
Luye Pharma Group Ltd.
2020 Phase 1 NCT04384666 United States;
2013 Phase 1 NCT02055274 United States;
Peking University Third Hospital
2021 - NCT04957420 China;
SCHWARZ PHARMA
2008 - EUCTR2006-006752-35-IT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
UCB BIOSCIENCES GMBH
2013 - EUCTR2012-002840-26-IT Austria;Bulgaria;Hungary;Italy;Russian Federation;Slovenia;Spain;Turkey;Ukraine;United States;
UCB Biosciences GmbH
2013 Phase 4 EUCTR2012-002608-42-GB Argentina;France;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-002840-26-SK Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States;
2013 - EUCTR2012-002840-26-SI Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States;
2013 - EUCTR2012-002840-26-RO Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States;
2013 - EUCTR2012-002840-26-HU Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States;
2013 - EUCTR2012-002840-26-ES Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States;
2013 - EUCTR2012-002840-26-BG Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States;
2013 - EUCTR2012-002840-26-AT Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States;
2013 - EUCTR2012-002608-42-HU Argentina;France;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-002608-42-DE Germany;Hungary;Poland;Slovakia;United Kingdom;United States;
2012 - EUCTR2012-002608-42-SK Argentina;France;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
Neupro (Reference)
Sandoz
2019 Phase 1 NCT04183634 Germany;
Neupro 2 mg/24 h transdermal patch
SCHWARZ PHARMA Deutschland GmbH
2007 - EUCTR2006-005438-19-DE Germany;
Schwarz Pharma Deutschland GmbH, UCB Group
- - EUCTR2009-014341-84-DE Germany;
Neupro 2mg/24 h transdermal patch
Schwarz Biosciences GmbH
2008 - EUCTR2006-006752-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006752-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Neupro 2mg/24h transdermal patch
Schwarz Biosciences GmbH
2007 Phase 3 EUCTR2006-006907-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
- - EUCTR2006-006907-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006907-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
UCB Pharma SA
2011 Phase 4 EUCTR2010-021394-37-SK Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
2011 Phase 4 EUCTR2010-021394-37-BE Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
2011 - EUCTR2010-021394-37-HU Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-DE Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-CZ Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-BG Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-AT Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
Neupro 4 mg/24 h transdermal patch
SCHWARZ PHARMA Deutschland GmbH
2007 - EUCTR2006-005438-19-DE Germany;
Schwarz Pharma Deutschland GmbH, UCB Group
- - EUCTR2009-014341-84-DE Germany;
Neupro 4Mg/24Hr Transdermal Patch
Luye Pharma Group Ltd.
2018 Phase 1 NCT03733561 United States;
Neupro 4mg/24 h transdermal patch
Schwarz Biosciences GmbH
2008 - EUCTR2006-006752-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006752-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Neupro 4mg/24h transdermal patch
Schwarz Biosciences GmbH
2007 Phase 3 EUCTR2006-006907-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
- - EUCTR2006-006907-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006907-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
UCB Celltech, UK - Registered Branch of UCB Pharma SA
2011 - EUCTR2011-000056-42-GB United Kingdom;
UCB Pharma SA
2011 Phase 4 EUCTR2010-021394-37-SK Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
2011 Phase 4 EUCTR2010-021394-37-BE Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
2011 - EUCTR2010-021394-37-HU Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-DE Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-CZ Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-BG Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-AT Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
Neupro 6 mg/24 h transdermal patch
SCHWARZ PHARMA Deutschland GmbH
2007 - EUCTR2006-005438-19-DE Germany;
Schwarz Pharma Deutschland GmbH, UCB Group
- - EUCTR2009-014341-84-DE Germany;
Neupro 6mg/24 h transdermal patch
Schwarz Biosciences GmbH
2008 - EUCTR2006-006752-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006752-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Neupro 6mg/24h transdermal patch
Schwarz Biosciences GmbH
2007 Phase 3 EUCTR2006-006907-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
- - EUCTR2006-006907-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006907-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
UCB Celltech, UK - Registered Branch of UCB Pharma SA
2011 - EUCTR2011-000056-42-GB United Kingdom;
UCB Pharma SA
2011 Phase 4 EUCTR2010-021394-37-SK Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
2011 Phase 4 EUCTR2010-021394-37-BE Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
2011 - EUCTR2010-021394-37-HU Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-DE Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-CZ Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-BG Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-AT Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
Neupro 8 mg/24 h transdermal patch
SCHWARZ PHARMA Deutschland GmbH
2007 - EUCTR2006-005438-19-DE Germany;
Schwarz Biosciences GmbH
2008 - EUCTR2006-006752-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006752-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Pharma Deutschland GmbH, UCB Group
- - EUCTR2009-014341-84-DE Germany;
Neupro 8mg/24h transdermal patch
Schwarz Biosciences GmbH
2007 Phase 3 EUCTR2006-006907-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
- - EUCTR2006-006907-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006907-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
UCB Celltech, UK - Registered Branch of UCB Pharma SA
2011 - EUCTR2011-000056-42-GB United Kingdom;
UCB Pharma SA
2011 Phase 4 EUCTR2010-021394-37-SK Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
2011 Phase 4 EUCTR2010-021394-37-BE Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
2011 - EUCTR2010-021394-37-HU Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-DE Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-CZ Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-BG Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-AT Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
Neupro®
UCB Pharma
2011 - NCT01330290 Germany;
Neupro® 8 mg/24 h
Luye Pharma Switzerland AG
2021 Phase 2 EUCTR2021-000867-65-DE Germany;
Neuraceq
Fundació Clínic per la Recerca Biomèdica
2016 Phase 4 EUCTR2014-001014-25-ES Spain;
Institute for Neurodegenerative Disorders
2016 Phase 2 EUCTR2015-004129-15-ES Spain;
NeuroEPO
International Center for Neurological Restoration, Cuba
2015 Phase 1/Phase 2 NCT04110678 Cuba;
Neurohormonal mechanisms
Institut National de la Santé Et de la Recherche Médicale, France
2017 - NCT03272230 France;
Neurpro
Unità Malattie Neurodegenerative, Ospedale Cardinale Giovanni Panico, Tricase
2013 - EUCTR2013-000827-15-IT Italy;
Niacin
VA Office of Research and Development
2020 - NCT03808961 United States;
2016 - NCT03462680 United States;
Niacinamide
VA Office of Research and Development
2020 - NCT03808961 United States;
Nicorette 10mg/ 16 h
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2008 - EUCTR2008-001336-13-FR France;
Nicorette 15 mg/ 16 h
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2008 - EUCTR2008-001336-13-FR France;
Nicorette 5 mg/ 16 h
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2008 - EUCTR2008-001336-13-FR France;
Nicotine
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2008 - EUCTR2008-001336-13-FR France;
Department of Clinical Pharmacology and Neurology Ehime University graduated School of Medicine
2015 - JPRN-UMIN000016664 Japan;
Neuraltus Pharmaceuticals, Inc.
2009 Phase 1/Phase 2 NCT00957918 United States;
Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)
El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
2019 Phase 2 NCT03865121 Mexico;
Nicotine gum
New York Institute of Technology
2015 - NCT02452125 United States;
Nicotine patch
University of Vermont
2010 Phase 4 NCT01216904 United States;
Nicotine transdermal patch
James BOYD MD
2012 Phase 2 NCT01560754 Germany;United States;
Nicotinell 17,5 mg/24-Stunden-Pflaster
Philipps-University Marburg
2011 Phase 2 EUCTR2010-020299-42-DE Germany;United States;
Nicotinell 35 mg/24-Stunden-Pflaster
Philipps-University Marburg
2011 Phase 2 EUCTR2010-020299-42-DE Germany;United States;
Nilotinib
Georgetown University
2014 Phase 1 NCT02281474 United States;
Nilotinib 150mg oral capsule [Tasigna]
Georgetown University
2017 Phase 2 NCT02954978 United States;
Nilotinib 300mg oral capsule [Tasigna]
Georgetown University
2017 Phase 2 NCT02954978 United States;
Nitrogen
Juntendo University School of Medicine, Neurology
2013 - JPRN-UMIN000010014 Japan;
None
The First Affiliated Hospital of University of Science and Technology of China (Southern District Phase 2)
2021 Phase 0 ChiCTR2100048680 China;
Normal Saline
Vanderbilt University
2008 Phase 2/Phase 3 NCT00608231 United States;
Normal saline
dr.dargahi
2020 Phase 2 NCT04687878 Iran, Islamic Republic of;
Northera
The Cooper Health System
2017 Phase 4 NCT03034564 United States;
Nortriptyline
Rutgers, The State University of New Jersey
2003 Phase 2 NCT00062738 United States;
University College, London
2019 Phase 3 NCT03652870 -
Nortriptyline hydrochloride
University College London Comprehensive Clinical Trials Unit
2019 Phase 3 EUCTR2018-002942-35-GB United Kingdom;
OC oral solution treatment A
Orient Pharma Co., Ltd.
2011 Phase 2 NCT01370811 United States;
OC oral solution treatment B
Orient Pharma Co., Ltd.
2011 Phase 2 NCT01370811 United States;
OC oral solution treatment C
Orient Pharma Co., Ltd.
2011 Phase 2 NCT01370811 United States;
OC oral solution treatment D
Orient Pharma Co., Ltd.
2011 Phase 2 NCT01370811 United States;
OCT - TCE
Massachusetts General Hospital
2019 - NCT04566341 United States;
ODM-101
Orion Corporation
2011 - EUCTR2010-022200-46-LV Finland;Germany;Latvia;Lithuania;
2011 - EUCTR2010-022200-46-LT Finland;Germany;Latvia;Lithuania;
2011 - EUCTR2010-022200-46-FI Finland;Germany;Latvia;Lithuania;
- - EUCTR2010-022200-46-DE Finland;Germany;Latvia;Lithuania;
ODM-101 105mg Carbidopa
Orion Corporation, Orion Pharma
2011 Phase 2 NCT01766258 -
ODM-101 65mg Carbidopa
Orion Corporation, Orion Pharma
2011 Phase 2 NCT01766258 -
ODM-104
Orion Corporation
2017 Phase 2 EUCTR2015-004507-23-HU Finland;Germany;Hungary;Latvia;
2017 Phase 2 EUCTR2015-004507-23-FI Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-LV Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-DE Finland;Germany;Hungary;Latvia;
OFF Dopaminergic Medication
The Cleveland Clinic
2021 Phase 1 NCT05022147 United States;
ON Dopaminergic Medication
The Cleveland Clinic
2021 Phase 1 NCT05022147 United States;
ONO-2160/CD
ONO PHARMACEUTICAL CO.,LTD.
2014 Phase 1 JPRN-JapicCTI-142702 -
2013 Phase 1 JPRN-JapicCTI-132189 -
ONO-2370
ONO PHARMACEUTICAL CO.,LTD.
2016 Phase 2 JPRN-JapicCTI-153112 Japan;
ONO-2506PO
Ono Pharmaceutical Co. Ltd
2004 Phase 2 NCT00212693 -
OPC
Bial - Portela C S.A.
2011 Phase 1 NCT02169427 Netherlands;
OSU 6162 similar to (-)-OSU 6162
Björn Holmberg
2010 Phase 1;Phase 2 EUCTR2009-016360-37-SE Sweden;
OSU6162 similar to (-)-OSU 6162
A. Carlsson Research AB
2014 Phase 2 EUCTR2013-002545-10-SE Sweden;
OTHER NERVOUS SYSTEM DRUGS
EISAI LTD UK
2007 - EUCTR2006-005714-12-IT Italy;
OXB-102
Sio Gene Therapies
2018 Phase 1/Phase 2 NCT03720418 France;United Kingdom;
OXN 10 mg / 5 mg PR
Mundipharma Research GmbH & Co. KG
2012 - EUCTR2011-002901-31-DE Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-GB Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-ES Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-HU Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-CZ Czech Republic;Germany;Hungary;Spain;United Kingdom;
OXN 20 mg / 10 mg PR
Mundipharma Research GmbH & Co. KG
2012 - EUCTR2011-002901-31-DE Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-GB Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-ES Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-HU Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-CZ Czech Republic;Germany;Hungary;Spain;United Kingdom;
OXN 5 mg/2.5 mg PR
Mundipharma Research GmbH & Co. KG
2012 - EUCTR2011-002901-31-DE Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-GB Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-ES Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-HU Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-CZ Czech Republic;Germany;Hungary;Spain;United Kingdom;
OXYCODO
Mundipharma Research GmbH & Co. KG
2011 Phase 3 EUCTR2011-002901-31-ES Czech Republic;Germany;Hungary;Spain;United Kingdom;
OXYCODONE HYDROCHLORIDE
UHToulouse
2016 Phase 2;Phase 3 EUCTR2015-001523-24-FR France;
OXYTOCIN SYNTHETIC
Abteilung für Neurologie der Medizinischen Universität Innsbruck
2019 Phase 2 EUCTR2018-002877-23-AT Austria;
Onabotulinumtoxin A Injection
University of North Carolina, Chapel Hill
2018 Phase 2 NCT03301272 United States;
OnabotulinumtoxinA
Johns Hopkins University
2018 Phase 1 NCT03069911 United States;
Ondansetron 8 mg film-coated tablets
University College London
2020 Phase 2 EUCTR2019-003962-41-GB United Kingdom;
Ondansetron hydrochloride dihydrate
University College London
2020 Phase 2 EUCTR2019-003962-41-GB United Kingdom;
Ongentys
BIAL - Portela & Ca, S.A.
2016 Phase 4 EUCTR2016-002391-27-GB Germany;United Kingdom;
2016 Phase 4 EUCTR2016-002391-27-DE Germany;United Kingdom;
BIAL – Portela & Cª, S.A.
2021 Phase 3 EUCTR2020-005011-52-FR Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
2021 Phase 3 EUCTR2020-005011-52-BE Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
BIAL-Portela & Ca, S.A.
2021 Phase 3 EUCTR2020-005011-52-IT Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
Bial - Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-001175-32-PT Germany;Italy;Portugal;Spain;United Kingdom;
2020 Phase 4 EUCTR2020-001175-32-GB Germany;Italy;Portugal;Spain;United Kingdom;
Bial - Portela C S.A.
2019 Phase 1 NCT03820037 United Kingdom;
2018 Phase 1 NCT04265027 United Kingdom;
SK Chemicals Co., Ltd.
2021 Phase 4 NCT04821687 Korea, Republic of;
Ongentys 50 mg capsule rigide
BIAL-Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-002754-24-IT Germany;Italy;Portugal;Spain;United Kingdom;
2020 Phase 4 EUCTR2020-001175-32-IT Germany;Italy;Portugal;Spain;United Kingdom;
Ongentys 50 mg hard capsules
BIAL-Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-002754-24-IT Germany;Italy;Portugal;Spain;United Kingdom;
Bial - Portela & Ca, S.A.
2022 Phase 4 EUCTR2020-002754-24-DE Germany;Italy;Portugal;Spain;United Kingdom;
2021 Phase 4 EUCTR2020-002754-24-ES Germany;Italy;Portugal;Spain;United Kingdom;
2021 Phase 4 EUCTR2020-001176-15-PT Germany;Portugal;
2021 Phase 4 EUCTR2020-001176-15-DE Germany;Portugal;
Opicapone
BIAL - Portela & Ca, S.A.
2011 - EUCTR2010-021860-13-DE Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
BIAL-Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-002754-24-IT Germany;Italy;Portugal;Spain;United Kingdom;
2020 Phase 4 EUCTR2020-001175-32-IT Germany;Italy;Portugal;Spain;United Kingdom;
Bial - Portela & Ca, S.A.
2020 Phase 4 EUCTR2020-001175-32-GB Germany;Italy;Portugal;Spain;United Kingdom;
Bial - Portela C S.A.
2021 Phase 4 NCT04990284 -
2021 Phase 4 NCT04986995 Portugal;
2021 Phase 4 NCT04986982 United Kingdom;
2021 Phase 3 NCT04978597 Bulgaria;
2020 - NCT03959540 United Kingdom;
Neurocrine Biosciences
2021 - NCT04787965 United States;
2018 Phase 1 NCT03496870 United States;
ONO PHARMACEUTICAL CO.,LTD.
2016 Phase 2 JPRN-JapicCTI-153112 Japan;
Rabin Medical Center
2013 Phase 3 NCT01851850 Israel;
Opicapone (OPC)
Bial - Portela C S.A.
2017 Phase 1 NCT03116295 Germany;
2014 Phase 1 NCT03116308 -
Opicapone 50 mg hard capsules
Bial - Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-001175-32-PT Germany;Italy;Portugal;Spain;United Kingdom;
Optimal drug therapy
Vanderbilt University Medical Center
2006 - NCT00282152 United States;
Optimized antiparkinsonian treatment
AbbVie
2017 Phase 3 NCT02799381 Finland;Greece;Hungary;Italy;Slovakia;Spain;United States;
Optimized oral treatment
University Hospital, Lille
2020 Phase 1/Phase 2 NCT04332276 France;
Optional pharmacogenetic assessment
Tools4Patient
2018 Phase 1/Phase 2 NCT03407378 Belgium;France;United States;
Oral Levodopa/Carbidopa
AbbVie (prior sponsor, Abbott)
2011 Phase 2 NCT01479127 Japan;
Oral escitalopram
New York University School of Medicine
2003 Phase 2/Phase 3 NCT00070941 United States;
Oral levodopa and carbidopa
NeuroDerm Ltd.
2014 Phase 1/Phase 2 NCT02096601 Israel;United States;
Orally disintegrating selegiline (Zelapar)
Parkinson's Disease and Movement Disorder Center of Boca Raton
2007 Phase 4 NCT00443872 United States;
Orfadin
Synosia Therapeutics AG
2009 - EUCTR2009-013670-41-FR Czech Republic;France;
2009 - EUCTR2009-013670-41-CZ Czech Republic;France;
Other Parkinson's Disease treatments
Merck Sharp & Dohme Corp.
2007 Phase 2 NCT00537017 Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Singapore;Spain;United States;
2006 Phase 2 NCT00406029 Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Italy;New Zealand;Peru;Singapore;South Africa;Spain;United States;
Over-encapsulated Entacapone Tablets
BIAL - Portela & Ca, S.A.
2011 Phase 3 EUCTR2010-021860-13-RO Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-SK Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-ES Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
2011 - EUCTR2010-021860-13-DE Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-CZ Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-BG Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-AT Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2010 - EUCTR2010-021860-13-PT Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2010 - EUCTR2010-021860-13-LV Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
2010 - EUCTR2010-021860-13-HU Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
Over-encapsulated Modafinil
Theranexus S.A.
2018 Phase 2 EUCTR2017-004475-31-HU Czech Republic;France;Germany;Hungary;United States;
2018 Phase 2 EUCTR2017-004475-31-CZ Czech Republic;France;Germany;Hungary;United States;
Oxaloacetate (OAA)
University of Kansas Medical Center
2012 Phase 2/Phase 3 NCT01741701 United States;
Oxybuprocaine
Utano National Hospital, National Hospital Organization
2013 - JPRN-UMIN000017695 Japan;
Oxybutynin and darifenacin
Department of Veterans Affairs
2009 - NCT00892450 United States;
Oxybutynin hydrochloride
Summit (Cambridge) Ltd.
2007 - EUCTR2007-004654-81-GB United Kingdom;
Oxycodone/Naloxone Prolonged Release tablets
Mundipharma Research GmbH & Co KG
2011 Phase 3 NCT01439100 Czech Republic;Germany;Hungary;Poland;Romania;Spain;United Kingdom;
Oxycodone/naloxone prolonged release tablets 10 mg /
Mundipharma Research GmbH & Co. KG
2012 - EUCTR2011-002901-31-DE Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-GB Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-ES Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-HU Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-CZ Czech Republic;Germany;Hungary;Spain;United Kingdom;
Oxycodone/naloxone prolonged release tablets 20 mg /
Mundipharma Research GmbH & Co. KG
2012 - EUCTR2011-002901-31-DE Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-GB Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-ES Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-HU Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-CZ Czech Republic;Germany;Hungary;Spain;United Kingdom;
Oxycodone/naloxone prolonged release tablets 5 mg /
Mundipharma Research GmbH & Co. KG
2012 - EUCTR2011-002901-31-DE Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-GB Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-ES Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-HU Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-CZ Czech Republic;Germany;Hungary;Spain;United Kingdom;
Oxycontin LP
UHToulouse
2016 Phase 2;Phase 3 EUCTR2015-001523-24-FR France;
Oxygen
Tools4Patient
2018 Phase 1/Phase 2 NCT03407378 Belgium;France;United States;
P2B001
Pharma Two B Ltd
2018 Phase 3 EUCTR2017-001420-21-ES Canada;France;Germany;Spain;United States;
2018 Phase 3 EUCTR2017-001420-21-DE Canada;France;Germany;Spain;United States;
Pharma Two B Ltd.
2018 Phase 3 NCT03329508 Canada;Germany;Spain;United States;
P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),
Pharma Two B Ltd.
2013 Phase 2/Phase 3 NCT01968460 Israel;United States;
P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),
Pharma Two B Ltd.
2013 Phase 2/Phase 3 NCT01968460 Israel;United States;
PARCOPA
UCB Pharma
2004 Phase 3 NCT00139867 United States;
PAT
NYU Langone Health
2017 - NCT03178786 United States;
PBF-509
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
2014 Phase 1 NCT02111330 Spain;
2012 Phase 1 NCT01691924 Spain;
PD patients H&Y=1.5-2 Medications OFF
Giovanni Mirabella
2020 - NCT03665493 Italy;
PD patients H&Y=1.5-2 Medications ON
Giovanni Mirabella
2020 - NCT03665493 Italy;
PD patients H&Y=3 Medications OFF
Giovanni Mirabella
2020 - NCT03665493 Italy;
PD patients H&Y=3 Medications ON
Giovanni Mirabella
2020 - NCT03665493 Italy;
PD vitamin supplementation
New York Institute of Technology
2008 - NCT01238926 United States;
PEG
The 988th Hospitail of Joint Logistic Support Force
2021 Phase 4 ChiCTR2100043303 China;
PEG tube
AbbVie
2013 Phase 3 NCT01960842 Japan;Korea, Republic of;Taiwan;
AbbVie (prior sponsor, Abbott)
2009 Phase 3 NCT00660387 New Zealand;United States;
2009 Phase 3 NCT00360568 Germany;New Zealand;United States;
2009 Phase 3 NCT00357994 Germany;United States;
2008 Phase 3 NCT00335153 Australia;Canada;Czech Republic;Finland;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
PET
Zionexa
2021 Phase 3 NCT04265209 -
PET/CT
Asan Medical Center
2006 Phase 3 NCT00468078 Korea, Republic of;
PF-06412562
Milton S. Hershey Medical Center
2018 Phase 1 NCT03665454 United States;
Pfizer
2014 Phase 1 NCT02006290 United States;
PF-06649751
Cerevel Therapeutics, LLC
2021 Phase 3 EUCTR2019-002952-17-DE Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2021 Phase 3 EUCTR2019-002952-17-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2021 Phase 3 EUCTR2019-002951-40-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2021 Phase 3 EUCTR2019-002949-38-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002952-17-HU Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002952-17-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002951-40-HU Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002951-40-ES Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002951-40-DE Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002951-40-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002950-22-HU Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002949-38-PL Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002949-38-HU Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002949-38-ES Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002949-38-DE Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002949-38-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States;
Pfizer
2016 Phase 2 NCT02847650 France;Germany;Israel;United States;
2015 Phase 1 NCT02373072 Belgium;United States;
2014 Phase 1 NCT02224664 Belgium;United States;
Pfizer, Inc.
2017 Phase 2 EUCTR2016-001575-71-ES France;Germany;Israel;Spain;United States;
2016 Phase 2 EUCTR2016-001575-71-DE France;Germany;Israel;Spain;United States;
2016 Phase 2 EUCTR2015-004912-39-ES France;Germany;Japan;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004912-39-DE France;Germany;Japan;Spain;United Kingdom;United States;
PF-06649751 -
Pfizer Inc., 235 East 42nd Street, New York, New York
2017 Phase 2 EUCTR2017-000128-81-ES Canada;France;Germany;Spain;United States;
2017 Phase 2 EUCTR2017-000128-81-DE Canada;France;Germany;Spain;United States;
PF-06649751 high dose (15 mg QD)
Pfizer
2016 Phase 2 NCT02687542 Canada;France;Germany;Japan;Spain;United States;
PF-06649751 low dose (1 mg QD)
Pfizer
2016 Phase 2 NCT02687542 Canada;France;Germany;Japan;Spain;United States;
PF-06649751 middle dose 1 (3 mg QD)
Pfizer
2016 Phase 2 NCT02687542 Canada;France;Germany;Japan;Spain;United States;
PF-06649751 middle dose 2 (7 mg QD)
Pfizer
2016 Phase 2 NCT02687542 Canada;France;Germany;Japan;Spain;United States;
PF-06669571
Pfizer
2015 Phase 1 NCT02565628 United States;
PG203
Celon Pharma S.A.
2021 Phase 2 EUCTR2020-006004-16-PL Poland;
PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj
Seoul National University Hospital
2011 Phase 4 NCT01313819 Korea, Republic of;
PR Oxycodone
University Hospital, Toulouse
2016 Phase 2/Phase 3 NCT02601586 France;
PR001
Prevail Therapeutics
2020 Phase 1/Phase 2 NCT04127578 Israel;United States;
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE
Pharma Two B Ltd
2018 Phase 3 EUCTR2017-001420-21-ES Canada;France;Germany;Spain;United States;
2018 Phase 3 EUCTR2017-001420-21-DE Canada;France;Germany;Spain;United States;
PRIM-DJ2727
The University of Texas Health Science Center, Houston
2019 Phase 1 NCT03671785 United States;
2017 Phase 1/Phase 2 NCT03026231 United States;
PROSCAR*30CPR RIV
AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI
2011 - EUCTR2011-000612-26-IT Italy;
PRX002
Prothena Biosciences Limited
2014 Phase 1 NCT02157714 United States;
2014 Phase 1 NCT02095171 United States;
PRX002, ELT2, anti-alpha-synuclein monoclonal antibody
F. HOFFMANN - LA ROCHE LTD.
2021 Phase 2 EUCTR2020-004997-23-IT Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
F. Hoffmann-La Roche Ltd
2021 Phase 2 EUCTR2020-004997-23-FR Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004997-23-AT Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000087-15-FR Austria;France;Germany;Spain;United States;
2017 Phase 2 EUCTR2017-000087-15-ES Austria;France;Germany;Spain;United States;
2017 Phase 2 EUCTR2017-000087-15-DE Austria;France;Germany;Spain;United States;
2017 Phase 2 EUCTR2017-000087-15-AT Austria;France;Germany;Spain;United States;
Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
2021 Phase 2 EUCTR2020-004997-23-ES Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
PS
Central Hospital, Nancy, France
2021 - NCT04933513 France;
PS128
Professor Lu Neurological Clinic
2020 - NCT04722211 Taiwan;
2020 - NCT04722198 Taiwan;
PT320
Peptron, Inc.
2020 Phase 2 NCT04269642 Korea, Republic of;
PXT002331
PREXTON THERAPEUTICS B.V.
2017 Phase 2 EUCTR2017-000135-14-IT Austria;France;Germany;Italy;Spain;United Kingdom;
Prexton Therapeutics
2016 Phase 1 NCT02639221 United Kingdom;
Prexton Therapeutics B.V.
2017 Phase 2 EUCTR2017-000135-14-GB Austria;Germany;Spain;United Kingdom;
2017 Phase 2 EUCTR2017-000135-14-ES Austria;Germany;Italy;Spain;United Kingdom;
2017 Phase 2 EUCTR2017-000135-14-DE Austria;Germany;Italy;Spain;United Kingdom;
2017 Phase 2 EUCTR2017-000135-14-AT Austria;Germany;Spain;United Kingdom;
PXT002331 -
Prexton Therapeutics
2018 Phase 2 NCT03331848 -
PXT002331 - dose 1
Prexton Therapeutics
2017 Phase 2 NCT03162874 Austria;France;Germany;Italy;Spain;United Kingdom;
PXT002331 - dose 2
Prexton Therapeutics
2017 Phase 2 NCT03162874 Austria;France;Germany;Italy;Spain;United Kingdom;
PYM50028
Phytopharm
2010 Phase 2 NCT01060878 Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
Phytopharm plc
2011 - EUCTR2010-018534-44-HU Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
2011 - EUCTR2010-018534-44-DE Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
2011 - EUCTR2010-018534-44-CZ Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
2010 Phase 2 EUCTR2010-018534-44-GB Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
PYRIDOSTIGMINE BROMIDE
Department of Neurology, Roskilde Hospital
2012 Phase 2 EUCTR2012-000122-21-DK Denmark;
Paracetamol
Bial - Portela C S.A.
2014 Phase 1 NCT02305017 -
Parapres
INSTITUT DE RECERCA HSCSP
2016 Phase 2 EUCTR2016-000679-25-ES Spain;
Parcopa
Baylor College of Medicine
2006 Phase 4 NCT00590122 United States;
UCB Pharma
2005 Phase 3 NCT00139880 United States;
Pardaprunox
Solvay Pharmaceuticals
2006 Phase 3 NCT00335166 Australia;Czech Republic;Estonia;France;Germany;India;Italy;Lithuania;Malaysia;Netherlands;Poland;Portugal;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States;
Pardoprunox
Abbott Products
2009 Phase 2 NCT00903838 Germany;Italy;Portugal;
Solvay Pharmaceuticals
2007 Phase 3 NCT00407095 Albania;Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Latvia;Lithuania;Peru;Russian Federation;Ukraine;United States;
2007 Phase 3 NCT00406588 Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Latvia;Lithuania;Peru;Russian Federation;Ukraine;United States;
2007 Phase 3 NCT00335374 Australia;Czech Republic;Estonia;France;Germany;India;Italy;Lithuania;Malaysia;Netherlands;Poland;Portugal;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States;
2007 Phase 3 NCT00332917 Argentina;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Finland;Former Serbia and Montenegro;India;Israel;Mexico;New Zealand;Peru;Romania;Russian Federation;Serbia;Slovakia;South Africa;Sweden;Ukraine;United States;
2006 Phase 3 NCT00269516 Argentina;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Finland;Former Serbia and Montenegro;India;Israel;Mexico;New Zealand;Peru;Romania;Russian Federation;Serbia;Slovakia;South Africa;Sweden;Ukraine;United States;
Pardoprunox hydrochloride
Abbott Healthcare Products B.V.
2009 - EUCTR2008-000400-81-DE Germany;Italy;Portugal;
SOLVAY PHARMACEUTICALS B.V.
2009 - EUCTR2008-000400-81-IT Germany;Italy;Portugal;
Solvay Pharmaceuticals
2009 Phase 3 EUCTR2007-001095-36-SK Hungary;Slovakia;
2008 Phase 3 EUCTR2007-001096-10-SK Hungary;Slovakia;
2008 - EUCTR2007-001096-10-HU Hungary;
2008 - EUCTR2007-001095-36-HU Hungary;
Solvay Pharmaceuticals B.V.
2008 Phase 2 EUCTR2008-004943-12-SK Slovakia;
Solvay Pharmaceuticals BV
2009 - EUCTR2008-000400-81-PT Germany;Italy;Portugal;
Paroxetine
Rutgers, The State University of New Jersey
2003 Phase 2 NCT00062738 United States;
University of Rochester
2005 Phase 3 NCT00086190 Canada;Puerto Rico;United States;
Part 1, JM-010 component Group A
Bukwang Pharmaceutical
2021 Phase 2 NCT04377945 United States;
Part 1, JM-010 component Group B
Bukwang Pharmaceutical
2021 Phase 2 NCT04377945 United States;
Part 1, JM-010 component Group C
Bukwang Pharmaceutical
2021 Phase 2 NCT04377945 United States;
Part 2, JM-010 combination Group A
Bukwang Pharmaceutical
2021 Phase 2 NCT04377945 United States;
Part 2, JM-010 combination Group B
Bukwang Pharmaceutical
2021 Phase 2 NCT04377945 United States;
Part 2, JM-010 component Group C
Bukwang Pharmaceutical
2021 Phase 2 NCT04377945 United States;
Perampanel
Eisai Inc.
2007 Phase 2 NCT00566462 United States;
2004 Phase 2 NCT01634360 -
Eisai Limited
2007 Phase 3 NCT00505622 France;
Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J)
AbbVie (prior sponsor, Abbott)
2013 Phase 3 NCT01736176 United States;
Percutaneous endoscopic gastrostomy tube
AbbVie
2017 Phase 3 NCT02799381 Finland;Greece;Hungary;Italy;Slovakia;Spain;United States;
Percutaneous endoscopic gastrostomy tube (PEG tube)
AbbVie (prior sponsor, Abbott)
2006 Phase 4 NCT00141518 Norway;Sweden;
Pergolide
Valeant Pharmaceuticals International, Inc.
2008 - NCT00624741 -
Phenlarmide Tablets
Yiling Pharmaceutical Inc.
2019 Phase 1 NCT04164121 China;
Physical exam and UPDRS part III assessment
Howard Gendelman, MD
2013 Phase 1 NCT01882010 United States;
Piclozotan
Asubio Pharmaceuticals, Inc.
2007 Phase 2 NCT00623363 Guatemala;Romania;United States;
Pilocarpine
Nagoya University
2017 - JPRN-UMIN000026128 Japan;
katsuno Masahisa
2017 Phase 2 JPRN-jRCTs041180018 Japan;
Pimavanserin
ACADIA Pharmaceuticals Inc.
2020 Phase 4 NCT04292223 United States;
2019 Phase 2 NCT04164758 United States;
2018 Phase 2 NCT03482882 United States;
VA Office of Research and Development
2022 Phase 4 NCT04373317 United States;
Pimavanserin (ACP-103)
ACADIA Pharmaceuticals Inc
2009 Phase 3 EUCTR2007-003035-22-PT Austria;Belgium;Canada;European Union;France;India;Italy;Portugal;Russian Federation;Sweden;Ukraine;United Kingdom;United States;
ACADIA Pharmaceuticals Inc.
2008 Phase 3 EUCTR2007-003035-22-GB Austria;Belgium;Canada;European Union;France;India;Italy;Portugal;Russian Federation;Sweden;Ukraine;United Kingdom;United States;
Acadia Pharmaceuticals Inc
2008 Phase 2;Phase 3 EUCTR2007-003035-22-SE Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
2008 Phase 2;Phase 3 EUCTR2007-003035-22-BE Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
Pimavanserin tartrate
ACADIA Pharmaceuticals Inc
2009 Phase 3 EUCTR2007-003035-22-PT Austria;Belgium;Canada;European Union;France;India;Italy;Portugal;Russian Federation;Sweden;Ukraine;United Kingdom;United States;
ACADIA Pharmaceuticals Inc.
2016 - NCT02762591 -
2010 Phase 3 NCT01174004 Canada;United States;
2008 Phase 3 EUCTR2007-003035-22-GB Austria;Belgium;Canada;European Union;France;India;Italy;Portugal;Russian Federation;Sweden;Ukraine;United Kingdom;United States;
Acadia Pharmaceuticals Inc
2009 Phase 2;Phase 3 EUCTR2007-003035-22-AT Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
2008 Phase 2;Phase 3 EUCTR2007-003035-22-SE Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
2008 Phase 2;Phase 3 EUCTR2007-003035-22-FR Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
2008 Phase 2;Phase 3 EUCTR2007-003035-22-BE Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
2008 - EUCTR2007-003051-36-SE Austria;Portugal;Spain;Sweden;
2008 - EUCTR2007-003051-36-PT Austria;Portugal;Spain;Sweden;
2008 - EUCTR2007-003051-36-ES Austria;Portugal;Spain;Sweden;
2008 - EUCTR2007-003051-36-BE Austria;Belgium;Portugal;Spain;Sweden;
2008 - EUCTR2007-003051-36-AT Austria;Portugal;Spain;Sweden;
2008 - EUCTR2007-002906-23-BG Bulgaria;France;United Kingdom;
2007 - EUCTR2007-002906-23-GB Bulgaria;France;United Kingdom;
2007 - EUCTR2007-002906-23-FR Bulgaria;France;United Kingdom;
Pimavanserin tartrate (ACP-103)
ACADIA Pharmaceuticals Inc.
2008 Phase 3 NCT00658567 Austria;Belgium;Italy;Poland;Portugal;Serbia;Spain;Sweden;United States;
2007 Phase 3 NCT00550238 Austria;Belgium;Canada;France;India;Italy;Poland;Portugal;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom;United States;
2007 Phase 3 NCT00477672 Bulgaria;France;India;Russian Federation;Ukraine;United Kingdom;United States;
2004 Phase 2 NCT01518309 United States;
Pioglitazone
University of Rochester
2011 Phase 2 NCT01280123 United States;
Pirepemat
Integrative Research Laboratories AB
2022 Phase 2 NCT05258071 -
Piribedil
Desitin Arzneimittel GmbH
2010 Phase 3 NCT01007864 Germany;
2009 - EUCTR2009-012419-16-DE Germany;
2008 - NCT00727727 Germany;
2008 - NCT00725478 -
Henan University of Traditional Chinese Medicine
2009 - ChiCTR-TRC-12002150 China;
Institut de Recherches Internationales Servier
2006 Phase 2 EUCTR2005-000314-12-DE Germany;Spain;
2005 Phase 2 EUCTR2005-000314-12-ES Germany;Spain;
Institut de Recherches Internationales Servier (I.R.I.S.)
2005 - EUCTR2005-002010-38-DE Germany;
Piribedil (Clarium)
Desitin Arzneimittel GmbH
2009 - NCT01519856 Germany;
Pitolisant
BIOPROJET
2010 - EUCTR2009-013886-24-SE Czech Republic;Germany;Sweden;
2010 - EUCTR2009-013886-24-DE Czech Republic;Germany;Sweden;
2009 - EUCTR2009-013886-24-CZ Czech Republic;Germany;Sweden;
2009 - EUCTR2009-013885-14-FR France;Spain;
2009 - EUCTR2009-013885-14-ES France;Spain;
Pittsburgh Compound B
Sunnybrook Health Sciences Centre
2016 - NCT02524405 Canada;
Placebo
Meiji Seika Pharma Co., Ltd.
2015 Phase 3 JPRN-JapicCTI-153057 Japan;
2015 Phase 2-3 JPRN-JapicCTI-153056 Japan;
ONO PHARMACEUTICAL CO.,LTD.
2016 Phase 2 JPRN-JapicCTI-153112 Japan;
Otsuka Pharmaceutical Co., Ltd.
2009 Phase 3 JPRN-JapicCTI-090888 -
Plantago ovata husk
Rottapharm Spain
2006 Phase 1 NCT00507715 Spain;
Posiphen
Annovis Bio Inc.
2020 Phase 1/Phase 2 NCT04524351 United States;
Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin)
Hospices Civils de Lyon
2019 - NCT03970239 France;
Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin)
Hospices Civils de Lyon
2019 - NCT03970239 France;
Pramipexol
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-DE Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-CZ Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
Shanghai General Hospital
2020 Phase 0 ChiCTR2000037624 China;
Pramipexol Extended Release
Boehringer Ingelheim
2007 Phase 3 NCT00479401 Argentina;Austria;Brazil;Czech Republic;Finland;Germany;Hungary;India;Japan;Malaysia;Russian Federation;Slovakia;Taiwan;Ukraine;United States;
2007 Phase 3 NCT00466167 Austria;Czech Republic;Hungary;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom;
Pramipexol Immediate Release
Boehringer Ingelheim
2007 Phase 3 NCT00479401 Argentina;Austria;Brazil;Czech Republic;Finland;Germany;Hungary;India;Japan;Malaysia;Russian Federation;Slovakia;Taiwan;Ukraine;United States;
2007 Phase 3 NCT00466167 Austria;Czech Republic;Hungary;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom;
Pramipexole
Abbott Products
2009 Phase 2 NCT00903838 Germany;Italy;Portugal;
Boehringer Ingelheim
2011 - NCT01361009 China;
2008 Phase 3 NCT00601523 Argentina;Austria;Czech Republic;Finland;France;Germany;Hungary;India;Japan;Malaysia;Netherlands;Russian Federation;Slovakia;Taiwan;Ukraine;United States;
2008 - NCT02236728 -
2007 Phase 3 NCT00577460 Austria;Czech Republic;Hungary;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom;
2006 Phase 4 NCT00402233 United States;
2006 Phase 4 NCT00321854 Austria;Finland;France;Germany;Italy;Japan;Spain;Sweden;United Kingdom;United States;
2006 Phase 4 NCT00297778 Austria;Finland;France;Germany;Italy;Netherlands;Norway;Romania;Russian Federation;South Africa;Spain;Sweden;Ukraine;United Kingdom;
2006 Phase 4 EUCTR2005-004949-34-FI Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - NCT00349310 Austria;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2004 - NCT02248181 -
2003 Phase 3 NCT00240409 China;
2003 - NCT02248207 -
2002 - NCT02248168 -
1999 Phase 3 NCT02172573 -
1998 Phase 4 NCT02233023 -
1998 Phase 3 NCT02177357 -
1998 - NCT02248220 -
Boehringer Ingelheim AB
2006 Phase 4 EUCTR2005-004949-34-SE Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003788-22-SE Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Austria GmbH
2006 - EUCTR2005-004949-34-AT Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003788-22-AT Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim España S.A.
2006 Phase 4 EUCTR2005-003788-22-ES Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim España, S.A.
2006 - EUCTR2005-004949-34-ES Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Limited
2006 Phase 4 EUCTR2005-003788-22-GB Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Ltd
2006 Phase 4 EUCTR2005-004949-34-GB Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Pharma GmbH & Co. KG
2006 - EUCTR2005-004949-34-DE Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003788-22-DE Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Department of Neurology, Brain Hospital Affiliated to Nanjing Medical University
2019 Phase 0 ChiCTR1900021708 China;
Department of Neurology, Juntendo University
2011 - JPRN-UMIN000006521 Japan;
Geriatric Hospital of Hainan
2019 - ChiCTR1900022534 China;
Huashan Hospital
2011 - NCT01470859 China;
Institute of Clinical Pharmacology, Central South University
2012 Phase 1 study ChiCTR-TTRCC-12002751 China;
Institute of Psychology, Chinese Academy of Sciences
2018 - ChiCTR1800015331 China;
Kissei Pharmaceutical Co., Ltd.
2019 Phase 2 NCT03845387 Japan;
NEUROBIOTEC GMBH
2007 - EUCTR2006-003732-30-IT Germany;Italy;Poland;
Oregon Health and Science University
2003 Phase 1 NCT00666653 United States;
Qualissima
2008 Phase 4 NCT01048229 -
SOLVAY PHARMACEUTICALS B.V.
2009 - EUCTR2008-000400-81-IT Germany;Italy;Portugal;
2006 - EUCTR2006-000678-57-IT Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
Sandoz
2012 Phase 4 NCT01673724 Korea, Republic of;
Solvay Pharmaceuticals
2006 Phase 3 NCT00335166 Australia;Czech Republic;Estonia;France;Germany;India;Italy;Lithuania;Malaysia;Netherlands;Poland;Portugal;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States;
The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital)
2020 Phase 4 ChiCTR2000039050 China;
The Affiliated Brain Hospital of Nanjing Medical University( Nanjing Brain Hospital)
2018 - ChiCTR1800019942 China;
Vanderbilt University Medical Center
2019 Phase 1 NCT04249544 United States;
West China Hospital of Sichuan University
2020 Phase 1 ChiCTR2000035564 China;
Pramipexole 0.125 mg tablets
Boehringer Ingelheim
1998 Phase 3 NCT00274131 -
Pramipexole 0.5 mg tablets
Boehringer Ingelheim
1998 Phase 3 NCT00274131 -
Pramipexole ER
BOEHRINGER ING.
2008 - EUCTR2007-004235-37-IT Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-000074-23-IT Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
BOEHRINGER INGELHEIM
2008 Phase 3 EUCTR2007-004234-16-FR Austria;Czech Republic;Finland;France;Hungary;Netherlands;Slovakia;
2007 Phase 3 EUCTR2007-003353-90-FR France;Germany;Netherlands;
Boehringer Ingelheim
2008 - EUCTR2007-004235-37-GB Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-003353-90-NL France;Germany;Netherlands;
Boehringer Ingelheim AB
2008 - EUCTR2007-004235-37-SE Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-000074-23-SE Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim España, S.A.
2008 Phase 3 EUCTR2007-004235-37-ES Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2007-000074-23-ES Austria;Czech Republic;Hungary;Italy;Slovakia;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Finland Ky
2008 - EUCTR2007-004234-16-FI Austria;Czech Republic;Finland;France;Hungary;Netherlands;
2007 - EUCTR2007-000073-39-FI Austria;Czech Republic;Finland;Hungary;
Boehringer Ingelheim Limited
2007 - EUCTR2007-000074-23-GB Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Pharma Ges mbH
2008 Phase 3 EUCTR2007-004235-37-HU Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-004235-37-PL Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-004235-37-CZ Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-004234-16-HU Austria;Czech Republic;Finland;France;Hungary;Netherlands;
2007 Phase 3 EUCTR2007-000074-23-SK Austria;Czech Republic;Hungary;Italy;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2007-000073-39-SK Austria;Czech Republic;Finland;Germany;Hungary;Slovakia;
2007 - EUCTR2007-000074-23-HU Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-000073-39-HU Austria;Czech Republic;Finland;Hungary;
2007 - EUCTR2007-000073-39-AT Austria;Czech Republic;Finland;Hungary;
Boehringer Ingelheim Pharma GmbH & Co. KG
2007 - EUCTR2007-003353-90-DE France;Germany;Netherlands;
2007 - EUCTR2007-000074-23-AT Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-000073-39-DE Austria;Czech Republic;Finland;Germany;Hungary;
Boehringer Ingelheim RCV GmbH & Co KG
2009 - EUCTR2007-004235-37-AT Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2009 - EUCTR2007-004234-16-AT Austria;Czech Republic;Finland;France;Hungary;Netherlands;
2008 Phase 3 EUCTR2007-004235-37-SK Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom;
2008 Phase 3 EUCTR2007-004234-16-SK Austria;Czech Republic;Finland;France;Hungary;Netherlands;Slovakia;
2008 - EUCTR2007-004234-16-CZ Austria;Czech Republic;Finland;France;Hungary;Netherlands;
2007 Phase 3 EUCTR2007-000074-23-CZ Austria;Czech Republic;Hungary;Italy;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-000073-39-CZ Austria;Czech Republic;Finland;Hungary;
Boehringer Ingelheim bv
2007 - EUCTR2007-004234-16-NL Austria;Czech Republic;Finland;France;Hungary;Netherlands;
Pharma Two B Ltd.
2018 Phase 3 NCT03329508 Canada;Germany;Spain;United States;
Pramipexole Extended Release
Boehringer Ingelheim
2010 - NCT01097421 Sweden;
2007 Phase 3 NCT00558025 France;Germany;Netherlands;
2007 Phase 2/Phase 3 NCT00560508 Japan;
Pramipexole IR
Boehringer Ingelheim
2018 Phase 4 NCT03521635 China;
Pramipexole Immediate Release
Boehringer Ingelheim
2007 Phase 3 NCT00558025 France;Germany;Netherlands;
2007 Phase 2/Phase 3 NCT00560508 Japan;
Pramipexole SR
Boehringer Ingelheim
2018 Phase 4 NCT03521635 China;
Pramipexole dihydrochloride extended-release tablets
Pharma Two B Ltd
2018 Phase 3 EUCTR2017-001420-21-ES Canada;France;Germany;Spain;United States;
2018 Phase 3 EUCTR2017-001420-21-DE Canada;France;Germany;Spain;United States;
Pramipexole dihydrochloride monohydrate
Abbott Healthcare Products B.V.
2009 - EUCTR2008-000400-81-DE Germany;Italy;Portugal;
Solvay Pharmaceuticals B.V.
2008 Phase 2 EUCTR2008-004943-12-SK Slovakia;
Solvay Pharmaceuticals BV
2009 - EUCTR2008-000400-81-PT Germany;Italy;Portugal;
Pramipexole dihydrochloride monohydrate extended release
University Hospital of North Staffordshire
2013 Phase 4 EUCTR2012-000801-64-GB United Kingdom;
Pramipexole extended release tablet
Boehringer Ingelheim
2010 Phase 3 NCT01191944 China;
Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole)
First Affiliated Hospital of Zhejiang University
2020 - NCT04275492 China;
Pramipexole immediate release
Boehringer Ingelheim
2008 - NCT00651183 Austria;
Pramipexole immediate release tablet
Boehringer Ingelheim
2010 Phase 3 NCT01191944 China;
Pramipexole or ropinirole
Desitin Arzneimittel GmbH
2010 Phase 3 NCT01007864 Germany;
Prasinezumab
F. HOFFMANN - LA ROCHE LTD.
2021 Phase 2 EUCTR2020-004997-23-IT Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
F. Hoffmann-La Roche Ltd
2021 Phase 2 EUCTR2020-004997-23-FR Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004997-23-AT Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
Hoffmann-La Roche
2021 Phase 2 NCT04777331 Austria;Canada;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
2021 Phase 2 EUCTR2020-004997-23-ES Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride)
First Affiliated Hospital of Zhejiang University
2020 - NCT04275492 China;
Prednisone
Prevail Therapeutics
2020 Phase 1/Phase 2 NCT04127578 Israel;United States;
Preladenant
Merck Sharp & Dohme Corp.
2011 Phase 2 NCT01294800 Japan;
2011 Phase 1 NCT01323855 Germany;
2010 Phase 3 NCT01227265 Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States;
2010 Phase 3 NCT01215227 Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2007 Phase 2 NCT00537017 Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Singapore;Spain;United States;
2006 Phase 2 NCT00406029 Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Italy;New Zealand;Peru;Singapore;South Africa;Spain;United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
2011 - EUCTR2009-015161-31-DE Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
2011 Phase 3 EUCTR2009-013552-72-GB Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015162-57-PT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015161-31-PT Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2011 Phase 3 EUCTR2009-015162-57-GB Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-BG Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015161-31-GB Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015161-31-BG Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-013552-72-BG Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
- - EUCTR2009-013552-72-DE Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Merck Sharp & Dohme corp.
2011 Phase 3 EUCTR2009-015162-57-NL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Schering Corporation, división Schering-Plough Research
2010 Phase 3 EUCTR2009-013552-72-ES Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
Schering-Plough Research Institute, a division of Schering Corporation
2011 Phase 3 EUCTR2009-015162-57-LV Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-LT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-FI Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-ES Austria;Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2011 Phase 3 EUCTR2009-015162-57-CZ Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-013552-72-CZ Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2010-020112-11-LV Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States;
2011 - EUCTR2010-020112-11-LT Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States;
2011 - EUCTR2009-015162-57-SE Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-PL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-AT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015161-31-PL Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015161-31-CZ Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-013552-72-PL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 Phase 3 EUCTR2009-015161-31-IT Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2009-015161-31-FR Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2009-013552-72-HU Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2009-013552-72-FI Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-SE Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-NL Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-FI Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-AT Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-013552-72-SE Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-013552-72-IT Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
Schering-Plough Research Institute, division of Schering Corporation
2011 - EUCTR2009-015162-57-IT Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
Tokyo Metropolitan Institute of Gerontology
2016 - JPRN-UMIN000025638 Japan;
Preladenant 10 mg tablet
Merck Sharp & Dohme Corp.
2010 Phase 3 NCT01155479 Argentina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 Phase 3 NCT01155466 Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Preladenant 2 mg tablet
Merck Sharp & Dohme Corp.
2010 Phase 3 NCT01155479 Argentina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 Phase 3 NCT01155466 Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Preladenant 5 mg tablet
Merck Sharp & Dohme Corp.
2010 Phase 3 NCT01155479 Argentina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 Phase 3 NCT01155466 Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Premarin ®
The Parkinson Study Group
2003 Phase 2 NCT00234676 United States;
Pridia (Donepezil Hydrochloride)
The Newcastle upon Tyne Hospitals NHS Foundation Trust
2012 Phase 3 EUCTR2009-015170-35-GB United Kingdom;
Pridopidine
Prilenia
2019 Phase 2 NCT03922711 United States;
Primary Cervical Dystonia (Trihexyphenidyl)
University of Florida
2014 - NCT02046447 United States;
Primavanserin tartrate
ACADIA PHARMACEUTICALS INC.
2009 - EUCTR2007-003035-22-IT Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
Prior Donepezil
Eisai Inc.
2003 Phase 3 NCT01327859 United Kingdom;
Prior Donzepezil
Eisai Inc.
2003 Phase 3 NCT01327859 United Kingdom;
ProSavin
Axovant Sciences Ltd.
2011 Phase 1/Phase 2 NCT01856439 France;United Kingdom;
Oxford BioMedica
2008 Phase 1/Phase 2 NCT00627588 France;United Kingdom;
Oxford BioMedica (UK) Ltd
2010 Phase 1;Phase 2 EUCTR2007-001109-26-GB United Kingdom;
2010 - EUCTR2009-017253-35-GB United Kingdom;
Probiotic
University of British Columbia
2020 Phase 2 NCT03968133 Canada;
Probiotic Capsule
University of Malaya
2017 - NCT03377322 Malaysia;
Probiotics
Franca Marino
2021 - NCT05173701 Italy;
Probiotics with prebiotic
National University of Malaysia
2018 Phase 3 NCT04451096 Malaysia;
Prolonged release tablet
Boehringer Ingelheim Finland Ky
2007 - EUCTR2007-000073-39-FI Austria;Czech Republic;Finland;Hungary;
Boehringer Ingelheim Pharma Ges mbH
2007 Phase 3 EUCTR2007-000073-39-SK Austria;Czech Republic;Finland;Germany;Hungary;Slovakia;
2007 - EUCTR2007-000073-39-HU Austria;Czech Republic;Finland;Hungary;
2007 - EUCTR2007-000073-39-AT Austria;Czech Republic;Finland;Hungary;
Boehringer Ingelheim Pharma GmbH & Co. KG
2007 - EUCTR2007-000073-39-DE Austria;Czech Republic;Finland;Germany;Hungary;
Boehringer Ingelheim RCV GmbH & Co KG
2007 - EUCTR2007-000073-39-CZ Austria;Czech Republic;Finland;Hungary;
Prolopa®
Bial - Portela C S.A.
2008 Phase 1 NCT02169895 Canada;
Propofol
Clinica Universidad de Navarra, Universidad de Navarra
2014 Phase 4 NCT02256319 Spain;
Columbia University
2003 - NCT00615472 United States;
Department of Anesthesiology, the First Affiliated Hospital of Sun Yat-Sen University
2020 Phase 4 ChiCTR2000039697 China;
The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
2019 - ChiCTR1900021760 China;
University of Texas Southwestern Medical Center
2020 - NCT04502550 United States;
West China Hospital, Sichuan University
2016 - ChiCTR-IOR-16010168 China;
Xuanwu Hospital of CCMU
2018 - ChiCTR1800014542 China;
Propofol-Lipuro
Clínica Universidad de Navarra/Universidad de Navarra
2014 - EUCTR2014-000868-17-ES Spain;
Propranolol HCl CF 40 mg tablet
Radboud University Nijmegen
2017 Phase 3 EUCTR2016-004629-18-NL Netherlands;
Psilocybin
Maastricht University
2022 Phase 2 EUCTR2021-000041-40-NL Netherlands;
Psilocybin therapy
Joshua Woolley, MD/PhD
2021 Phase 2 NCT04932434 United States;
Psilocybine
Maastricht University
2022 Phase 2 EUCTR2021-000041-40-NL Netherlands;
Psyllium
University of Florida
2021 - NCT04829760 United States;
Pyridostigmine bromide
Christian Baumann
2012 Phase 2 NCT01993680 Switzerland;
QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD
Pfizer
2017 Phase 2 NCT03185481 United States;
QD to 15 mg QD PF-06649751
Pfizer
2017 Phase 2 NCT03185481 United States;
QD to 7 mg QD PF-06649751 (de-escalated in parent study)
Pfizer
2017 Phase 2 NCT03185481 United States;
QD to 7 mg QD PF-06649751 (if de-escalated in parent study)
Pfizer
2017 Phase 2 NCT03185481 United States;
Quetiapine
ACADIA Pharmaceuticals Inc.
2019 Phase 2 NCT04164758 United States;
National Institute on Aging (NIA)
2002 Phase 4 NCT00043849 United States;
VA Office of Research and Development
2022 Phase 4 NCT04373317 United States;
R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride
Fujimoto Pharmaceutical Corporation
2006 Phase 2 EUCTR2006-000361-11-GB United Kingdom;
R-metHuGDNF
North Bristol NHS Trust (NBT)
2013 Phase 2 EUCTR2013-001881-40-GB United Kingdom;
2012 Phase 2 EUCTR2011-003866-34-GB United Kingdom;
RAAV-GAD
Neurologix, Inc.
2011 - NCT01301573 United States;
RAS
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
2021 Phase 0 ChiCTR2100045506 China;
University of Toronto
2009 - NCT03316365 -
RASAGILINA MESILATO
Teva Pharmaceutical Industries Ltd
2009 Phase 4 EUCTR2009-011541-24-ES France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
RASAGILINE MESILATE
Dresden University of Technology
2011 - EUCTR2010-023756-82-DE Germany;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
2011 - EUCTR2009-015162-57-PT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2011 Phase 3 EUCTR2009-015162-57-GB Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-BG Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Merck Sharp & Dohme corp.
2011 Phase 3 EUCTR2009-015162-57-NL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Pharma Two B Ltd
2018 Phase 3 EUCTR2017-001420-21-ES Canada;France;Germany;Spain;United States;
2018 Phase 3 EUCTR2017-001420-21-DE Canada;France;Germany;Spain;United States;
Schering-Plough Research Institute, a division of Schering Corporation
2011 Phase 3 EUCTR2009-015162-57-LV Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-LT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-FI Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-ES Austria;Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2011 Phase 3 EUCTR2009-015162-57-CZ Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-SE Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-PL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-AT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
REQUIP 21 CPR 0,
SCHWARZ PHARMA
2004 - EUCTR2004-002609-66-IT Germany;Italy;
REQUIP*21CPR
CASA DI CURA PRIVATA S.RAFFAELE - PISANA
2009 - EUCTR2009-015833-66-IT Italy;
REQUIP*21CPR 0,
GlaxoSmithKline R D
2006 - EUCTR2005-005423-34-IT Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
REQUIP*28CPR 8MG R.P.
CASA DI CURA PRIVATA S.RAFFAELE - PISANA
2009 - EUCTR2009-015833-66-IT Italy;
REQUIP-LP
CHU de Toulouse
2009 - EUCTR2009-012529-12-FR France;
REQUIP-MODUTAB ,
GlaxoSmithKline Research & Development Limited
2013 - EUCTR2011-002827-17-EE Estonia;Korea, Republic of;Russian Federation;Slovakia;United States;
REQUIP-MODUTAB,
GlaxoSmithKline Research & Development Limited
2013 - EUCTR2011-002828-41-EE Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States;
RIV-TDS 13.3 mg/24 h
University of Bristol
2019 Phase 3 EUCTR2018-003219-23-GB United Kingdom;
RM-131
Motus Therapeutics, Inc.
2013 Phase 2 NCT01955616 United States;
RO
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2011 - EUCTR2010-022363-35-DE Germany;
RO7046015
F. HOFFMANN - LA ROCHE LTD.
2021 Phase 2 EUCTR2020-004997-23-IT Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
F. Hoffmann-La Roche Ltd
2021 Phase 2 EUCTR2020-004997-23-FR Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004997-23-AT Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000087-15-FR Austria;France;Germany;Spain;United States;
2017 Phase 2 EUCTR2017-000087-15-ES Austria;France;Germany;Spain;United States;
2017 Phase 2 EUCTR2017-000087-15-AT Austria;France;Germany;Spain;United States;
Hoffmann-La Roche
2017 Phase 2 NCT03100149 Austria;France;Germany;Spain;United States;
Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
2021 Phase 2 EUCTR2020-004997-23-ES Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
RO7046015/PRASINEZUMAB
F. Hoffmann-La Roche Ltd
2017 Phase 2 EUCTR2017-000087-15-DE Austria;France;Germany;Spain;United States;
ROP+L-Dopa
GlaxoSmithKline
2007 Phase 4 NCT00485069 Japan;
ROT-TDS 8 mg/24 h
Luye Pharma Switzerland AG
2021 Phase 2 EUCTR2021-000867-65-DE Germany;
RQ-00000010
Virginia Commonwealth University
2016 Phase 1 NCT02838797 United States;
RVG 08740
Centre for Human Drug Research
2020 Phase 2 EUCTR2020-000686-16-NL Netherlands;
RVG 55618
Radboud University Nijmegen
2017 Phase 3 EUCTR2016-004629-18-NL Netherlands;
RVT-101
Axovant Sciences Ltd.
2016 Phase 2 NCT02910102 United States;
RYAH-Medtech Inhaler
OMNI Medical Services, LLC
2018 Phase 2 NCT03944447 United States;
Raclopride
Institute of Biomedical Research and Innovation
2015 - JPRN-UMIN000016485 Japan;
Nagoya City Rehabilitation Agency
2019 - JPRN-UMIN000036952 Japan;
National Institute of Neurological Disorders and Stroke (NINDS)
2002 - NCT00032812 United States;
Tokyo Metropolitan Institute of Gerontology
2014 - JPRN-UMIN000014709 Japan;
Racol
St. Mariannna University School of Medicine
2012 - JPRN-UMIN000008057 Japan;
Radotinib HCl
Il-Yang Pharm. Co., Ltd.
2021 Phase 2 NCT04691661 France;
Ramelteon
Massachusetts General Hospital
2009 - NCT00907595 United States;
Southern California Institute for Research and Education
2007 Phase 4 NCT00462254 United States;
Rasagilin
Technische Universität Dresden
2009 - EUCTR2008-005085-30-DE Germany;
Rasagilina mesilato (12 weeks)
Universita di Verona
2018 - NCT03648671 Italy;
Rasagiline
Beijing Hospital
2018 - ChiCTR1800016949 China;
Bial - Portela C S.A.
2009 Phase 1 NCT01532141 France;
2009 Phase 1 NCT01532128 France;
Brown University
2011 Phase 4 NCT01382342 United States;
Chongqing Fortune Pharmaceutical Co., Ltd.
2011 Phase 3 NCT01736891 China;
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
2008 Phase 4 NCT00755027 Spain;
Georgetown University
2012 Phase 4 NCT01497652 United States;
H. Lundbeck A/S
2012 Phase 3 NCT01556165 China;
2012 Phase 1 NCT01652313 China;
Istanbul University
2007 Phase 4 NCT00696215 Turkey;
Lundbeck Italia S.p.A.
2010 Phase 4 NCT01055379 Italy;
Merck Sharp & Dohme Corp.
2010 Phase 3 NCT01215227 Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
Pharma Two B Ltd.
2018 Phase 3 NCT03329508 Canada;Germany;Spain;United States;
Qualissima
2008 Phase 4 NCT01048229 -
Research and Development University Hospital of North Staffordshire
2014 - EUCTR2014-000335-17-GB United Kingdom;
Schering-Plough Research Institute, a division of Schering Corporation
2010 Phase 3 EUCTR2009-015161-31-IT Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2010 - EUCTR2009-013552-72-IT Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
Schering-Plough Research Institute, division of Schering Corporation
2011 - EUCTR2009-015162-57-IT Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
St. Josef Hospital Bochum
2011 Phase 4 NCT01385735 Germany;
TAKEDA PHARMACEUTICAL COMPANY LTD.
2018 - JPRN-JapicCTI-184181 Japan;
TEVA
2005 - EUCTR2005-001416-42-IT Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
Takeda
2018 - NCT03727139 Japan;
Technische Universität Dresden
2011 Phase 4 NCT01442610 Germany;
Teva Branded Pharmaceutical Products R&D, Inc.
2012 Phase 4 NCT01723228 United States;
Teva Neuroscience, Inc.
2009 Phase 4 NCT01049984 United States;
Teva Pharmaceutical Industries
2013 Phase 1 NCT01879748 United States;
Teva Pharmaceutical Industries Ltd
2009 - EUCTR2009-011541-24-IT France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
The Parkinson's Institute
2009 Phase 4 NCT01007630 United States;
Thomas Guttuso
2014 - NCT02278588 United States;
UNIVERSITA` DEGLI STUDI DI PARMA
2009 - EUCTR2009-013004-31-IT Italy;
University of Florida
2016 Phase 2 NCT02789020 United States;
2009 Phase 4 NCT01168596 United States;
University of Zurich
2011 Phase 4 NCT01178047 Switzerland;
Rasagiline 1 mg capsule
Merck Sharp & Dohme Corp.
2010 Phase 3 NCT01155479 Argentina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 Phase 3 NCT01155466 Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Rasagiline 1mg tablet
TEVA Pharmaceuticals Industries Ltd
2006 - EUCTR2006-005140-89-NL Netherlands;
Rasagiline 2 mg tablet
TEVA Pharmaceuticals Industries Ltd
2006 - EUCTR2006-005140-89-NL Netherlands;
Rasagiline Mesylate
Teva Neuroscience, Inc.
1997 Phase 3 NCT00203060 United States;
Teva Pharmaceutical Industries
2005 Phase 3 NCT00256204 Argentina;Austria;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Romania;Spain;United Kingdom;United States;
Rasagiline mesilate
TEVA Pharmaceuticals Industries Ltd
2006 - EUCTR2006-005140-89-NL Netherlands;
Teva Pharmaceuticals Industries LtD
2005 Phase 3 EUCTR2005-001416-42-GB Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-001416-42-ES Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-PT Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-HU Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-DE Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-AT Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
Rasagiline mesylate
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
2011 - EUCTR2009-015162-57-PT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2011 Phase 3 EUCTR2009-015162-57-GB Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-BG Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Merck Sharp & Dohme corp.
2011 Phase 3 EUCTR2009-015162-57-NL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Pharma Two B Ltd
2018 Phase 3 EUCTR2017-001420-21-ES Canada;France;Germany;Spain;United States;
2018 Phase 3 EUCTR2017-001420-21-DE Canada;France;Germany;Spain;United States;
Schering-Plough Research Institute, a division of Schering Corporation
2011 Phase 3 EUCTR2009-015162-57-LV Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-LT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-FI Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-ES Austria;Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2011 Phase 3 EUCTR2009-015162-57-CZ Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-SE Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-PL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-AT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Teva Pharmaceutical Industries
2009 - NCT01032486 Canada;
2009 - NCT00936676 Argentina;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Romania;Spain;United Kingdom;United States;
2004 Phase 3 NCT00203138 United States;
2002 Phase 3 NCT00203164 United States;
2001 Phase 3 NCT00203177 Canada;United States;
2000 Phase 3 NCT00203125 United States;
Teva Pharmaceutical Industries Ltd
2009 Phase 4 EUCTR2009-011541-24-HU France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 Phase 4 EUCTR2009-011541-24-GB Argentina;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Romania;Spain;United Kingdom;United States;
2009 Phase 4 EUCTR2009-011541-24-FR France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 - EUCTR2009-011541-24-PT France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 - EUCTR2009-011541-24-NL France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 - EUCTR2009-011541-24-DE France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
Rasagiline mesylate plus Mirapex
Teva Neuroscience, Inc.
2006 Phase 4 NCT00399477 United States;
Rasagiline mesylate with Levodopa
Teva Neuroscience, Inc.
2006 Phase 4 NCT00399477 United States;
Rasagiline mesylate with Requip
Teva Neuroscience, Inc.
2006 Phase 4 NCT00399477 United States;
Rasagiline tablets
Teva Pharmaceuticals Industries LtD
2005 Phase 3 EUCTR2005-001416-42-GB Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-001416-42-ES Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-PT Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-HU Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-DE Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-AT Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
ReQuip PR
GlaxoSmithKline
2010 Phase 3 NCT01154166 China;
Recombinant human Cerebral Dopamine Neurotrophic Factor
Herantis Pharma Plc
2018 Phase 1;Phase 2 EUCTR2018-000346-19-SE Finland;Sweden;
2018 Phase 1;Phase 2 EUCTR2018-000346-19-FI Finland;Sweden;
2017 Phase 1;Phase 2 EUCTR2015-004175-73-FI Finland;
Renishaw Neuro Solutions Ltd.
2019 Phase 1;Phase 2 EUCTR2017-005170-19-FI Finland;Sweden;
2018 Phase 1;Phase 2 EUCTR2017-005170-19-SE Finland;Sweden;
Recombinant-methionyl human glial cell line-derived neurotrophic factor
National Center for Research Resources (NCRR)
2000 Phase 1 NCT00006488 United States;
Reduced Glutathione
Bastyr University
2015 Phase 2 NCT02424708 United States;
University of Washington
2014 Phase 1 NCT02324426 United States;
Regular Novolin R
HealthPartners Institute
2020 Phase 2 NCT04251585 United States;
Remifentanil
Columbia University
2003 - NCT00615472 United States;
The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
2019 - ChiCTR1900021760 China;
Remifentanyl
West China Hospital, Sichuan University
2016 - ChiCTR-IOR-16010168 China;
Reminyl
Otto-von-Guericke University, Medical Faculty, Dpt. of Neurology
2009 - EUCTR2009-011093-15-DE Germany;
Reminyl Retard
UMCG
2009 - EUCTR2008-006278-13-NL Netherlands;
Renishaw Drug Delivery System
Herantis Pharma Plc.
2018 Phase 1/Phase 2 NCT03775538 Finland;Sweden;
2017 Phase 1/Phase 2 NCT03295786 Finland;Sweden;
Repaglinide
Bial - Portela C S.A.
2009 Phase 1 NCT01536366 Portugal;
Requip
Boehringer Ingelheim
2005 Phase 4 NCT00144300 United States;
Schwarz Biosciences GmbH
2004 - EUCTR2004-002609-66-DE Germany;Italy;
Requip Modutab,
GlaxoSmithKline Research & Development Limited
2013 - EUCTR2011-002828-41-SK Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States;
Requip PR
GlaxoSmithKline
2010 Phase 3 NCT01536574 China;
Rajesh Pahwa, MD
2006 Phase 3 NCT00275275 United States;
Requip XL prolonged-release
University Hospital of North Staffordshire
2013 Phase 4 EUCTR2012-000801-64-GB United Kingdom;
Requip prolonged release
University Hospital of North Staffordshire
2013 Phase 4 EUCTR2012-000801-64-GB United Kingdom;
Requip-Modutab
GlaxoSmithKline Research & Development Limited
2007 - EUCTR2006-006209-94-DE Germany;
Resistant maltodextrin
Northwestern University
2018 Phase 2 NCT03667404 United States;
Resistant starch
Saarland University
2016 - NCT02784145 Germany;
Resistive respiratory loads
University of Florida
2017 - NCT03321019 United States;
Restex Tabletten
BIAL-Portela & Ca, SA
2009 - EUCTR2009-012897-12-RO Romania;
Rifampicin
Kyowa Kirin Co., Ltd.
2019 Phase 1 NCT04070495 Japan;
Rifampin 300mg BID + istradefylline 40mg Day 8 only
Kyowa Hakko Kirin Pharma, Inc.
2014 Phase 1 NCT02174250 United States;
Rifaximin
Mayo Clinic
2012 Phase 3 NCT01662791 United States;
Taipei Medical University Shuang Ho Hospital
2019 Phase 1/Phase 2 NCT03958708 Taiwan;
University of California, San Francisco
2019 Phase 1/Phase 2 NCT03575195 United States;
University of Cincinnati
2015 Phase 2/Phase 3 NCT02470780 United States;
Ritalin
University Medical Center Groningen
2010 - EUCTR2009-012643-42-NL Netherlands;
Rituximab
Prevail Therapeutics
2020 Phase 1/Phase 2 NCT04127578 Israel;United States;
Rivastigmin Luye Transdermal Patches - 4.6mg/24h
University of Bristol
2019 Phase 3 EUCTR2018-003219-23-GB United Kingdom;
Rivastigmine
NOVARTIS FARMA
2008 - EUCTR2007-000350-31-IT France;Italy;Spain;
Novartis Farmacéutica S.A
2008 Phase 3 EUCTR2007-000350-31-ES France;Italy;Spain;
Novartis Pharma AG
2008 - EUCTR2007-000350-31-FR France;Italy;Spain;
Research and Enterprise Department
2012 Phase 2 EUCTR2011-003053-25-GB United Kingdom;
University Hospital, Lille
2009 Phase 3 NCT00767091 France;
VU University Medical Center
2013 Phase 4 NCT01856738 Netherlands;
Rivastigmine CF
VU University Medical Center
2013 Phase 4 EUCTR2013-001722-25-NL Netherlands;
Rivastigmine Luye Transdermal Patch- 9.5mg/24h
University of Bristol
2019 Phase 3 EUCTR2018-003219-23-GB United Kingdom;
Rivastigmine Patch 9.5 cm2
University of California, San Francisco
2010 Phase 4 NCT00988117 United States;
Rivastigmine Transdermal System
University of Bristol
2020 Phase 3 NCT04226248 United Kingdom;
Rivastigmine capsule
Novartis
2008 Phase 3 NCT00623103 Argentina;Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Turkey;United Kingdom;United States;
Rivastigmine transdermal patch
Novartis
2008 Phase 3 NCT00623103 Argentina;Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Turkey;United Kingdom;United States;
University of Maryland, Baltimore
2019 Phase 4 NCT03840837 United States;
Rivastigmine transdermal system 13.3 mg/24 h
University of Bristol
2019 Phase 3 EUCTR2018-003219-23-GB United Kingdom;
Ropinirole
CHU de Toulouse
2009 - EUCTR2009-012529-12-FR France;
GlaxoSmithKline
2010 Phase 1 NCT01435915 China;
2007 Phase 2 NCT00460148 Germany;South Africa;
2003 Phase 3 NCT00381472 Belgium;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
GlaxoSmithKline Research & Development Limited
2007 - EUCTR2006-006209-94-DE Germany;
Kansai Medical University
2010 - JPRN-UMIN000003601 Japan;
Otsuka Pharmaceutical Co., Ltd.
2009 Phase 3 NCT01628926 Japan;
2009 Phase 3 JPRN-JapicCTI-090888 -
Pfizer
2001 Phase 3 NCT00036218 Argentina;Mexico;Puerto Rico;United States;
SCHWARZ PHARMA
2004 - EUCTR2004-002609-66-IT Germany;Italy;
Schwarz Biosciences GmbH
2004 - EUCTR2004-002609-66-DE Germany;Italy;
UNIVERSITA` DEGLI STUDI DI PARMA
2009 - EUCTR2009-013004-31-IT Italy;
Ropinirole (as hydrochloride)
University Hospital of North Staffordshire
2013 Phase 4 EUCTR2012-000801-64-GB United Kingdom;
Ropinirole CR 2mg tablet
GlaxoSmithKline
2013 Phase 3 NCT01929317 Japan;
Ropinirole CR 8mg tablet
GlaxoSmithKline
2013 Phase 3 NCT01929317 Japan;
Ropinirole Hydrochloride
Agarwal, Pinky, M.D.
2005 Phase 3 NCT00260793 United States;
Roxane Laboratories
2004 - NCT00674310 -
2004 - NCT00673088 -
Ropinirole IR
GlaxoSmithKline
2009 Phase 3 NCT00823836 Japan;
Ropinirole IR Tablets
GlaxoSmithKline
2006 Phase 3 EUCTR2005-005423-34-ES Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
GlaxoSmithKline Research & Development Ltd
2006 Phase 3 EUCTR2005-005423-34-GB Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-005423-34-HU Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-005423-34-DE Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-005423-34-CZ Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
Ropinirole Implant
Titan Pharmaceuticals
2017 Phase 1/Phase 2 NCT03250117 United States;
Ropinirole PR,
GlaxoSmithKline Research & Development Limited
2013 - EUCTR2011-002828-41-SK Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States;
2013 - EUCTR2011-002828-41-EE Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States;
2013 - EUCTR2011-002827-17-SK Estonia;Korea, Republic of;Russian Federation;Slovakia;United States;
2013 - EUCTR2011-002827-17-EE Estonia;Korea, Republic of;Russian Federation;Slovakia;United States;
Ropinirole PR/XR
GlaxoSmithKline
2009 Phase 3 NCT00823836 Japan;
Ropinirole PR/XR Tablets
GlaxoSmithKline
2006 Phase 3 EUCTR2005-005423-34-ES Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
GlaxoSmithKline Research & Development Ltd
2006 Phase 3 EUCTR2005-005423-34-GB Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-005423-34-HU Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-005423-34-DE Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-005423-34-CZ Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
Ropinirole PR/XR tablets
GlaxoSmithKline R D
2006 - EUCTR2005-005423-34-IT Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
Ropinirole Prolonged release
Seoul National University Hospital
2009 Phase 4 NCT00986245 Korea, Republic of;
Ropinirole XL
GlaxoSmithKline
2009 Phase 1 NCT01371682 Belgium;
Ropinirole XL (formerly CR)
GlaxoSmithKline
2004 Phase 3 NCT00632736 Belgium;Czech Republic;France;Germany;Hungary;Italy;Philippines;Poland;Spain;United Kingdom;United States;
2002 Phase 3 NCT00650104 Belgium;France;Netherlands;Norway;United States;
Ropinirole controlled-release (REQUIP CR) for RLS
GlaxoSmithKline
2003 Phase 3 NCT00363727 United States;
Ropinirole hydrochloride
GlaxoSmithKline
2006 Phase 3 EUCTR2005-005423-34-ES Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
GlaxoSmithKline Research & Development Ltd
2006 Phase 3 EUCTR2005-005423-34-GB Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-005423-34-HU Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-005423-34-DE Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-005423-34-CZ Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
Ropinirole hydrochloride extended-release tablet placebo
Hisamitsu Pharmaceutical Co.,Inc.
2015 Phase 3 JPRN-JapicCTI-152870 -
Ropinirole hydrochloride prolonged release
University Hospital of North Staffordshire
2013 Phase 4 EUCTR2012-000801-64-GB United Kingdom;
Ropinirole immediate release
GlaxoSmithKline
2006 Phase 3 NCT00331149 Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
Ropinirole monotherapy
GlaxoSmithKline
2012 Phase 4 NCT01485172 Estonia;Korea, Republic of;Poland;Russian Federation;Slovakia;United States;
Ropinirole oral product
Titan Pharmaceuticals
2017 Phase 1/Phase 2 NCT03250117 United States;
Ropinirole prolonged release
GlaxoSmithKline
2006 Phase 3 NCT00331149 Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
Ropinirole prolonged release/extended release(PR/XR)
GlaxoSmithKline
2007 Phase 2 NCT00434304 Japan;
Ropinirole/L-dopa
GlaxoSmithKline
2012 Phase 4 NCT01494532 Argentina;Chile;Estonia;Korea, Republic of;Poland;Russian Federation;Slovakia;United States;
Rosuvastatin
Kyowa Kirin Co., Ltd.
2019 Phase 1 NCT03970798 Japan;
Rotigotin
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2011 - EUCTR2010-022363-35-DE Germany;
Rotigotina
FONDAZIONE SANTA LUCIA
2012 - EUCTR2012-001218-40-IT Italy;
Rotigotine
Azienda Ospedaliera Cardinale G. Panico
2013 Phase 2 NCT02103465 Italy;
Department of Neurology, Changzheng Hospital, Second Military Medical University
2016 - ChiCTR-CPC-15007223 China;
Ospedale Generale Di Zona Moriggia-Pelascini
2013 - NCT02100176 Italy;
Research and Development University Hospital of North Staffordshire
2014 - EUCTR2014-000335-17-GB United Kingdom;
SCHWARZ BIOSCIENCES
2005 Phase 3 EUCTR2004-002650-59-GB United Kingdom;
SCHWARZ PHARMA
2007 - EUCTR2006-006907-35-IT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2004 - EUCTR2004-002609-66-IT Germany;Italy;
2004 - EUCTR2004-000148-26-IT Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
SCHWARZ PHARMA Deutschland GmbH
2007 - EUCTR2006-005438-19-DE Germany;
Schwarz BioSciences Inc.
2008 - EUCTR2004-000148-26-HU Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2008 - EUCTR2004-000148-26-AT Austria;Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 Phase 3 EUCTR2004-000148-26-ES Austria;Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 - EUCTR2004-000148-26-SE Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 - EUCTR2004-000148-26-FI Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 - EUCTR2004-000148-26-CZ Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
Schwarz Biosciences GmbH
2008 - EUCTR2006-006752-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006907-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-002641-12-GB Austria;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-002641-12-ES Austria;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-002598-21-GB Austria;United Kingdom;
2005 - EUCTR2004-002641-12-AT Austria;Italy;Spain;United Kingdom;
2004 - EUCTR2004-002609-66-DE Germany;Italy;
2004 - EUCTR2004-002598-21-AT Austria;United Kingdom;
- - EUCTR2006-006907-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006907-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Shandong Luye Pharmaceutical Co., Ltd./CMIC Co., Ltd.
2019 Phase 1 JPRN-JapicCTI-194763 Japan;
UCB BIOSCIENCES GmbH
2013 Phase 4 NCT01782222 Austria;Hungary;Poland;Slovakia;Slovenia;Spain;United States;
2012 Phase 4 NCT01744496 Germany;Hungary;Korea, Republic of;Poland;Slovakia;United States;
2012 Phase 4 NCT01711866 Korea, Republic of;Malaysia;Singapore;Taiwan;United States;
2012 Phase 3 NCT01723904 Australia;Korea, Republic of;Malaysia;Singapore;Taiwan;
UCB Korea Co., Ltd.
2012 Phase 4 NCT01523301 Korea, Republic of;
UCB Pharma
2012 Phase 3 NCT01646268 China;
2012 Phase 3 NCT01646255 China;
2012 Phase 3 NCT01536015 United States;
2011 Phase 4 NCT01300819 Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Hungary;Italy;Romania;Slovakia;Spain;Switzerland;
2007 Phase 4 NCT00594464 Germany;
2007 Phase 3 NCT00593606 -
2007 Phase 3 NCT00522379 Chile;India;Mexico;Peru;United States;
2007 Phase 3 NCT00519532 Australia;Austria;Finland;Germany;Hungary;Italy;New Zealand;Poland;South Africa;Spain;United Kingdom;United States;
2007 Phase 3 NCT00474058 Australia;Austria;Finland;Germany;Hungary;Italy;New Zealand;Poland;South Africa;Spain;United Kingdom;United States;
2006 Phase 1 NCT01964573 Korea, Republic of;
2006 Phase 1 NCT00292227 South Africa;
2005 Phase 3 NCT00505687 Austria;Germany;Israel;Italy;South Africa;Spain;United Kingdom;United States;
2004 Phase 3 NCT00501969 Australia;Austria;Croatia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;New Zealand;Norway;Poland;South Africa;Spain;Sweden;United Kingdom;
2004 Phase 3 NCT00243945 Germany;
2004 Phase 3 NCT00242008 United States;
2002 Phase 3 NCT00599196 Australia;Austria;Belgium;Croatia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;South Africa;Spain;Sweden;Switzerland;United Kingdom;
2002 Phase 3 NCT00594386 Canada;United States;
2002 Phase 3 NCT00594165 Canada;United States;
UCB Pharma SA
2012 Phase 4 NCT01519882 United Kingdom;
2011 - EUCTR2010-021394-37-IT Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;
Unità Malattie Neurodegenerative, Ospedale Cardinale Giovanni Panico, Tricase
2013 - EUCTR2013-000827-15-IT Italy;
University Hospital, Grenoble
2012 Phase 3 NCT02786667 France;
Wakayama Medical University
2018 Phase 1 JPRN-UMIN000033409 Japan;
Rotigotine (Reference product PR 2.1.1)
UCB BIOSCIENCES GmbH
2014 Phase 1 NCT02230904 Germany;
Rotigotine (Test product PR 2.3.1)
UCB BIOSCIENCES GmbH
2014 Phase 1 NCT02230904 Germany;
Rotigotine Nasal Spray
Schwarz Biosciences GmbH
2006 Phase 2 EUCTR2005-004290-19-GB Austria;Germany;Spain;United Kingdom;
2006 - EUCTR2005-004290-19-DE Germany;Spain;United Kingdom;
2005 - EUCTR2005-004290-19-AT Austria;Germany;Spain;United Kingdom;
Rotigotine TTS (Test)
Sandoz
2019 Phase 1 NCT04183634 Germany;
Rotigotine hydrochloride
Schwarz Biosciences GmbH
2006 Phase 2 EUCTR2005-004290-19-GB Austria;Germany;Spain;United Kingdom;
2006 - EUCTR2005-004290-19-DE Germany;Spain;United Kingdom;
2005 - EUCTR2005-004290-19-AT Austria;Germany;Spain;United Kingdom;
Rotigotine nasal spray
UCB Pharma
2006 Phase 2 NCT00296192 Germany;
Rotigotine transdermal patch
Johns Hopkins University
2016 Phase 4 NCT02365870 United States;
UCB Pharma
2011 Phase 1 NCT01338896 Austria;Germany;United Kingdom;
Rotigotine transdermal patch 2mg/24h(10cm2)
Schwarz Pharma Deutschland GmbH, UCB Group
- - EUCTR2009-014341-84-DE Germany;
Rotigotine transdermal patch 4mg/24h (20cm2)
Schwarz Pharma Deutschland GmbH, UCB Group
- - EUCTR2009-014341-84-DE Germany;
Rotigotine transdermal patch 6mg/24h (30cm2)
Schwarz Pharma Deutschland GmbH, UCB Group
- - EUCTR2009-014341-84-DE Germany;
Rotigotine transdermal patch 8mg/24h (40cm2)
Schwarz Pharma Deutschland GmbH, UCB Group
- - EUCTR2009-014341-84-DE Germany;
Rotigotine, extended-release microspheres
Luye Pharma Group Ltd.
2013 Phase 1 NCT04044547 -
Rytary
Impax Laboratories, LLC
2015 Phase 2 NCT02271503 United States;
S 90049
Institut de Recherches Internationales Servier (I.R.I.S.)
2005 - EUCTR2005-002010-38-DE Germany;
S 90049 - F36
Institut de Recherches Internationales Servier
2005 Phase 2 EUCTR2005-000314-12-ES Germany;Spain;
S 90049 - F38
Institut de Recherches Internationales Servier
2005 Phase 2 EUCTR2005-000314-12-ES Germany;Spain;
S.c. apomorphine
SUNOVION PHARMACEUTICALS INC
2018 Phase 3 EUCTR2016-003456-70-IT Austria;France;Germany;Italy;Spain;United Kingdom;
Sunovion Pharmaceuticals Inc.
2018 Phase 3 EUCTR2016-003456-70-ES Austria;Spain;United Kingdom;
2018 Phase 3 EUCTR2016-003456-70-DE Austria;France;Germany;Italy;Spain;United Kingdom;
2018 Phase 3 EUCTR2016-003456-70-AT Austria;France;Germany;Italy;Spain;United Kingdom;
2017 Phase 3 EUCTR2016-003456-70-GB Austria;France;Germany;Italy;Spain;United Kingdom;
S90049
Institut de Recherches Internationales Servier
2006 Phase 2 EUCTR2005-000314-12-DE Germany;Spain;
SA
HKBU School of Chinese Medicine
2017 - ChiCTR-IPR-17011987 China;
SAFINAMIDE METANSOLFONATO
OSPEDALE SANTA MARIA DELLA MISERICORDIA
2021 Phase 3 EUCTR2018-004892-11-IT Italy;
ZAMBON SPA
2019 Phase 4 EUCTR2017-002426-20-IT Austria;France;Germany;Italy;Spain;
2015 Phase 3 EUCTR2014-002600-24-IT Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
SAFINAMIDE METHANESULFONATE
ZAMBON SPA
2019 Phase 4 EUCTR2017-002426-20-IT Austria;France;Germany;Italy;Spain;
Zambon SpA
2019 Phase 4 EUCTR2017-002426-20-FR Austria;France;Spain;
2019 Phase 4 EUCTR2017-002426-20-AT Austria;Spain;
2018 Phase 4 EUCTR2017-002426-20-ES Spain;
SAGE-217
Sage Therapeutics
2016 Phase 2 NCT03000569 United States;
SAGE-718
Sage Therapeutics
2020 Phase 2 NCT04476017 United States;
SAM
Shenzhen People's Hospital
2017 - ChiCTR1800019216 China;
University of Valencia
2020 - NCT04353947 Spain;
SAM-e
New York University School of Medicine
2003 Phase 2/Phase 3 NCT00070941 United States;
SAR402671, GZ402671 or GZ/SAR402671
Genzyme Corporation
2019 Phase 2 EUCTR2016-000657-12-GR Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2016-000657-12-AT Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000657-12-PT Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000657-12-IT Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000657-12-DE Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000657-12-SE Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000657-12-ES Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
SCH 420814
Merck Sharp & Dohme Corp.
2009 Phase 1 NCT00845000 United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
2011 - EUCTR2009-015161-31-DE Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
2011 Phase 3 EUCTR2009-013552-72-GB Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015162-57-PT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015161-31-PT Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2011 Phase 3 EUCTR2009-015162-57-GB Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-BG Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015161-31-GB Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015161-31-BG Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-013552-72-BG Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
- - EUCTR2009-013552-72-DE Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Merck Sharp & Dohme corp.
2011 Phase 3 EUCTR2009-015162-57-NL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Schering Corporation, división Schering-Plough Research
2010 Phase 3 EUCTR2009-013552-72-ES Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
Schering Plough Research Institute
2007 - EUCTR2007-001717-42-FR France;Spain;
2006 - EUCTR2005-005146-39-IT Italy;
Schering-Plough Research Institute, a division of Schering Corporation
2011 Phase 3 EUCTR2009-015162-57-LV Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-LT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-FI Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-ES Austria;Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2011 Phase 3 EUCTR2009-015162-57-CZ Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-013552-72-CZ Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2010-020112-11-LV Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States;
2011 - EUCTR2010-020112-11-LT Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States;
2011 - EUCTR2009-015162-57-SE Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-PL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-AT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015161-31-PL Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015161-31-CZ Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-013552-72-PL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 Phase 3 EUCTR2009-015161-31-FR Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2009-013552-72-HU Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2009-013552-72-FI Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-SE Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-NL Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-FI Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-AT Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-013552-72-SE Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
SCH 900800
Merck Sharp & Dohme Corp.
2013 Phase 1 NCT01500707 -
SCH420814
Schering-Plough Research Institute, a division of Schering Corporation
2010 Phase 3 EUCTR2009-015161-31-IT Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2010 - EUCTR2009-013552-72-IT Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
Schering-Plough Research Institute, division of Schering Corporation
2011 - EUCTR2009-015162-57-IT Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
SEP-363856
Sunovion
2016 Phase 2 NCT02969369 United States;
SER-214
Serina Therapeutics
2016 Phase 1 NCT02579473 United States;
SIFROL
Boehringer Ingelheim AB
2007 - EUCTR2007-000074-23-SE Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Limited
2007 - EUCTR2007-000074-23-GB Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Pharma Ges mbH
2007 Phase 3 EUCTR2007-000074-23-SK Austria;Czech Republic;Hungary;Italy;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-000074-23-HU Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Pharma GmbH & Co. KG
2007 - EUCTR2007-000074-23-AT Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim RCV GmbH & Co KG
2007 Phase 3 EUCTR2007-000074-23-CZ Austria;Czech Republic;Hungary;Italy;Spain;Sweden;United Kingdom;
SINEMET
EISAI LTD UK
2007 - EUCTR2006-005714-12-IT Italy;
Institute for Neurodegenerative Disorders
2005 - EUCTR2004-001485-41-ES Spain;United Kingdom;
SINEMET - 100 MG + 25 MG COMPRESSE 50 COMPRESSE DIVISIBILI
INTEC PHARMA LTD
2018 Phase 2 EUCTR2018-001209-95-IT Italy;Spain;
SINEMET 10-100
Intec Pharma, Ltd.
2016 Phase 3 EUCTR2015-003512-20-SK Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-HU Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-ES Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
SINEMET 100 mg + 25 mg compresse
BIAL-Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-002754-24-IT Germany;Italy;Portugal;Spain;United Kingdom;
SynAgile Corporation
2014 Phase 2 EUCTR2014-002295-87-IT Italy;
SINEMET 100 mg + 25 mg tablets
BIAL-Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-002754-24-IT Germany;Italy;Portugal;Spain;United Kingdom;
Bial - Portela & Ca, S.A.
2022 Phase 4 EUCTR2020-002754-24-DE Germany;Italy;Portugal;Spain;United Kingdom;
2021 Phase 4 EUCTR2020-002754-24-ES Germany;Italy;Portugal;Spain;United Kingdom;
SINEMET 125
Centre for Human Drug Research
2020 Phase 2 EUCTR2020-000686-16-NL Netherlands;
SINEMET 25-100
INTEC PHARMA LTD
2016 Phase 3 EUCTR2015-003512-20-IT Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Intec Pharma, Ltd.
2016 Phase 3 EUCTR2015-003512-20-SK Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-PL Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-HU Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-GB Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-ES Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
SINEMET 25/100
BIAL-Portela & Ca, SA
2009 - EUCTR2009-012897-12-RO Romania;
Bial - Portela & Cª, S.A.
2008 - EUCTR2008-003869-72-PT Portugal;
SINEMET CR
Novartis Pharma AG
2006 - EUCTR2005-001032-72-CZ Czech Republic;Italy;Portugal;
SINEMET Plus
NEURODERM LTD.
2018 Phase 3 EUCTR2017-002780-17-IT Austria;France;Italy;Netherlands;Spain;United States;
NeuroDerm Ltd.
2018 Phase 3 EUCTR2017-002780-17-FR Austria;France;Italy;Netherlands;Spain;United States;
2018 Phase 3 EUCTR2017-002780-17-ES Austria;France;Italy;Netherlands;Spain;United States;
SINEMET*50CPR 100MG+
VERNALIS DEVELOPMENT LIMITED
2006 - EUCTR2006-004112-51-IT Italy;
SINEMET® Plus 25 mg/100 mg Tablets
Civitas Therapeutics, Inc.
2012 - EUCTR2012-000181-37-GB Israel;Serbia;United Kingdom;
SINEMET®-Plus Tablets
Impax Laboratories, Inc.
2010 - EUCTR2009-014688-37-PL France;Germany;Poland;Spain;
2009 Phase 3 EUCTR2009-014688-37-FR France;Germany;Poland;Spain;
2009 - EUCTR2009-014688-37-DE France;Germany;Poland;Spain;
SIRIO*30CPR EFF 25MG+
VERNALIS DEVELOPMENT LIMITED
2006 - EUCTR2006-004112-51-IT Italy;
SK&F101468
GlaxoSmithKline Research & Development Limited
2013 - EUCTR2011-002828-41-SK Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States;
2013 - EUCTR2011-002828-41-EE Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States;
2013 - EUCTR2011-002827-17-SK Estonia;Korea, Republic of;Russian Federation;Slovakia;United States;
2013 - EUCTR2011-002827-17-EE Estonia;Korea, Republic of;Russian Federation;Slovakia;United States;
2007 - EUCTR2006-006209-94-DE Germany;
SKF-101468A
GlaxoSmithKline R D
2006 - EUCTR2005-005423-34-IT Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
SLV308
SOLVAY PHARMACEUTICALS B.V.
2009 - EUCTR2008-000400-81-IT Germany;Italy;Portugal;
Solvay Pharmaceuticals
2009 Phase 3 EUCTR2007-001095-36-SK Hungary;Slovakia;
2008 Phase 3 EUCTR2007-001096-10-SK Hungary;Slovakia;
2008 - EUCTR2007-001096-10-HU Hungary;
2008 - EUCTR2007-001095-36-HU Hungary;
2005 Phase 3 NCT00134251 Bulgaria;Former Serbia and Montenegro;Malta;Serbia;
SLV308 (mono) hydro
Solvay pharmaceuticals
2006 Phase 3 EUCTR2006-000678-57-GB Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
SLV308 (mono) hydrochlo
Solvay Pharmaceuticals
2006 Phase 3 EUCTR2006-000858-45-SK Finland;Slovakia;Sweden;
SLV308 (mono) hydrochlori
Solvay Pharmaceuticals
2006 - EUCTR2006-000859-18-CZ Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
Solvay pharmaceuticals
2007 - EUCTR2006-000859-18-PT Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
2007 - EUCTR2006-000859-18-NL Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
2007 - EUCTR2006-000678-57-CZ Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
2006 - EUCTR2006-000859-18-LT Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
2006 - EUCTR2006-000859-18-EE Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
2006 - EUCTR2006-000678-57-NL Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
2006 - EUCTR2006-000678-57-LT Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
2006 - EUCTR2006-000678-57-EE Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
2006 - EUCTR2006-000678-57-DE Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
Solvay pharmaceuticals B.V.
2006 - EUCTR2006-000678-57-PT Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
SLV308 (mono) hydrochloride
Solvay Pharmaceuticals
2007 - EUCTR2006-000858-45-SE Finland;Sweden;
2006 Phase 3 EUCTR2006-000858-45-SK Finland;Slovakia;Sweden;
2006 - EUCTR2006-000859-18-CZ Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
2006 - EUCTR2006-000858-45-FI Finland;Sweden;
2006 - EUCTR2005-006033-32-SK Finland;Slovakia;Sweden;
2006 - EUCTR2005-006033-32-SE Finland;Slovakia;Sweden;
2006 - EUCTR2005-006033-32-FI Finland;Slovakia;Sweden;
2005 - EUCTR2005-002432-10-MT Malta;
Solvay pharmaceuticals
2007 Phase 3 EUCTR2006-000678-57-FR Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
2007 - EUCTR2006-000859-18-PT Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
2007 - EUCTR2006-000859-18-NL Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
2007 - EUCTR2006-000859-18-DE Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
2007 - EUCTR2006-000678-57-CZ Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
2006 Phase 3 EUCTR2006-000678-57-GB Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
2006 - EUCTR2006-000859-18-LT Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
2006 - EUCTR2006-000859-18-EE Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
2006 - EUCTR2006-000678-57-NL Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
2006 - EUCTR2006-000678-57-LT Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
2006 - EUCTR2006-000678-57-EE Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
2006 - EUCTR2006-000678-57-DE Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
Solvay pharmaceuticals B.V.
2006 - EUCTR2006-000678-57-PT Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
SLV308 (mono)hydrochloride
SOLVAY PHARMACEUTICALS B.V.
2006 - EUCTR2006-000678-57-IT Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
SLV308 hydrochloride
Abbott Healthcare Products B.V.
2009 - EUCTR2008-000400-81-DE Germany;Italy;Portugal;
Solvay Pharmaceuticals B.V.
2008 Phase 2 EUCTR2008-004943-12-SK Slovakia;
Solvay Pharmaceuticals BV
2009 - EUCTR2008-000400-81-PT Germany;Italy;Portugal;
SLV308(mono)hydrochloride
Solvay Pharmaceuticals
2007 - EUCTR2006-005183-91-LV Latvia;Lithuania;
2007 - EUCTR2006-005183-91-LT Latvia;Lithuania;
2007 - EUCTR2006-005182-20-LV Latvia;Lithuania;
2007 - EUCTR2006-005182-20-LT Latvia;Lithuania;
SND 919 CL2 Y
BOEHRINGER INGELHEIM
2008 Phase 3 EUCTR2007-004234-16-FR Austria;Czech Republic;Finland;France;Hungary;Netherlands;Slovakia;
2007 Phase 3 EUCTR2007-003353-90-FR France;Germany;Netherlands;
Boehringer Ingelheim
2008 - EUCTR2007-004235-37-GB Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-003353-90-NL France;Germany;Netherlands;
2006 Phase 4 EUCTR2005-004949-34-FI Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim AB
2008 - EUCTR2007-004235-37-SE Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2006 Phase 4 EUCTR2005-004949-34-SE Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003788-22-SE Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Austria GmbH
2006 - EUCTR2005-004949-34-AT Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003788-22-AT Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim España S.A.
2006 Phase 4 EUCTR2005-003788-22-ES Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim España, S.A.
2008 Phase 3 EUCTR2007-004235-37-ES Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004949-34-ES Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Finland Ky
2008 - EUCTR2007-004234-16-FI Austria;Czech Republic;Finland;France;Hungary;Netherlands;
2007 - EUCTR2007-000073-39-FI Austria;Czech Republic;Finland;Hungary;
Boehringer Ingelheim Limited
2006 Phase 4 EUCTR2005-003788-22-GB Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Ltd
2006 Phase 4 EUCTR2005-004949-34-GB Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Pharma Ges mbH
2008 Phase 3 EUCTR2007-004235-37-HU Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-004235-37-PL Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-004235-37-CZ Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-004234-16-HU Austria;Czech Republic;Finland;France;Hungary;Netherlands;
2007 Phase 3 EUCTR2007-000073-39-SK Austria;Czech Republic;Finland;Germany;Hungary;Slovakia;
2007 - EUCTR2007-000073-39-HU Austria;Czech Republic;Finland;Hungary;
2007 - EUCTR2007-000073-39-AT Austria;Czech Republic;Finland;Hungary;
Boehringer Ingelheim Pharma GmbH & Co. KG
2007 - EUCTR2007-003353-90-DE France;Germany;Netherlands;
2007 - EUCTR2007-000073-39-DE Austria;Czech Republic;Finland;Germany;Hungary;
2006 - EUCTR2005-004949-34-DE Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003788-22-DE Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim RCV GmbH & Co KG
2009 - EUCTR2007-004235-37-AT Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2009 - EUCTR2007-004234-16-AT Austria;Czech Republic;Finland;France;Hungary;Netherlands;
2008 Phase 3 EUCTR2007-004235-37-SK Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom;
2008 Phase 3 EUCTR2007-004234-16-SK Austria;Czech Republic;Finland;France;Hungary;Netherlands;Slovakia;
2008 - EUCTR2007-004234-16-CZ Austria;Czech Republic;Finland;France;Hungary;Netherlands;
2007 - EUCTR2007-000073-39-CZ Austria;Czech Republic;Finland;Hungary;
Boehringer Ingelheim bv
2007 - EUCTR2007-004234-16-NL Austria;Czech Republic;Finland;France;Hungary;Netherlands;
SND 919 CL2Y
BOEHRINGER ING.
2008 - EUCTR2007-004235-37-IT Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-000074-23-IT Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim AB
2007 - EUCTR2007-000074-23-SE Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim España, S.A.
2007 Phase 3 EUCTR2007-000074-23-ES Austria;Czech Republic;Hungary;Italy;Slovakia;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Limited
2007 - EUCTR2007-000074-23-GB Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Pharma Ges mbH
2007 Phase 3 EUCTR2007-000074-23-SK Austria;Czech Republic;Hungary;Italy;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-000074-23-HU Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Pharma GmbH & Co. KG
2007 - EUCTR2007-000074-23-AT Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim RCV GmbH & Co KG
2007 Phase 3 EUCTR2007-000074-23-CZ Austria;Czech Republic;Hungary;Italy;Spain;Sweden;United Kingdom;
SNN0031
NeuroNova AB
2009 - EUCTR2007-007853-30-SE Sweden;
Newron Sweden AB
2013 Phase 1 NCT01829867 Sweden;
2009 Phase 1/Phase 2 NCT00866502 Sweden;
SOLIGEN
Institute for Neurodegenerative Disorders
2005 - EUCTR2004-001485-41-ES Spain;United Kingdom;
SPECT
Zionexa
2021 Phase 3 NCT04265209 -
SPECT imaging
Tel-Aviv Sourasky Medical Center
2013 Phase 2 NCT01931488 Israel;
SPM 926
SCHWARZ PHARMA
2004 - EUCTR2004-002609-66-IT Germany;Italy;
SPM 962
Otsuka Pharmaceutical Co., Ltd.
2009 Phase 3 NCT01631825 Japan;
2009 Phase 3 NCT01628926 Japan;
2009 Phase 3 JPRN-JapicCTI-090888 -
2008 Phase 2/Phase 3 NCT01628965 Japan;
2007 Phase 2/Phase 3 NCT00537485 Japan;
2006 Phase 2 NCT01631812 Japan;
2006 Phase 2 NCT01628848 Japan;
2005 Phase 2 NCT01634243 Japan;
SCHWARZ BIOSCIENCES
2005 Phase 3 EUCTR2004-002650-59-GB United Kingdom;
SCHWARZ PHARMA
2004 - EUCTR2004-002609-66-IT Germany;Italy;
Schwarz BioSciences Inc.
2008 - EUCTR2004-000148-26-HU Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2008 - EUCTR2004-000148-26-AT Austria;Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 Phase 3 EUCTR2004-000148-26-ES Austria;Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 - EUCTR2004-000148-26-SE Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 - EUCTR2004-000148-26-FI Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 - EUCTR2004-000148-26-CZ Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
Schwarz Biosciences GmbH
2005 Phase 3 EUCTR2004-002641-12-GB Austria;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-002641-12-ES Austria;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-002598-21-GB Austria;United Kingdom;
2005 - EUCTR2004-002641-12-AT Austria;Italy;Spain;United Kingdom;
2004 - EUCTR2004-002598-21-AT Austria;United Kingdom;
UCB Pharma
2004 Phase 3 NCT00244387 Germany;
2004 Phase 3 NCT00243971 Germany;
SPM962
Schwarz Biosciences GmbH
2004 - EUCTR2004-002609-66-DE Germany;Italy;
Unità Malattie Neurodegenerative, Ospedale Cardinale Giovanni Panico, Tricase
2013 - EUCTR2013-000827-15-IT Italy;
SQJZ herbal mixtures
Dongzhimen Hospital, Beijing
2015 Phase 2 NCT02616120 China;
SR57667B
Sanofi
2004 Phase 2 NCT00220272 Canada;Finland;France;Netherlands;Spain;Switzerland;United Kingdom;
2003 Phase 2 NCT00228150 Austria;Canada;Denmark;France;Germany;Morocco;Netherlands;Portugal;South Africa;Spain;Sweden;Tunisia;United Kingdom;
STALEVO*100CPR 100/25/
AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
2010 - EUCTR2010-019396-29-IT Italy;
STALEVO*100CPR 50/12,5/
AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
2010 - EUCTR2010-019396-29-IT Italy;
SYN115
BIOTIE THERAPIES INC.
2015 Phase 3 EUCTR2014-005630-60-IT Austria;Canada;Czech Republic;Germany;Italy;Spain;United States;
Biotie Therapies Inc.
2015 Phase 3 EUCTR2014-005630-60-ES Austria;Canada;Czech Republic;European Union;Germany;Spain;United States;
Biotie Therapies Inc. (a wholly owned subsidiary of Acorda Therapeutics Inc.)
2015 Phase 3 EUCTR2014-005630-60-CZ Austria;Canada;Czech Republic;European Union;Germany;Spain;United States;
Biotie Therapies Inc.(a wholly owned subsidiary of Acorda Therapeutics Inc.)
2016 Phase 3 EUCTR2014-005630-60-AT Austria;Canada;Czech Republic;European Union;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-005630-60-DE Austria;Canada;Czech Republic;European Union;Germany;Spain;United States;
SYN115 Tablets,
Biotie Therapies Inc.
2012 - EUCTR2011-005054-59-RO Argentina;Canada;Chile;Romania;Ukraine;United States;
SYN120
Biotie Therapies Inc.
2014 Phase 2 NCT02258152 United States;
Safety observation
Amgen
2005 - NCT00148369 Canada;United Kingdom;United States;
Safinamida
Merck Serono S.A. - Geneva
2010 - EUCTR2010-020109-34-ES Italy;Spain;
Safinamide
Alain Kaelin
2019 Phase 4 NCT03968744 Switzerland;
IRCCS San Raffaele
2018 Phase 4 NCT03843944 Italy;
MERCK SERONO INTERNATIONAL SA
2008 Phase 3 EUCTR2007-002963-28-IT Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
MERCK SERONO SA
2009 Phase 3 EUCTR2008-004146-88-IT Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
2009 - EUCTR2008-002769-30-IT Italy;
Merck Serono International S.A.
2008 Phase 3 EUCTR2007-002963-28-ES Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
2008 - EUCTR2007-002964-90-ES Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2007 - EUCTR2007-002964-90-NL Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2007 - EUCTR2007-002964-90-FI Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Merck Serono S.A - Geneva
2008 Phase 3 EUCTR2007-002964-90-GB Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom;
Merck Serono S.A-Geneva
2009 - EUCTR2007-002963-28-PT Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
Merck Serono S.A. - Geneva
2011 - EUCTR2009-017174-20-AT Austria;Canada;France;Germany;South Africa;
2010 Phase 3 EUCTR2008-005492-94-BE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
2010 Phase 2 EUCTR2009-017174-20-FR Austria;France;Germany;
2010 - EUCTR2009-017174-20-DE Austria;Canada;France;Germany;South Africa;
2010 - EUCTR2008-005492-94-NL Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
2010 - EUCTR2007-002964-90-CZ Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-005492-94-SK Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-005492-94-GB Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-005492-94-FR Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-005492-94-ES Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
2009 - EUCTR2008-005492-94-HU Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 - EUCTR2007-002964-90-FR Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-002964-90-DE Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2007 Phase 3 EUCTR2007-002964-90-SK Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom;
2007 Phase 3 EUCTR2007-002963-28-SK Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
Merck Serono S.A.-Geneva
2008 - EUCTR2007-002964-90-HU Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Merck Serono SA - Geneva
2009 Phase 3 EUCTR2008-004146-88-SK Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
2009 Phase 3 EUCTR2008-004146-88-ES Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
2009 Phase 3 EUCTR2008-001966-10-SK Austria;Estonia;Hungary;Slovakia;United Kingdom;
2009 - EUCTR2008-004146-88-PT Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
2009 - EUCTR2008-004146-88-PL Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
2009 - EUCTR2008-001966-10-HU Austria;Estonia;Hungary;United Kingdom;
2009 - EUCTR2008-001966-10-GB Austria;Estonia;Hungary;United Kingdom;
2009 - EUCTR2008-001966-10-EE Austria;Estonia;Hungary;United Kingdom;
2009 - EUCTR2008-001966-10-AT Austria;Estonia;Hungary;United Kingdom;
NEWRON PHARMACEUTICALS
2007 - EUCTR2006-005861-21-IT Italy;
2006 - EUCTR2006-005860-14-IT Italy;
2004 - EUCTR2004-000835-27-IT Italy;Spain;
2004 - EUCTR2004-000833-12-IT Italy;Spain;
Newron
2011 Phase 2 NCT01264861 United States;
2010 Phase 2 NCT01211587 Spain;United States;
2010 Phase 2 NCT01113320 Austria;Canada;France;Germany;South Africa;
2009 Phase 3 NCT00865579 Romania;
2007 Phase 3 NCT01286935 -
2007 Phase 3 NCT01187966 -
2005 Phase 3 NCT00642889 -
2004 Phase 3 NCT00643045 -
Newron Pharmaceuticals
2011 - EUCTR2008-005492-94-PT Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2011 - EUCTR2008-005492-94-FI Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2011 - EUCTR2008-005492-94-CZ Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2011 - EUCTR2008-005492-94-BG Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2010 - EUCTR2008-004146-88-DE Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
2009 Phase 3 EUCTR2008-004146-88-BG Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
2009 - EUCTR2008-005492-94-EE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2009 - EUCTR2008-005492-94-AT Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2009 - EUCTR2008-004146-88-FI Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
2009 - EUCTR2008-004146-88-CZ Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
- - EUCTR2008-005492-94-DE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States;
Newron Pharmaceuticals S.P.A
2005 Phase 3 EUCTR2004-000835-27-ES Italy;Spain;
Newron Pharmaceuticals S.p.A.
2004 Phase 3 EUCTR2004-000833-12-ES Italy;Spain;
Newron Pharmaceuticals SpA
2011 Phase 3 EUCTR2007-002964-90-BE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Slovakia;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2010 - EUCTR2007-002963-28-DE Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States;
2009 - EUCTR2007-002964-90-AT Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2009 - EUCTR2007-002963-28-PL Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
2009 - EUCTR2007-002963-28-CZ Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States;
2009 - EUCTR2007-002963-28-BG Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States;
2008 - EUCTR2007-002964-90-EE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2007 - EUCTR2007-002963-28-FI Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Poland;Portugal;South Africa;Spain;United States;
Zambon SpA
2019 Phase 3 NCT03881371 China;
Safinamide (as add-on therapy)
Newron
2007 Phase 3 NCT00605683 Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Israel;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
Safinamide + Levodopa
Newron
2009 Phase 1/Phase 2 NCT01026428 Italy;
Safinamide Methanesulfonate
Zambon SpA
2019 Phase 4 NCT03841604 Austria;France;Germany;Italy;Spain;
2019 Phase 3 NCT03987750 -
Safinamide metansolfonato (12 weeks)
Universita di Verona
2018 - NCT03648671 Italy;
Safinamide methansulfonate
Zambon SpA
2019 Phase 4 EUCTR2017-002426-20-FR Austria;France;Spain;
2019 Phase 4 EUCTR2017-002426-20-AT Austria;Spain;
2018 Phase 4 EUCTR2017-002426-20-ES Spain;
Safinamide, MAO-B inhibitor
Newron
2009 Phase 3 NCT01028586 Switzerland;
Safinimide 50-100 mg/day
Newron
2009 Phase 3 NCT00627640 Australia;Austria;Belgium;Canada;Estonia;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Slovakia;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
Sage leaf
Newcastle Upon tyne Hospitals NHS Foundation Trust
2007 - EUCTR2007-002899-34-GB United Kingdom;
Saline
NeuroDerm Ltd.
2011 Phase 1/Phase 2 NCT01229332 Israel;
Yale University
2012 Phase 2 NCT02419313 United States;
Saline Intranasal Delivery
Bastyr University
2012 Phase 1 NCT01398748 United States;
Saracatinib
King's College London
2019 Early Phase 1 NCT03661125 United Kingdom;
Sarcosine Capsule
China Medical University Hospital
2010 - NCT01785628 Taiwan;
Sargramostim
Howard Gendelman, MD
2013 Phase 1 NCT01882010 United States;
University of Nebraska
2019 Phase 1 NCT03790670 United States;
Sarizotan
EMD Serono
2004 Phase 3 NCT00105508 United States;
Sarizotan HC1
EMD Serono
2004 Phase 3 NCT00105521 United States;
Sarizotan HCl
EMD Serono
2002 Phase 2 NCT00314288 Belgium;Bulgaria;Canada;France;Germany;Hungary;Portugal;Romania;South Africa;United Kingdom;United States;
Sarizotan Hydrochloride
MERCK KGaA
2004 Phase 3 EUCTR2004-001594-25-ES Austria;Finland;Spain;
Sarizotan hydrochloride
MERCK S.P.A.
2004 - EUCTR2004-001593-10-IT Italy;United Kingdom;
Merck KGaA
2005 Phase 3 EUCTR2005-000444-84-GB Austria;Finland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000444-84-ES Austria;Finland;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000444-84-FI Finland;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000444-84-AT Austria;Finland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-001594-25-AT Austria;Finland;Spain;
2004 - EUCTR2004-001594-25-FI Finland;Spain;
Sedation with IV propofol
Hadassah Medical Organization
2006 - NCT00355927 Israel;
Selegiline
Department of Neurology, Juntendo Koshigaya Hospital
2012 - JPRN-UMIN000008477 Japan;
FP Pharmaceutical Corp.
2012 Phase 2 JPRN-JapicCTI-122000 -
- Phase 3 JPRN-JapicCTI-121954 -
- Phase 2 JPRN-JapicCTI-101020 -
Institute of Psychology, Chinese Academy of Sciences
2018 - ChiCTR1800015331 China;
Ito Hidefumi
2016 Phase 2 JPRN-jRCTs051180098 Japan;
Longhua Hospital Shanghai University of Traditional Chinese Medicine
2018 - ChiCTR1800018017 China;
2018 - ChiCTR1800017949 China;
Osaka Redcross HospitalWakayama Prefectural Medical College
2016 Phase 2 JPRN-UMIN000022533 Japan;
Research and Development University Hospital of North Staffordshire
2014 - EUCTR2014-000335-17-GB United Kingdom;
Second Affiliated Hospital of Soochow University
2020 Phase 4 NCT04870372 China;
The Second Affiliated Hospital of Soochow University
2020 Phase 4 ChiCTR2100045946 China;
Union Medical College Affiliated Hospital of Tongji Medical College, Huazhong University of science and technology
2020 Phase 0 ChiCTR2000037828 China;
University of South Florida
2014 Phase 4 NCT02225548 United States;
Selegiline HCl 5 PCH
TEVA Pharmaceuticals Industries Ltd
2006 - EUCTR2006-005140-89-NL Netherlands;
Semaglutide
Oslo University Hospital
2019 Phase 2 NCT03659682 -
Semi continuous intra-oral administration of LD/CD
IRCCS San Raffaele
2015 Phase 2 NCT02763137 Italy;
Senfrol monotherapy
Peking University Third Hospital
2018 Phase 4 NCT04968613 China;
Seroquel
King’s College London & King’s College Hospital
2005 Phase 4 EUCTR2004-002608-13-GB United Kingdom;
Sertraline
National Cheng-Kung University Hospital
2015 Phase 1/Phase 2 NCT02917122 -
Zhejiang University
2011 - NCT01437189 China;
Sevoflurane
The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
2019 - ChiCTR1900026956 China;
Sham Surgery
Ceregene
2006 Phase 2 NCT00400634 United States;
Sangamo Therapeutics
2009 Phase 1/Phase 2 NCT00985517 United States;
Sham compression
Vanderbilt University Medical Center
2020 Early Phase 1 NCT04620382 United States;
Sham tDCS
National Cheng-Kung University Hospital
2015 Phase 1/Phase 2 NCT02917122 -
Sham tPCS
Western University, Canada
2019 - NCT04054960 Canada;
Sifol
Boehringer Ingelheim AB
2006 - EUCTR2005-003788-22-SE Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Austria GmbH
2006 - EUCTR2005-003788-22-AT Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim España S.A.
2006 Phase 4 EUCTR2005-003788-22-ES Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Limited
2006 Phase 4 EUCTR2005-003788-22-GB Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Sifrol
BOEHRINGER ING.
2007 - EUCTR2007-000074-23-IT Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim
2007 - EUCTR2007-003353-90-NL France;Germany;Netherlands;
2006 Phase 4 EUCTR2005-004949-34-FI Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim AB
2006 Phase 4 EUCTR2005-004949-34-SE Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003788-22-SE Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Austria GmbH
2006 - EUCTR2005-004949-34-AT Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003788-22-AT Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Limited
2006 Phase 4 EUCTR2005-003788-22-GB Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Ltd
2006 Phase 4 EUCTR2005-004949-34-GB Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Pharma GmbH & Co. KG
2007 - EUCTR2007-003353-90-DE France;Germany;Netherlands;
2006 - EUCTR2005-003788-22-DE Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Sifrol 0,088
Axxonis Pharma AG
2007 - EUCTR2006-003732-30-DE Germany;Italy;Poland;
NeuroBiotec Pharma AG
2008 - EUCTR2006-003732-30-PL Germany;Italy;Poland;
Sifrol 0,18
Axxonis Pharma AG
2007 - EUCTR2006-003732-30-DE Germany;Italy;Poland;
NeuroBiotec Pharma AG
2008 - EUCTR2006-003732-30-PL Germany;Italy;Poland;
Sifrol 0,35
Axxonis Pharma AG
2007 - EUCTR2006-003732-30-DE Germany;Italy;Poland;
NeuroBiotec Pharma AG
2008 - EUCTR2006-003732-30-PL Germany;Italy;Poland;
Sifrol 0,7
Axxonis Pharma AG
2007 - EUCTR2006-003732-30-DE Germany;Italy;Poland;
NeuroBiotec Pharma AG
2008 - EUCTR2006-003732-30-PL Germany;Italy;Poland;
Sifrol, 0,35 mg Tablette
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
Sifrol, 0,70 mg Tablette
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
Sifrol, Mirapexin
Boehringer Ingelheim España, S.A.
2006 - EUCTR2005-004949-34-ES Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Sifrol®
Boehringer Ingelheim
2002 - NCT02231255 -
2000 - NCT02231294 -
Sildenafil
Bispebjerg Hospital
2003 Phase 4 NCT01941732 Denmark;
Loma Linda University
2002 Phase 2 NCT02162979 United States;
Silodosin
Juntendo University School of Medicine
2012 - JPRN-UMIN000008138 Japan;
Simvastatin
Plymouth Hospitals NHS Trust
2015 Phase 3 EUCTR2015-000148-40-GB United Kingdom;
University Hospital Plymouth NHS Trust
2016 Phase 2 NCT02787590 United Kingdom;
Simvastatine
CHU de Bordeaux
2009 - EUCTR2009-011736-35-FR France;
Sinemet
Acorda Therapeutics
2019 Phase 1 NCT03887884 United States;
DR. REDDY’S LABORATORIES LIMITED
2017 Phase 2 EUCTR2017-000262-30-IT Italy;
Institut de Recerca del Hospital de la Santa Creu i Sant Pau
2007 - EUCTR2006-002408-32-ES Spain;
Institute for Neurodegenerative Disorders
2005 - EUCTR2004-001485-41-GB Spain;United Kingdom;
2005 - EUCTR2004-001485-41-AT Austria;Spain;United Kingdom;
NOVARTIS FARMA
2005 - EUCTR2005-001032-72-IT Czech Republic;Italy;Portugal;
2004 - EUCTR2004-000185-12-IT Finland;Italy;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA
2005 - EUCTR2004-005234-39-FI Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-FI Finland;Italy;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA, Finland
2005 Phase 4 EUCTR2004-005234-39-GB Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA, 02200 Espoo, Finland
2008 - EUCTR2004-005234-39-DE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2007 Phase 3 EUCTR2004-000185-12-GB Austria;Finland;Italy;Sweden;United Kingdom;
2006 - EUCTR2004-005234-39-LV Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2006 - EUCTR2004-005234-39-LT Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 Phase 4 EUCTR2004-005234-39-IE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-005234-39-SE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-005234-39-DK Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-SE Finland;Italy;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-AT Austria;Finland;Italy;Sweden;United Kingdom;
UMCG
2009 - EUCTR2008-006278-13-NL Netherlands;
Sinemet (carbidopa/levodopa)
Acorda Therapeutics
2012 Phase 2 NCT01617135 Israel;Serbia;United Kingdom;
Sinemet (comparator)
XenoPort, Inc.
2010 Phase 2 NCT01171313 United States;
Sinemet (levodopa/carbidopa)
Orion Corporation, Orion Pharma
2009 Phase 1 NCT01070628 Finland;
Sinemet 200mg/
Orion Corporation, Orion Pharma
2008 Phase 2 NCT00562198 Finland;
Sinemet 25-100 Oral Tablet
XenoPort, Inc.
2009 Phase 1/Phase 2 NCT00914602 United States;
Sinemet 25/100
Bial - Portela C S.A.
2001 Phase 1 NCT02763839 Portugal;
Sinemet CR
CombinatoRx, Inc
2008 - EUCTR2007-005033-11-DE Germany;
Huashan Hospital
2011 - NCT01470859 China;
McGill University Health Centre/Research Institute of the McGill University Health Centre
2017 Phase 4 NCT03111485 Canada;
Sinemet CR 25Mg-100Mg Extended-Release Tablet
Intec Pharma Ltd.
2018 Phase 2 NCT03576638 -
Sinemet IR
Depomed
2012 Phase 2 NCT01515410 United States;
Sinemet Plus
Institut de Recerca del Hospital de la Santa Creu i Sant Pau
2015 Phase 4 EUCTR2015-002631-17-ES Spain;
Sinemet plus (levodopa/carbidopa)
NOVARTIS FARMACEUTICA, S.A
2006 - EUCTR2006-000680-28-ES Spain;
Sinemet-Plus Tablets
Impax Laboratories, Inc.
2009 - EUCTR2009-014688-37-ES France;Germany;Poland;Spain;
Sinemet®
Acorda Therapeutics
2016 Phase 1 NCT02812394 United States;
Bial - Portela C S.A.
2005 Phase 2 NCT02834507 -
2005 Phase 1 NCT02774564 Portugal;
Civitas Therapeutics, Inc.
2012 - EUCTR2012-000181-37-GB Israel;Serbia;United Kingdom;
Intec Pharma Ltd.
2016 Phase 3 NCT02605434 Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
Orion Corporation Orion Pharma
2007 - EUCTR2007-002496-14-FI Finland;
Sinemet® 100/
Bial - Portela C S.A.
2009 Phase 1 NCT01533077 Canada;
Sinemet® 100/25
Bial - Portela C S.A.
2008 Phase 1 NCT02169479 Canada;
2004 Phase 1 NCT03091868 Portugal;
Sinemet® CR
CombinatoRx, Inc
2008 - EUCTR2007-005033-11-DE Germany;
Sinemet® CR 100/25
Bial - Portela C S.A.
2008 Phase 1 NCT02169453 Canada;
Sinemet® controlled release (Carbidopa/levodopa)
Bristol-Myers Squibb
2007 - NCT00460954 Canada;
Sinemet®25-100
Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
2007 - EUCTR2006-000577-29-DE Germany;United States;
Sirolimus
Prevail Therapeutics
2020 Phase 1/Phase 2 NCT04127578 Israel;United States;
Sitagliptin
Peking Union Medical College Hospital
2020 Phase 4 ChiCTR2000029465 China;
Sodium chloride
Shanghai Tongji Hospital, Tongji University
2017 - ChiCTR-INR-17012013 China;
Sodium oxybate
Baylor College of Medicine
2004 - NCT00641186 -
Sodium phosphate enema, oral rifaximin and polyethylene glycol
Torre Médica Santé
2018 Phase 1 NCT04730245 Mexico;
Solifenacin
VA Office of Research and Development
2018 Phase 3 NCT03149809 United States;
Solifenacin Succinate (VESIcare)
University of South Florida
2007 Phase 4 NCT00584090 United States;
Solifenacin succinate (VESIcare)
University of South Florida
2010 Phase 4 NCT01018264 United States;
Solu-Cortef, powder for solution for injection, 100mg, and 'Act-O-Vial'
University Medical Center Groningen
2015 Phase 2 EUCTR2014-000657-36-NL Netherlands;
Solution de chlorhydrate de dopamine anaérobie
InBrain Pharma SAS
2020 Phase 1;Phase 2 EUCTR2020-000155-12-FR France;
Soluzione di levodopa/carbidopa
NEURODERM LTD.
2016 Phase 2 EUCTR2015-005814-31-IT Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
2016 Phase 2 EUCTR2015-005078-39-IT Austria;Germany;Israel;Italy;United States;
Sorbitol
Istanbul Medipol University Hospital
2019 Phase 2 NCT04044131 Turkey;
Soy protein
Chulalongkorn University
2011 Phase 4 NCT01662414 Thailand;
Spheramine (BAY86-5280)
Bayer
2003 Phase 2 NCT00206687 Austria;France;Germany;Spain;United States;
2000 Phase 2 NCT00761436 United States;
Spiropent
CuraSen Therapeutics, Inc.
2020 Phase 2 EUCTR2020-003796-17-GB United Kingdom;
- Phase 2 EUCTR2020-006067-28-BE Australia;Belgium;New Zealand;United Kingdom;
SpotOn balance glasses
SpotOn Therapeutics Ltd.
2018 - NCT03942172 Israel;
Stalevo
Molecular NeuroImaging
2004 Phase 2 NCT00200447 -
NOVARTIS FARMA
2005 - EUCTR2005-001032-72-IT Czech Republic;Italy;Portugal;
2004 - EUCTR2004-000185-12-IT Finland;Italy;Sweden;United Kingdom;
Novartis Pharma AG
2006 - EUCTR2005-001032-72-PT Czech Republic;Italy;Portugal;
Orion Corporation Orion Pharma
2006 Phase 4 EUCTR2006-001755-36-GB Germany;Sweden;United Kingdom;
- - EUCTR2006-001755-36-DE Germany;Sweden;United Kingdom;
Orion Corporation Orion Pharma, FI-02200 Espoo, Finland
2006 - EUCTR2006-001755-36-SE Germany;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA
2005 - EUCTR2004-005234-39-FI Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-FI Finland;Italy;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA, Finland
2005 Phase 4 EUCTR2004-005234-39-GB Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA, 02200 Espoo, Finland
2008 - EUCTR2004-005234-39-DE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2007 Phase 3 EUCTR2004-000185-12-GB Austria;Finland;Italy;Sweden;United Kingdom;
2006 - EUCTR2004-005234-39-LV Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2006 - EUCTR2004-005234-39-LT Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 Phase 4 EUCTR2004-005234-39-IE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-005234-39-SE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-005234-39-DK Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-SE Finland;Italy;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-AT Austria;Finland;Italy;Sweden;United Kingdom;
Orion Corporation, Orion Pharma
2016 Phase 2 NCT02764125 Finland;Germany;Hungary;Latvia;
2011 Phase 2 NCT01766258 -
2006 Phase 4 NCT00462007 Germany;Sweden;United Kingdom;
Second Affiliated Hospital, School of Medicine, Zhejiang University
2022 Phase 4 NCT04952194 -
Stalevo (levodopa/ carbidopa/ entacapone)
Orion Corporation, Orion Pharma
2009 Phase 1 NCT01070628 Finland;
Stalevo (levodopa/carbidopa/entacapona)
NOVARTIS FARMACEUTICA, S.A
2006 - EUCTR2006-000680-28-ES Spain;
Stalevo (levodopa/carbidopa/entacapone)
Orion Corporation, Orion Pharma
2005 Phase 4 NCT00125567 Denmark;Finland;Germany;Ireland;Sweden;United Kingdom;
Stalevo 100
NOVARTIS FARMACEUTICA, S.A
2006 - EUCTR2006-000680-28-ES Spain;
Stalevo 100 mg/ 25 mg/ 200 mg Filmtabletten
Novartis Pharma Services AG
2008 - EUCTR2007-003134-42-DE Germany;
Stalevo 100 mg/25 mg /
Novartis Pharma AG
2006 - EUCTR2005-001032-72-CZ Czech Republic;Italy;Portugal;
Stalevo 100/25/
Orion Corporation
2011 - EUCTR2010-022915-21-SE Finland;Sweden;
2011 - EUCTR2010-022915-21-FI Finland;Sweden;
Stalevo 150
Institut de Recerca del Hospital de la Santa Creu i Sant Pau
2007 - EUCTR2006-002408-32-ES Spain;
NOVARTIS FARMACEUTICA, S.A
2006 - EUCTR2006-000680-28-ES Spain;
Stalevo 150/37.5/
Orion Corporation
2011 - EUCTR2010-022915-21-SE Finland;Sweden;
2011 - EUCTR2010-022915-21-FI Finland;Sweden;
Stalevo®
Asan Medical Center
2015 - NCT02452606 Korea, Republic of;
Orion Corporation Orion Pharma
2007 - EUCTR2007-002496-14-FI Finland;
Standard LD/CD
IRCCS San Raffaele
2015 Phase 2 NCT02763137 Italy;
Static, dynamic and functional balance exercises with dual task
Istanbul University-Cerrahpasa
2019 - NCT03939559 -
Stilnoct
Aston University
2018 Phase 2 EUCTR2017-004297-34-GB United Kingdom;
Stimulator OFF
Maastricht University Medical Center
2015 - NCT02632279 Netherlands;
Stimulator ON
Maastricht University Medical Center
2015 - NCT02632279 Netherlands;
Strattera
Oregon Health and Science University
2011 Phase 4 NCT01340885 United States;
Study Drug
Pfizer
2010 - NCT01270711 -
Subcutaneous apomorphine
Sunovion
2018 Phase 3 NCT03391882 Austria;France;Germany;Italy;Spain;United Kingdom;
Subcutaneous hydrocortisone
University Medical Center Groningen
2015 Phase 2 NCT02230930 Netherlands;
Subjects will undergo the 123-I IBVM imaging visit
Institute for Neurodegenerative Disorders
2007 Phase 0 NCT00556764 United States;
Sugar Pill
New York Institute of Technology
2014 Phase 0 NCT02259049 United States;
Oregon Health and Science University
2009 - NCT00794313 United States;
Sugar pill
Henry Ford Health System
2015 Phase 2 NCT02066571 United States;
Rush University Medical Center
2011 Phase 2 NCT01351168 United States;
2010 Phase 2 NCT01341080 United States;
Sulforaphane
Central South University
2021 Phase 2 NCT05084365 -
Sumanirole
Pfizer
2003 Phase 3 NCT00058838 Argentina;Australia;Austria;Belgium;Colombia;France;Germany;Greece;Italy;Mexico;Peru;Puerto Rico;Spain;United States;
2001 Phase 3 NCT00036218 Argentina;Mexico;Puerto Rico;United States;
2000 Phase 3 NCT00036205 Argentina;Colombia;Puerto Rico;United States;
Supressi. T-Diet plus Range
Vegenat, S.A.
2010 - NCT01192529 Spain;
Suvorexant
Burdick, Daniel, M.D.
2016 Phase 4 NCT02729714 United States;
Synthetic Oxytocin
Abteilung für Neurologie der Medizinischen Universität Innsbruck
2019 Phase 2 EUCTR2018-002877-23-AT Austria;
Syntocinon 40 IU/ml nasal spray
Abteilung für Neurologie der Medizinischen Universität Innsbruck
2019 Phase 2 EUCTR2018-002877-23-AT Austria;
TACROLIMUS TABLETS
Kyoto University Hospital
2018 Phase 3 JPRN-JMA-IIA00385 Japan;
TAK-071
Takeda
2020 Phase 2 NCT04334317 United States;
TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)
Novartis
2002 Phase 1/Phase 2 NCT00407212 Brazil;Canada;France;Germany;Italy;Netherlands;Portugal;United Kingdom;United States;
TD-9855
THERAVANCE BIOPHARMA ANTIBIOTICS, INC.
2019 Phase 3 EUCTR2018-003289-15-IT Austria;Bulgaria;Canada;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Theravance Biopharma
2016 Phase 2 NCT02705755 United States;
Theravance Biopharma Ireland Limited
2020 Phase 3 EUCTR2018-003941-41-PT Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-003941-41-AT Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-003289-15-PT Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-003289-15-DE Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-PL Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-IT Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-HU Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-GB Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-ES Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-EE Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-BG Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-PL Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-HU Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-GB Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-ES Austria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-EE Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-DK Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-BG Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-AT Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
TECHNETIUM (99MTC) EXAMETAZIME
IDIBAPS
2016 Phase 2 EUCTR2015-004238-85-ES Spain;
THN02
Theranexus S.A.
2018 Phase 2 EUCTR2017-004475-31-HU Czech Republic;France;Germany;Hungary;United States;
2018 Phase 2 EUCTR2017-004475-31-CZ Czech Republic;France;Germany;Hungary;United States;
THN102 Dosage A
Theranexus
2018 Phase 2 NCT03624920 Czechia;France;Germany;Hungary;United States;
THN102 Dosage B
Theranexus
2018 Phase 2 NCT03624920 Czechia;France;Germany;Hungary;United States;
THN102 Dosage C
Theranexus
2018 Phase 2 NCT03624920 Czechia;France;Germany;Hungary;United States;
TO
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2010 - EUCTR2009-017416-33-DE Germany;
TOZ
Biotie Therapies
2017 Phase 3 EUCTR2016-003961-25-HU Australia;Canada;Czech Republic;European Union;Germany;Hungary;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003961-25-GB Australia;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003961-25-ES Australia;Canada;Czech Republic;European Union;Germany;Hungary;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003961-25-DE Australia;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003961-25-CZ Australia;Canada;Czech Republic;European Union;Germany;Hungary;Spain;United Kingdom;United States;
TRIGEL
LobSor Pharmaceuticals AB
2015 Phase 1 NCT02448914 Sweden;
TULOBUTEROL HYDROCHLORIDE
CuraSen Therapeutics, Inc.
2020 Phase 2 EUCTR2020-003796-17-GB United Kingdom;
TVP-1012
TEVA
2005 - EUCTR2005-001416-42-IT Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
TEVA Pharmaceuticals Industries Ltd
2006 - EUCTR2006-005140-89-NL Netherlands;
Takeda
2015 Phase 3 NCT02337764 Japan;
2015 Phase 3 NCT02337751 Japan;
2015 Phase 3 NCT02337725 Japan;
2015 Phase 2/Phase 3 NCT02337738 Japan;
Teva Pharmaceuticals Industries LtD
2005 Phase 3 EUCTR2005-001416-42-GB Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-001416-42-ES Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-PT Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-HU Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-DE Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-AT Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
TVP-1012 (1 mg/day) with levodopa
TAKEDA PHARMACEUTICAL COMPANY LTD.
2015 Phase 3 JPRN-JapicCTI-152762 -
Tadalafil
University of South Florida
2014 Phase 4 NCT02225548 United States;
Talampanel
National Institute of Neurological Disorders and Stroke (NINDS)
2005 Phase 2 NCT00108667 United States;
Teva Pharmaceutical Industries
2006 Phase 1/Phase 2 NCT00036296 Canada;United States;
Talineuren
InnoMedica Schweiz AG
2021 Phase 1 NCT04976127 Switzerland;
Targinact 10 mg/5 mg prolonged-release tablets
Mundipharma Research GmbH & Co. KG
2012 - EUCTR2011-002901-31-DE Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-GB Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-ES Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-HU Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-CZ Czech Republic;Germany;Hungary;Spain;United Kingdom;
Targinact 20 mg/10 mg prolonged-release tablets
Mundipharma Research GmbH & Co. KG
2012 - EUCTR2011-002901-31-DE Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-GB Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-ES Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-HU Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-CZ Czech Republic;Germany;Hungary;Spain;United Kingdom;
Targinact 5 mg/2.5 mg prolonged-release tablets
Mundipharma Research GmbH & Co. KG
2012 - EUCTR2011-002901-31-DE Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-GB Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-ES Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-HU Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-CZ Czech Republic;Germany;Hungary;Spain;United Kingdom;
Tasmar
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2010 - EUCTR2009-017416-33-DE Germany;
Dept of Neuroscience, Uppsala University
2008 - EUCTR2008-003581-26-SE Sweden;
Tavapadon
Cerevel Therapeutics, LLC
2021 Phase 3 NCT04760769 Australia;Czechia;France;Germany;Italy;Poland;Spain;United States;
2020 Phase 3 NCT04542499 Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 NCT04223193 Australia;France;Germany;Hungary;Italy;Poland;Serbia;Spain;Ukraine;United States;
2019 Phase 3 NCT04201093 Australia;Bulgaria;Canada;Czechia;France;Germany;Israel;Italy;Poland;Spain;Ukraine;United States;
Terazosin
Cedars-Sinai Medical Center
2020 Phase 2 NCT04386317 United States;
Jordan Schultz
2019 Phase 1/Phase 2 NCT03905811 United States;
Terazosin therapy
Cedars-Sinai Medical Center
2021 Phase 2 NCT05109364 -
Tigan®
Ipsen
2007 Phase 4 NCT00489255 United States;
Tissue samplings
Michael J. Fox Foundation for Parkinson's Research
2015 - NCT02572713 Canada;United States;
Tocovid Suprabio (HOV-12020)
National Neuroscience Institute
2021 Phase 2 NCT04491383 Singapore;
Tolcapon
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2010 - EUCTR2009-017416-33-DE Germany;
Tolcapone
Dept of Neuroscience, Uppsala University
2008 - EUCTR2008-003581-26-SE Sweden;
Uppsala University
2008 Phase 4 NCT00906828 Sweden;
Tolubuterol Hydrochloride
CuraSen Therapeutics, Inc.
2020 Phase 2 EUCTR2020-003796-17-GB United Kingdom;
Topiramate
Oregon Health and Science University
2009 - NCT00794313 United States;
Rush University Medical Center
2013 Phase 2 NCT01789047 United States;
Topiramate (drug)
University Health Network, Toronto
2004 Phase 2 NCT00296959 Canada;
Tozadenant
Biotie Therapies Inc.
2017 Phase 3 NCT03051607 Canada;United Kingdom;United States;
2015 Phase 3 NCT02453386 Austria;Canada;Czech Republic;Czechia;Germany;Italy;Spain;United States;
2012 - EUCTR2011-005054-59-RO Argentina;Canada;Chile;Romania;Ukraine;United States;
2008 Phase 2 NCT00605553 United States;
Tozadenant (SYN115) 120 mg BID
Biotie Therapies Inc.
2011 Phase 2/Phase 3 NCT01283594 Argentina;Canada;Chile;Romania;Ukraine;United States;
Tozadenant (SYN115) 180 mg BID
Biotie Therapies Inc.
2011 Phase 2/Phase 3 NCT01283594 Argentina;Canada;Chile;Romania;Ukraine;United States;
Tozadenant (SYN115) 240 mg BID
Biotie Therapies Inc.
2011 Phase 2/Phase 3 NCT01283594 Argentina;Canada;Chile;Romania;Ukraine;United States;
Tozadenant (SYN115) 60 mg BID
Biotie Therapies Inc.
2011 Phase 2/Phase 3 NCT01283594 Argentina;Canada;Chile;Romania;Ukraine;United States;
Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant)
Fudan University
2008 Phase 2/Phase 3 NCT00629161 China;
Transdermal flumazenil (Added 4/2020)
Nicolaas Bohnen, MD, PhD
2018 Phase 1/Phase 2 NCT03440112 United States;
Transdermal nicotine
Assistance Publique - Hôpitaux de Paris
2009 Phase 2 NCT00873392 France;
Trimethobenzamide
US WorldMeds LLC
2012 Phase 4 NCT01770145 United States;
Trimethobenzamide Hydrochloride
Pfizer
2015 Phase 1 NCT02373072 Belgium;United States;
Trivastal
Institut de Recherches Internationales Servier (I.R.I.S.)
2005 - EUCTR2005-002010-38-DE Germany;
Tryptophan (TRP) depletion
Maastricht University Medical Center
2015 - NCT02632279 Netherlands;
Tyramine
Teva Pharmaceutical Industries
2000 Phase 3 NCT00203125 United States;
Tyrosine
New York Institute of Technology
2012 Phase 1/Phase 2 NCT01676103 United States;
UB-312
United Neuroscience Ltd.
2019 Phase 1 NCT04075318 Netherlands;
UCB0022
UCB Biopharma SRL
2021 Phase 1 NCT04867642 United Kingdom;
UCB0599
UCB Biopharma S.P.R.L.
2019 Phase 1 NCT04875962 United States;
UCB Biopharma SRL
2021 Phase 2 EUCTR2020-003265-19-PL Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003265-19-NL Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003265-19-IT Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003265-19-FR Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003265-19-ES Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003265-19-DE Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 NCT04658186 Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
UCB7853
UCB Biopharma SRL
2020 Phase 1 NCT04651153 Netherlands;United Kingdom;
Ubiquinol
Weill Medical College of Cornell University
2012 Phase 2 NCT03061513 -
Umbilical cord blood therapy
MinYoung Kim, M.D.
2014 - NCT02236065 Korea, Republic of;
Urate
Ehime University Graduate School of Medicine
2016 Phase 2 JPRN-UMIN000020527 Japan;
Nagai Masahiro
2016 Phase 2 JPRN-jRCTs061180060 Japan;
Ursodeoxycholic acid
Sheffield Teaching Hospitals NHS Foundation Trust
2018 Phase 2 EUCTR2018-001887-46-GB United Kingdom;
University of Minnesota
2020 Phase 1 NCT02967250 United States;
Ursonorm
Sheffield Teaching Hospitals NHS Foundation Trust
2018 Phase 2 NCT03840005 United Kingdom;
2018 Phase 2 EUCTR2018-001887-46-GB United Kingdom;
Usual dopaminergic per os treatment
Rennes University Hospital
2009 Phase 3 NCT01039090 France;
V1512 and Entacapone
Vernalis (R&D) Ltd
2006 Phase 1/Phase 2 NCT00491998 Italy;
V81444
Vernalis (R&D) Ltd
2012 Phase 1 NCT02764892 -
2011 Phase 1 NCT01634568 United Kingdom;
VARENICLINE TARTRATE
VU University Medical Center
2012 Phase 3 EUCTR2012-001530-34-NL Netherlands;
VIUSID/ALZER
Catalysis SL
2009 Phase 3 NCT01016470 Cuba;
VR040
Vectura Group plc
2006 Phase 2 EUCTR2006-005509-79-GB United Kingdom;
2006 Phase 2 EUCTR2006-004582-33-GB United Kingdom;
2005 Phase 2 EUCTR2005-005120-13-GB United Kingdom;
Vectura Limited
2009 - EUCTR2008-004447-11-GB Germany;Italy;United Kingdom;
- - EUCTR2008-004447-11-DE Germany;Italy;United Kingdom;
VR040/Aspirair® inhaler
South Glasgow University Hospitals NHS Trust
2007 Phase 2 NCT01693081 Serbia;United Kingdom;
VY-AADC01
Neurocrine Biosciences
2017 Phase 1 NCT03065192 United States;
2013 Phase 1 NCT01973543 United States;
VY-AADC02
Neurocrine Biosciences
2018 Phase 2 NCT03562494 United States;
Valerian
National Center for Complementary and Integrative Health (NCCIH)
2000 Phase 2 NCT00070928 United States;
Valiloxybate
XWPharma
2021 Phase 2 NCT05056194 -
Varenicline
Rush University Medical Center
2010 Phase 2 NCT01341080 United States;
University of Michigan
2017 Phase 2 NCT04403399 United States;
2015 Phase 2 NCT02933372 -
VU University Medical Center
2013 Phase 4 NCT02473562 Netherlands;
Variation of behaviors of Parkinson's disease
Centre Hospitalier Universitaire, Amiens
2018 Phase 3 NCT03146130 France;
Vehicle
Neuraly, Inc.
2020 Phase 2 NCT04154072 Canada;United States;
Venglustat GZ/SAR402671
Genzyme, a Sanofi Company
2016 Phase 2 NCT02906020 Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
Venglustat malate
Genzyme Corporation
2018 Phase 2 EUCTR2016-000657-12-AT Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000657-12-PT Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000657-12-DE Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000657-12-SE Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
Venlafaxine
The Third Affiliated Hospital of Beijing University of Traditional Chinese Medicine
2014 Phase 2 study ChiCTR-TRC-14005143 China;
University of Rochester
2005 Phase 3 NCT00086190 Canada;Puerto Rico;United States;
ViNeuro
Hospital Authority, Hong Kong
2005 - NCT00517842 China;
Vitamin B12 Supplementation
Emory University
2006 Phase 2/Phase 3 NCT00208611 United States;
Vitamin D3
Jikei University School of Medicine
2009 - JPRN-UMIN000001841 Japan;
Memorial Medical Center
2009 Phase 2 NCT00907972 United States;
VA Office of Research and Development
2011 Phase 2 NCT01119131 United States;
Vitamin D3 - high dose
Emory University
2007 Phase 4 NCT00571285 United States;
Vortioxetine
IRCCS San Raffaele
2020 Phase 4 NCT04301492 Italy;
WD-1603
Hong Kong WD Pharmaceutical Co., Limited
2020 Phase 1 NCT04553978 -
WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS
Hong Kong WD Pharmaceutical Co., Limited
2020 Phase 1 NCT04513340 India;
WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
Hong Kong WD Pharmaceutical Co., Limited
2020 Phase 1 NCT04591535 India;
WD-1603 Carbidopa-Levodopa Extended-Release Tablets
Shanghai WD Pharmaceutical Co., Ltd.
2021 Phase 2 NCT05036473 China;
2021 Phase 1 NCT05128175 India;
WIN-1001X
Medi Help Line
2020 Phase 2 NCT04220762 Korea, Republic of;
Warfarin
Bial - Portela C S.A.
2014 Phase 1 NCT02305030 -
2009 Phase 1 NCT02169440 Portugal;
Water
Department of Neurology, Juntendo University School of Medicine
2010 - JPRN-UMIN000007497 Japan;
Federal University of Health Science of Porto Alegre
2021 - NCT04863118 -
Juntendo University Koshigaya Hospital
2015 - JPRN-UMIN000019090 Japan;
Juntendo University School of Medicine, Neurology
2013 - JPRN-UMIN000010014 Japan;
Kaida Wang
2019 Phase 0 ChiCTR1900025894 China;
Nagoya graduate school of medicine university
2015 - JPRN-UMIN000019654 Japan;
Weancare-domus
Milko Zanini
2021 - NCT04983290 Italy;
Whey protein
Chulalongkorn University
2011 Phase 4 NCT01662414 Thailand;
White chocolate ( cocoa)
Technische Universität Dresden
2013 - NCT02275884 Germany;
Wuling Powder
Beijing Hospital
2017 Phase 4 NCT03195231 -
XADAGO (safinamide)
Supernus Pharmaceuticals, Inc.
2017 - NCT03944785 United States;
XADAGO - 100 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE
OSPEDALE SANTA MARIA DELLA MISERICORDIA
2021 Phase 3 EUCTR2018-004892-11-IT Italy;
XADAGO - 50 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE
OSPEDALE SANTA MARIA DELLA MISERICORDIA
2021 Phase 3 EUCTR2018-004892-11-IT Italy;
XC130-A10H
Xoc Pharmaceuticals
2019 Phase 1 NCT04043338 United States;
XP21279
XenoPort, Inc.
2009 Phase 1/Phase 2 NCT00914602 United States;
XP21279 and carbidopa (experimental)
XenoPort, Inc.
2010 Phase 2 NCT01171313 United States;
Xadago
Institut de Recerca Hospital de la Santa Creu i Sant Pau
2017 Phase 4 EUCTR2017-003254-17-ES Spain;
ZAMBON SPA
2019 Phase 4 EUCTR2017-002426-20-IT Austria;France;Germany;Italy;Spain;
2015 Phase 3 EUCTR2014-002600-24-IT Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
Zambon S.P.A.
2015 Phase 3 EUCTR2014-002600-24-SE Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2015 Phase 3 EUCTR2014-002600-24-GB Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2015 Phase 3 EUCTR2014-002600-24-ES Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2015 Phase 3 EUCTR2014-002600-24-AT Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
Zambon SpA
2019 Phase 4 EUCTR2017-002426-20-FR Austria;France;Spain;
2019 Phase 4 EUCTR2017-002426-20-AT Austria;Spain;
2018 Phase 4 EUCTR2017-002426-20-ES Spain;
Xeomin
Merz Pharmaceuticals GmbH
2014 Phase 3 EUCTR2012-005539-10-DE Germany;Poland;United States;
Xiaoyao Pill
Xuanwu Hospital, Beijing
2008 Phase 2 NCT01416818 China;
Yohimbine HCl
Nathaniel M. Robbins
2021 Early Phase 1 NCT04346394 United States;
Zelapar
Baylor College of Medicine
2007 Phase 4 NCT00640159 United States;
Zoledronic Acid 5Mg/Bag 100Ml Inj
California Pacific Medical Center Research Institute
2019 Phase 4 NCT03924414 United States;
Zoledronic acid
Department of Orthopaedic Surgery, Niigata University Medical and Dental Hospital
2018 - JPRN-UMIN000033285 Japan;
Zolmitriptan
Contera Pharma
2020 Phase 2 EUCTR2017-003415-19-IT France;Germany;Italy;Spain;
2018 Phase 2 EUCTR2017-003415-19-ES France;Germany;Spain;
Zolpidem
Aston University
2018 Phase 2 NCT03621046 United Kingdom;
Zolpidem Tartrate
Aston University
2018 Phase 2 EUCTR2017-004297-34-GB United Kingdom;
Zolpidem first dose
Rush University Medical Center
2011 Phase 2 NCT01351168 United States;
Zolpidem second dose
Rush University Medical Center
2011 Phase 2 NCT01351168 United States;
Zonegran
The Cooper Health System
2016 Phase 4 NCT03034538 United States;
Zonisamide
Dainippon Sumitomo Pharma Co., Ltd.
2010 Phase 3 JPRN-JapicCTI-101198 -
Department of Neurology, University of Yamanashi
2013 - JPRN-UMIN000010371 Japan;
Hamamatsu University School of Medicine
2015 - JPRN-UMIN000019524 Japan;
Hiroshi Kataoka
2021 Phase 2-3 JPRN-jRCTs051200160 Japan;
Ito Hidefumi
2016 Phase 2 JPRN-jRCTs051180098 Japan;
Katsuno Masahisa
2021 Phase 2 JPRN-jRCTs041190126 Japan;
Mazandaran University of Medical Sciences
2013 Phase 2/Phase 3 NCT01766128 -
Medical Corporation Abe Neurology Clinic
2016 - JPRN-UMIN000024859 Japan;
Osaka Redcross HospitalWakayama Prefectural Medical College
2016 Phase 2 JPRN-UMIN000022533 Japan;
Ouchi Yasuomi
2015 - JPRN-jRCTs041180070 Japan;
Zonisamide Capsules
Ain Shams University
2020 - NCT04182399 Egypt;
[11C]-PIB
Vanderbilt University Medical Center
2020 Early Phase 1 NCT04768101 United States;
[11C]PXT012253
H. Lundbeck A/S
2019 Early Phase 1 NCT03826134 Sweden;
[123I] 5-IA
Institute for Neurodegenerative Disorders
2006 Phase 2 NCT00397696 United States;
[123I] IBVM and SPECT imaging
Institute for Neurodegenerative Disorders
2007 Phase 0 NCT00556764 United States;
[123I] mZINT injection and serial dynamic SPECT imaging
Institute for Neurodegenerative Disorders
2007 Phase 1 NCT00427674 United States;
[123I]-IBVM
Institute for Neurodegenerative Disorders
2007 Phase 2 NCT00480701 United States;
[123I]-IBZM imaging
Molecular NeuroImaging
2004 Phase 2 NCT00200447 -
[123I]B-CIT
Institute for Neurodegenerative Disorders
2006 Phase 2 NCT00273351 United States;
[123I]B-CIT SPECT imaging
Institute for Neurodegenerative Disorders
2000 Phase 2 NCT00134784 -
[123I]CLINDE
Institute for Neurodegenerative Disorders
2008 Phase 1 NCT00612872 United States;
[123I]MNI-420
Institute for Neurodegenerative Disorders
2009 Phase 1 NCT00970229 United States;
[123I]beta CIT
Institute for Neurodegenerative Disorders
2003 Phase 2 NCT00129675 United States;
[123I]beta CIT and SPECT imaging
Institute for Neurodegenerative Disorders
2001 Phase 2 NCT00117819 United States;
[123I]beta-CIT
Institute for Neurodegenerative Disorders
2006 Phase 2 NCT00387075 United States;
2006 Phase 2 NCT00315250 United States;
[123I]beta-CIT and SPECT imaging
Institute for Neurodegenerative Disorders
2006 Phase 2 NCT00387075 United States;
2004 Phase 2 NCT00096720 United States;
1992 Phase 2 NCT00132626 -
[123I]ß CIT
Institute for Neurodegenerative Disorders
2003 Phase 2 NCT00129675 United States;
[123I]ß CIT and SPECT imaging
Institute for Neurodegenerative Disorders
2001 Phase 2 NCT00117819 United States;
[123I]ß-CIT
Institute for Neurodegenerative Disorders
2006 Phase 2 NCT00387075 United States;
2006 Phase 2 NCT00315250 United States;
[123I]ß-CIT and SPECT imaging
Institute for Neurodegenerative Disorders
2006 Phase 2 NCT00387075 United States;
2004 Phase 2 NCT00096720 United States;
1992 Phase 2 NCT00132626 -
[14C]-BIA 9-1067
Bial - Portela C S.A.
2017 Phase 1 NCT03119194 United Kingdom;
[18F] CFPyPB
Institute for Neurodegenerative Disorders
2011 Phase 1 NCT01461109 United States;
[18F] LBT-999 PET
University Hospital, Tours
2015 Early Phase 1 NCT02393027 France;
[18F] PBR06
Institute for Neurodegenerative Disorders
2009 Phase 1 NCT01028209 United States;
[18F] PI-2620
Michael J. Fox Foundation for Parkinson's Research
2021 Phase 2 NCT04906590 United States;
[18F]-FEPPA
Institute for Neurodegenerative Disorders
2009 Phase 1 NCT00970333 United States;
[18F]DPA-714 PET scan
Nantes University Hospital
2018 Phase 2 NCT03230526 France;
[18F]FDOPA
Daniel Claassen
2020 Phase 1 NCT04246437 United States;
[18F]FDOPA PET/CT
University of Saskatchewan
2016 - NCT02538315 Canada;
[18F]FPEB
Institute for Neurodegenerative Disorders
2009 Phase 1 NCT00870974 United States;
[18F]MK-9470
Institute for Neurodegenerative Disorders
2011 Phase 1 NCT01462708 United States;
[18F]MNI-1126
Invicro
2018 Phase 1 NCT03587649 United States;
[18F]MNI-444
Invicro
2021 Phase 1 NCT05009199 United States;
[18F]MPPF
Institute for Neurodegenerative Disorders
2011 Phase 1 NCT01461083 United States;
[18F]NOS
University of Pennsylvania
2019 Early Phase 1 NCT04062526 United States;
[18F]P17-059
Five Eleven Pharma, Inc.
2021 Phase 1 NCT03903549 United States;
[18F]PI-2620
Asan Medical Center
2018 Early Phase 1 NCT03510572 Korea, Republic of;
[18F]T807 ([18F]MNI-777)
Molecular NeuroImaging
2014 Phase 1 NCT02103894 United States;
[18F]UCB-2897
Invicro
2022 Phase 1 NCT05274568 United States;
[21CFR640.30] Plasma from 18 - 25 year old volunteer donors
The Neurology Center
2018 Phase 4 NCT04202757 United States;
[F-18] Fluorodopa Positron Emission Tomography
Andrew Newberg
2022 Phase 2 NCT05103618 United States;
Thomas Jefferson University
2020 Phase 2 NCT04459052 United States;
saline
Beijing Tiantan Hospital
2022 - NCT05197439 China;
sodium chloride (normal saline)
Asubio Pharmaceuticals, Inc.
2007 Phase 2 NCT00623363 Guatemala;Romania;United States;
Weill Medical College of Cornell University
2018 Phase 1/Phase 2 NCT03675282 United States;
(2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide)
Juha Rinne / PET Centre
2018 Phase 2 EUCTR2018-000405-23-FI Finland;
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
AbbVie Inc
2011 Phase 3 EUCTR2008-001329-33-GB Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
2010 Phase 3 EUCTR2008-001329-33-CZ Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
2009 - EUCTR2008-001329-33-PT Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
Abbott Healthcare Products B.V.
2009 - EUCTR2006-005186-18-CZ Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
2008 Phase 3 EUCTR2006-005186-18-GB Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
2008 - EUCTR2006-005186-18-PT Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2006-005186-18-DE Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
Abbott Laboratories
2009 - EUCTR2006-000578-53-DE Germany;New Zealand;United States;
Solvay Pharmaceuticals B.V.
2009 - EUCTR2006-005186-18-NL Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2006-005186-18-ES Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2007 - EUCTR2006-005186-18-FI Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
(2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylprop acid
AbbVie Inc
2011 Phase 3 EUCTR2008-001329-33-GB Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
2010 Phase 3 EUCTR2008-001329-33-CZ Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
2009 - EUCTR2008-001329-33-PT Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
(2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylpropanoic acid
Abbott Healthcare Products B.V.
2009 - EUCTR2006-005186-18-CZ Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
2008 Phase 3 EUCTR2006-005186-18-GB Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
2008 - EUCTR2006-005186-18-PT Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2006-005186-18-DE Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
Abbott Laboratories
2009 - EUCTR2006-000578-53-DE Germany;New Zealand;United States;
Solvay Pharmaceuticals B.V.
2009 - EUCTR2006-005186-18-NL Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2006-005186-18-ES Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2007 - EUCTR2006-005186-18-FI Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
(3beta, 5beta, 25R)-spirostan-3-ol
Phytopharm plc
2011 - EUCTR2010-018534-44-HU Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
2011 - EUCTR2010-018534-44-DE Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
2011 - EUCTR2010-018534-44-CZ Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
2010 Phase 2 EUCTR2010-018534-44-GB Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
(3ß, 5ß, 25R)-spirostan-3-ol
Phytopharm plc
2011 - EUCTR2010-018534-44-HU Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
2011 - EUCTR2010-018534-44-DE Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
2011 - EUCTR2010-018534-44-CZ Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
2010 Phase 2 EUCTR2010-018534-44-GB Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
(6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol
Schwarz BioSciences Inc.
2008 - EUCTR2004-000148-26-HU Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2008 - EUCTR2004-000148-26-AT Austria;Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 Phase 3 EUCTR2004-000148-26-ES Austria;Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 - EUCTR2004-000148-26-SE Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 - EUCTR2004-000148-26-FI Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 - EUCTR2004-000148-26-CZ Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
(R)-troloxamide quinone
BioElectron Technology Corporation (formerly Edison Pharmaceuticals Inc.)
2016 Phase 2 EUCTR2015-001786-10-GB Germany;United Kingdom;United States;
2016 Phase 2 EUCTR2015-001786-10-DE Germany;United Kingdom;United States;
(S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-DE Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-CZ Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
(S)-(+)-2-(4-(3-fluorobenzyl)oxybenzyl)aminopropanamide methanesulfonate
Merck Serono S.A. - Geneva
2011 - EUCTR2009-017174-20-AT Austria;Canada;France;Germany;South Africa;
2010 - EUCTR2009-017174-20-DE Austria;Canada;France;Germany;South Africa;
(minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
2007 - EUCTR2006-000577-29-DE Germany;United States;
00000
Genzyme Corporation
2017 Phase 2 EUCTR2016-000657-12-IT Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
000000
Genzyme Corporation
2017 Phase 2 EUCTR2016-000657-12-IT Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
009-0
Alexza Pharmaceuticals, Inc.
2018 Phase 1 NCT03822364 Netherlands;
009-1
Alexza Pharmaceuticals, Inc.
2018 Phase 1 NCT03822364 Netherlands;
009-2
Alexza Pharmaceuticals, Inc.
2018 Phase 1 NCT03822364 Netherlands;
009-3
Alexza Pharmaceuticals, Inc.
2018 Phase 1 NCT03822364 Netherlands;
009-4
Alexza Pharmaceuticals, Inc.
2018 Phase 1 NCT03822364 Netherlands;
009-5
Alexza Pharmaceuticals, Inc.
2018 Phase 1 NCT03822364 Netherlands;
009-A0
Alexza Pharmaceuticals, Inc.
2019 Phase 1 NCT04157933 Netherlands;
009-A1
Alexza Pharmaceuticals, Inc.
2019 Phase 1 NCT04157933 Netherlands;
009-A2
Alexza Pharmaceuticals, Inc.
2019 Phase 1 NCT04157933 Netherlands;
009-A3
Alexza Pharmaceuticals, Inc.
2019 Phase 1 NCT04157933 Netherlands;
023145028
BIAL-Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-002754-24-IT Germany;Italy;Portugal;Spain;United Kingdom;
043906039
OSPEDALE SANTA MARIA DELLA MISERICORDIA
2021 Phase 3 EUCTR2018-004892-11-IT Italy;
1. Tesofensine (NS 2330)
Boehringer Ingelheim
2003 Phase 2 NCT00148512 Austria;El Salvador;France;Germany;Netherlands;Spain;United Kingdom;
100
Orion Corporation
2011 - EUCTR2010-022200-46-LV Finland;Germany;Latvia;Lithuania;
2011 - EUCTR2010-022200-46-LT Finland;Germany;Latvia;Lithuania;
2011 - EUCTR2010-022200-46-FI Finland;Germany;Latvia;Lithuania;
- - EUCTR2010-022200-46-DE Finland;Germany;Latvia;Lithuania;
11C-PBR28
William Charles Kreisl
2015 Phase 2 NCT02702102 United States;
11C-PiB
Oriental Neurosurgery Evidence-Based-Study Team
2017 Phase 2 NCT03555292 China;
11C-Raclopride
Orion Corporation Orion Pharma
2007 - EUCTR2007-002496-14-FI Finland;
11C]PBR28
AstraZeneca AB
2012 - EUCTR2011-004803-19-SE Finland;Sweden;
2012 - EUCTR2011-004803-19-FI Finland;Sweden;
11C]SMW139
Juha Rinne / PET Centre
2018 Phase 2 EUCTR2018-000405-23-FI Finland;
125
Orion Corporation
2011 - EUCTR2010-022200-46-LV Finland;Germany;Latvia;Lithuania;
2011 - EUCTR2010-022200-46-LT Finland;Germany;Latvia;Lithuania;
2011 - EUCTR2010-022200-46-FI Finland;Germany;Latvia;Lithuania;
- - EUCTR2010-022200-46-DE Finland;Germany;Latvia;Lithuania;
15O H2O
Umeå University Hospital
2015 Phase 2 EUCTR2015-003045-26-SE Sweden;
15O]H2O
Umeå University Hospital
2015 Phase 2 EUCTR2015-003045-26-SE Sweden;
18-FDTBZ
Chang Gung Memorial Hospital
2015 Phase 2 NCT02599753 Taiwan;
18F florbetaben
Institute for Neurodegenerative Disorders
2016 Phase 2 EUCTR2015-004129-15-ES Spain;
18F- DTBZ
Chang Gung Memorial Hospital
2012 Phase 2 NCT02039024 Taiwan;
18F-AV-133
Avid Radiopharmaceuticals
2012 Phase 2/Phase 3 NCT01550484 Australia;United States;
2010 Phase 1/Phase 2 NCT01503944 United States;
Renji Hospital (South Court), School of Medicine, Shanghai Jiao Tong University
2020 Phase 0 ChiCTR2000036137 China;
18F-AV-45
Avid Radiopharmaceuticals
2010 Phase 1/Phase 2 NCT01503944 United States;
18F-DOPA
University of Alberta
2021 Phase 3 NCT04706910 Canada;
2017 Phase 3 NCT03042416 Canada;
18F-DOPA PET
National Taiwan University Hospital
2017 - NCT03973502 Taiwan;
18F-DTBZ
Chang Gung Memorial Hospital
2013 Phase 2 NCT02059733 Taiwan;
2011 Phase 2 NCT01759888 Taiwan;
2010 Phase 2 NCT01283347 Taiwan;
18F-DTBZ AV-133
Chang Gung Memorial Hospital
2011 Phase 2 NCT01556100 -
18F-FDG
Chang Gung Memorial Hospital
2010 Phase 2 NCT01824056 Taiwan;
Huashan Hospital Affiliated to Fudan University
2020 Phase 0 ChiCTR2000037856 China;
Nagoya City Rehabilitation Agency
2019 - JPRN-UMIN000036908 Japan;
Renji Hospital (South Court), School of Medicine, Shanghai Jiao Tong University
2020 Phase 0 ChiCTR2000036137 China;
18F] LBT-999
ZIONEXA
2021 Phase 3 EUCTR2019-000247-27-FR France;
18F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane
Umeå University Hospital
2015 Phase 2 EUCTR2015-003045-26-SE Sweden;
18F]FE-PE2I
AstraZeneca AB
2012 - EUCTR2011-004803-19-SE Finland;Sweden;
2012 - EUCTR2011-004803-19-FI Finland;Sweden;
Umeå University Hospital
2015 Phase 2 EUCTR2015-003045-26-SE Sweden;
18F]MC225
University Medical Center Groningen
2022 Phase 2 EUCTR2021-005024-37-NL Netherlands;
1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]-
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-DE Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-CZ Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]-
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-DE Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-CZ Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
2,5-Dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide
BIAL Portela & Cª, S.A.
2011 Phase 3 EUCTR2010-022366-27-GB Argentina;Australia;Belgium;Chile;Czech Republic;Estonia;India;Israel;Korea, Republic of;Russian Federation;South Africa;United Kingdom;
2011 Phase 3 EUCTR2010-022366-27-BE Belgium;Czech Republic;Estonia;United Kingdom;
2011 - EUCTR2010-022366-27-CZ Argentina;Australia;Belgium;Chile;Czech Republic;Estonia;India;Israel;Korea, Republic of;Russian Federation;South Africa;United Kingdom;
2010 - EUCTR2010-022366-27-EE Belgium;Czech Republic;Estonia;United Kingdom;
2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE
Alkahest, Inc.
2020 Phase 2 EUCTR2019-001657-42-SK Estonia;Germany;Hungary;Poland;Slovakia;United States;
2019 Phase 2 EUCTR2019-001657-42-DE Estonia;Germany;Hungary;Poland;Slovakia;United States;
207-3120
Aston University
2018 Phase 2 EUCTR2017-004297-34-GB United Kingdom;
25330
Regional Dementia Research Centre, Dept of Neurology
2018 Phase 4 EUCTR2017-002707-10-DK Denmark;
3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-DE Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-CZ Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
3-(3,4-Dihydroxyphenyl)-L-alanine
Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
2007 - EUCTR2006-000577-29-DE Germany;United States;
6036937.00.01
BIAL-Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-002754-24-IT Germany;Italy;Portugal;Spain;United Kingdom;
6abeta - apomorphine-10,11-diol hydrochloride hemihydrate
Britannia Pharmaceuticals Limited
2006 Phase 3 EUCTR2006-000391-32-GB Germany;Netherlands;United Kingdom;
2006 - EUCTR2006-000391-32-NL Germany;Netherlands;United Kingdom;
2006 - EUCTR2006-000391-32-DE Germany;Netherlands;United Kingdom;
6aß - apomorphine-10,11-diol hydrochloride hemihydrate
Britannia Pharmaceuticals Limited
2006 Phase 3 EUCTR2006-000391-32-GB Germany;Netherlands;United Kingdom;
2006 - EUCTR2006-000391-32-NL Germany;Netherlands;United Kingdom;
2006 - EUCTR2006-000391-32-DE Germany;Netherlands;United Kingdom;
75
Orion Corporation
2011 - EUCTR2010-022200-46-LV Finland;Germany;Latvia;Lithuania;
2011 - EUCTR2010-022200-46-LT Finland;Germany;Latvia;Lithuania;
2011 - EUCTR2010-022200-46-FI Finland;Germany;Latvia;Lithuania;
- - EUCTR2010-022200-46-DE Finland;Germany;Latvia;Lithuania;
8-OHdG
Nagoya University Graduate School of Medicine
2015 - JPRN-UMIN000019082 Japan;
A-dopamine
InBrain Pharma SAS
2020 Phase 1;Phase 2 EUCTR2020-000155-12-FR France;
University Hospital, Lille
2020 Phase 1/Phase 2 NCT04332276 France;
AAV2-GDNF
Brain Neurotherapy Bio, Inc.
2020 Phase 1 NCT04167540 United States;
AB1010
AB Science
2015 Phase 2 EUCTR2010-024424-26-SK Bulgaria;Czech Republic;France;Germany;Hungary;Romania;Slovakia;South Africa;Spain;United States;
ABBV-0805
AbbVie
2020 Phase 1 NCT04127695 Puerto Rico;United States;
ABBV-951
ABBVIE DEUTSCHLAND GMBH & CO. KG
2020 Phase 3 EUCTR2019-004235-23-IT Australia;Canada;Italy;Japan;Netherlands;Russian Federation;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-IT Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
AbbVie
2022 Phase 1 NCT05094050 United States;
2021 Phase 3 NCT04750226 Australia;United States;
2020 Phase 3 NCT04380142 Australia;United States;
2020 Phase 3 NCT04379050 Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 NCT03781167 Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
2018 Phase 1 NCT03374917 United States;
2017 Phase 1 NCT03033498 United States;
AbbVie Deutschland
2020 Phase 3 EUCTR2018-002144-85-DE Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-NL Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-GB Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-ES Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-DK Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-BE Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
Abbvie Deutschland GmbH & Co. KG
2021 Phase 3 EUCTR2019-004235-23-SE Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004235-23-DE Australia;Canada;Germany;Italy;Japan;Netherlands;Russian Federation;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-NL Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-GB Australia;Canada;Japan;Russian Federation;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-DK Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
ABT-SLV187
AbbVie
2015 Phase 3 NCT02549092 Australia;Canada;Germany;Greece;Italy;Korea, Republic of;Spain;Sweden;United States;
2014 Phase 3 NCT02082249 Japan;Korea, Republic of;Taiwan;
AbbVie (prior sponsor, Abbott)
2011 Phase 2 NCT01479127 Japan;
Abbott Japan Co., Ltd.
- Phase 2 JPRN-JapicCTI-111699 -
ACP-103
ACADIA PHARMACEUTICALS INC.
2009 - EUCTR2007-003035-22-IT Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
ACADIA Pharmaceuticals Inc.
2004 Phase 2 NCT00087542 United States;
Acadia Pharmaceuticals Inc
2009 Phase 2;Phase 3 EUCTR2007-003035-22-AT Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
2008 Phase 2;Phase 3 EUCTR2007-003035-22-FR Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
2008 - EUCTR2007-003051-36-SE Austria;Portugal;Spain;Sweden;
2008 - EUCTR2007-003051-36-PT Austria;Portugal;Spain;Sweden;
2008 - EUCTR2007-003051-36-ES Austria;Portugal;Spain;Sweden;
2008 - EUCTR2007-003051-36-BE Austria;Belgium;Portugal;Spain;Sweden;
2008 - EUCTR2007-003051-36-AT Austria;Portugal;Spain;Sweden;
2008 - EUCTR2007-002906-23-BG Bulgaria;France;United Kingdom;
2007 - EUCTR2007-002906-23-GB Bulgaria;France;United Kingdom;
2007 - EUCTR2007-002906-23-FR Bulgaria;France;United Kingdom;
National Institute of Neurological Disorders and Stroke (NINDS)
2004 Phase 2 NCT00086294 United States;
ACR325
NeuroSearch A/S
2009 Phase 1 NCT01023282 Germany;
AD-810N (zonisamide)
Dainippon Sumitomo Pharma Co., Ltd.
- Phase 3 JPRN-JapicCTI-070377 -
- - JPRN-JapicCTI-050099 -
ADS-5102
Adamas Pharmaceuticals, Inc.
2015 Phase 3 EUCTR2014-003739-20-FR Austria;France;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003739-20-ES Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003739-20-DE Austria;France;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003739-20-AT Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003738-24-ES Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003738-24-DE Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003738-24-AT Austria;Germany;Spain;United States;
2014 Phase 3 NCT02274766 Austria;France;Germany;Spain;United States;
2014 Phase 3 NCT02202551 Austria;Canada;France;Germany;Spain;United States;
2014 Phase 3 NCT02136914 Canada;United States;
ADS-5102 (extended release amantadine HCl)
Adamas Pharmaceuticals, Inc.
2011 Phase 2/Phase 3 NCT01397422 United States;
ADX48621
Addex Pharma S.A.
2011 Phase 2 NCT01336088 Austria;France;Germany;United States;
Addex Pharma SA
2011 Phase 2 EUCTR2010-022517-25-DE Austria;France;Germany;United States;
2011 - EUCTR2010-022517-25-AT Austria;France;Germany;United States;
AFFITOPE® PD01A
Affiris AG
2016 Phase 1 NCT02618941 Austria;
2014 Phase 1 NCT02216188 Austria;
2012 Phase 1 NCT01568099 Austria;
AFFITOPE® PD01A + Adjuvant
Affiris AG
2015 Phase 1 NCT02758730 Germany;
AFQ056
NOVARTIS FARMA
2012 - EUCTR2011-004378-27-IT Austria;Canada;Germany;Hungary;Italy;Spain;United States;
2012 - EUCTR2011-002074-23-IT Austria;Canada;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
2011 - EUCTR2011-002073-30-IT Canada;European Union;Germany;Italy;Spain;Switzerland;United States;
2009 - EUCTR2008-008712-98-IT Finland;France;Germany;Italy;Spain;
Novartis
2009 Phase 2 NCT00986414 Australia;Canada;Finland;France;Germany;Italy;Japan;Spain;
2009 Phase 2 NCT00888004 Germany;
2007 Phase 2 NCT00582673 Germany;
Novartis Farmacéutica, S.A.
2012 - EUCTR2011-002074-23-ES Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
Novartis Pharma AG
2010 - EUCTR2010-019418-25-FR Finland;France;Germany;Italy;
2010 - EUCTR2010-019418-25-FI Finland;France;Germany;Italy;
2009 - EUCTR2008-008712-98-FR Finland;France;Germany;Italy;Spain;
2009 - EUCTR2008-008712-98-FI Finland;France;Germany;Italy;Spain;
2009 - EUCTR2008-008712-98-DE Finland;France;Germany;Italy;Spain;
Novartis Pharma Services AG
2012 - EUCTR2011-004378-27-SK Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
2012 - EUCTR2011-004378-27-HU Austria;Canada;France;Germany;Hungary;Italy;Spain;United States;
2012 - EUCTR2011-004378-27-DE Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
2012 - EUCTR2011-004378-27-AT Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
2012 - EUCTR2011-002074-23-SK Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
2012 - EUCTR2011-002074-23-HU Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
2012 - EUCTR2011-002074-23-DE Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
2012 - EUCTR2011-002074-23-AT Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
2007 - EUCTR2007-002900-16-DE Germany;
- - EUCTR2011-002073-30-DE Canada;France;Germany;Hungary;Italy;Spain;United States;
Novartis Pharma Sevices AG
2010 - EUCTR2010-019418-25-DE Australia;Canada;Finland;France;Germany;Italy;Japan;
Novartis Pharmaceuticals
2012 Phase 2 NCT01491932 Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
2012 Phase 2 NCT01491529 Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
2011 Phase 2 NCT01385592 Canada;France;Germany;Hungary;Italy;Spain;United States;
2010 Phase 2 NCT01173731 Australia;Canada;Finland;France;Germany;Italy;Spain;United States;
AFQ056 with L-dopa
Novartis
2010 Phase 2 NCT01092065 United States;
AFQ065
Novartis Pharma AG
2010 - EUCTR2010-019418-25-FI Finland;France;Germany;Italy;
Novartis Pharma Sevices AG
2010 - EUCTR2010-019418-25-DE Australia;Canada;Finland;France;Germany;Italy;Japan;
AHA Exergame System
Campus Neurológico Sénior
2018 - NCT03891069 Portugal;
AKST4290
Alkahest, Inc.
2020 Phase 2 NCT04369430 Estonia;Germany;Hungary;Poland;Slovakia;United States;
2020 Phase 2 EUCTR2019-001657-42-SK Estonia;Germany;Hungary;Poland;Slovakia;United States;
2019 Phase 2 EUCTR2019-001657-42-DE Estonia;Germany;Hungary;Poland;Slovakia;United States;
ALTROPANE®
Molecular NeuroImaging
2006 Phase 2 NCT00397228 United States;
AMANTADINE HYDROCHLORIDE
CHU de Toulouse
2010 - EUCTR2009-016143-19-AT Austria;France;
AMBROSAN 60mg Tablets
Joint Research Office
2016 Phase 2 EUCTR2015-002571-24-GB United Kingdom;
ANAVEX2-73
Anavex Life Sciences Corp.
2019 Phase 2 NCT04575259 Australia;Spain;
2018 Phase 2 EUCTR2017-004335-36-ES Spain;
ANHYDROUS CARBIDOPA
BIAL-Portela & Ca, SA
2009 - EUCTR2009-012897-12-RO Romania;
Impax Laboratories, LLC
2020 Phase 3 EUCTR2018-002234-21-GB Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2018-002233-37-PL Canada;Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002234-21-ES Czech Republic;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002234-21-DE Czech Republic;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002234-21-CZ Czech Republic;Czechia;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-IT Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-GB Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-DE Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-CZ Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
AP-CD/LD
Intec Pharma Ltd.
2012 Phase 2 NCT00947037 Israel;
AP09004
Intec Pharma Ltd.
2009 Phase 2 NCT00918177 Israel;
APL-130277
SUNOVION PHARMACEUTICALS
2016 Phase 2 EUCTR2016-001762-29-IT Italy;
SUNOVION PHARMACEUTICALS INC
2018 Phase 3 EUCTR2016-003456-70-IT Austria;France;Germany;Italy;Spain;United Kingdom;
2018 Phase 3 EUCTR2016-000637-43-IT Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States;
Sunovion
2018 Phase 3 NCT03391882 Austria;France;Germany;Italy;Spain;United Kingdom;
2017 Phase 2 NCT03292016 United States;
2017 Phase 2 NCT03187301 Italy;United States;
2015 Phase 3 NCT02542696 Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States;
2015 Phase 3 NCT02469090 Canada;United Kingdom;United States;
2014 Phase 2 NCT02228590 United States;
Sunovion Pharmaceuticals Inc.
2018 Phase 3 EUCTR2016-003456-70-ES Austria;Spain;United Kingdom;
2018 Phase 3 EUCTR2016-003456-70-DE Austria;France;Germany;Italy;Spain;United Kingdom;
2018 Phase 3 EUCTR2016-003456-70-AT Austria;France;Germany;Italy;Spain;United Kingdom;
2018 Phase 3 EUCTR2016-000637-43-ES Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2016-000637-43-AT Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003456-70-GB Austria;France;Germany;Italy;Spain;United Kingdom;
2016 Phase 3 EUCTR2016-000637-43-GB Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States;
Sunuvion Pharmaceuticals Inc
2016 Phase 3 EUCTR2016-000636-18-GB Canada;United Kingdom;United States;
APO-go
SUNOVION PHARMACEUTICALS INC
2018 Phase 3 EUCTR2016-003456-70-IT Austria;France;Germany;Italy;Spain;United Kingdom;
Sunovion
2017 Phase 2 NCT03292016 United States;
Sunovion Pharmaceuticals Inc.
2018 Phase 3 EUCTR2016-003456-70-ES Austria;Spain;United Kingdom;
2018 Phase 3 EUCTR2016-003456-70-DE Austria;France;Germany;Italy;Spain;United Kingdom;
2018 Phase 3 EUCTR2016-003456-70-AT Austria;France;Germany;Italy;Spain;United Kingdom;
2017 Phase 3 EUCTR2016-003456-70-GB Austria;France;Germany;Italy;Spain;United Kingdom;
University Medical Center Groningen
2016 Phase 2;Phase 3 EUCTR2016-000102-11-NL Netherlands;
2015 Phase 2 EUCTR2014-000657-36-NL Netherlands;
APO-go®
Criceto IKM B.V.
2020 Phase 1;Phase 2 EUCTR2019-003315-60-NL Netherlands;
APOKINON
CHU Rennes
2021 Phase 4 EUCTR2021-000826-89-FR France;
CHU Toulouse
2007 - EUCTR2006-005318-11-FR France;
CHU de Rennes
2016 Phase 3 EUCTR2016-002454-20-FR France;
CHU de Toulouse
2010 Phase 3 EUCTR2010-018650-12-FR France;
APOMORFINA CLORIDRATO
SUNOVION PHARMACEUTICALS INC
2018 Phase 3 EUCTR2016-003456-70-IT Austria;France;Germany;Italy;Spain;United Kingdom;
APOMORPHINE HYDROCHLORIDE HEMIHYDRATE
Criceto IKM B.V.
2020 Phase 1;Phase 2 EUCTR2019-003315-60-NL Netherlands;
APORON
Criceto IKM B.V.
2020 Phase 1;Phase 2 EUCTR2019-003315-60-NL Netherlands;
AQW051
NOVARTIS FARMA
2012 - EUCTR2011-001092-39-IT Germany;Italy;United States;
Novartis Pharma Services AG
2011 - EUCTR2011-001092-39-DE France;Germany;Italy;United States;
Novartis Pharmaceuticals
2011 Phase 2 NCT01474421 France;Germany;Italy;United States;
ARICEPT
Eisai Limited
2002 Phase 3 NCT00165815 Germany;Ireland;
AS2
University College London
2015 Phase 2 EUCTR2014-002697-37-GB United Kingdom;
ASyn Mab
F. HOFFMANN - LA ROCHE LTD.
2021 Phase 2 EUCTR2020-004997-23-IT Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
F. Hoffmann-La Roche Ltd
2021 Phase 2 EUCTR2020-004997-23-FR Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004997-23-AT Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000087-15-FR Austria;France;Germany;Spain;United States;
2017 Phase 2 EUCTR2017-000087-15-ES Austria;France;Germany;Spain;United States;
2017 Phase 2 EUCTR2017-000087-15-DE Austria;France;Germany;Spain;United States;
2017 Phase 2 EUCTR2017-000087-15-AT Austria;France;Germany;Spain;United States;
Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
2021 Phase 2 EUCTR2020-004997-23-ES Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
ATH-1017
Athira Pharma
2022 Phase 2 NCT04831281 United States;
ATM FOG in PD
Medical University of South Carolina
2013 Phase 3 NCT03651856 United States;
AV-101
VistaGen Therapeutics, Inc.
2022 Phase 2 NCT04147949 -
AVALOX - 400
SUNOVION PHARMACEUTICALS
2016 Phase 2 EUCTR2016-001762-29-IT Italy;
AVE8112
Michael J. Fox Foundation for Parkinson's Research
2013 Phase 1 NCT01803945 United States;
AVP-923
Avanir Pharmaceuticals
2003 Phase 3 NCT00056524 United States;
AVP-923-45
Avanir Pharmaceuticals
2013 Phase 2 NCT01767129 Canada;United States;
AZD0328
King's College London
2021 Phase 2 NCT04810104 Norway;
AZD3241 300 mg BID
AstraZeneca
2012 Phase 2 NCT01603069 United States;
AZD3241 600 mg BID
AstraZeneca
2012 Phase 2 NCT01603069 United States;
AZD3241 Alternative titration scheme with formulation 1 or 2
AstraZeneca
2011 Phase 1 NCT01457807 United Kingdom;
AZD3241 ER formulation 1
AstraZeneca
2011 Phase 1 NCT01457807 United Kingdom;
AZD3241 Extended release tablets
AstraZeneca AB
2012 - EUCTR2011-004803-19-SE Finland;Sweden;
2012 - EUCTR2011-004803-19-FI Finland;Sweden;
AZILECT 1 mg comprimidos
Teva Pharmaceutical Industries Ltd
2009 Phase 4 EUCTR2009-011541-24-ES France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
AZILECT®
University Hospital, Clermont-Ferrand
2013 Phase 4 NCT01765257 France;
Aadipose-Derived Mesenchymal Stem Cells
Taiwan Mitochondrion Applied Technology Co., Ltd.
2022 Phase 1 NCT05094011 -
Abdominal compression
Vanderbilt University Medical Center
2020 Early Phase 1 NCT04620382 United States;
Acamprosate
Baylor College of Medicine
2006 - NCT00640952 United States;
Accordion Pill Carbidopa/Levodopa
Intec Pharma Ltd.
2018 Phase 2 NCT03576638 -
Accordion Pill ¿ Carbidopa/Levodopa 50/
INTEC PHARMA LTD
2016 Phase 3 EUCTR2015-003513-24-IT Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-IT Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Accordion Pill? Carbidopa/Levodopa 50/
Intec Pharma, Ltd.
2016 Phase 3 EUCTR2015-003513-24-ES Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-ES Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Accordion Pill¿ Carbidopa/levodopa
INTEC PHARMA LTD
2018 Phase 2 EUCTR2018-001209-95-IT Italy;Spain;
Accordion Pill™ Carbidopa/Levodopa
Intec Pharma Ltd.
2016 Phase 3 NCT02615873 Bulgaria;Germany;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 NCT02605434 Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
Accordion Pill™ Carbidopa/Levodopa 50/
Intec Pharma, Ltd.
2017 Phase 3 EUCTR2015-003513-24-SK Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003513-24-HU Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003513-24-GB Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003513-24-DE Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003513-24-BG Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-SK Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-PL Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-HU Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-GB Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
ActiMyo recording
Institut de Myologie, France
2016 - NCT02785978 France;
Active Investigational Treatment ENT-01
Enterin Inc.
2020 Phase 2 NCT04483479 United States;
2019 Phase 1 NCT03938922 United States;
2018 Phase 2 NCT03781791 United States;
Active comparator
Alexza Pharmaceuticals, Inc.
2018 Phase 1 NCT03822364 Netherlands;
Active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.
Biogen Idec
2003 Phase 2 NCT00451815 -
Active drug: pimavanserin 17mg (2 strength tablets)
University Hospital, Strasbourg, France
2020 Phase 2 NCT03947216 France;
Active tDCS
National Cheng-Kung University Hospital
2015 Phase 1/Phase 2 NCT02917122 -
Active tPCS
Western University, Canada
2019 - NCT04054960 Canada;
Adaptor: Hakko Adaptor
AbbVie (prior sponsor, Abbott)
2011 Phase 2 NCT01479127 Japan;
Adjuvant without active component
Affiris AG
2015 Phase 1 NCT02758730 Germany;
2014 Phase 1 NCT02267434 Austria;
Administration of stable isotope-labelled leucine-
University Hospital, Montpellier
2013 - NCT02263235 France;
Agomelatine or PIacebo
Second Affiliated Hospital of Soochow University
2019 Phase 4 NCT03977441 -
AlloRx
The Foundation for Orthopaedics and Regenerative Medicine
2022 Phase 1 NCT05152394 Antigua and Barbuda;
Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)
The University of Texas Health Science Center, Houston
2017 Phase 1 NCT02611167 United States;
Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)
The University of Texas Health Science Center, Houston
2017 Phase 1 NCT02611167 United States;
Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)
The University of Texas Health Science Center, Houston
2017 Phase 1 NCT02611167 United States;
Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)
The University of Texas Health Science Center, Houston
2017 Phase 1 NCT02611167 United States;
Allopurinol
Kamatani Naoyuki
2019 Phase 1 JPRN-jRCTs031190115 Japan;
Alternating, 10 sec High-Frequency, 10 sec Low-Frequency Stimulation
The Cleveland Clinic
2021 Phase 1 NCT05022147 United States;
Alternating, 10 sec High-Frequency, 50 sec Low-Frequency Stimulation
The Cleveland Clinic
2021 Phase 1 NCT05022147 United States;
Alternating, 50 sec High-Frequency, 10 sec Low-Frequency Stimulation
The Cleveland Clinic
2021 Phase 1 NCT05022147 United States;
Alternating, 50 sec High-Frequency, 50 sec Low-Frequency Stimulation
The Cleveland Clinic
2021 Phase 1 NCT05022147 United States;
Amantadin-ratiopharm
CHU de Toulouse
2010 - EUCTR2009-016143-19-AT Austria;France;
Amantadine
CHU de Toulouse
2012 Phase 2 EUCTR2011-005201-75-FR France;
Comprehensive clinical study group concerning diagnosis, treatment, and prevention of the neurological disorders
2007 - JPRN-UMIN000000780 Japan;
Department of Neurology, Juntendo University School of Medicine
2013 - JPRN-UMIN000010596 Japan;
Northwestern University
2011 Phase 3 NCT01652534 United States;
Oregon Health and Science University
2009 - NCT00794313 United States;
Rabin Medical Center
2010 - NCT01190553 -
2008 Phase 2 NCT00600093 Israel;
Rush University Medical Center
2013 Phase 2 NCT01789047 United States;
2010 Phase 4 NCT01071395 Austria;Canada;France;United States;
University Hospital, Toulouse
2012 Phase 2 NCT01538329 France;
Amantadine HCl ER
Adamas Pharmaceuticals, Inc.
2014 Phase 3 NCT02153632 Canada;France;Germany;Spain;United States;
Amantadine HCl ER tablets
Adamas Pharmaceuticals, Inc.
2014 Phase 3 NCT02153645 Canada;France;Germany;Spain;United States;
Amantadine HCl Extended Release
Osmotica Pharmaceutical Corp.
2014 Phase 3 EUCTR2014-001132-10-ES Canada;France;Germany;Spain;United States;
2014 Phase 3 EUCTR2014-001131-36-ES Canada;France;Germany;Spain;United States;
2014 - EUCTR2014-001132-10-FR Canada;France;Germany;Spain;United States;
Amantadine HCl Extended Release Capsule
Adamas Pharmaceuticals, Inc.
2015 Phase 3 EUCTR2014-003739-20-FR Austria;France;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003739-20-ES Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003739-20-DE Austria;France;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003739-20-AT Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003738-24-ES Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003738-24-DE Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003738-24-AT Austria;Germany;Spain;United States;
Amantadine hydrochloride (HCl)
Adamas Pharmaceuticals, Inc.
2015 Phase 3 EUCTR2014-003739-20-FR Austria;France;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003739-20-ES Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003739-20-DE Austria;France;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003739-20-AT Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003738-24-ES Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003738-24-DE Austria;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-003738-24-AT Austria;Germany;Spain;United States;
Amantadine sulfate
Jee-Young Lee
2011 Phase 4 NCT01313845 Korea, Republic of;
Ambroxol
Lawson Health Research Institute
2015 Phase 2 NCT02914366 Canada;
University College, London
2016 Phase 2 NCT02941822 United Kingdom;
Ambroxol Hydrochloride
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
2022 Phase 2 NCT05287503 Italy;
Ambroxol hydrochloride
Joint Research Office
2016 Phase 2 EUCTR2015-002571-24-GB United Kingdom;
Ampreloxetine
THERAVANCE BIOPHARMA ANTIBIOTICS, INC.
2019 Phase 3 EUCTR2018-003289-15-IT Austria;Bulgaria;Canada;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Theravance Biopharma
2019 Phase 3 NCT03829657 Argentina;Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Theravance Biopharma Ireland Limited
2020 Phase 3 EUCTR2018-003289-15-DE Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-HU Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-ES Austria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Ampreloxetine chydrochloride
Theravance Biopharma Ireland Limited
2019 Phase 3 EUCTR2018-003289-15-PL Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Ampreloxetine hydrochloride
Theravance Biopharma Ireland Limited
2020 Phase 3 EUCTR2018-003941-41-PT Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-003941-41-AT Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-003289-15-PT Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-PL Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-IT Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-HU Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-GB Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-ES Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-EE Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-BG Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-GB Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-EE Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-DK Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-BG Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-AT Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Ampyra first,
University of Miami
2012 Phase 1/Phase 2 NCT01491022 United States;
Anle138b
MODAG GmbH
2020 Phase 1 NCT04685265 United Kingdom;
Anti-Parkinson medication
Beth Israel Deaconess Medical Center
2016 - NCT02994719 United States;
Anti-Parkinsonian Drugs
Second Affiliated Hospital, School of Medicine, Zhejiang University
2014 - NCT04928079 -
Antiparkinsonian Agent(s)
Sage Therapeutics
2016 Phase 2 NCT03000569 United States;
Aplindore
Ligand Pharmaceuticals
2008 Phase 2 NCT00623324 United States;
Aplindore MR tablets
Neurogen Corporation
2008 Phase 2 NCT00809302 United States;
Apo-go®
Britannia Pharmaceuticals Limited
2014 Phase 3 EUCTR2013-000980-10-NL Austria;Denmark;France;Germany;Netherlands;Spain;
2014 Phase 3 EUCTR2013-000980-10-DK Austria;Denmark;France;Germany;Netherlands;Spain;
2013 Phase 3 EUCTR2013-000980-10-AT Austria;Denmark;France;Germany;Netherlands;Spain;
STADA Arzneimittel AG
2014 Phase 3 EUCTR2013-000980-10-FR Austria;Denmark;France;Germany;Netherlands;Spain;
2014 Phase 3 EUCTR2013-000980-10-ES Austria;Denmark;France;Germany;Netherlands;Spain;
Apokinon
CHU de Rennes
2009 Phase 3 EUCTR2008-006045-10-FR France;
Apokyn
Sunovion
2017 Phase 2 NCT03292016 United States;
Apomor
Sunovion Pharmaceuticals Inc.
2018 Phase 3 EUCTR2016-003456-70-DE Austria;France;Germany;Italy;Spain;United Kingdom;
2018 Phase 3 EUCTR2016-003456-70-AT Austria;France;Germany;Italy;Spain;United Kingdom;
Apomorp
Sunovion Pharmaceuticals Inc.
2017 Phase 3 EUCTR2016-003456-70-GB Austria;France;Germany;Italy;Spain;United Kingdom;
Apomorphine
CHU de Toulouse
2010 Phase 3 EUCTR2010-018650-12-FR France;
Clinique Beau Soleil
2018 Phase 4 NCT02940912 France;
Fondation Ophtalmologique Adolphe de Rothschild
2016 Phase 4 NCT02688465 France;
Oregon Health and Science University
2009 Phase 2 NCT00758368 United States;
2005 Phase 2 NCT00472355 United States;
Rennes University Hospital
2021 Phase 4 NCT04887467 France;
2017 Phase 3 NCT02864004 France;
University Hospital, Toulouse
2007 - NCT00524914 France;
University Medical Center Groningen
2017 Phase 2 NCT02702076 Netherlands;
2016 Phase 2;Phase 3 EUCTR2016-000102-11-NL Netherlands;
2015 Phase 2 EUCTR2014-000657-36-NL Netherlands;
Apomorphine (2.5mg/ml)
University Medical Center Groningen
2015 Phase 2 NCT02230930 Netherlands;
Apomorphine HCl injection
Mylan Bertek Pharmaceuticals
2001 Phase 3 NCT00200525 -
2001 Phase 3 NCT00145171 -
1999 Phase 3 NCT00142545 United States;
1999 Phase 2/Phase 3 NCT00200512 United Kingdom;
Apomorphine Hydrocloride Hemihydrate
SUNOVION PHARMACEUTICALS
2016 Phase 2 EUCTR2016-001762-29-IT Italy;
Apomorphine Injectable Solution
University of Calgary
2021 Phase 2/Phase 3 NCT04879134 Canada;
Apomorphine Nasal Powder
Britannia Pharmaceuticals Limited
2006 Phase 3 EUCTR2006-000391-32-GB Germany;Netherlands;United Kingdom;
2006 - EUCTR2006-000391-32-NL Germany;Netherlands;United Kingdom;
2006 - EUCTR2006-000391-32-DE Germany;Netherlands;United Kingdom;
Britannia Pharmaceuticals Ltd.
2006 Phase 2/Phase 3 NCT00346827 -
Apomorphine hydrochloride
Britannia Pharmaceuticals Limited
2014 Phase 3 EUCTR2013-000980-10-NL Austria;Denmark;France;Germany;Netherlands;Spain;
2014 Phase 3 EUCTR2013-000980-10-DK Austria;Denmark;France;Germany;Netherlands;Spain;
2013 Phase 3 EUCTR2013-000980-10-AT Austria;Denmark;France;Germany;Netherlands;Spain;
Britannia Pharmaceuticals Ltd.
2014 Phase 3 NCT02006121 Austria;Denmark;France;Germany;Netherlands;Spain;United Kingdom;
Kyowa Kirin Co., Ltd.
2007 Phase 2 NCT00610103 Japan;
STADA Arzneimittel AG
2014 Phase 3 EUCTR2013-000980-10-FR Austria;Denmark;France;Germany;Netherlands;Spain;
2014 Phase 3 EUCTR2013-000980-10-ES Austria;Denmark;France;Germany;Netherlands;Spain;
SUNOVION PHARMACEUTICALS INC
2018 Phase 3 EUCTR2016-000637-43-IT Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States;
Vectura Group plc
2006 Phase 2 EUCTR2006-005509-79-GB United Kingdom;
2006 Phase 2 EUCTR2006-004582-33-GB United Kingdom;
2005 Phase 2 EUCTR2005-005120-13-GB United Kingdom;
Apomorphine hydrochloride 1.8mg inhalation powder, pre-dispensed
Vectura Limited
2009 - EUCTR2008-004447-11-GB Germany;Italy;United Kingdom;
- - EUCTR2008-004447-11-DE Germany;Italy;United Kingdom;
Apomorphine hydrochloride 2.8mg inhalation powder, pre-dispensed
Vectura Limited
2009 - EUCTR2008-004447-11-GB Germany;Italy;United Kingdom;
- - EUCTR2008-004447-11-DE Germany;Italy;United Kingdom;
Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed
Vectura Limited
2009 - EUCTR2008-004447-11-GB Germany;Italy;United Kingdom;
- - EUCTR2008-004447-11-DE Germany;Italy;United Kingdom;
Apomorphine hydrochloride 5.8 mg inhalation powder, pre-dispensed
Vectura Limited
2009 - EUCTR2008-004447-11-GB Germany;Italy;United Kingdom;
- - EUCTR2008-004447-11-DE Germany;Italy;United Kingdom;
Apomorphine infusion
US WorldMeds LLC
2015 Phase 3 NCT02339064 United States;
Aricept 5 mg-Filmtabletten
Eisai Limited
2004 - EUCTR2004-003355-39-AT Austria;
Aricept 5mg-Filmtabletten
Eisai Limited
2004 - EUCTR2004-003355-39-AT Austria;
Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc.
2003 Phase 4 NCT00095810 United States;
Armodafinil
NYU Langone Health
2011 - NCT01256905 United States;
Artane
First Affiliated Hospital of Xinjiang Medical University
2007 - ChiCTR-TRC-07000027 China;
Atomoxetine
Hubert Fernandez
2016 Early Phase 1 NCT02879136 United States;
Johns Hopkins University
2005 - NCT00286949 United States;
Medical University of South Carolina
2012 Phase 2 NCT01738191 United States;
University of Pennsylvania
2004 Phase 4 NCT00304161 United States;
Atypical Antipsychotics
Pontifical Catholic University of Argentina
2015 - NCT02409823 -
Autologous mesenchymal stem cells
Belarusian Medical Academy of Post-Graduate Education
2017 Phase 2/Phase 3 NCT04146519 Belarus;
Azathioprine
Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
2019 Phase 2 EUCTR2018-003089-14-GB United Kingdom;
Azilect
Dresden University of Technology
2011 - EUCTR2010-023756-82-DE Germany;
Institut de Recerca de l'Hospital de la santa Creu i Sant Pau
2007 - EUCTR2007-004400-12-ES Spain;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
2011 - EUCTR2009-015161-31-DE Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
2011 Phase 3 EUCTR2009-013552-72-GB Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015162-57-PT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015161-31-PT Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2011 Phase 3 EUCTR2009-015162-57-GB Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-BG Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015161-31-GB Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015161-31-BG Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-013552-72-BG Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
- - EUCTR2009-013552-72-DE Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Merck Sharp & Dohme corp.
2011 Phase 3 EUCTR2009-015162-57-NL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Schering Corporation, división Schering-Plough Research
2010 Phase 3 EUCTR2009-013552-72-ES Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
Schering-Plough Research Institute, a division of Schering Corporation
2011 Phase 3 EUCTR2009-015162-57-LV Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-LT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-FI Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-ES Austria;Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2011 Phase 3 EUCTR2009-015162-57-CZ Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-013552-72-CZ Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015162-57-SE Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-PL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-AT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015161-31-PL Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015161-31-CZ Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-013552-72-PL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 Phase 3 EUCTR2009-015161-31-IT Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2009-015161-31-FR Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2009-013552-72-HU Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2009-013552-72-FI Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-SE Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-NL Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-FI Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-AT Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-013552-72-SE Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-013552-72-IT Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
Schering-Plough Research Institute, division of Schering Corporation
2011 - EUCTR2009-015162-57-IT Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
Technische Universität Dresden
2009 Phase 4 NCT00902941 Germany;
2009 - EUCTR2008-005085-30-DE Germany;
Teva Pharmaceuticals Industries LtD
2005 Phase 3 EUCTR2005-001416-42-GB Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
University of British Columbia
2013 - NCT02207387 Canada;
Azilect®
H. Lundbeck A/S
2011 Phase 3 NCT01479530 China;
2011 Phase 3 NCT01268891 Korea, Republic of;
Teva Pharma GmbH
2014 - NCT02384512 Germany;
B-CIT and SPECT imaging
Institute for Neurodegenerative Disorders
2006 Phase 2 NCT00404170 United States;
B-STN DBS
Vanderbilt University Medical Center
2006 - NCT00282152 United States;
B6, B12, L-methylfolate
North Shore Long Island Jewish Health System
2006 - NCT00853879 United States;
BAVISANT HYDROCHLORIDE MONOHYDRATE
BenevolentAI Bio
2017 Phase 2 EUCTR2017-000877-35-GB Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000877-35-ES Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000877-35-DE Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000877-35-CZ Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
BEFIRADOL
Neurolixis SAS
2021 Phase 2 EUCTR2020-006053-22-SE Sweden;
BEN-2001
BenevolentAI Bio
2017 Phase 2 NCT03194217 United States;
BENSERAZIDE HYDROCHLORIDE
BIAL-Portela & Ca, SA
2009 - EUCTR2009-012897-12-RO Romania;
Bial - Portela & Ca, S.A.
2022 Phase 4 EUCTR2020-002754-24-DE Germany;Italy;Portugal;Spain;United Kingdom;
2021 Phase 4 EUCTR2020-002754-24-ES Germany;Italy;Portugal;Spain;United Kingdom;
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2011 - EUCTR2010-022363-35-DE Germany;
BF 2.649
Bioprojet
2007 Phase 2 NCT00642928 France;
2007 - EUCTR2007-003512-57-FR France;
BF2.649
BIOPROJET
2010 - EUCTR2009-013886-24-SE Czech Republic;Germany;Sweden;
2010 - EUCTR2009-013886-24-DE Czech Republic;Germany;Sweden;
2009 - EUCTR2009-013886-24-CZ Czech Republic;Germany;Sweden;
2009 - EUCTR2009-013885-14-FR France;Spain;
2009 - EUCTR2009-013885-14-ES France;Spain;
BF2.649 (Pitolisant)
Bioprojet
2010 Phase 3 NCT01066442 Germany;
BF2.649 (pitolisant)
Bioprojet
2009 Phase 3 NCT01036139 France;
BI-Sifrol®
Boehringer Ingelheim
2004 Phase 4 NCT02231905 -
BIA 3-202
BIAL - Portela & Cª, SA
2006 - EUCTR2006-001793-24-PT Austria;Portugal;
2006 - EUCTR2006-001793-24-AT Austria;Portugal;
Bial - Portela C S.A.
2005 Phase 2 NCT02834507 -
2005 Phase 1 NCT02778594 Portugal;
2005 Phase 1 NCT02774564 Portugal;
2001 Phase 1 NCT02763852 Portugal;
2001 Phase 1 NCT02763839 Portugal;
2000 Phase 1 NCT02763800 United Kingdom;
2000 Phase 1 NCT02763787 United Kingdom;
BIA 3-202 (200 mg)
Bial - Portela C S.A.
2006 Phase 1 NCT02772614 Switzerland;
BIA 6-512
Bial - Portela C S.A.
2006 Phase 1 NCT03097211 Portugal;
2006 Phase 1 NCT03095105 Germany;
2006 Phase 1 NCT03094156 Portugal;
2005 Phase 1 NCT03095092 Portugal;
2005 Phase 1 NCT03093389 Portugal;
2004 Phase 1 NCT03091868 Portugal;
BIA 6-512 100 mg dose
Bial - Portela C S.A.
2004 Phase 1 NCT03091543 Portugal;
BIA 6-512 200 mg dose
Bial - Portela C S.A.
2004 Phase 1 NCT03091543 Portugal;
BIA 6-512 25 mg dose
Bial - Portela C S.A.
2004 Phase 1 NCT03091543 Portugal;
BIA 6-512 50 mg dose
Bial - Portela C S.A.
2004 Phase 1 NCT03091543 Portugal;
BIA 9 1067
Bial - Portela C S.A.
2018 Phase 1 NCT04265027 United Kingdom;
BIA 9-1067
BIAL - PORTELA & Cª, S.A.
2011 - EUCTR2010-021860-13-IT Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Russian Federation;Slovakia;Spain;
BIAL - Portela & Ca, S.A.
2011 Phase 3 EUCTR2010-021860-13-RO Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-SK Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-ES Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
2011 - EUCTR2010-021860-13-DE Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-CZ Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-BG Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-AT Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2010 - EUCTR2010-021860-13-PT Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2010 - EUCTR2010-021860-13-LV Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
2010 - EUCTR2010-021860-13-LT Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2010 - EUCTR2010-021860-13-HU Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
BIAL Portela & Cª, S.A.
2011 Phase 3 EUCTR2010-022366-27-GB Argentina;Australia;Belgium;Chile;Czech Republic;Estonia;India;Israel;Korea, Republic of;Russian Federation;South Africa;United Kingdom;
2011 Phase 3 EUCTR2010-022366-27-BE Belgium;Czech Republic;Estonia;United Kingdom;
2011 - EUCTR2010-022366-27-CZ Argentina;Australia;Belgium;Chile;Czech Republic;Estonia;India;Israel;Korea, Republic of;Russian Federation;South Africa;United Kingdom;
2010 - EUCTR2010-022366-27-EE Belgium;Czech Republic;Estonia;United Kingdom;
BIAL – Portela & Cª, S.A.
2021 Phase 3 EUCTR2020-005011-52-PT Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
2021 Phase 3 EUCTR2020-005011-52-FR Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
2021 Phase 3 EUCTR2020-005011-52-CZ Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
2021 Phase 3 EUCTR2020-005011-52-BG Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
2021 Phase 3 EUCTR2020-005011-52-BE Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
BIAL-Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-002754-24-IT Germany;Italy;Portugal;Spain;United Kingdom;
2021 Phase 3 EUCTR2020-005011-52-IT Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
2020 Phase 4 EUCTR2020-001175-32-IT Germany;Italy;Portugal;Spain;United Kingdom;
BIAL-Portela & Ca, SA
2009 - EUCTR2009-012897-12-RO Romania;
Bial - Portela & Cª, S.A.
2008 - EUCTR2008-003869-72-PT Portugal;
Bial - Portela C S.A.
2016 Phase 4 NCT02847442 Germany;
2014 Phase 1 NCT02305030 -
2014 Phase 1 NCT02305017 -
2011 Phase 3 NCT01568073 Austria;Portugal;
2011 Phase 3 NCT01227655 Portugal;
2011 Phase 1 NCT02170376 France;
2011 Phase 1 NCT01520987 United States;
2010 Phase 2 NCT01568047 Romania;Ukraine;
2010 Phase 1 NCT02169414 France;
2010 Phase 1 NCT02101190 France;Russian Federation;
2010 Phase 1 NCT01532115 France;
2009 Phase 2 NCT01568034 Portugal;Romania;Ukraine;
2009 Phase 1 NCT02169466 Portugal;
2009 Phase 1 NCT02169440 Portugal;
2009 Phase 1 NCT01536366 Portugal;
2009 Phase 1 NCT01533116 Canada;
2009 Phase 1 NCT01533077 Canada;
2009 Phase 1 NCT01532141 France;
2009 Phase 1 NCT01532128 France;
2009 Phase 1 NCT01519284 Portugal;
2009 Phase 1 NCT01515891 Switzerland;
2008 Phase 1 NCT02169895 Canada;
2008 Phase 1 NCT02169479 Canada;
2008 Phase 1 NCT02169453 Canada;
2008 Phase 1 NCT02092168 France;
2008 Phase 1 NCT02071810 France;
2007 Phase 1 NCT01520727 France;
BIA 9-1067 (test)
Bial - Portela C S.A.
2019 Phase 1 NCT03820037 United Kingdom;
BIA 9-1067 micronized
Bial - Portela C S.A.
2014 Phase 1 NCT02305316 -
BIA 9-1067 non-micronized
Bial - Portela C S.A.
2014 Phase 1 NCT02305316 -
BIA9 1067
Bial - Portela C S.A.
2018 Phase 1 NCT04265027 United Kingdom;
BIIB014
BIOGEN IDEC LTD
2006 Phase 2 EUCTR2006-003490-27-GB United Kingdom;
Biogen Idec
2007 Phase 2 NCT00442780 Former Serbia and Montenegro;Israel;Poland;Serbia;
2007 Phase 2 NCT00438607 India;Israel;United Kingdom;
BIIB054
BIOGEN IDEC RESEARCH LIMITED
2018 Phase 2 EUCTR2016-004610-95-IT Australia;Austria;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;United States;
Biogen
2019 Phase 1 NCT03716570 Japan;
2018 Phase 2 NCT03318523 Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom;United States;
2015 Phase 1 NCT02459886 United States;
Biogen Idec Research Limited
2018 Phase 2 EUCTR2016-004610-95-GB Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom;United States;
2018 Phase 2 EUCTR2016-004610-95-FR Austria;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2016-004610-95-ES Austria;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;United States;
2018 Phase 2 EUCTR2016-004610-95-DE Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom;United States;
2018 Phase 2 EUCTR2016-004610-95-AT Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom;United States;
BIIB094
Biogen
2019 Phase 1 NCT03976349 Canada;Israel;Norway;Spain;United Kingdom;United States;
BT
University of Valencia
2020 - NCT04353947 Spain;
BTRX-246040
BlackThorn Therapeutics, Inc.
2018 Phase 2 NCT03608371 United States;
BTX-A
Shanghai Tongji Hospital, Tongji University
2017 - ChiCTR-INR-17012013 China;
Balance
Affiliated Lianyungang Hospital of Xuzhou Medical University
2017 - ChiCTR-IPR-17011875 China;
Ankara Yildirim Beyazit University
2019 - NCT04420910 Turkey;
Boston University Charles River Campus
2011 - NCT02302144 United States;
Domen Kazuhisa
2018 - JPRN-jRCTs052180158 Japan;
Gansu Provincial Hospital
2020 Phase 0 ChiCTR2000035872 China;
Gazi University
2018 - NCT03587168 Turkey;
Hyogo College of Medicine
2018 - JPRN-UMIN000033454 Japan;
Istanbul Kültür University
2018 - NCT03827746 Turkey;
Juntendo University
2015 - JPRN-UMIN000016591 Japan;
Karolinska Institutet
2010 - NCT01417598 Sweden;
National Taiwan University Hospital
2007 Phase 1 NCT01301651 Taiwan;
Rehabilitation Institute of Chicago
2010 - NCT01228851 United States;
Sage Bionetworks
2015 - NCT02696603 United States;
Shanghai Tongji Hospital
2014 - ChiCTR-TRC-14004707 China;
Shanghai University of Sport
2020 - ChiCTR2000038852 china;
The Hong Kong Polytechnic University
2021 - NCT04665869 Hong Kong;
2018 - NCT04048291 Hong Kong;
Tianjin Huanhu Hospital
2019 - ChiCTR1900022715 China;
Tsinghua University Yuquan Hospital
2019 Phase 0 ChiCTR1900027210 China;
University Hospital, Basel, Switzerland
2016 - NCT02935842 Switzerland;
University of California, San Francisco
2010 Phase 2 NCT01162226 United States;
University of Houston
2019 - NCT04146454 United States;
University of Kiel
2011 - NCT02253563 -
University of Manitoba
2017 - NCT03232996 Canada;
University of Nevada, Las Vegas
2014 Phase 2 NCT02230267 United States;
University of Pavia
2014 - NCT03314597 -
University of Sao Paulo General Hospital
2015 - NCT02488265 Brazil;
University of Valencia
2021 - NCT04963894 Spain;
University of Vigo
2018 - NCT03882398 Spain;
Xianhui Feng
2020 Phase 0 ChiCTR2000034323 China;
Yeditepe University
2021 - NCT04694872 Turkey;
Balance Training
Bezmialem Vakif University
2018 - NCT04228887 Turkey;
Balance Training with Nintendo Wii Fit
Sao Camilo University Center
2009 - NCT01580787 -
Bavisant dihydrochloride monohydrate
BENEVOLENTAI BIO
2017 Phase 2 EUCTR2017-000877-35-IT Czech Republic;Czechia;Germany;Italy;Poland;Spain;United Kingdom;United States;
BenevolentAI Bio
2017 Phase 2 EUCTR2017-000877-35-GB Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000877-35-ES Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000877-35-DE Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000877-35-CZ Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
Beam
University Medical Center Groningen
2018 - NCT03532984 Brazil;Germany;Hungary;Japan;Netherlands;
Bee venom
Assistance Publique - Hôpitaux de Paris
2011 Phase 2 NCT01341431 France;
Benserazide
Bial - Portela C S.A.
2011 Phase 3 NCT01568073 Austria;Portugal;
2011 Phase 3 NCT01227655 Portugal;
First Affiliated Hospital of Xinjiang Medical University
2007 - ChiCTR-TRC-07000027 China;
The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital)
2020 Phase 4 ChiCTR2000039201 China;
Berachin
CuraSen Therapeutics, Inc.
2020 Phase 2 EUCTR2020-003796-17-GB United Kingdom;
Best Medical Treatment
German Parkinson Study Group (GPS)
2006 Phase 4 NCT00354133 France;Germany;
Best médical treatment
Poitiers University Hospital
2011 Phase 2 NCT01291537 France;
Betaquik MCT supplement
Université de Sherbrooke
2021 - NCT04322461 -
Better
University of California, San Francisco
2020 - NCT04428112 United States;
Biofluid samplings
Michael J. Fox Foundation for Parkinson's Research
2015 - NCT02572713 Canada;United States;
Biological/Vaccine: Allogeneic HB-adMSCs
Hope Biosciences Stem Cell Research Foundation
2021 Phase 2 NCT04995081 United States;
Bisphosphonates
FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE
2010 - EUCTR2010-018904-94-IT Italy;
Blood analysis
University Hospital, Strasbourg, France
2020 Phase 2 NCT03947216 France;
Blood draw
Howard Gendelman, MD
2013 Phase 1 NCT01882010 United States;
BoNT-A
Western University, Canada
2011 Phase 2 NCT02427646 -
Bone marrow derived mesenchymal stem cells
Guangzhou General Hospital of Guangzhou Military Command
2011 Phase 1/Phase 2 NCT01446614 China;
Botulinum Toxin
University Health Network, Toronto
2014 Phase 4 NCT02472210 -
Botulinum Toxin Type B (Myobloc)
Solstice Neurosciences
2007 Phase 2 NCT00515437 United States;
Botulinum Toxin: Xeomin
University Hospital, Clermont-Ferrand
2009 Phase 3 NCT00909883 France;
Botulinum toxin
AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
2011 - EUCTR2009-017412-32-IT Italy;
Rabin Medical Center
2009 Phase 1 NCT00767546 -
Botulinum toxin type A
University of Calgary
2020 Phase 2/Phase 3 NCT04277247 Canada;
Bromocriptine
Boehringer Ingelheim
2003 Phase 3 NCT00240409 China;
1999 Phase 3 NCT02172573 -
Sandoz
2012 Phase 4 NCT01673724 Korea, Republic of;
Bromocriptine and other dopamine agonists
Boehringer Ingelheim
1998 Phase 4 NCT02233023 -
Bumetanide white, oblong, scored tablet
B&A Therapeutics
2019 Phase 2 NCT03899324 France;
Bupleurum+Ginkgo
Xuanwu Hospital, Beijing
2008 Phase 2 NCT01416818 China;
Buspirone
Oregon Health and Science University
2016 Phase 1 NCT02589340 United States;
University of Rochester
2016 Phase 2 NCT02803749 United States;
Buspirone Hydrochloride
Imperial College London-Imperial College Healthcare NHS Trust
2015 Phase 4 EUCTR2014-005422-35-GB United Kingdom;
Buspirone hydrochloride
Contera Pharma
2020 Phase 2 EUCTR2017-003415-19-IT France;Germany;Italy;Spain;
2018 Phase 2 EUCTR2017-003415-19-ES France;Germany;Spain;
Butylphthalide
The Second Affiliated Hospital of Soochow University
2016 - ChiCTR-IPR-16009395 China;
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2018 Phase 4 ChiCTR1800017084 China;
Zhujiang Hospital of Southern Medical University
2019 Phase 0 ChiCTR1900023725 China;
Bydureon
University College London
2014 Phase 2 EUCTR2013-003363-64-GB United Kingdom;
University College London Comprehensive Clinical Trial Unit
2019 Phase 3 EUCTR2018-003028-35-GB United Kingdom;
Bydureon 2 mg powder and solvent for prolonged-release suspension
Stockholm Health Care Services
2019 Phase 2 EUCTR2019-000732-26-SE Sweden;
Byetta 5 micrograms
University College London
2010 Phase 2 EUCTR2009-018137-37-GB United Kingdom;
CADD-Legacy ambulatory infusion pump
AbbVie
2017 Phase 3 NCT02799381 Finland;Greece;Hungary;Italy;Slovakia;Spain;United States;
CADD-Legacy® 1400 ambulatory infusion pump
AbbVie
2013 Phase 3 NCT01960842 Japan;Korea, Republic of;Taiwan;
2009 Phase 3 NCT00660673 Australia;Canada;Czech Republic;Czechia;Israel;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;United States;
AbbVie (prior sponsor, Abbott)
2009 Phase 3 NCT00660387 New Zealand;United States;
2009 Phase 3 NCT00360568 Germany;New Zealand;United States;
2009 Phase 3 NCT00357994 Germany;United States;
2008 Phase 3 NCT00335153 Australia;Canada;Czech Republic;Finland;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
2006 Phase 4 NCT00141518 Norway;Sweden;
CAPTURE
Westfälische Wilhelms-Universität Münster
2019 - NCT03638479 Germany;
CARBIDOPA (CD)
NEURODERM LTD.
2016 Phase 2 EUCTR2015-005814-31-IT Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
CARBIDOPA (FU)
NOVARTIS FARMA
2004 - EUCTR2004-000185-12-IT Finland;Italy;Sweden;United Kingdom;
CARBIDOPA ANIDRA
NOVARTIS FARMA
2005 - EUCTR2005-001032-72-IT Czech Republic;Italy;Portugal;
CARBIDOPA FU
VERNALIS DEVELOPMENT LIMITED
2006 - EUCTR2006-004112-51-IT Italy;
CARBIDOPA INN
NOVARTIS FARMA
2005 - EUCTR2005-001032-72-IT Czech Republic;Italy;Portugal;
CARBIDOPA LEVODOPA
IMPAX LABORATORIES, INC.
2010 - EUCTR2009-017238-39-IT France;Germany;Italy;
CARBIDOPA MONOHYDRATE
ABBVIE DEUTSCHLAND GMBH & CO. KG
2016 Phase 3 EUCTR2016-001403-23-IT European Union;Finland;Greece;Hungary;Italy;Slovakia;Spain;United States;
AbbVie Deutschland GmbH & Co. KG
2018 Phase 3 EUCTR2016-001403-23-HU European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
2017 Phase 3 EUCTR2016-001403-23-GR European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
2017 Phase 3 EUCTR2016-001403-23-FI European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
2017 Phase 3 EUCTR2014-004865-26-GR Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;United States;
2016 Phase 3 EUCTR2016-001403-23-SK European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
2016 Phase 3 EUCTR2016-001403-23-ES European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
2015 Phase 3 EUCTR2014-004865-26-SE Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;United States;
2015 Phase 3 EUCTR2014-004865-26-ES Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;
2015 Phase 3 EUCTR2014-004865-26-DE Australia;Canada;European Union;Germany;Italy;Spain;Sweden;
2015 - EUCTR2014-004865-26-IT Australia;Canada;European Union;Germany;Italy;Spain;Sweden;
Centre for Human Drug Research
2020 Phase 2 EUCTR2020-000686-16-NL Netherlands;
Civitas Therapeutics, Inc.
2012 - EUCTR2012-000181-37-GB Israel;Serbia;United Kingdom;
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2010 - EUCTR2009-017416-33-DE Germany;
Novartis Pharma Services AG
2008 - EUCTR2007-003134-42-DE Germany;
CARBODOPA LEVADOPA
Institute for Neurodegenerative Disorders
2005 - EUCTR2004-001485-41-ES Spain;United Kingdom;
CD
Yagi Michio
2021 Phase 1 JPRN-jRCT2051200104 Japan;
CD-LD CR
Impax Laboratories, LLC
2006 Phase 2 NCT00279825 United States;
CD-LD IR
Impax Laboratories, LLC
2015 Phase 2 NCT02271503 United States;
2006 Phase 2 NCT00279825 United States;
2005 Phase 2 NCT00253084 United States;
CDNF
Herantis Pharma Plc
2018 Phase 1;Phase 2 EUCTR2018-000346-19-SE Finland;Sweden;
2018 Phase 1;Phase 2 EUCTR2018-000346-19-FI Finland;Sweden;
2017 Phase 1;Phase 2 EUCTR2015-004175-73-FI Finland;
Renishaw Neuro Solutions Ltd.
2019 Phase 1;Phase 2 EUCTR2017-005170-19-FI Finland;Sweden;
2018 Phase 1;Phase 2 EUCTR2017-005170-19-SE Finland;Sweden;
CEP-1347
Cephalon
2002 Phase 2/Phase 3 NCT00040404 Canada;Puerto Rico;United States;
CEP1347
Cephalon
2002 Phase 2/Phase 3 NCT00040404 Canada;Puerto Rico;United States;
CERE-120
Ceregene Inc.
2008 - EUCTR2007-006721-27-GB United Kingdom;
2008 - EUCTR2007-006721-27-AT Austria;United Kingdom;
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])
Ceregene
2006 Phase 2 NCT00400634 United States;
CERE-120: Adeno-Associated Virus Delivery of Neurturin
Sangamo Therapeutics
2009 Phase 1/Phase 2 NCT00985517 United States;
CERETEC (TM) Estabilizado
IDIBAPS
2016 Phase 2 EUCTR2015-004238-85-ES Spain;
CITICOLIN*1G/4ML IM IV 5 F
PIAM FARMACEUTICI S.P.A.
2016 Phase 4 EUCTR2014-005562-30-IT Italy;
CITICOLINA SODICA
PIAM FARMACEUTICI S.P.A.
2016 Phase 4 EUCTR2014-005562-30-IT Italy;
CJH1 (CLR4001)
Alexandra Marine and General Hospital
2012 Phase 1/Phase 2 NCT01684475 Canada;
CLE
Impax Laboratories, LLC
2010 Phase 3 NCT01130493 France;Germany;Italy;United States;
CLENBUTEROL HYDROCHLORIDE
CuraSen Therapeutics, Inc.
2020 Phase 2 EUCTR2020-003796-17-GB United Kingdom;
CO
University of Manitoba
2014 - NCT02007785 Canada;
COMTAN
AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
2010 - EUCTR2010-019396-29-IT Italy;
IMPAX LABORATORIES, INC.
2010 - EUCTR2009-017238-39-IT France;Germany;Italy;
COMTAN 200* 60 CPR
KYOWA HAKKO UK LTD
2005 - EUCTR2004-000817-20-IT Italy;Latvia;Lithuania;Spain;
COMTAN®
BIAL - Portela & Cª, SA
2006 - EUCTR2006-001793-24-PT Austria;Portugal;
CP
Nagai Masahiro
2016 Phase 2 JPRN-jRCTs061180060 Japan;
CPL500036
Celon Pharma S.A.
2021 Phase 2 EUCTR2020-006004-16-PL Poland;
CST-103
CuraSen Therapeutics, Inc.
2020 Phase 2 EUCTR2020-003796-17-GB United Kingdom;
- Phase 2 EUCTR2020-006067-28-BE Australia;Belgium;New Zealand;United Kingdom;
CST-107
CuraSen Therapeutics, Inc.
- Phase 2 EUCTR2020-006067-28-BE Australia;Belgium;New Zealand;United Kingdom;
CST-139
CuraSen Therapeutics, Inc.
2020 Phase 2 EUCTR2020-003796-17-GB United Kingdom;
CVD00118-E
PREXTON THERAPEUTICS B.V.
2017 Phase 2 EUCTR2017-000135-14-IT Austria;France;Germany;Italy;Spain;United Kingdom;
Prexton Therapeutics B.V.
2017 Phase 2 EUCTR2017-000135-14-GB Austria;Germany;Spain;United Kingdom;
2017 Phase 2 EUCTR2017-000135-14-ES Austria;Germany;Italy;Spain;United Kingdom;
2017 Phase 2 EUCTR2017-000135-14-DE Austria;Germany;Italy;Spain;United Kingdom;
2017 Phase 2 EUCTR2017-000135-14-AT Austria;Germany;Spain;United Kingdom;
CVL-751
Cerevel Therapeutics LLC
2021 Phase 3 EUCTR2019-002952-17-IT Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002951-40-IT Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002950-22-IT Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002949-38-IT Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
Cerevel Therapeutics, LLC
2021 Phase 3 EUCTR2019-002952-17-DE Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2021 Phase 3 EUCTR2019-002952-17-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2021 Phase 3 EUCTR2019-002951-40-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2021 Phase 3 EUCTR2019-002949-38-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002952-17-HU Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002952-17-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002951-40-HU Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002951-40-ES Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002951-40-DE Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002951-40-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002950-22-HU Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002949-38-PL Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002949-38-HU Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002949-38-ES Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002949-38-DE Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002949-38-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States;
2020 Phase 1 NCT04295642 United States;
CVN424 High Dose
Cerevance Beta, Inc.
2019 Phase 2 NCT04191577 United States;
CVN424 Low Dose
Cerevance Beta, Inc.
2019 Phase 2 NCT04191577 United States;
CVT-301
Acorda Therapeutics
2019 Phase 1 NCT03887884 United States;
2015 Phase 3 NCT02352363 Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 NCT02242487 Canada;Czech Republic;Czechia;Poland;Spain;United States;
2013 Phase 2 NCT01777555 Italy;Serbia;United Kingdom;United States;
2012 Phase 2 NCT01617135 Israel;Serbia;United Kingdom;
Civitas Therapeutics, Inc.
2016 Phase 3 EUCTR2015-005626-19-CZ Canada;Czech Republic;Poland;Spain;United States;
2016 Phase 3 EUCTR2015-005067-17-CZ Canada;Czech Republic;Poland;Spain;United States;
2015 Phase 3 EUCTR2014-003799-22-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;
2015 Phase 3 EUCTR2014-003799-22-GB Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003799-22-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;
2015 Phase 3 EUCTR2014-003799-22-DE Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003799-22-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003799-22-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-003799-22-AT Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States;
2013 - EUCTR2012-005822-31-IT Italy;Serbia;United Kingdom;United States;
2013 - EUCTR2012-005822-31-GB Italy;Serbia;United Kingdom;United States;
2012 - EUCTR2012-000181-37-GB Israel;Serbia;United Kingdom;
Civitas Therapeutics, a wholly owned subsidiary of Acorda
2016 Phase 3 EUCTR2015-005626-19-ES Canada;Czech Republic;Poland;Spain;United States;
Civitas Therapeutics, a wholly owned subsidiary of Acorda Therapeutics, Inc.
2016 Phase 3 EUCTR2015-005067-17-ES Canada;Czech Republic;Poland;Spain;United States;
CVT-301 (Dose Level 1)
Acorda Therapeutics
2016 Phase 1 NCT02812394 United States;
CVT-301 (Dose Level 2)
Acorda Therapeutics
2016 Phase 1 NCT02812394 United States;
CVT-301 High Dose
Acorda Therapeutics
2014 Phase 3 NCT02240030 Canada;Czech Republic;Czechia;Poland;Spain;United States;
CVT-301 Low Dose
Acorda Therapeutics
2014 Phase 3 NCT02240030 Canada;Czech Republic;Czechia;Poland;Spain;United States;
CVT-301, LIP
Acorda Therapeutics
2016 Phase 1 NCT02807675 United States;
CVXL-0107
CleveXel Pharma
2016 Phase 2 NCT02641054 France;
CX-8998
Jazz Pharmaceuticals
2019 Phase 2 NCT03436953 United States;
CYMBALTA
CHU de Toulouse
2010 Phase 3 EUCTR2010-018650-12-FR France;
Cabaser
Institute for Neurodegenerative Disorders
2005 - EUCTR2004-001485-41-GB Spain;United Kingdom;
Cabaseril
Institute for Neurodegenerative Disorders
2005 - EUCTR2004-001485-41-GB Spain;United Kingdom;
2005 - EUCTR2004-001485-41-AT Austria;Spain;United Kingdom;
Cabaseril, 1,0 mg Tablette
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
Cabaseril, 2,0 mg Tablette
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
Cabergoline
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-DE Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-CZ Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
Institute for Neurodegenerative Disorders
2005 - NCT00129181 Austria;Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2004-001485-41-GB Spain;United Kingdom;
2005 - EUCTR2004-001485-41-ES Spain;United Kingdom;
2005 - EUCTR2004-001485-41-AT Austria;Spain;United Kingdom;
Pfizer
2004 Phase 4 NCT00174239 Australia;Italy;Spain;United Kingdom;
Technische Universität Dresden
2005 Phase 4 NCT00153972 Germany;
Caffeine
Department of Neurology, Juntendo University
2016 - JPRN-UMIN000022187 Japan;
Kyowa Kirin Co., Ltd.
2019 Phase 1 NCT03970798 Japan;
McGill University Health Center
2014 Phase 3 NCT01738178 Brazil;Canada;
Caffeine 100-200 mg BID
Ron Postuma
2007 Phase 2/Phase 3 NCT00459420 Canada;
Caffeine alkaloid
Ron Postuma
2010 Phase 2 NCT01190735 Canada;
Calcium
VA Office of Research and Development
2011 Phase 2 NCT01119131 United States;
Cannabidiol
University of Colorado, Denver
2018 Phase 2 NCT03582137 United States;
2016 Phase 2 NCT02818777 United States;
Cannabidiol (CBD)
King's College London
2020 Phase 2 EUCTR2019-003623-37-GB United Kingdom;
Cannabis Oil
University Health Network, Toronto
2018 Phase 2 NCT03639064 -
Cannabis, Medical
OMNI Medical Services, LLC
2018 Phase 2 NCT03944447 United States;
Capsaicin
University of Florida
2017 - NCT03321019 United States;
2014 Phase 1/Phase 2 NCT02183519 United States;
Capsaicin vapor
University of Florida
2015 Phase 1 NCT02390089 United States;
Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)
Novartis
2005 Phase 3 NCT00134966 Canada;Czech Republic;Czechia;Israel;Italy;Poland;Portugal;Turkey;United States;
Carbidopa
BIAL-Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-002754-24-IT Germany;Italy;Portugal;Spain;United Kingdom;
Bial - Portela C S.A.
2011 Phase 3 NCT01568073 Austria;Portugal;
2011 Phase 3 NCT01227655 Portugal;
Department of Neuroscience, neurology
2007 - EUCTR2007-004985-41-SE Sweden;
Dept of Neuroscience, Uppsala University
2008 - EUCTR2008-003581-26-SE Sweden;
Fujita Health University School of MedicineDepartment of Gastroenterology
2020 Phase 4 JPRN-UMIN000040889 Japan;
Juntendo University School of Medicine
2017 - JPRN-UMIN000025645 Japan;
Kansai Medical University
2012 - JPRN-UMIN000007896 Japan;
Kyoto University
2017 Phase 1,2 JPRN-UMIN000030084 Japan;
Merck Sharp & Dohme Corp.
2009 Phase 1 NCT00845000 United States;
National Institute of Neurological Disorders and Stroke (NINDS)
2007 Phase 1/Phase 2 NCT00547911 United States;
NeuroDerm Ltd.
2011 Phase 1/Phase 2 NCT01229332 Israel;
Oregon Health and Science University
2009 Phase 2 NCT01399905 United States;
Orion Corporation Orion Pharma
2007 - EUCTR2007-002496-14-FI Finland;
2006 Phase 4 EUCTR2006-001755-36-GB Germany;Sweden;United Kingdom;
- - EUCTR2006-001755-36-DE Germany;Sweden;United Kingdom;
Orion Corporation Orion Pharma, FI-02200 Espoo, Finland
2006 - EUCTR2006-001755-36-SE Germany;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA
2005 - EUCTR2004-005234-39-FI Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-FI Finland;Italy;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA, Finland
2005 Phase 4 EUCTR2004-005234-39-GB Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA, 02200 Espoo, Finland
2008 - EUCTR2004-005234-39-DE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2007 Phase 3 EUCTR2004-000185-12-GB Austria;Finland;Italy;Sweden;United Kingdom;
2006 - EUCTR2004-005234-39-LV Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2006 - EUCTR2004-005234-39-LT Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 Phase 4 EUCTR2004-005234-39-IE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-005234-39-SE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-005234-39-DK Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-SE Finland;Italy;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-AT Austria;Finland;Italy;Sweden;United Kingdom;
Orion Corporation, Orion Pharma
2011 Phase 2 NCT01296464 Finland;Sweden;
Solvay Pharmaceuticals BV.
2008 - EUCTR2006-005186-18-IT Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
Solvay Pharmaceuticals GmbH
2006 - EUCTR2005-002654-21-NO Norway;Sweden;
2005 - EUCTR2005-002654-21-SE Sweden;
The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital)
2020 Phase 4 ChiCTR2000039201 China;
Vanderbilt University Medical Center
2017 Phase 4 NCT03115827 United States;
Yagi Michio
2021 Phase 1 JPRN-jRCT2051200104 Japan;
Carbidopa 200mg oral dose
Daniel Claassen
2020 Phase 1 NCT04246437 United States;
Carbidopa 65 mg capsule
Orion Corporation
2017 Phase 2 EUCTR2015-004507-23-HU Finland;Germany;Hungary;Latvia;
2017 Phase 2 EUCTR2015-004507-23-FI Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-LV Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-DE Finland;Germany;Hungary;Latvia;
Carbidopa Levodopa
Neurocrine Biosciences
2018 Phase 1 NCT03496870 United States;
Carbidopa Monohydrate
Abbott Healthcare Products B.V.
2009 - EUCTR2006-005186-18-CZ Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
2008 Phase 3 EUCTR2006-005186-18-GB Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
2008 - EUCTR2006-005186-18-PT Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2006-005186-18-DE Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
Abbott Laboratories
2009 - EUCTR2006-000578-53-DE Germany;New Zealand;United States;
Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
2007 - EUCTR2006-000577-29-DE Germany;United States;
Solvay Pharmaceuticals B.V.
2009 - EUCTR2006-005186-18-NL Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2006-005186-18-ES Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2007 - EUCTR2006-005186-18-FI Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
Carbidopa Pill
XenoPort, Inc.
2009 Phase 1/Phase 2 NCT00914602 United States;
Carbidopa and Levodopa 25mg/
NeuroDerm Ltd.
2019 Phase 3 NCT04006210 Austria;Belgium;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
Carbidopa and Levodopa Controlled Release Tablets
Second Affiliated Hospital, School of Medicine, Zhejiang University
2022 Phase 4 NCT04952194 -
Carbidopa and Levodopa Tablets, USP
Impax Laboratories, LLC
2020 Phase 3 EUCTR2018-002233-37-PL Canada;Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-IT Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-GB Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-DE Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-CZ Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
Carbidopa and Levodopa tablets, USP
NEURODERM LTD.
2020 Phase 3 EUCTR2018-004156-37-IT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
NeuroDerm Ltd.
2020 Phase 3 EUCTR2018-004156-37-SK Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-SE Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-PT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-NL Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-GB Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-ES Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-BE Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-AT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004156-37-HU Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004156-37-CZ Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
Carbidopa monohydrate
AbbVie Inc
2011 Phase 3 EUCTR2008-001329-33-GB Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
2010 Phase 3 EUCTR2008-001329-33-CZ Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
2009 - EUCTR2008-001329-33-PT Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
Carbidopa, levodopa, entacapone
Novartis
2005 Phase 4 NCT00143026 Australia;Philippines;Taiwan;Thailand;
Carbidopa- Levodopa
Oregon Health and Science University
2008 Phase 2 NCT00745277 United States;
Carbidopa-4'-Monophosphate
ABBVIE DEUTSCHLAND GMBH & CO. KG
2019 Phase 3 EUCTR2018-002144-85-IT Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
AbbVie Deutschland
2020 Phase 3 EUCTR2018-002144-85-DE Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-NL Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-GB Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-ES Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-DK Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-BE Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
Abbvie Deutschland GmbH & Co. KG
2021 Phase 3 EUCTR2019-004235-23-SE Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004235-23-DE Australia;Canada;Germany;Italy;Japan;Netherlands;Russian Federation;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-NL Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-GB Australia;Canada;Japan;Russian Federation;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-DK Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
Carbidopa-Levodopa
Northwestern University
2011 - NCT01528592 United States;
Oregon Health and Science University
2008 Phase 2 NCT00745277 United States;
Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet
Western University, Canada
2021 - NCT04590612 -
Carbidopa-levodopa
Baylor College of Medicine
2006 Phase 4 NCT00590122 United States;
Carbidopa/Levodopa, immediate release
Intec Pharma Ltd.
2009 Phase 2 NCT00918177 Israel;
Carbidopa/Levodopa/Entacapone
Novartis Pharmaceuticals
2008 Phase 4 NCT00601978 United States;
Carbidopa/l-dopa/entacapone
Molecular NeuroImaging
2004 Phase 2 NCT00200447 -
Carbidopa/levodopa
Institute for Neurodegenerative Disorders
2005 - NCT00129181 Austria;Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2004-001485-41-GB Spain;United Kingdom;
2005 - EUCTR2004-001485-41-AT Austria;Spain;United Kingdom;
Carbidopa/levodopa, as prescribed by treating physician
University of Michigan
2020 - NCT04821830 United States;
Carbidopa/levodopa/entacapone
Novartis
2008 Phase 4 NCT00642356 United States;
Novartis Pharmaceuticals
2005 Phase 4 NCT00219284 Puerto Rico;United States;
2004 Phase 3 NCT00099268 Austria;Belgium;Canada;Finland;France;Germany;Greece;Italy;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Carbidopamonohydraat
Centre for Human Drug Research
2020 Phase 2 EUCTR2020-000686-16-NL Netherlands;
Carbodopa/levadopa
Institute for Neurodegenerative Disorders
2005 - EUCTR2004-001485-41-ES Spain;United Kingdom;
Carbon Fiber Ankle Foot Orthosis (AFO)
University of Texas Southwestern Medical Center
2016 - NCT03192046 United States;
Carbon-14 BIA 28-6156
Bial R&D Investments, S.A.
2021 Phase 1 NCT05220072 United Kingdom;
Cardiac monitoring
University Hospital, Strasbourg, France
2020 Phase 2 NCT03947216 France;
Carnosine supplementation
Slovak Academy of Sciences
2017 - NCT03330470 Slovakia;Taiwan;
Carvedilol
Cedars-Sinai Medical Center
2019 Phase 2 NCT04218968 United States;
Michele Tagliati, MD
2019 Phase 2 NCT03775096 United States;
Catapres ampoules
Summit (Cambridge) Ltd.
2007 - EUCTR2007-004654-81-GB United Kingdom;
Ceftriaxone
BrainX Corporation
2019 Phase 2 NCT03413384 Taiwan;
Cerebral Dopamine Neurotrophic Factor
Herantis Pharma Plc.
2018 Phase 1/Phase 2 NCT03775538 Finland;Sweden;
2017 Phase 1/Phase 2 NCT03295786 Finland;Sweden;
Champix
VU University Medical Center
2012 Phase 3 EUCTR2012-001530-34-NL Netherlands;
Chinese herbal medicine treatment
Hong Kong Baptist University
2021 Phase 2/Phase 3 NCT05001217 -
Chocolate
Technische Universität Dresden
2009 - NCT00906763 Germany;
Circadin®
University College London
2015 Phase 2 EUCTR2014-002697-37-GB United Kingdom;
Citalopram
University of Michigan
2021 Phase 2 NCT04497168 United States;
Western University, Canada
2021 - NCT04590612 -
Citicolina 1000 mg/die
PIAM FARMACEUTICI S.P.A.
2016 Phase 4 EUCTR2014-005562-30-IT Italy;
Clarithromycin
Kyowa Kirin Co., Ltd.
2019 Phase 1 NCT04070495 Japan;
Clarithromycin (Not used as of 4/2020)
Nicolaas Bohnen, MD, PhD
2018 Phase 1/Phase 2 NCT03440112 United States;
Clarium 50 mg Retardtabletten
Desitin Arzneimittel GmbH
2009 - EUCTR2009-012419-16-DE Germany;
Clartihromycin, amoxicillin, and omeprazole
University of California, Los Angeles
2008 Phase 3 NCT00664209 United States;
Clenbuterol HCl
CuraSen Therapeutics, Inc.
2020 Phase 2 EUCTR2020-003796-17-GB United Kingdom;
Clenbuterol Hydrochloride
CuraSen Therapeutics, Inc.
- Phase 2 EUCTR2020-006067-28-BE Australia;Belgium;New Zealand;United Kingdom;
Clonazepam
Seoul National University Hospital
2016 Phase 2 NCT02789592 Korea, Republic of;
Clonidine
Hospices Civils de Lyon
2019 Phase 2 NCT03552068 France;
Clonidine (Catapressan)
Hospices Civils de Lyon
2012 - NCT01796483 France;
Clonidine hydrochloride
Summit (Cambridge) Ltd.
2007 - EUCTR2007-004654-81-GB United Kingdom;
Clozapine
Memorial Hospital of Rhode Island
1993 - NCT00004826 -
CoQ10
University of Rochester
2004 Phase 2 NCT00076492 United States;
Coarse wheat bran
University of Florida
2021 - NCT04829760 United States;
Cocoa
Oxford Brookes University
2017 - NCT03288155 Italy;
Coenzyme Q10
National Institute of Neurological Disorders and Stroke (NINDS)
1998 Phase 2 NCT00004731 United States;
Coenzyme Q10 Nanodispersion (Nanoquinone)
Technische Universität Dresden
2003 Phase 3 NCT00180037 Germany;
Coenzyme Q10 with vitamin E
Weill Medical College of Cornell University
2008 Phase 3 NCT00740714 Canada;United States;
Cogane™ (PYM50028)
Phytopharm
2009 Phase 1 NCT00875316 United Kingdom;
Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)
Northwestern University
2017 Phase 2 NCT03205488 United States;
Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)
Northwestern University
2017 Phase 2 NCT03205488 United States;
Combination Product: L-dopa 70mg/carbidopa
Impel NeuroPharma Inc.
2018 Phase 2 NCT03541356 Australia;
Combination Product: ND0612 Solution for SC infusion
NeuroDerm Ltd.
2019 Phase 3 NCT04006210 Austria;Belgium;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
Combination Product: Sanacoach Parkinson (SCP)
Zuyderland Medisch Centrum
2021 - NCT05164783 Netherlands;
Combination Product: continuous oral delivery of levodopa/carbidopa
SynAgile Corporation
2021 Phase 2 NCT04778176 Italy;Luxembourg;
Combination injection of EPO and G-CSF
Yonsei University
2013 Phase 1/Phase 2 NCT02018406 Korea, Republic of;
Comparator: carbidopa
Merck Sharp & Dohme Corp.
2007 Phase 1 NCT00505843 United States;
Comparator: levodopa
Merck Sharp & Dohme Corp.
2007 Phase 1 NCT00505843 United States;
Comtan
Kyowa Hakko U.K. Limited
2004 - EUCTR2004-000817-20-ES Italy;Latvia;Lithuania;Spain;
Comtan®
BIAL - Portela & Ca, S.A.
2011 Phase 3 EUCTR2010-021860-13-RO Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-SK Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-ES Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
2011 - EUCTR2010-021860-13-DE Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-CZ Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-BG Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-AT Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2010 - EUCTR2010-021860-13-PT Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2010 - EUCTR2010-021860-13-LV Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
2010 - EUCTR2010-021860-13-LT Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2010 - EUCTR2010-021860-13-HU Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
Bial - Portela C S.A.
2006 Phase 2 NCT03103399 -
2006 Phase 1 NCT03094156 Portugal;
2005 Phase 2 NCT02834507 -
2004 Phase 1 NCT03091868 Portugal;
Comtan®
BIAL - PORTELA & Cª, S.A.
2011 - EUCTR2010-021860-13-IT Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Russian Federation;Slovakia;Spain;
Comtess
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2010 - EUCTR2009-017416-33-DE Germany;
Dept of Neuroscience, Uppsala University
2008 - EUCTR2008-003581-26-SE Sweden;
Eisai Limited
2007 Phase 3 EUCTR2006-002937-20-FR Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2007 - EUCTR2006-002937-20-HU Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2007 - EUCTR2006-002937-20-ES Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-LV Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-LT Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-EE Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-CZ Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
Kyowa Hakko U.K. Limited
2005 - EUCTR2004-000817-20-AT Austria;Italy;Latvia;Lithuania;Spain;
2004 Phase 3 EUCTR2004-000817-20-GB Austria;Italy;Latvia;Lithuania;Spain;United Kingdom;
2004 - EUCTR2004-000817-20-LV Italy;Latvia;Lithuania;Spain;
2004 - EUCTR2004-000817-20-LT Italy;Latvia;Lithuania;Spain;
2004 - EUCTR2004-000817-20-ES Italy;Latvia;Lithuania;Spain;
Comtess®
Orion Corporation, Orion Pharma
2002 Phase 4 NCT00247247 Germany;
Continuous Apomorphine infusion
Rennes University Hospital
2009 Phase 3 NCT01039090 France;
Continuous Release Dopamine Agonists
University of Toledo Health Science Campus
2007 Phase 3 NCT00465452 United States;
Continuous Subcutaneous Lisuride Infusion
Axxonis Pharma AG
2006 Phase 3 NCT00408915 Germany;
Continuous intrajejunal infusion of levodopa-carbidopa
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2014 Phase 4 NCT02480803 Netherlands;
Control
Johns Hopkins University
2018 Phase 1 NCT03069911 United States;
Controlled-release levodopa / carbidopa
Pfizer
2004 Phase 4 NCT00174239 Australia;Italy;Spain;United Kingdom;
Conventional medication
Hong Kong Baptist University
2021 Phase 2/Phase 3 NCT05001217 -
Creatine
University of Rochester
2007 Phase 3 NCT00449865 Canada;United States;
2003 Phase 2 NCT00063193 United States;
Cu(II)ATSM
Collaborative Medicinal Development Pty Limited
2017 Phase 1 NCT03204929 Australia;
CyberKnife
Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology
2015 Phase 2 NCT02406105 Poland;
Cystoscopic injection of Botox into the urinary bladder
Stanford University
2009 Phase 4 NCT01421719 United States;
D-serine (~2g/day)
Herzog Hospital
2003 Phase 4 NCT00215904 Israel;
DA-9701
Seoul National University Hospital
2016 Phase 4 NCT02775591 Korea, Republic of;
2013 Phase 4 NCT03022201 Korea, Republic of;
DA-9805
Dong-A ST Co., Ltd.
2018 Phase 2 NCT03189563 United States;
DAAOI-P
China Medical University Hospital
2016 Phase 2 NCT04470037 Taiwan;
DATscan and SPECT imaging
Institute for Neurodegenerative Disorders
2005 - NCT00129181 Austria;Germany;Italy;Spain;United Kingdom;
DC158AM
PIERRE FABRE MEDICAMENT
2008 Phase 3 EUCTR2007-002195-34-FR France;
DCI
Hamamatsu University School of Medicine
2015 - JPRN-UMIN000019524 Japan;
Ito Hidefumi
2016 Phase 2 JPRN-jRCTs051180098 Japan;
Osaka Redcross HospitalWakayama Prefectural Medical College
2016 Phase 2 JPRN-UMIN000022533 Japan;
Ouchi Yasuomi
2015 - JPRN-jRCTs041180070 Japan;
DCS
IRCCS National Neurological Institute C. Mondino Foundation
2019 - NCT04620863 Italy;
DEBRUMYL
PIERRE FABRE MEDICAMENT
2008 Phase 3 EUCTR2007-002195-34-FR France;
DM
Guangdong Provincial People's Hospital
2020 Phase 0 ChiCTR2000039475 China;
DM-1992
Depomed
2012 Phase 2 NCT01515410 United States;
DNL151
Denali Therapeutics Inc.
2019 Phase 1 NCT04056689 Belgium;Netherlands;United Kingdom;United States;
DNL201
Denali Therapeutics Inc.
2018 Phase 1 NCT03710707 United States;
DNS-7801 (high dose)
Dart NeuroScience, LLC
2017 Phase 2 NCT03306329 United States;
DNS-7801 (low-dose)
Dart NeuroScience, LLC
2017 Phase 2 NCT03306329 United States;
DPA
Assistance Publique - Hôpitaux de Paris
2012 - NCT02319382 France;
DPA-714-PET/MRI
University of Alabama at Birmingham
2018 Phase 1/Phase 2 NCT03457493 United States;
DUODOPA
CHU de Poitiers
2010 - EUCTR2010-020769-25-FR France;
DUODOPA®Intestinal Gel
Abbott Healthcare Products B.V.
2009 - EUCTR2006-005186-18-CZ Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
2008 Phase 3 EUCTR2006-005186-18-GB Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
2008 - EUCTR2006-005186-18-PT Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2006-005186-18-DE Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
2007 - EUCTR2006-000577-29-DE Germany;United States;
Solvay Pharmaceuticals B.V.
2009 - EUCTR2006-005186-18-NL Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2006-005186-18-ES Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2007 - EUCTR2006-005186-18-FI Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
DaTSCAN 74 MBq/ml solution for injection
ZIONEXA
2021 Phase 3 EUCTR2019-000247-27-FR France;
DaTSCAN™
Michael J. Fox Foundation for Parkinson's Research
2015 - NCT02572713 Canada;United States;
DaTSCAN™ Ioflupane (123I) Injection
GE Healthcare
2020 Phase 3 NCT04193527 China;
Dacepton 5 mg/ml infuusioneste, liuos
Eero Pekkonen
2016 Phase 4 EUCTR2016-001690-33-FI Finland;
Daily ingestion of Lactobacillus plantarum PS128
Professor Lu Neurological Clinic
2019 - NCT04389762 Taiwan;
Dark chocolate ( cocoa)
Technische Universität Dresden
2013 - NCT02275884 Germany;
Deanol pyroglutamate
PIERRE FABRE MEDICAMENT
2008 Phase 3 EUCTR2007-002195-34-FR France;
Deep Brain Stimulation
Beth Israel Deaconess Medical Center
2016 - NCT02994719 United States;
Deep brain stimulation
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2014 Phase 4 NCT02480803 Netherlands;
Second Affiliated Hospital, School of Medicine, Zhejiang University
2014 - NCT04928079 -
Deferiprone
ApoPharma
2016 Phase 2 NCT02728843 Canada;France;Germany;United Kingdom;
Imperial College London
2012 Phase 2 NCT01539837 United Kingdom;
University Hospital, Lille
2016 Phase 2 NCT02655315 Austria;Czech Republic;Czechia;France;Germany;Netherlands;Portugal;Spain;United Kingdom;
2011 - NCT02880033 France;
2009 Phase 2/Phase 3 NCT00943748 France;
Deferiprone (Ferriprox)
Imperial College London
2011 Phase 2 EUCTR2011-001148-31-GB United Kingdom;
Deferiprone 600 mg delayed release tablet
ApoPharma
2017 Phase 2 EUCTR2015-004344-19-DE Canada;France;Germany;United Kingdom;
2016 Phase 2 EUCTR2015-004344-19-GB Canada;France;Germany;United Kingdom;
ApoPharma Inc.
2016 Phase 2 EUCTR2015-004344-19-FR Canada;France;Germany;Italy;United Kingdom;United States;
Deferiprone DR
Centre Hospitalier Régional et Universitaire de Lille
2016 Phase 3 EUCTR2015-003679-31-ES Spain;
2016 Phase 2 EUCTR2015-003679-31-PT Austria;Czech Republic;Netherlands;Portugal;Spain;
2016 Phase 2 EUCTR2015-003679-31-NL Austria;Czech Republic;Netherlands;Portugal;Spain;
2016 Phase 2 EUCTR2015-003679-31-FR Austria;Czech Republic;France;Netherlands;Portugal;Spain;
2016 Phase 2 EUCTR2015-003679-31-CZ Austria;Czech Republic;Netherlands;Portugal;Spain;
2016 Phase 2 EUCTR2015-003679-31-AT Austria;Czech Republic;France;Germany;Netherlands;Portugal;Spain;United Kingdom;
Desmopressin Acetat
Universität Mainz, Klinik und Poliklinik für Neurologie
2008 - EUCTR2008-003966-25-DE Germany;
Desmotabs
Johannes Gutenberg University Mainz
2009 Phase 4 NCT00806468 Germany;
Desmotabs® 0,2 mg Tabletten
Universität Mainz, Klinik und Poliklinik für Neurologie
2008 - EUCTR2008-003966-25-DE Germany;
Desmotabs® 0,2mg Tabletten
Universität Mainz, Klinik und Poliklinik für Neurologie
2008 - EUCTR2008-003966-25-DE Germany;
Determination of drug effects through amantadine cessation
Seoul National University Hospital
2020 - NCT04260581 Korea, Republic of;
Dexdor
Clínica Universidad de Navarra/Universidad de Navarra
2016 Phase 4 EUCTR2016-002680-34-ES Spain;
2014 - EUCTR2014-000868-17-ES Spain;
Dexmedetomidine
Beijing Tiantan Hospital
2022 - NCT05197439 China;
Clinica Universidad de Navarra, Universidad de Navarra
2017 Phase 4 NCT02982512 Spain;
2014 Phase 4 NCT02256319 Spain;
Diskapi Teaching and Research Hospital
2013 Phase 4 NCT01789385 Turkey;
Shanghai Jing'an District Central Hospital
2016 Phase 0 ChiCTR2000037957 China;
The First Affiliated Hospital of University of Science and Technology of China (Southern District Phase 2)
2021 Phase 0 ChiCTR2100048680 China;
University of Wisconsin, Madison
2012 Phase 4 NCT01721460 United States;
West China Hospital, Sichuan University
2016 - ChiCTR-IOR-16010168 China;
Dexmedetomidine Hydrochloride Infusion
Vanderbilt University
2008 Phase 2/Phase 3 NCT00608231 United States;
Dextromethorphan
National Institute of Neurological Disorders and Stroke (NINDS)
1993 Phase 2 NCT00001365 United States;
Different diets
Sheba Medical Center
2014 - NCT02274324 -
Dihydroergotoxine Mesylate
Nanjing First Hospital Affiliated to Nanjing Medical University
2017 - ChiCTR-IPR-17011155 China;
Dipivefrin
katsuno Masahisa
2017 Phase 2 JPRN-jRCTs041180018 Japan;
Dipivefrine
Nagoya University
2017 - JPRN-UMIN000026128 Japan;
Dipraglurant
Addex Pharma S.A.
2021 Phase 2/Phase 3 NCT05116813 United States;
2021 Phase 2/Phase 3 NCT04857359 United States;
Addex Pharma SA
2011 Phase 2 EUCTR2010-022517-25-DE Austria;France;Germany;United States;
2011 - EUCTR2010-022517-25-AT Austria;France;Germany;United States;
Ditropan elixir
Summit (Cambridge) Ltd.
2007 - EUCTR2007-004654-81-GB United Kingdom;
Docosahexaenoic Acid (DHA)
VA Office of Research and Development
2012 Phase 1 NCT01563913 United States;
Domperidone
Canadian Network for Observational Drug Effect Studies, CNODES
2013 - NCT02500108 Canada;
Kansai Medical University
2012 - JPRN-UMIN000007896 Japan;
Royal Brisbane and Women's Hospital
2005 Phase 1 NCT00103597 Australia;
Seoul National University Hospital
2013 Phase 4 NCT03022201 Korea, Republic of;
Domperidone (drug)
University Health Network, Toronto
2006 Phase 2 NCT00305331 Canada;
Dompéridone
CHU de Toulouse
2010 Phase 3 EUCTR2010-018650-12-FR France;
Donepezil
Clinical Research Center, Utano National Hospital, National Hospital Organization
2010 - JPRN-UMIN000003080 Japan;
Designated Research, National Hospital Organization
2011 Phase 3 JPRN-UMIN000005403 Japan;
Inje University
2015 Phase 2 NCT02415062 Korea, Republic of;
Kansai Medical University
2013 - JPRN-UMIN000010752 Japan;
Kyung Hee University Hospital
2017 Phase 4 NCT03011476 Korea, Republic of;
National Hospital Organization, Sendai-Nishitaga Hospital
2013 - JPRN-UMIN000009958 Japan;
National Hospital of Utano
2013 - JPRN-UMIN000010778 Japan;
National Institute of Neurological Disorders and Stroke (NINDS)
2002 Phase 4 NCT00030979 United States;
Newcastle-upon-Tyne Hospitals NHS Trust
2013 Phase 3 NCT01014858 United Kingdom;
Oregon Health and Science University
2018 Early Phase 1 NCT03599726 United States;
2014 Phase 2 NCT02206620 United States;
2011 Phase 4 NCT01521117 United States;
2005 - NCT00912808 -
Per Borghammer
2013 - NCT02012595 Denmark;
2013 - NCT01877538 Denmark;
University of Chicago
2016 Phase 2 NCT02857244 United States;
Yonsei University
2015 Phase 2 NCT02450786 Korea, Republic of;
Zealand University Hospital
2020 Phase 4 NCT04117178 Denmark;
Donepezil Sandoz
Regional Dementia Research Centre, Dept of Neurology
2018 Phase 4 EUCTR2017-002707-10-DK Denmark;
DopaFuse Delivery System
SynAgile Corporation
2021 Phase 2 EUCTR2020-003372-41-IT Italy;Luxembourg;Spain;
2021 Phase 1;Phase 2 EUCTR2020-003372-41-ES Italy;Luxembourg;Spain;
Dopamine
Medical Corporation Abe Neurology Clinic
2016 - JPRN-UMIN000024859 Japan;
University Hospital, Clermont-Ferrand
2013 Phase 4 NCT01780467 France;
Dopamine Agent
I.R.C.C.S. Fondazione Santa Lucia
2014 Phase 4 NCT03151460 Italy;
Dopamine Agonists (pramipexole, ropirinole)
University of Toronto
2015 Phase 2 NCT02347059 Canada;
Dopaminergic Agonist + Apomorphine
Rennes University Hospital
2019 - NCT03693872 France;
Dopaminergic Agonists
Sandoz
2012 Phase 4 NCT01683253 Korea, Republic of;
Doxepin and Zopiclone
McGill University Health Center
2011 Phase 0 NCT01489982 Canada;
Droxidopa
Chelsea Therapeutics
2013 Phase 3 NCT01927055 United States;
2012 Phase 1/Phase 2 NCT01331122 Canada;United States;
2010 Phase 3 NCT01176240 United States;
Colorado Springs Neurological Associates
2016 - NCT03173781 United States;
Henry Ford Health System
2015 Phase 2 NCT02066571 United States;
Loma Linda University
2021 Phase 2 NCT03446807 United States;
National Institute of Neurological Disorders and Stroke (NINDS)
2007 Phase 1/Phase 2 NCT00547911 United States;
St. Joseph's Hospital and Medical Center, Phoenix
2018 Phase 2 NCT03567447 United States;
Vanderbilt University Medical Center
2017 Phase 4 NCT03115827 United States;
2016 Phase 1 NCT02897063 United States;
William Ondo, MD
2018 Phase 4 NCT03229174 United States;
Droxidopa 100 MG [Northera]
Alberto Espay, MD, MSc
2019 Phase 4 NCT04510922 United States;
Duloxetine
Ando Rina
2015 Phase 2 JPRN-jRCTs061180028 Japan;
CHU de Toulouse
2010 Phase 3 EUCTR2010-018650-12-FR France;
Department of Neurology, Juntendo University School of Medicine
2015 - JPRN-UMIN000016734 Japan;
Ehime University HospitalDept. of Clinical pharmacology and Neurology
2014 Phase 2 JPRN-UMIN000016893 Japan;
University Hospital, Toulouse
2011 Phase 3 NCT01504178 France;
University of Chicago
2016 Phase 2 NCT02857244 United States;
Duloxetine hydrochloride
Eli Lilly and Company
2007 Phase 4 NCT00437125 Italy;
Duodopa
ABBVIE DEUTSCHLAND GMBH & CO. KG
2016 Phase 3 EUCTR2016-001403-23-IT European Union;Finland;Greece;Hungary;Italy;Slovakia;Spain;United States;
AbbVie Deutschland GmbH & Co. KG
2018 Phase 3 EUCTR2016-001403-23-HU European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
2017 Phase 3 EUCTR2016-001403-23-GR European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
2017 Phase 3 EUCTR2016-001403-23-FI European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
2017 Phase 3 EUCTR2014-004865-26-GR Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;United States;
2016 Phase 3 EUCTR2016-001403-23-SK European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
2016 Phase 3 EUCTR2016-001403-23-ES European Union;Finland;Greece;Hungary;Slovakia;Spain;United States;
2015 Phase 3 EUCTR2014-004865-26-SE Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;United States;
2015 Phase 3 EUCTR2014-004865-26-ES Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;
2015 Phase 3 EUCTR2014-004865-26-DE Australia;Canada;European Union;Germany;Italy;Spain;Sweden;
2015 - EUCTR2014-004865-26-IT Australia;Canada;European Union;Germany;Italy;Spain;Sweden;
Department of Neuroscience, neurology
2007 - EUCTR2007-004985-41-SE Sweden;
Dept of Neuroscience, Uppsala University
2008 - EUCTR2008-003581-26-SE Sweden;
Institut de Recerca del Hospital de la Santa Creu i Sant Pau
2015 Phase 4 EUCTR2015-002631-17-ES Spain;
LobSor Pharmaceuticals AB
2015 Phase 1 NCT02448914 Sweden;
Organisation name was not entered
2008 - EUCTR2008-003225-16-FI Finland;
Poitiers University Hospital
2011 Phase 2 NCT01291537 France;
Duodopa LD/CD 20/5 mg/mL
NEURODERM LTD.
2018 Phase 3 EUCTR2017-002780-17-IT Austria;France;Italy;Netherlands;Spain;United States;
NeuroDerm Ltd.
2018 Phase 3 EUCTR2017-002780-17-FR Austria;France;Italy;Netherlands;Spain;United States;
2018 Phase 3 EUCTR2017-002780-17-ES Austria;France;Italy;Netherlands;Spain;United States;
Duodopa gel intestinale
Solvay Pharmaceuticals BV.
2008 - EUCTR2006-005186-18-IT Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
Duodopa intestinal gel
Solvay Pharmaceuticals GmbH
2005 - EUCTR2005-002654-21-SE Sweden;
Duodopa intestinalgel
Solvay Pharmaceuticals GmbH
2006 - EUCTR2005-002654-21-NO Norway;Sweden;
Duodopa, 20 mg/ml + 5 mg/ml, intestinal gel
AbbVie Inc
2011 Phase 3 EUCTR2008-001329-33-GB Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
2010 Phase 3 EUCTR2008-001329-33-CZ Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
2009 - EUCTR2008-001329-33-PT Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
Abbott Laboratories
2009 - EUCTR2006-000578-53-DE Germany;New Zealand;United States;
Duodopa, levodopa 20 mg/ml + carbidopa 5 mg/ml, intestinal gel
Academic Medical Center
2014 - EUCTR2014-004501-32-NL Netherlands;
Dynacirc CR (Isradipine)
Northwestern University
2008 Phase 2 NCT00753636 United States;
E2007
EISAI LTD UK
2007 Phase 3 EUCTR2007-000801-30-IT Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 - EUCTR2006-005714-12-IT Italy;
2006 Phase 3 EUCTR2006-002339-26-IT Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-IT Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2004 - EUCTR2004-000361-35-IT Czech Republic;Italy;
Eisai Inc.
2007 Phase 2 NCT00451633 Germany;Italy;
2007 Phase 2 NCT00427011 United States;
2006 Phase 3 NCT00360412 Germany;
2005 Phase 2 NCT00165789 United States;
Eisai Limited
2007 Phase 3 EUCTR2007-000801-30-PL Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 Phase 3 EUCTR2007-000801-30-FR Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 Phase 3 EUCTR2007-000801-30-ES Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 Phase 3 EUCTR2006-002937-20-FR Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2007 - EUCTR2007-000801-30-LV Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 - EUCTR2007-000801-30-LT Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 - EUCTR2007-000801-30-HU Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 - EUCTR2007-000801-30-EE Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 - EUCTR2007-000801-30-CZ Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 - EUCTR2006-002937-20-HU Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2007 - EUCTR2006-002937-20-ES Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2007 - EUCTR2006-002339-26-PT Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-002339-26-HU Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-002339-26-ES Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-002339-26-DE Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3 NCT00360308 France;
2006 Phase 3 NCT00286897 Austria;Belgium;Czech Republic;Estonia;Former Serbia and Montenegro;France;Germany;Hungary;Israel;Italy;Lithuania;Poland;Portugal;Serbia;South Africa;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-004314-33-GB Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-004314-33-ES Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002937-20-LV Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-LT Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-EE Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-CZ Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002339-26-SE Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-LT Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-GB Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-EE Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-CZ Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-BE Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-AT Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-SE Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-PT Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-LT Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-HU Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-EE Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-DE Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-CZ Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-BE Austria;Belgium;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-004314-33-AT Austria;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2004 Phase 2 NCT01172379 Czech Republic;France;Germany;Italy;Serbia;Spain;
2004 - EUCTR2004-000361-35-CZ Czech Republic;Italy;
E2027
Eisai Inc.
2021 Phase 2 NCT04764669 Canada;United States;
EBIXA®
Chru de Lille
2009 - EUCTR2008-008210-38-FR France;
ELC200
Novartis Pharma AG
2006 - EUCTR2005-001032-72-PT Czech Republic;Italy;Portugal;
2006 - EUCTR2005-001032-72-CZ Czech Republic;Italy;Portugal;
EMD 128130
MERCK KGaA
2004 Phase 3 EUCTR2004-001594-25-ES Austria;Finland;Spain;
MERCK S.P.A.
2004 - EUCTR2004-001593-10-IT Italy;United Kingdom;
National Institute of Neurological Disorders and Stroke (NINDS)
2001 Phase 2 NCT00009048 United States;
EMD128130
Merck KGaA
2005 Phase 3 EUCTR2005-000444-84-GB Austria;Finland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000444-84-ES Austria;Finland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-001593-10-GB Italy;United Kingdom;
2005 - EUCTR2005-000444-84-FI Finland;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000444-84-AT Austria;Finland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-001594-25-AT Austria;Finland;Spain;
2004 - EUCTR2004-001594-25-FI Finland;Spain;
EN
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2010 - EUCTR2009-017416-33-DE Germany;
ENA713
Research and Enterprise Department
2012 Phase 2 EUCTR2011-003053-25-GB United Kingdom;
ENA713B
NOVARTIS FARMA
2008 - EUCTR2007-000350-31-IT France;Italy;Spain;
ENT-01
Enterin Inc.
2017 Phase 1/Phase 2 NCT03047629 United States;
ENTACAPONE INN
NOVARTIS FARMA
2005 - EUCTR2005-001032-72-IT Czech Republic;Italy;Portugal;
EPI-589
BioElectron Technology Corporation (formerly Edison Pharmaceuticals Inc.)
2016 Phase 2 EUCTR2015-001786-10-GB Germany;United Kingdom;United States;
2016 Phase 2 EUCTR2015-001786-10-DE Germany;United Kingdom;United States;
PTC Therapeutics
2016 Phase 2 NCT02462603 Germany;United Kingdom;United States;
EPI-743
University of South Florida
2013 Phase 2 NCT01923584 United States;
ER CD-LD
Impax Laboratories, LLC
2016 Phase 2 NCT03007888 United States;
ER tablet 100 mg AZD3241
AstraZeneca
2012 Phase 2 NCT01527695 Sweden;
ER tablet 25 mg AZD3241
AstraZeneca
2012 Phase 2 NCT01527695 Sweden;
ETHNODYNE VISIO
University Hospital, Strasbourg, France
2016 - NCT02815800 France;
EXN-32 (CARBIDOPA E LEVODOPA)
DR. REDDY’S LABORATORIES LIMITED
2017 Phase 2 EUCTR2017-000262-30-IT Italy;
EXN-44(LEVODOPA)
DR. REDDY’S LABORATORIES LIMITED
2017 Phase 2 EUCTR2017-000262-30-IT Italy;
Ebixa
H. Lundbeck A/S
2007 Phase 3 EUCTR2005-002038-36-GR Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
2006 Phase 4 EUCTR2005-002038-36-GB Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
2006 Phase 3 EUCTR2005-002038-36-FR Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
2006 - EUCTR2005-002038-36-DE Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
2006 - EUCTR2005-002038-36-AT Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
Neurologisk afdeling F
2005 Phase 2 EUCTR2004-004139-74-DK Denmark;
Neuropsychiatric clinic
2006 - EUCTR2005-004109-27-SE Sweden;
Electroacupuncture
Nantes University Hospital
2014 - NCT02236260 France;
Eliprodil
National Institute of Neurological Disorders and Stroke (NINDS)
1999 Phase 2 NCT00001929 United States;
Elobixibat
Hatano Taku
2020 - JPRN-jRCTs031200172 Japan;
Eltoprazine HCl
Amarantus BioScience Holdings, Inc.
2015 Phase 2 NCT02439125 United States;
PsychoGenics Inc
2010 - EUCTR2009-015928-28-SE Sweden;
Eltoprazine Hydrochloride
Amarantus BioScience Holdings, Inc.
2015 - EUCTR2015-000373-13-DE France;Germany;Sweden;United States;
Embryonic dopamine cell implant surgery
University of Colorado, Denver
1995 Phase 3 NCT00038116 United States;
Entacapon
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2010 - EUCTR2009-017416-33-DE Germany;
Entacapone
AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
2010 - EUCTR2010-019396-29-IT Italy;
Assistance Publique - Hôpitaux de Paris
2006 Phase 4 NCT00373087 France;
BIAL - Portela & Cª, SA
2006 - EUCTR2006-001793-24-PT Austria;Portugal;
2006 - EUCTR2006-001793-24-AT Austria;Portugal;
Bial - Portela C S.A.
2011 Phase 3 NCT01568073 Austria;Portugal;
2011 Phase 1 NCT02170376 France;
2009 Phase 1 NCT01519284 Portugal;
Dept of Neuroscience, Uppsala University
2008 - EUCTR2008-003581-26-SE Sweden;
Eisai Limited
2007 Phase 3 EUCTR2006-002937-20-FR Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2007 - EUCTR2006-002937-20-HU Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2007 - EUCTR2006-002937-20-ES Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-LV Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-LT Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-EE Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-CZ Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
Geriatric Hospital of Hainan
2019 - ChiCTR1900022534 China;
IMPAX LABORATORIES, INC.
2010 - EUCTR2009-017238-39-IT France;Germany;Italy;
KYOWA HAKKO UK LTD
2005 - EUCTR2004-000817-20-IT Italy;Latvia;Lithuania;Spain;
Kansai Medical University
2010 - JPRN-UMIN000003601 Japan;
Kyowa Hakko U.K. Limited
2005 - EUCTR2004-000817-20-AT Austria;Italy;Latvia;Lithuania;Spain;
2004 Phase 3 EUCTR2004-000817-20-GB Austria;Italy;Latvia;Lithuania;Spain;United Kingdom;
2004 - EUCTR2004-000817-20-LV Italy;Latvia;Lithuania;Spain;
2004 - EUCTR2004-000817-20-LT Italy;Latvia;Lithuania;Spain;
2004 - EUCTR2004-000817-20-ES Italy;Latvia;Lithuania;Spain;
National Institute of Neurological Disorders and Stroke (NINDS)
2007 Phase 1/Phase 2 NCT00547911 United States;
Novartis
2003 Phase 2 NCT00237263 United States;
Orion Corporation Orion Pharma
2007 - EUCTR2007-002496-14-FI Finland;
2006 Phase 4 EUCTR2006-001755-36-GB Germany;Sweden;United Kingdom;
- - EUCTR2006-001755-36-DE Germany;Sweden;United Kingdom;
Orion Corporation Orion Pharma, FI-02200 Espoo, Finland
2006 - EUCTR2006-001755-36-SE Germany;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA
2005 - EUCTR2004-005234-39-FI Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-FI Finland;Italy;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA, Finland
2005 Phase 4 EUCTR2004-005234-39-GB Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA, 02200 Espoo, Finland
2008 - EUCTR2004-005234-39-DE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2007 Phase 3 EUCTR2004-000185-12-GB Austria;Finland;Italy;Sweden;United Kingdom;
2006 - EUCTR2004-005234-39-LV Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2006 - EUCTR2004-005234-39-LT Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 Phase 4 EUCTR2004-005234-39-IE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-005234-39-SE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-005234-39-DK Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-SE Finland;Italy;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-AT Austria;Finland;Italy;Sweden;United Kingdom;
Uppsala University
2008 Phase 4 NCT00906828 Sweden;
Yagi Michio
2021 Phase 1 JPRN-jRCT2051200104 Japan;
Entacapone 400mg oral dose
Daniel Claassen
2020 Phase 1 NCT04246437 United States;
Entacapone and carbidopa
Orion Corporation, Orion Pharma
2008 Phase 2 NCT00562198 Finland;
Entecapone
NOVARTIS FARMA
2004 - EUCTR2004-000185-12-IT Finland;Italy;Sweden;United Kingdom;
Equal
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
2006 - EUCTR2006-003717-41-IT Italy;
Equfina
Eisai Co., Ltd.
2020 - NCT04724109 Japan;
Eisai Korea Inc.
2021 - NCT05225324 Korea, Republic of;
Eradication of Helcobacter Pylori
National University of Malaysia
2012 - NCT02112812 Malaysia;
Eradication therapy for H.pylori infection
National University of Malaysia
2012 - NCT02112812 Malaysia;
Eradication therapy for Helicobacter pylori
National University of Malaysia
2012 - NCT02112812 Malaysia;
Erythromycin
Virginia Commonwealth University
2013 - NCT02005029 United States;
Erythropoietin human recombinant (EPOrh)
International Center for Neurological Restoration, Cuba
2008 Phase 1 NCT01010802 Cuba;
Escitalopram
LUNDBECK ITALIA
2008 - EUCTR2007-004009-93-IT Italy;
University College, London
2019 Phase 3 NCT03652870 -
Escitalopram oxalate
University College London Comprehensive Clinical Trials Unit
2019 Phase 3 EUCTR2018-002942-35-GB United Kingdom;
Eszopiclone
University of Medicine and Dentistry of New Jersey
2006 Phase 3 NCT00324896 United States;
Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below)
University of Bristol
2019 Phase 3 EUCTR2018-003219-23-GB United Kingdom;
Etomidate
Department of Anesthesiology, the First Affiliated Hospital of Sun Yat-Sen University
2020 Phase 4 ChiCTR2000039697 China;
Exelon
Oregon Health and Science University
2011 Phase 4 NCT01340885 United States;
Exelon 4.6 mg/24 h transdermal patch
Novartis Farmacéutica S.A
2008 Phase 3 EUCTR2007-000350-31-ES France;Italy;Spain;
Novartis Pharma AG
2008 - EUCTR2007-000350-31-FR France;Italy;Spain;
Exelon 9.5 mg/24 h transdermal patch
Novartis Farmacéutica S.A
2008 Phase 3 EUCTR2007-000350-31-ES France;Italy;Spain;
Novartis Pharma AG
2008 - EUCTR2007-000350-31-FR France;Italy;Spain;
Exelon Patch (rivastigmine transdermal system)
University of Pennsylvania
2011 Phase 4 NCT01519271 United States;
Exelon path transdermal
NOVARTIS FARMA
2008 - EUCTR2007-000350-31-IT France;Italy;Spain;
Exelon ®
Research and Enterprise Department
2012 Phase 2 EUCTR2011-003053-25-GB United Kingdom;
Exenatide
Center for Neurology, Stockholm
2020 Phase 2 NCT04305002 Sweden;
University College London
2014 Phase 2 EUCTR2013-003363-64-GB United Kingdom;
University College London Comprehensive Clinical Trial Unit
2019 Phase 3 EUCTR2018-003028-35-GB United Kingdom;
University College, London
2014 Phase 2 NCT01971242 United Kingdom;
2010 Phase 2 NCT01174810 United Kingdom;
University of Florida
2018 Phase 1 NCT03456687 United States;
Exenatide 10 micrograms
University College London
2010 Phase 2 EUCTR2009-018137-37-GB United Kingdom;
Exenatide 5 micrograms
University College London
2010 Phase 2 EUCTR2009-018137-37-GB United Kingdom;
Exenatide extended release 2mg (Bydureon)
University College, London
2020 Phase 3 NCT04232969 United Kingdom;
Exergame
University of Arizona
2014 - NCT02777060 United States;
F-18 FPCIT
Asan Medical Center
2006 Phase 3 NCT00468078 Korea, Republic of;
FB-101
1ST Biotherapeutics, Inc.
2019 Phase 1 NCT04165837 United States;
FLORBETABEN (18F)
Fundació Clínic per la Recerca Biomèdica
2016 Phase 4 EUCTR2014-001014-25-ES Spain;
Institute for Neurodegenerative Disorders
2016 Phase 2 EUCTR2015-004129-15-ES Spain;
FPF1100NW
FP Pharmaceutical Corp.
2012 Phase 2 JPRN-JapicCTI-122000 -
- Phase 3 JPRN-JapicCTI-121954 -
- Phase 2 JPRN-JapicCTI-101020 -
FPFS-1169
Fujimoto Pharmaceutical Corporation
2006 Phase 2 EUCTR2006-000361-11-GB United Kingdom;
Famotidine
University Health Network, Toronto
2011 Phase 2 NCT01937078 Canada;
Febuxostat
Kamatani Naoyuki
2019 Phase 1 JPRN-jRCTs031190115 Japan;
StaGen Co. Ltd.
2018 - JPRN-UMIN000030930 Japan;
Tsukuba International Clinical Pharmacology Clinic
2016 - JPRN-UMIN000024312 Japan;
Ferriprox
Centre Hospitalier Régional et Universitaire de Lille
2016 Phase 3 EUCTR2015-003679-31-ES Spain;
Ferrprox (Deferiprone)
Imperial College London
2011 Phase 2 EUCTR2011-001148-31-GB United Kingdom;
Fesoterodine
Sir Mortimer B. Davis - Jewish General Hospital
2016 Phase 4 NCT02385500 Canada;
Fetal porcine cells, Neurocell-PD
Genzyme, a Sanofi Company
1997 Phase 2 NCT00226460 United States;
Filgrastim
MinYoung Kim, M.D.
2014 - NCT02236065 Korea, Republic of;
Finamine tablets
Yiling Pharmaceutical Inc.
2017 Phase 1 NCT04162275 China;
Finasteride
AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI
2011 - EUCTR2011-000612-26-IT Italy;
Fipamezole
Juvantia Pharma Ltd
2008 Phase 2 NCT00758849 France;Portugal;
2007 Phase 2 NCT00559871 India;United States;
Fipamezole ODT
Valeant Pharmaceuticals International, Inc.
2010 - NCT01140841 United States;
Fipamezole ODT Cohort 2
Valeant Pharmaceuticals International, Inc.
2010 - NCT01149811 United States;
Fipamezole hydrochloride 30 mg oral disintegrating tablets
Juvantia Pharma Ltd
2008 - EUCTR2007-004890-24-PT France;Portugal;
2008 - EUCTR2007-004890-24-FR France;Portugal;
Fipamezole hydrochloride 60 mg oral disintegrating tablets
Juvantia Pharma Ltd
2008 - EUCTR2007-004890-24-PT France;Portugal;
2008 - EUCTR2007-004890-24-FR France;Portugal;
Fipamezole hydrochloride 90 mg oral disintegrating tablets
Juvantia Pharma Ltd
2008 - EUCTR2007-004890-24-PT France;Portugal;
2008 - EUCTR2007-004890-24-FR France;Portugal;
Flecainidum
Theranexus S.A.
2018 Phase 2 EUCTR2017-004475-31-HU Czech Republic;France;Germany;Hungary;United States;
2018 Phase 2 EUCTR2017-004475-31-CZ Czech Republic;France;Germany;Hungary;United States;
Florbetapir F 18
Avid Radiopharmaceuticals
2009 Phase 2 NCT00857532 United States;
Fludrocortisone
Christian Baumann
2012 Phase 2 NCT01993680 Switzerland;
Royal Brisbane and Women's Hospital
2005 Phase 1 NCT00103597 Australia;
Flumazenil
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
2013 - JPRN-UMIN000011111 Japan;
University of Michigan
2018 Phase 1/Phase 2 NCT03462641 United States;
Fluoroscopic swallow evaluation
University of Florida
2017 - NCT03321019 United States;
Flutemetamol
Itoh Yoshiaki
2019 - JPRN-jRCTs051180214 Japan;
Flutemetamol F18
Skane University Hospital
2017 - NCT03174938 Sweden;
Folic Acid, Vitamin B6, Vitamin B12
North Shore Long Island Jewish Health System
2006 - NCT00853879 United States;
Foliglurax
H. Lundbeck A/S
2019 Phase 1 NCT04175132 Sweden;
PREXTON THERAPEUTICS B.V.
2017 Phase 2 EUCTR2017-000135-14-IT Austria;France;Germany;Italy;Spain;United Kingdom;
Prexton Therapeutics B.V.
2017 Phase 2 EUCTR2017-000135-14-GB Austria;Germany;Spain;United Kingdom;
2017 Phase 2 EUCTR2017-000135-14-ES Austria;Germany;Italy;Spain;United Kingdom;
2017 Phase 2 EUCTR2017-000135-14-DE Austria;Germany;Italy;Spain;United Kingdom;
2017 Phase 2 EUCTR2017-000135-14-AT Austria;Germany;Spain;United Kingdom;
Foliglurax 10 mg (treatment A)
H. Lundbeck A/S
2020 Phase 1 NCT04322227 France;
Foliglurax 30 mg (treatment B)
H. Lundbeck A/S
2020 Phase 1 NCT04322227 France;
Foscarbidopa
ABBVIE DEUTSCHLAND GMBH & CO. KG
2019 Phase 3 EUCTR2018-002144-85-IT Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
AbbVie Deutschland
2020 Phase 3 EUCTR2018-002144-85-DE Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-NL Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-GB Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-ES Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-DK Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-BE Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
Foscarbidopa and Foslevodopa
ABBVIE DEUTSCHLAND GMBH & CO. KG
2020 Phase 3 EUCTR2019-004235-23-IT Australia;Canada;Italy;Japan;Netherlands;Russian Federation;United Kingdom;United States;
Abbvie Deutschland GmbH & Co. KG
2021 Phase 3 EUCTR2019-004235-23-SE Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004235-23-DE Australia;Canada;Germany;Italy;Japan;Netherlands;Russian Federation;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-NL Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-GB Australia;Canada;Japan;Russian Federation;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-DK Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
Foslevodopa
ABBVIE DEUTSCHLAND GMBH & CO. KG
2019 Phase 3 EUCTR2018-002144-85-IT Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
AbbVie Deutschland
2020 Phase 3 EUCTR2018-002144-85-DE Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-NL Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-GB Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-ES Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-DK Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-BE Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
Functional Magnetic Resonance Imaging
University of Florida
2016 Phase 2 NCT02789020 United States;
Furosemide Injection
University of Alberta
2021 Phase 3 NCT04706910 Canada;
G-CSF
Buddhist Tzu Chi General Hospital
2010 Phase 2 NCT01227681 Taiwan;
GABAPENTINA KERN PHARMA
ASOCIACIÓN INSTITUTO BIODONOSTIA
2012 Phase 2 EUCTR2011-005839-91-ES Spain;
GE180 PET Scan
Aaron Ritter, MD
2018 Phase 2 NCT03702816 United States;
GM1 ganglioside
Thomas Jefferson University
1999 Phase 2 NCT00037830 United States;
GM608
Genervon Biopharmaceuticals, LLC
2013 Phase 2 NCT01850381 United States;
GOCOVRI
Oregon Health and Science University
2020 Phase 4 NCT04387773 United States;
GPI 1485
Eisai Inc.
2002 Phase 2 NCT00209508 -
University of Rochester
2004 Phase 2 NCT00076492 United States;
GRF6021
Alkahest, Inc.
2018 Phase 2 NCT03713957 Australia;France;United States;
GSK962040
GlaxoSmithKline Research and Development Limited
2013 - EUCTR2011-004438-32-SE Australia;Germany;Sweden;United Kingdom;
2013 - EUCTR2011-004438-32-DE Australia;Germany;Sweden;United Kingdom;
2012 Phase 2 EUCTR2011-004438-32-GB Germany;Sweden;United Kingdom;
GSK962040 (25 mg tablet)
GlaxoSmithKline
2012 Phase 2 NCT01602549 Australia;Germany;Sweden;United Kingdom;
Galantamine
Memorial Hospital of Rhode Island
2004 - NCT00211588 United States;
Galantamine hydrobromide
Otto-von-Guericke University, Medical Faculty, Dpt. of Neurology
2009 - EUCTR2009-011093-15-DE Germany;
Ganoderma
Xuanwu Hospital, Beijing
2018 Phase 3 NCT03594656 China;
Genz-682452-AU
Genzyme Corporation
2019 Phase 2 EUCTR2016-000657-12-GR Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2016-000657-12-AT Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000657-12-PT Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000657-12-IT Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000657-12-DE Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000657-12-SE Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000657-12-ES Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
Ghrelin
Nagoya University Graduate School of Medicine
2015 - JPRN-UMIN000017036 Japan;
Glial Cell Line-Derived Neurotrophic Factor (GDNF)
North Bristol NHS Trust (NBT)
2013 Phase 2 EUCTR2013-001881-40-GB United Kingdom;
2012 Phase 2 EUCTR2011-003866-34-GB United Kingdom;
Glial cell line-derived neurotrophic factor
North Bristol NHS Trust
2012 Phase 2 NCT03652363 -
Glucose
National Institute of Mental Health (NIMH)
1998 - NCT00004451 United States;
Glutathione
University of South Florida
2003 Phase 2 NCT01177319 United States;
Glycopyrrolate
Ottawa Hospital Research Institute
2016 Phase 2 NCT02382198 Canada;
Gold
101th Hospital of PLA
2016 - ChiCTR-DOC-16008645 -
Department of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital
2014 - ChiCTR-DDD-17010794 China;
Guangdong General Hospital, Guangdong Academy of Medical Sciences
2015 - ChiCTR-DOD-15006097 China;
Huashan Hospital Affiliated to Fudan University
2020 Phase 0 ChiCTR2000037856 China;
Huashan Hospital, Fudan University
2020 Phase 0 ChiCTR2000038937 China;
Renji Hospital (South Court), School of Medicine, Shanghai Jiao Tong University
2020 Phase 0 ChiCTR2000036137 China;
Renji hospital, School of Medicine, Shanghai Jiao Tong University
2017 - ChiCTR-DDD-16009569 China;
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
2020 Phase 0 ChiCTR2000037239 China;
Shanghai Jiao Tong University School of Medicine affiliated Shanghai General Hospital
2020 Phase 0 ChiCTR2000032616 China;
The First Affiliated Hospital of Chengdu Medical College
2019 Phase 0 ChiCTR1900027306 China;
The First Affiliated Hospital, Sun Yat-sen University
2021 Phase 0 ChiCTR2100044662 China;
Tongji hospital, Tongji University
2019 - ChiCTR1800015757 China;
Xiangyang Hospital, Hubei University of Medicine
2016 - ChiCTR-DRD-16008778 China;
Zhongshan Hospital, Fudan University
2020 Phase 0 ChiCTR2000036006 China;
Gold Nanocrystals
Clene Nanomedicine
2019 Phase 2 NCT03815916 United States;
Grapefruit
Osaka University Graduate School of Medicine Department of Neurosurgery
2016 Phase 1 JPRN-UMIN000021236 Japan;
Green Tea Polyphenols (EGCG/ECG)
Xuanwu Hospital, Beijing
2006 Phase 2 NCT00461942 China;
Group AD Anti-PD + Antidepressant
Teva Pharmaceutical Industries
2009 - NCT00955604 United States;
Group R Rasagiline
Teva Pharmaceutical Industries
2009 - NCT00955604 United States;
Group R+AD Rasagiline + Antidepressant
Teva Pharmaceutical Industries
2009 - NCT00955604 United States;
HA 1A ANTICORPO MONOCLONALE UMANO CLASSE IGM
BIOGEN IDEC RESEARCH LIMITED
2018 Phase 2 EUCTR2016-004610-95-IT Australia;Austria;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;United States;
HB-adMSCs
Hope Biosciences
2019 - NCT04064983 United States;
Hope Biosciences Stem Cell Research Foundation
2021 Phase 2 NCT04928287 United States;
2021 - NCT04772378 United States;
HEC122505MsOH
Sunshine Lake Pharma Co., Ltd.
2021 Phase 1 NCT04625361 China;
HF0220
Hunter-Fleming Ltd
2007 - EUCTR2005-005791-32-SE Sweden;United Kingdom;
2006 Phase 2 EUCTR2005-005791-32-GB Sweden;United Kingdom;
HP-3000 (ropinirole hydrochloride patch)
Hisamitsu Pharmaceutical Co., Inc.
2011 Phase 2 JPRN-JapicCTI-111673 -
Hisamitsu Pharmaceutical Co.,Inc.
2015 Phase 3 JPRN-JapicCTI-152870 -
HP-3000 placebo
Hisamitsu Pharmaceutical Co.,Inc.
2015 Phase 3 JPRN-JapicCTI-152870 -
2012 Phase 2 JPRN-JapicCTI-121880 -
2012 Phase 2 JPRN-JapicCTI-121879 -
HP-3000(ropinirole hydrochloride patch)
Hisamitsu Pharmaceutical Co.,Inc.
2014 Phase 3 JPRN-JapicCTI-142748 -
2012 Phase 2 JPRN-JapicCTI-121880 -
2012 Phase 2 JPRN-JapicCTI-121879 -
Helicobacter pylori eradication therapy
University of Malaya
2013 - NCT02108704 Malaysia;
Heptaminol hydrochloride
PIERRE FABRE MEDICAMENT
2008 Phase 3 EUCTR2007-002195-34-FR France;
Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.)
Fudan University
2008 Phase 2/Phase 3 NCT00656253 China;
Hericium erinaceus mycelium
National Cheng-Kung University Hospital
2020 - NCT04428983 Taiwan;
High Protein. T-Diet plus Range
Vegenat, S.A.
2010 - NCT01192529 Spain;
High dose AFFITOPE® PD03A + Adjuvant
Affiris AG
2014 Phase 1 NCT02267434 Austria;
High dose ANAVEX2-73
Anavex Life Sciences Corp.
2018 Phase 2 NCT03774459 Australia;Spain;
High dose levodopa
Rush University Medical Center
2018 - NCT04956939 United States;
High-Frequency-Only Stimulation
The Cleveland Clinic
2021 Phase 1 NCT05022147 United States;
Home based balance training
University of Arizona
2014 - NCT02777060 United States;
Human Amniotic Epithelial Stem Cells
Shanghai East Hospital
2020 Early Phase 1 NCT04414813 -
Human Stem Cells
Celavie Bioscences, LLC
2014 Phase 1 NCT02780895 Mexico;
Human neural stem cell
Second Affiliated Hospital of Soochow University
2017 Phase 2/Phase 3 NCT03128450 China;
Hydrocortisone cream
University Medical Center Groningen
2015 Phase 2 NCT02230930 Netherlands;
Hydrocortisone cream 10mg/g FNA Fagron
University Medical Center Groningen
2015 Phase 2 EUCTR2014-000657-36-NL Netherlands;
Hydrogen
Department of Neurology, Juntendo University School of Medicine
2010 - JPRN-UMIN000007497 Japan;
Juntendo University Koshigaya Hospital
2019 - JPRN-UMIN000035602 Japan;
2015 - JPRN-UMIN000019090 Japan;
Juntendo University School of Medicine, Neurology
2013 - JPRN-UMIN000010014 Japan;
Nagoya University Graduate School of Medicine
2015 - JPRN-UMIN000019082 Japan;
Nagoya graduate school of medicine university
2015 - JPRN-UMIN000019654 Japan;
Stony Brook University
2019 Phase 2/Phase 3 NCT03971617 United States;
Hydrolyzed guar gum
IRCCS San Raffaele
2016 Phase 2 NCT04569656 Italy;
Hypoestoxide
University of Ibadan
2022 Phase 1/Phase 2 NCT04858074 Nigeria;
Hypoxic Gas Mixture
Radboud University Medical Center
2022 Phase 1/Phase 2 NCT05214287 Netherlands;
I-123-5-IA85380
National Institute of Neurological Disorders and Stroke (NINDS)
2003 - NCT00058721 United States;
I123
Tel-Aviv Sourasky Medical Center
2013 Phase 2 NCT01931488 Israel;
IBEROGAST
Nantes University Hospital
2016 Phase 2 NCT02719496 France;
INS-GSH
Gateway Institute for Brain Research
2022 Phase 2 NCT05266417 United States;
IODIO IOFLUPANO-123I
UCB Biopharma SRL
2021 Phase 2 EUCTR2020-003265-19-IT Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
IOFLUPANE (123I)
MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
2012 - EUCTR2010-019894-13-IT Italy;United States;
Umeå University Hospital
2015 Phase 2 EUCTR2015-003045-26-SE Sweden;
IPT803
Tools4Patient
2018 Phase 1/Phase 2 NCT03407378 Belgium;France;United States;
IPX054
Impax Laboratories, LLC
2006 Phase 2 NCT00279825 United States;
2005 Phase 2 NCT00253084 United States;
2005 Phase 1/Phase 2 NCT00239564 United States;
IPX066
Impax Laboratories, LLC
2011 Phase 3 NCT01411137 United States;
2010 Phase 3 NCT01130493 France;Germany;Italy;United States;
2010 Phase 3 NCT01096186 Canada;Estonia;Germany;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United States;
2009 Phase 3 NCT00974974 Canada;France;Germany;Poland;Romania;Spain;Ukraine;United States;
2008 Phase 2 NCT00869791 United States;
IPX066 145 mg LD
Impax Laboratories, LLC
2009 Phase 3 NCT00880620 Canada;Estonia;Latvia;Lithuania;Romania;Ukraine;United States;
IPX066 195 mg LD
Impax Laboratories, LLC
2009 Phase 3 NCT00880620 Canada;Estonia;Latvia;Lithuania;Romania;Ukraine;United States;
IPX066 245 mg LD
Impax Laboratories, LLC
2009 Phase 3 NCT00880620 Canada;Estonia;Latvia;Lithuania;Romania;Ukraine;United States;
IPX066 95 mg LD
Impax Laboratories, LLC
2009 Phase 3 NCT00880620 Canada;Estonia;Latvia;Lithuania;Romania;Ukraine;United States;
IPX066-145
IMPAX LABORATORIES, INC.
2010 - EUCTR2009-017238-39-IT France;Germany;Italy;
IMPAX Laboratories, Inc.
2009 - EUCTR2009-010193-38-LV Estonia;Latvia;Lithuania;
2009 - EUCTR2009-010193-38-EE Estonia;Latvia;Lithuania;
IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.
2009 - EUCTR2009-010193-38-LT Estonia;Latvia;Lithuania;
Impax Laboratories, Inc.
2010 - EUCTR2009-017182-38-PL Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-014688-37-PL France;Germany;Poland;Spain;
2009 Phase 3 EUCTR2009-014688-37-FR France;Germany;Poland;Spain;
2009 - EUCTR2009-014688-37-ES France;Germany;Poland;Spain;
2009 - EUCTR2009-014688-37-DE France;Germany;Poland;Spain;
Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)
2010 - EUCTR2009-017182-38-LV Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-LT Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-EE Estonia;Germany;Latvia;Lithuania;Poland;Spain;
Impax Laboratories, Inc. acting through its Impax Pharmaceuticals Division
2010 Phase 3 EUCTR2009-017182-38-ES Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-DE Estonia;Germany;Latvia;Lithuania;Poland;Spain;
Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
2010 Phase 3 EUCTR2009-017238-39-FR Belgium;France;Germany;Italy;
2010 Phase 3 EUCTR2009-017238-39-DE Belgium;France;Germany;Italy;
2010 Phase 3 EUCTR2009-017238-39-BE Belgium;France;Germany;Italy;
IPX066-195
IMPAX LABORATORIES, INC.
2010 - EUCTR2009-017238-39-IT France;Germany;Italy;
IMPAX Laboratories, Inc.
2009 - EUCTR2009-010193-38-LV Estonia;Latvia;Lithuania;
2009 - EUCTR2009-010193-38-EE Estonia;Latvia;Lithuania;
IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.
2009 - EUCTR2009-010193-38-LT Estonia;Latvia;Lithuania;
Impax Laboratories, Inc.
2010 - EUCTR2009-017182-38-PL Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-014688-37-PL France;Germany;Poland;Spain;
2009 Phase 3 EUCTR2009-014688-37-FR France;Germany;Poland;Spain;
2009 - EUCTR2009-014688-37-ES France;Germany;Poland;Spain;
2009 - EUCTR2009-014688-37-DE France;Germany;Poland;Spain;
Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)
2010 - EUCTR2009-017182-38-LV Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-LT Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-EE Estonia;Germany;Latvia;Lithuania;Poland;Spain;
Impax Laboratories, Inc. acting through its Impax Pharmaceuticals Division
2010 Phase 3 EUCTR2009-017182-38-ES Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-DE Estonia;Germany;Latvia;Lithuania;Poland;Spain;
Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
2010 Phase 3 EUCTR2009-017238-39-FR Belgium;France;Germany;Italy;
2010 Phase 3 EUCTR2009-017238-39-DE Belgium;France;Germany;Italy;
2010 Phase 3 EUCTR2009-017238-39-BE Belgium;France;Germany;Italy;
IPX066-245
IMPAX LABORATORIES, INC.
2010 - EUCTR2009-017238-39-IT France;Germany;Italy;
IMPAX Laboratories, Inc.
2009 - EUCTR2009-010193-38-LV Estonia;Latvia;Lithuania;
2009 - EUCTR2009-010193-38-EE Estonia;Latvia;Lithuania;
IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.
2009 - EUCTR2009-010193-38-LT Estonia;Latvia;Lithuania;
Impax Laboratories, Inc.
2010 - EUCTR2009-017182-38-PL Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-014688-37-PL France;Germany;Poland;Spain;
2009 - EUCTR2009-014688-37-ES France;Germany;Poland;Spain;
2009 - EUCTR2009-014688-37-DE France;Germany;Poland;Spain;
Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)
2010 - EUCTR2009-017182-38-LV Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-LT Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-EE Estonia;Germany;Latvia;Lithuania;Poland;Spain;
Impax Laboratories, Inc. acting through its Impax Pharmaceuticals Division
2010 Phase 3 EUCTR2009-017182-38-ES Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-DE Estonia;Germany;Latvia;Lithuania;Poland;Spain;
Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
2010 Phase 3 EUCTR2009-017238-39-FR Belgium;France;Germany;Italy;
2010 Phase 3 EUCTR2009-017238-39-DE Belgium;France;Germany;Italy;
2010 Phase 3 EUCTR2009-017238-39-BE Belgium;France;Germany;Italy;
IPX066-95
IMPAX LABORATORIES, INC.
2010 - EUCTR2009-017238-39-IT France;Germany;Italy;
IMPAX Laboratories, Inc.
2009 - EUCTR2009-010193-38-LV Estonia;Latvia;Lithuania;
2009 - EUCTR2009-010193-38-EE Estonia;Latvia;Lithuania;
IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.
2009 - EUCTR2009-010193-38-LT Estonia;Latvia;Lithuania;
Impax Laboratories, Inc.
2010 - EUCTR2009-017182-38-PL Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-014688-37-PL France;Germany;Poland;Spain;
2009 Phase 3 EUCTR2009-014688-37-FR France;Germany;Poland;Spain;
2009 - EUCTR2009-014688-37-ES France;Germany;Poland;Spain;
2009 - EUCTR2009-014688-37-DE France;Germany;Poland;Spain;
Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)
2010 - EUCTR2009-017182-38-LV Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-LT Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-EE Estonia;Germany;Latvia;Lithuania;Poland;Spain;
Impax Laboratories, Inc. acting through its Impax Pharmaceuticals Division
2010 Phase 3 EUCTR2009-017182-38-ES Estonia;Germany;Latvia;Lithuania;Poland;Spain;
2010 - EUCTR2009-017182-38-DE Estonia;Germany;Latvia;Lithuania;Poland;Spain;
Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
2010 Phase 3 EUCTR2009-017238-39-FR Belgium;France;Germany;Italy;
2010 Phase 3 EUCTR2009-017238-39-DE Belgium;France;Germany;Italy;
2010 Phase 3 EUCTR2009-017238-39-BE Belgium;France;Germany;Italy;
IPX203
Impax Laboratories, LLC
2020 Phase 3 EUCTR2018-002234-21-GB Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2018-002233-37-PL Canada;Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 NCT03877510 Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002234-21-ES Czech Republic;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002234-21-DE Czech Republic;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002234-21-CZ Czech Republic;Czechia;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-IT Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-GB Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-DE Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-CZ Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2015 Phase 2 NCT02271503 United States;
IPX203 ER CD-LD
Impax Laboratories, LLC
2018 Phase 3 NCT03670953 Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
IR CD-LD
Impax Laboratories, Inc.
2010 - EUCTR2009-014688-37-PL France;Germany;Poland;Spain;
2009 Phase 3 EUCTR2009-014688-37-FR France;Germany;Poland;Spain;
2009 - EUCTR2009-014688-37-ES France;Germany;Poland;Spain;
2009 - EUCTR2009-014688-37-DE France;Germany;Poland;Spain;
Impax Laboratories, LLC
2018 Phase 3 NCT03670953 Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2016 Phase 2 NCT03007888 United States;
2009 Phase 3 NCT00974974 Canada;France;Germany;Poland;Romania;Spain;Ukraine;United States;
2008 Phase 2 NCT00869791 United States;
IR CD-LD (carbidopa-levodopa) tablets
Impax Laboratories, LLC
2020 Phase 3 EUCTR2018-002233-37-PL Canada;Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-IT Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-GB Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-DE Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002233-37-CZ Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
IR LD / CD
NEURODERM LTD.
2020 Phase 3 EUCTR2018-004156-37-IT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
NeuroDerm Ltd.
2020 Phase 3 EUCTR2018-004156-37-SK Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-SE Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-NL Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-BE Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-AT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004156-37-CZ Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
IR LD/CD
NeuroDerm Ltd.
2020 Phase 3 EUCTR2018-004156-37-PT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
IRL752
Integrative Research Laboratories AB
2017 Phase 2 EUCTR2017-001673-17-FI Finland;Sweden;
IRL790
Integrative Research Laboratories AB
2016 Phase 1/Phase 2 NCT03531060 -
Integrative Research Laboratories AB (IRLAB)
2019 Phase 2 EUCTR2017-003458-18-SE Sweden;
2017 Phase 2 EUCTR2017-003458-18-GB Sweden;United Kingdom;
Integrative Research Laboratories Sweden AB
2021 Phase 2 EUCTR2020-002010-41-IT France;Israel;Italy;Poland;Serbia;United States;
Integrative Research Laboratories Sweden AB (IRLAB)
2020 Phase 2 EUCTR2020-002010-41-FR France;Israel;Italy;Poland;Serbia;United States;
IRX4204
Io Therapeutics
2014 Phase 1 NCT02438215 United States;
ISC-hpNSC
Cyto Therapeutics Pty Limited
2016 Phase 1 NCT02452723 Australia;
ITI-214
Intra-Cellular Therapies, Inc.
2017 Phase 1/Phase 2 NCT03257046 United States;
IV Apomorphine
National Institute of Neurological Disorders and Stroke (NINDS)
2002 Phase 2 NCT00040209 United States;
IV Levodopa
National Institute of Neurological Disorders and Stroke (NINDS)
2005 Phase 2 NCT00108667 United States;
2002 Phase 2 NCT00040209 United States;
2001 Phase 2 NCT00013624 United States;
2001 Phase 2 NCT00009048 United States;
2000 Phase 2 NCT00006337 United States;
IZD174
Inflazome UK Ltd
2020 Phase 1 NCT04338997 -
Idebenone
Second Affiliated Hospital of Soochow University
2019 Phase 4 NCT03727295 -
Second Affiliated Hospital, School of Medicine, Zhejiang University
2020 Phase 2/Phase 3 NCT04152655 China;
IkT-148009
Inhibikase Therapeutics, Inc.
2021 Phase 1 NCT04350177 United States;
Immediate Release carbidopa/levodopa 10/
Intec Pharma, Ltd.
2016 Phase 3 EUCTR2015-003512-20-SK Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-HU Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-ES Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Immediate Release carbidopa/levodopa 25/
INTEC PHARMA LTD
2016 Phase 3 EUCTR2015-003512-20-IT Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Intec Pharma, Ltd.
2016 Phase 3 EUCTR2015-003512-20-SK Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-PL Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-HU Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-GB Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-ES Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Immediate release carbidopa/levodopa
Novartis
2008 Phase 4 NCT00642356 United States;
Novartis Pharmaceuticals
2004 Phase 3 NCT00099268 Austria;Belgium;Canada;Finland;France;Germany;Greece;Italy;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Impact
Oregon Research Institute
2008 Phase 2 NCT00611481 United States;
Inbrija
University of Texas Southwestern Medical Center
2022 - NCT04957095 United States;
Incobotulinum Toxin A
Beth Israel Deaconess Medical Center
2012 Phase 2 NCT01653132 United States;
2012 Phase 2 NCT01565395 United States;
IncobotulinumtoxinA
Yale University
2012 Phase 2 NCT02419313 United States;
IncobotulinumtoxinA (100 Units)
Merz Pharmaceuticals GmbH
2014 Phase 3 NCT02091739 Germany;Poland;United States;
IncobotulinumtoxinA (75 Units)
Merz Pharmaceuticals GmbH
2014 Phase 3 NCT02091739 Germany;Poland;United States;
Infudopa i.v.
Vastra Gotaland Region
2018 Phase 1 NCT03419806 Sweden;
Infudopa s.c.
Vastra Gotaland Region
2018 Phase 1 NCT03419806 Sweden;
Infusion Pump: CADD-Legacy® 1400 Pump
AbbVie (prior sponsor, Abbott)
2011 Phase 2 NCT01479127 Japan;
Infusions of young plasma
Stanford University
2016 Phase 1 NCT02968433 United States;
Inhaled VR040
South Glasgow University Hospitals NHS Trust
2006 Phase 2 NCT01683292 United Kingdom;
Injection of Umbilical cord derived MSCs
University of Jordan
2018 Phase 1/Phase 2 NCT03684122 Jordan;
Injection of apomorphine
University Hospital, Toulouse
2011 Phase 3 NCT01504178 France;
Injection of normal saline
Yonsei University
2013 Phase 1/Phase 2 NCT02018406 Korea, Republic of;
Inosine
Dept. of Clinical pharmacology and Neurology
2016 Phase 1 JPRN-UMIN000009062 Japan;
Ehime University Graduate School of Medicine
2016 Phase 2 JPRN-UMIN000020527 Japan;
Kamatani Naoyuki
2019 Phase 1 JPRN-jRCTs031190115 Japan;
Michael Alan Schwarzschild
2016 Phase 3 NCT02642393 Puerto Rico;United States;
Nagai Masahiro
2016 Phase 2 JPRN-jRCTs061180060 Japan;
StaGen Co. Ltd.
2018 - JPRN-UMIN000030930 Japan;
The Parkinson Study Group
2009 Phase 2 NCT00833690 United States;
Tsukuba International Clinical Pharmacology Clinic
2016 - JPRN-UMIN000024312 Japan;
Inspiratory Muscle Training
Bezmialem Vakif University
2018 - NCT04228887 Turkey;
Insulin
dr.dargahi
2020 Phase 2 NCT04687878 Iran, Islamic Republic of;
Intracerebral microinjections
NeuroGeneration
2021 Phase 1/Phase 2 NCT03309514 -
Intranasal Insulin
Peter Novak
2014 Phase 2 NCT02064166 United States;
Intranasal glutathione - (in)GSH
Bastyr University
2012 Phase 1 NCT01398748 United States;
Intravenous Infusion
VA Office of Research and Development
2019 - NCT04064294 United States;
Intravenous Levodopa
National Institute of Neurological Disorders and Stroke (NINDS)
2004 Phase 2 NCT00089622 United States;
2004 Phase 2 NCT00086294 United States;
2004 Phase 2 NCT00076674 United States;
Intravenous and Oral n-acetyl cysteine
Thomas Jefferson University
2014 - NCT02445651 United States;
Intravesical injection of Botulinum A toxin
University Of Perugia
2008 Phase 4 NCT00822913 -
Ioflupane
Weill Medical College of Cornell University
2018 Phase 1/Phase 2 NCT03675282 United States;
Ioflupane 123I (DATSCAN®)
University Hospital, Toulouse
2009 Phase 2 NCT00940914 France;
Ioflupane I 123
Julie Gurwell
2018 - NCT03531086 United States;
Ioflupane [123 I]
Institute for Neurodegenerative Disorders
2005 - EUCTR2004-001485-41-GB Spain;United Kingdom;
2005 - EUCTR2004-001485-41-AT Austria;Spain;United Kingdom;
Ioflupane [123I]
Institute for Neurodegenerative Disorders
2005 - EUCTR2004-001485-41-ES Spain;United Kingdom;
Ipratropium bromide (drug)
University Health Network, Toronto
2004 Phase 2 NCT00296946 Canada;
Ips-nsc cells
Allife Medical Science and Technology Co., Ltd.
2019 Early Phase 1 NCT03815071 -
Isicom
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2010 - EUCTR2009-017416-33-DE Germany;
Isoflurane
Columbia University
2003 - NCT00615472 United States;
Isradipine
University of Rochester
2014 Phase 3 NCT02168842 Canada;United States;
Isradipine CR
Northwestern University
2009 Phase 2 NCT00909545 Canada;United States;
Istradefylline
Fukuoka University
2016 - JPRN-UMIN000024536 Japan;
Hatano Taku
2019 - JPRN-jRCTs031180248 Japan;
Ichinomiya Nishi Hospital
2019 - JPRN-UMIN000037422 Japan;
2019 - JPRN-UMIN000037421 Japan;
Juntendo University Shizuoka Hospital
2016 - JPRN-UMIN000020288 Japan;
KYOWA HAKKO UK LTD
2005 - EUCTR2004-002844-93-IT Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-000817-20-IT Italy;Latvia;Lithuania;Spain;
Kyowa Hakko Kirin Company, Limited
2009 Phase 3 NCT00957203 Japan;
2009 Phase 3 NCT00955526 Japan;
2007 Phase 2 NCT00455507 Japan;
Kyowa Hakko Kirin Pharma, Inc.
2013 Phase 3 NCT01968031 Canada;Czech Republic;Czechia;Germany;Israel;Italy;Poland;Serbia;United States;
Kyowa Hakko U.K. Limited
2005 - EUCTR2004-002844-93-LV Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-002844-93-LT Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-002844-93-GB Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-002844-93-ES Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-002844-93-EE Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-002844-93-AT Austria;Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-000817-20-AT Austria;Italy;Latvia;Lithuania;Spain;
2004 Phase 3 EUCTR2004-000817-20-GB Austria;Italy;Latvia;Lithuania;Spain;United Kingdom;
2004 - EUCTR2004-000817-20-LV Italy;Latvia;Lithuania;Spain;
2004 - EUCTR2004-000817-20-LT Italy;Latvia;Lithuania;Spain;
2004 - EUCTR2004-000817-20-ES Italy;Latvia;Lithuania;Spain;
Kyowa Kirin Pharmaceutical Development, Inc.
2005 Phase 3 NCT00199381 United States;
2002 Phase 2/Phase 3 NCT00955045 United States;
Osaka Red Cross Hospital
2017 - JPRN-UMIN000026492 Japan;
Takahashi Makio
2017 - JPRN-jRCTs051180185 Japan;
Tsuboi Yoshio
2017 - JPRN-jRCTs071180014 Japan;N A;
University of Chicago
2005 Phase 3 NCT00203957 United States;
Istradefylline ( KW-6002)
Kyowa Kirin Pharmaceutical Development, Inc.
2004 Phase 3 NCT00199368 United States;
Istradefylline (KW-6002)
Kyowa Hakko Kirin Company, Limited
2005 Phase 2 NCT00250393 Japan;
2005 Phase 2 NCT00199355 Japan;
Kyowa Hakko Kirin UK, Ltd.
2004 Phase 3 NCT00199394 United Kingdom;
Kyowa Kirin Pharmaceutical Development, Inc.
2005 Phase 2 NCT00199433 United States;
2004 Phase 3 NCT00199420 United States;
2004 Phase 3 NCT00199407 United States;
2002 Phase 2 NCT00456794 United States;
Istradefylline 20 mg or
Kyowa Hakko Kirin Pharma, Inc.
2015 Phase 3 NCT02610231 Canada;Czech Republic;Czechia;Germany;Israel;Italy;Poland;Serbia;United States;
J-tube
AbbVie
2013 Phase 3 NCT01960842 Japan;Korea, Republic of;Taiwan;
AbbVie (prior sponsor, Abbott)
2009 Phase 3 NCT00660387 New Zealand;United States;
2009 Phase 3 NCT00360568 Germany;New Zealand;United States;
2009 Phase 3 NCT00357994 Germany;United States;
2008 Phase 3 NCT00335153 Australia;Canada;Czech Republic;Finland;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
JM-010
Bukwang Pharmaceutical
2015 Phase 2 NCT02439203 South Africa;
Contera Pharma
2020 Phase 2 EUCTR2017-003415-19-IT France;Germany;Italy;Spain;
2018 Phase 2 EUCTR2017-003415-19-ES France;Germany;Spain;
JM-010 group A
Contera Pharma
2019 Phase 2 NCT03956979 France;Germany;Italy;Spain;
JM-010 group B
Contera Pharma
2019 Phase 2 NCT03956979 France;Germany;Italy;Spain;
JNJ-31001074
BENEVOLENTAI BIO
2017 Phase 2 EUCTR2017-000877-35-IT Czech Republic;Czechia;Germany;Italy;Poland;Spain;United Kingdom;United States;
BenevolentAI Bio
2017 Phase 2 EUCTR2017-000877-35-GB Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000877-35-ES Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000877-35-DE Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000877-35-CZ Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States;
JNJ31-31001074
BENEVOLENTAI BIO
2017 Phase 2 EUCTR2017-000877-35-IT Czech Republic;Czechia;Germany;Italy;Poland;Spain;United Kingdom;United States;
JP 1730
National Institute of Neurological Disorders and Stroke (NINDS)
2002 Phase 2 NCT00040209 United States;
JP-1730/F01
Juvantia Pharma Ltd
2008 - EUCTR2007-004890-24-PT France;Portugal;
2008 - EUCTR2007-004890-24-FR France;Portugal;
JP-1730/F02
Juvantia Pharma Ltd
2008 - EUCTR2007-004890-24-PT France;Portugal;
2008 - EUCTR2007-004890-24-FR France;Portugal;
JP-1730/F03
Juvantia Pharma Ltd
2008 - EUCTR2007-004890-24-PT France;Portugal;
2008 - EUCTR2007-004890-24-FR France;Portugal;
JZP-110
Jazz Pharmaceuticals
2017 Phase 2 NCT03037203 United States;
Jejunal extension tube
AbbVie
2017 Phase 3 NCT02799381 Finland;Greece;Hungary;Italy;Slovakia;Spain;United States;
Jejunal extension tube (J-tube)
AbbVie (prior sponsor, Abbott)
2006 Phase 4 NCT00141518 Norway;Sweden;
Juvit D3
Medical University of Gdansk
2019 - NCT04768023 Poland;
K0706
Sun Pharma Advanced Research Company (SPARC) Limited
2019 Phase 2 EUCTR2018-003337-15-SK Hungary;India;Poland;Slovakia;Spain;United States;
2019 Phase 2 EUCTR2018-003337-15-HU Hungary;India;Poland;Slovakia;Spain;United States;
2019 Phase 2 EUCTR2018-003337-15-ES Czech Republic;Hungary;India;Poland;Slovakia;Spain;United States;
Sun Pharma Advanced Research Company Limited
2019 Phase 2 NCT03655236 Hungary;India;Poland;Slovakia;Spain;United States;
2017 Phase 1 NCT02970019 United States;
KDT-3594
Kissei Pharmaceutical Co., Ltd.
2021 Phase 2 NCT04867551 Japan;
2019 Phase 2 NCT03845387 Japan;
2017 Phase 1 NCT03068481 Japan;
KM-819
Kainos Medicine Inc.
2016 Phase 1 NCT03022799 Korea, Republic of;
KW-6002
KYOWA HAKKO UK LTD
2005 - EUCTR2004-002844-93-IT Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-000817-20-IT Italy;Latvia;Lithuania;Spain;
Kyowa Hakko U.K. Limited
2005 - EUCTR2004-002844-93-LV Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-002844-93-LT Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-002844-93-GB Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-002844-93-ES Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-002844-93-EE Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-002844-93-AT Austria;Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2004-000817-20-AT Austria;Italy;Latvia;Lithuania;Spain;
2004 Phase 3 EUCTR2004-000817-20-GB Austria;Italy;Latvia;Lithuania;Spain;United Kingdom;
2004 - EUCTR2004-000817-20-LV Italy;Latvia;Lithuania;Spain;
2004 - EUCTR2004-000817-20-LT Italy;Latvia;Lithuania;Spain;
2004 - EUCTR2004-000817-20-ES Italy;Latvia;Lithuania;Spain;
National Institute of Neurological Disorders and Stroke (NINDS)
2000 Phase 2 NCT00006337 United States;
KW-6002 (istradefylline)
KYOWA HAKKO KIRIN PHARMA, INC.
2016 Phase 3 EUCTR2015-003887-34-IT Canada;Czech Republic;Germany;Israel;Italy;Poland;Serbia;United States;
Kyowa Hakko Kirin Pharma, Inc.
2014 Phase 3 EUCTR2013-002254-70-IT Canada;Czech Republic;Germany;Israel;Italy;Poland;Serbia;United States;
Kyowa Kirin Pharmaceutical Development, Inc.
2016 Phase 3 EUCTR2015-003887-34-PL Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States;
2016 Phase 3 EUCTR2015-003887-34-DE Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States;
2016 Phase 3 EUCTR2015-003887-34-CZ Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States;
2014 Phase 3 EUCTR2013-002254-70-PL Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States;
2014 Phase 3 EUCTR2013-002254-70-DE Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States;
2014 Phase 3 EUCTR2013-002254-70-CZ Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States;
2002 Phase 2 NCT00456586 United States;
KW-6356
Kyowa Kirin Co., Ltd.
2020 Phase 1 NCT04342273 Japan;
2019 Phase 1 NCT04070495 Japan;
2019 Phase 1 NCT03970798 Japan;
2018 Phase 2 NCT03703570 Japan;
2016 Phase 2 NCT02939391 Japan;
KW-6356 High Dose
Kyowa Kirin Co., Ltd.
2019 Phase 1 NCT03830528 Japan;
KW-6356 Low Dose
Kyowa Kirin Co., Ltd.
2019 Phase 1 NCT03830528 Japan;
KW-6356 Middle Dose
Kyowa Kirin Co., Ltd.
2019 Phase 1 NCT03830528 Japan;
KW-6356 X Dose
Kyowa Kirin Co., Ltd.
2019 Phase 1 NCT03830528 Japan;
KW-6356 Y Dose
Kyowa Kirin Co., Ltd.
2019 Phase 1 NCT03830528 Japan;
KW-6500
Kyowa Hakko Kirin Co., Ltd
2010 Phase 3 NCT01063621 Japan;
2010 Phase 3 NCT01058291 Japan;
2009 Phase 3 NCT00955318 Japan;
Ketamine
PharmaTher Inc.
2021 Phase 2 NCT04912115 United States;
Ketamine Infusion
Yale University
2021 Phase 2 NCT04944017 United States;
Ketone Ester Elite endurance Nutrition Drink
University of Florida
2019 - NCT04477161 United States;
Ketone ester drink
University of Oxford
2011 - NCT01364545 United Kingdom;
Kinetra and Soletra (neurostimulator, Medtronic)
German Parkinson Study Group (GPS)
2006 Phase 4 NCT00354133 France;Germany;
Kinoquinone (proposed)
BioElectron Technology Corporation (formerly Edison Pharmaceuticals Inc.)
2016 Phase 2 EUCTR2015-001786-10-DE Germany;United Kingdom;United States;
L-123 Ioflupane
Wisconsin Institute for Neurologic and Sleep Disorders S.C.
2014 - NCT02138682 United States;
L-3-(3,4-Dihydroxyphenyl)alanine
Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
2007 - EUCTR2006-000577-29-DE Germany;United States;
L-DOPA
Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
2007 - EUCTR2006-000577-29-DE Germany;United States;
Ito Hidefumi
2016 Phase 2 JPRN-jRCTs051180098 Japan;
Osaka Redcross HospitalWakayama Prefectural Medical College
2016 Phase 2 JPRN-UMIN000022533 Japan;
Utano National Hospital, National Hospital Organization
2016 Phase 3 JPRN-UMIN000022529 Japan;
L-DOPA/DDCI
Bial - Portela C S.A.
2021 Phase 4 NCT04990284 -
L-DOPS
St. Joseph's Hospital and Medical Center, Phoenix
2016 Phase 2 NCT02812147 United States;
L-Dopa/ MODOPAR
Chru de Lille
2009 - EUCTR2008-008210-38-FR France;
L-tyrosine
New York Institute of Technology
2014 Phase 0 NCT02259049 United States;
LCIG
NeuroDerm Ltd.
2015 Phase 1 NCT02604914 United Kingdom;
LCIG (Duodopa)
Vastra Gotaland Region
2018 Phase 1 NCT03419806 Sweden;
LD / BE
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2011 - EUCTR2010-022363-35-DE Germany;
LD+DDCI
ASST Gaetano Pini-CTO
2016 Phase 2 NCT02680977 Bolivia;
LD-DDCI
ASST Gaetano Pini-CTO
2016 Phase 2 NCT02680977 Bolivia;
LD/CD
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2010 - EUCTR2009-017416-33-DE Germany;
LEVODOPA (DC.IT) (FU)
NOVARTIS FARMA
2004 - EUCTR2004-000185-12-IT Finland;Italy;Sweden;United Kingdom;
LEVODOPA (LD)
NEURODERM LTD.
2016 Phase 2 EUCTR2015-005814-31-IT Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
LEVODOPA / BENSERAZIDE 200 +
LEVODOPA DC.IT FU
VERNALIS DEVELOPMENT LIMITED
2006 - EUCTR2006-004112-51-IT Italy;
LEVODOPA INN
NOVARTIS FARMA
2005 - EUCTR2005-001032-72-IT Czech Republic;Italy;Portugal;
LEVODOPA/BENZERASIDE
CHU de Poitiers
2010 - EUCTR2010-020769-25-FR France;
LEVODOPA/CARBIDOPA
CHU de Poitiers
2010 - EUCTR2010-020769-25-FR France;
LODALÈS®
CHU de Bordeaux
2009 - EUCTR2009-011736-35-FR France;
LY03003
Luye Pharma Group Ltd.
2020 Phase 1 NCT04630860 China;
2018 Phase 1 NCT04629404 China;
2018 Phase 1 NCT03733561 United States;
2018 Phase 1 NCT03589066 United States;
2013 Phase 1 NCT04627155 -
2013 Phase 1 NCT02055274 United States;
LY03003 ( Rotigotine, extended-release microspheres)
Luye Pharma Group Ltd.
2017 Phase 1 NCT04045678 China;
LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)
Luye Pharma Group Ltd.
2020 Phase 1 NCT04384666 United States;
LY03003( the name of rotigotine)
Peking University Third Hospital
2018 Phase 3 NCT04455555 China;
LY03003(Rotigotine,extended-release microspheres)
Luye Pharma Group Ltd.
2020 Phase 3 NCT04571164 China;
LY03009 F1
Luye Pharma Group Ltd.
2021 Phase 1 NCT04593511 Australia;
LY03009 F2
Luye Pharma Group Ltd.
2021 Phase 1 NCT04593511 Australia;
LY03009 F3
Luye Pharma Group Ltd.
2021 Phase 1 NCT04593511 Australia;
LY03009 F4
Luye Pharma Group Ltd.
2021 Phase 1 NCT04593511 Australia;
LY300164
National Institute of Neurological Disorders and Stroke (NINDS)
2000 Phase 2 NCT00004576 United States;
LY3154207
Eli Lilly and Company
2017 Phase 2 NCT03305809 Canada;China;Puerto Rico;United States;
2015 Phase 1 NCT02562768 United States;
Lactobacillus casei DG (Enterolactis duo®)
University of Salerno
2019 - NCT04293159 Italy;
Lactobacillus plantarum PS128
Professor Lu Neurological Clinic
2018 - NCT03566589 Taiwan;
Lactose
Ehime University Graduate School of Medicine
2016 Phase 2 JPRN-UMIN000020527 Japan;
Kansai Medical University
2012 - JPRN-UMIN000007896 Japan;
Utano National Hospital, National Hospital Organization
2016 Phase 3 JPRN-UMIN000022529 Japan;
Leptin
Nagoya University Graduate School of Medicine
2015 - JPRN-UMIN000017036 Japan;
Levetiracetam
1st Hospital of Social Security Services
2006 Phase 2 NCT00291733 Greece;
Technische Universität Dresden
2006 Phase 4 NCT00307450 Germany;
The University of Queensland
2021 Phase 2 NCT04643327 Australia;
UCB Pharma
2003 Phase 2 NCT00160576 -
University of South Florida
2007 Phase 4 NCT00584025 United States;
Levodopa
AbbVie Inc
2011 Phase 3 EUCTR2008-001329-33-GB Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
2010 Phase 3 EUCTR2008-001329-33-CZ Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
2009 - EUCTR2008-001329-33-PT Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;
Abbott Healthcare Products B.V.
2009 - EUCTR2006-005186-18-CZ Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
2008 Phase 3 EUCTR2006-005186-18-GB Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
2008 - EUCTR2006-005186-18-PT Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 - EUCTR2006-005186-18-DE Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
Abbott Laboratories
2009 - EUCTR2006-000578-53-DE Germany;New Zealand;United States;
Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
2007 - EUCTR2006-000577-29-DE Germany;United States;
Bial - Portela C S.A.
2011 Phase 3 NCT01568073 Austria;Portugal;
2011 Phase 3 NCT01227655 Portugal;
CHU de Toulouse
2010 Phase 3 EUCTR2010-018650-12-FR France;
Chinese Academy of Sciences
2017 Phase 1/Phase 2 NCT03119636 China;
CleveXel Pharma
2016 Phase 2 NCT02641054 France;
Department of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital
2014 - ChiCTR-DDD-17010794 China;
Department of Neuroscience, neurology
2007 - EUCTR2007-004985-41-SE Sweden;
Dept of Neuroscience, Uppsala University
2008 - EUCTR2008-003581-26-SE Sweden;
First Affiliated Hospital of Xinjiang Medical University
2007 - ChiCTR-TRC-07000027 China;
Fujita Health University School of MedicineDepartment of Gastroenterology
2020 Phase 4 JPRN-UMIN000040889 Japan;
GlaxoSmithKline
2011 - NCT01545856 -
Hamamatsu University School of Medicine
2015 - JPRN-UMIN000019524 Japan;
Hatano Taku
2019 - JPRN-jRCTs031180248 Japan;
Institute for Neurodegenerative Disorders
2004 Phase 2 NCT00096720 United States;
Institute of Clinical Pharmacology, Central South University
2012 - ChiCTR-OCS-12002720 -
Institute of Psychology, Chinese Academy of Sciences
2018 - ChiCTR1800015331 China;
Juntendo University School of Medicine
2017 - JPRN-UMIN000025645 Japan;
Kansai Medical University
2012 - JPRN-UMIN000007896 Japan;
Kevin J. Black, MD
2017 Phase 1 NCT03205956 United States;
Merck Sharp & Dohme Corp.
2009 Phase 1 NCT00845000 United States;
National Institute of Neurological Disorders and Stroke (NINDS)
1998 Phase 3 NCT00004733 United States;
Oregon Health and Science University
2005 - NCT00692328 United States;
Orion Corporation Orion Pharma
2007 - EUCTR2007-002496-14-FI Finland;
2006 Phase 4 EUCTR2006-001755-36-GB Germany;Sweden;United Kingdom;
- - EUCTR2006-001755-36-DE Germany;Sweden;United Kingdom;
Orion Corporation Orion Pharma, FI-02200 Espoo, Finland
2006 - EUCTR2006-001755-36-SE Germany;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA
2005 - EUCTR2004-005234-39-FI Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-FI Finland;Italy;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA, Finland
2005 Phase 4 EUCTR2004-005234-39-GB Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA, 02200 Espoo, Finland
2008 - EUCTR2004-005234-39-DE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2007 Phase 3 EUCTR2004-000185-12-GB Austria;Finland;Italy;Sweden;United Kingdom;
2006 - EUCTR2004-005234-39-LV Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2006 - EUCTR2004-005234-39-LT Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 Phase 4 EUCTR2004-005234-39-IE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-005234-39-SE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-005234-39-DK Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-SE Finland;Italy;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-AT Austria;Finland;Italy;Sweden;United Kingdom;
Ouchi Yasuomi
2015 - JPRN-jRCTs041180070 Japan;
Rush University Medical Center
2011 Phase 2 NCT01351168 United States;
Sage Therapeutics
2016 Phase 2 NCT03000569 United States;
Solvay Pharmaceuticals B.V.
2009 - EUCTR2006-005186-18-NL Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2008 Phase 3 EUCTR2006-005186-18-ES Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
2007 - EUCTR2006-005186-18-FI Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
Solvay Pharmaceuticals BV.
2008 - EUCTR2006-005186-18-IT Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
Solvay Pharmaceuticals GmbH
2006 - EUCTR2005-002654-21-NO Norway;Sweden;
2005 - EUCTR2005-002654-21-SE Sweden;
Technische Universität Dresden
2005 Phase 4 NCT00153972 Germany;
The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital)
2020 Phase 4 ChiCTR2000039201 China;
Tianjin Huanhu Hospital
2019 Phase 0 ChiCTR1900025372 China;
University Hospital, Toulouse
2016 Phase 2/Phase 3 NCT02601586 France;
2002 - NCT01044992 France;
Yagi Michio
2021 Phase 1 JPRN-jRCT2051200104 Japan;
Levodopa (L-DOPA) + Standard care
Bial - Portela C S.A.
2020 - NCT03959540 United Kingdom;
Levodopa (L-dopa)
Biotie Therapies Inc.
2011 Phase 2/Phase 3 NCT01283594 Argentina;Canada;Chile;Romania;Ukraine;United States;
Levodopa (delivered intravenously)
Oregon Health and Science University
2010 - NCT01003002 United States;
VA Office of Research and Development
2006 - NCT00467597 United States;
Levodopa (drug), intraduodenal administration
University Hospital, Akershus
2006 Phase 4 NCT00272688 Norway;
Levodopa / Benserazid
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2011 - EUCTR2010-022363-35-DE Germany;
Levodopa 100 mg / benserazide
Bial - Portela C S.A.
2005 Phase 1 NCT02778594 Portugal;
Levodopa 100 mg A CAP
Orion Corporation
2017 Phase 2 EUCTR2015-004507-23-HU Finland;Germany;Hungary;Latvia;
2017 Phase 2 EUCTR2015-004507-23-FI Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-LV Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-DE Finland;Germany;Hungary;Latvia;
Levodopa 125 mg A CAP
Orion Corporation
2017 Phase 2 EUCTR2015-004507-23-HU Finland;Germany;Hungary;Latvia;
2017 Phase 2 EUCTR2015-004507-23-FI Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-LV Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-DE Finland;Germany;Hungary;Latvia;
Levodopa 150 mg A CAP
Orion Corporation
2017 Phase 2 EUCTR2015-004507-23-HU Finland;Germany;Hungary;Latvia;
2017 Phase 2 EUCTR2015-004507-23-FI Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-LV Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-DE Finland;Germany;Hungary;Latvia;
Levodopa 25mg/
NeuroDerm Ltd.
2019 Phase 3 NCT04006210 Austria;Belgium;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
Levodopa 75 mg A CAP
Orion Corporation
2017 Phase 2 EUCTR2015-004507-23-HU Finland;Germany;Hungary;Latvia;
2017 Phase 2 EUCTR2015-004507-23-FI Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-LV Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-DE Finland;Germany;Hungary;Latvia;
Levodopa Benserazide Madopar
IRCCS San Raffaele
2014 Phase 4 NCT02741947 Italy;
Levodopa Benserazide Teva Italia
IRCCS San Raffaele
2014 Phase 4 NCT02741947 Italy;
Levodopa CR (controlled release)
Research and Development University Hospital of North Staffordshire
2014 - EUCTR2014-000335-17-GB United Kingdom;
Levodopa Cyclops
Pharmaceutical Technology and Biopharmacy, University of Groningen
2018 Phase 2 EUCTR2017-004006-18-NL Netherlands;
Levodopa MR
Orion Corporation, Orion Pharma
2016 Phase 2 NCT02764125 Finland;Germany;Hungary;Latvia;
Levodopa acute challenge
Institut de Myologie, France
2016 - NCT02785978 France;
Levodopa and Domperidone
National Institute of Neurological Disorders and Stroke (NINDS)
2000 Phase 2 NCT00006077 United States;
Levodopa and carbidopa
NeuroDerm Ltd.
2013 Phase 2 NCT01883505 Israel;
Levodopa and carbidopa SC solution
NeuroDerm Ltd.
2014 Phase 1/Phase 2 NCT02096601 Israel;United States;
Levodopa and carbidopa solution for SC administration
NeuroDerm Ltd.
2012 Phase 1/Phase 2 NCT01725802 Israel;
Levodopa and decarboxylase inhibitor
AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
2010 - EUCTR2010-019396-29-IT Italy;
IMPAX LABORATORIES, INC.
2010 - EUCTR2009-017238-39-IT France;Germany;Italy;
Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets
AbbVie (prior sponsor, Abbott)
2009 Phase 3 NCT00357994 Germany;United States;
Levodopa carbidopa intestinal gel (LCIG)
AbbVie (prior sponsor, Abbott)
2009 Phase 3 NCT00660387 New Zealand;United States;
2009 Phase 3 NCT00357994 Germany;United States;
Levodopa dispersible
Seoul National University Hospital
2015 Phase 4 NCT02769793 Korea, Republic of;
Levodopa infusion
Helsinki University
2009 Phase 4 NCT00914134 Finland;
Levodopa powder for inhalation
Pharmaceutical Technology and Biopharmacy, University of Groningen
2018 Phase 2 EUCTR2017-004006-18-NL Netherlands;
Levodopa tablet
Western University, Canada
2019 - NCT04054960 Canada;
Levodopa, carbidopa, ODM-104
Orion Corporation, Orion Pharma
2017 Phase 1 NCT03140956 Finland;
2015 Phase 1 NCT02554734 Finland;
2014 Phase 1 NCT02312232 Finland;
Levodopa, carbidopa, entacapone
Orion Corporation, Orion Pharma
2015 Phase 1 NCT02554734 Finland;
Levodopa, decarboxylase inhibitor and COMT inhibitor
AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
2010 - EUCTR2010-019396-29-IT Italy;
Levodopa-4'-Monophosphate
ABBVIE DEUTSCHLAND GMBH & CO. KG
2020 Phase 3 EUCTR2019-004235-23-IT Australia;Canada;Italy;Japan;Netherlands;Russian Federation;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-IT Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
AbbVie Deutschland
2020 Phase 3 EUCTR2018-002144-85-DE Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-NL Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-GB Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-ES Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-DK Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002144-85-BE Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States;
Abbvie Deutschland GmbH & Co. KG
2021 Phase 3 EUCTR2019-004235-23-SE Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004235-23-DE Australia;Canada;Germany;Italy;Japan;Netherlands;Russian Federation;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-NL Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-GB Australia;Canada;Japan;Russian Federation;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004235-23-DK Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States;
Levodopa-Carbidopa
AbbVie
2010 Phase 1 NCT01484990 Germany;Sweden;
Levodopa-Carbidopa Intestinal Gel
AbbVie (prior sponsor, Abbott)
2013 Phase 3 NCT01736176 United States;
Levodopa-Carbidopa Intestinal Gel (LCIG)
AbbVie
2017 Phase 3 NCT02799381 Finland;Greece;Hungary;Italy;Slovakia;Spain;United States;
Levodopa-Carbidopa Multilayer Extended Release Tablet
CombinatoRx, Inc
2008 - EUCTR2007-005033-11-DE Germany;
Levodopa-Carbidopa XL tablet (M)
CombinatoRx, Inc
2008 - EUCTR2007-005033-11-DE Germany;
Levodopa-carbidopa
EISAI LTD UK
2007 - EUCTR2006-005714-12-IT Italy;
Osmotica Pharmaceutical Corp.
2007 Phase 2 NCT00558337 Argentina;
Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets
AbbVie (prior sponsor, Abbott)
2009 Phase 3 NCT00660387 New Zealand;United States;
Levodopa-carbidopa Immediate Release (LC-IR) Tablets
AbbVie (prior sponsor, Abbott)
2013 Phase 3 NCT01736176 United States;
Levodopa-carbidopa intestinal gel
AbbVie
2013 Phase 3 NCT01960842 Japan;Korea, Republic of;Taiwan;
2009 Phase 3 NCT00660673 Australia;Canada;Czech Republic;Czechia;Israel;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;United States;
AbbVie (prior sponsor, Abbott)
2009 Phase 3 NCT00360568 Germany;New Zealand;United States;
2008 Phase 3 NCT00335153 Australia;Canada;Czech Republic;Finland;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
Levodopa-carbidopa intestinal gel (LCIG)
AbbVie (prior sponsor, Abbott)
2006 Phase 4 NCT00141518 Norway;Sweden;
Levodopa-carbidopa-entacapone
Institut de Recerca del Hospital de la Santa Creu i Sant Pau
2007 - EUCTR2006-002408-32-ES Spain;
Levodopa/Benzerazide
Bial - Portela C S.A.
2010 Phase 2 NCT01568047 Romania;Ukraine;
2009 Phase 2 NCT01568034 Portugal;Romania;Ukraine;
Levodopa/Carbidopa
Bial - Portela C S.A.
2010 Phase 2 NCT01568047 Romania;Ukraine;
2009 Phase 2 NCT01568034 Portugal;Romania;Ukraine;
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2010 - EUCTR2009-017416-33-DE Germany;
Institut de Recerca del Hospital de la Santa Creu i Sant Pau
2007 - EUCTR2006-002408-32-ES Spain;
Levodopa/Carbidopa (LD/CD)
AbbVie
2020 Phase 3 NCT04380142 Australia;United States;
Levodopa/Carbidopa (Sinemet)
NeuroDerm Ltd.
2015 Phase 1 NCT02486432 -
Levodopa/Carbidopa Solution
NeuroDerm Ltd.
2020 Phase 3 EUCTR2018-004156-37-SK Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
Levodopa/Carbidopa(200mg/50mg)
Sandoz
2012 Phase 4 NCT01683253 Korea, Republic of;
Levodopa/DDCI
Bial - Portela C S.A.
2006 Phase 2 NCT03103399 -
Levodopa/benserazide
Bial - Portela C S.A.
2009 Phase 1 NCT01533116 Canada;
Levodopa/benserazide 100/
Bial - Portela C S.A.
2010 Phase 1 NCT02169414 France;
Levodopa/carbidopa
Bial - Portela C S.A.
2011 Phase 1 NCT02170376 France;
2009 Phase 1 NCT01533116 Canada;
2009 Phase 1 NCT01519284 Portugal;
Uppsala University
2008 Phase 4 NCT00906828 Sweden;
2008 Phase 4 NCT00888186 Sweden;
Levodopa/carbidopa 100/25
Bial - Portela C S.A.
2010 Phase 1 NCT02169414 France;
Levodopa/carbidopa hydrate
ONO PHARMACEUTICAL CO.,LTD.
2014 Phase 1 JPRN-JapicCTI-142702 -
Levodopa/carbidopa solution
NEURODERM LTD.
2020 Phase 3 EUCTR2018-004156-37-IT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
NeuroDerm Ltd.
2020 Phase 3 EUCTR2018-004156-37-SE Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-PT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-NL Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-GB Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-ES Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-BE Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-AT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004156-37-HU Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004156-37-CZ Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-002033-30-NL Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002033-30-HU Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002033-30-GB Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2015-005814-31-PL Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
2017 Phase 2 EUCTR2015-005814-31-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States;
2017 Phase 2 EUCTR2015-005814-31-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States;
2017 Phase 2 EUCTR2015-005814-31-DE Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2015-005814-31-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
2017 Phase 2 EUCTR2015-005814-31-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States;
2016 Phase 3 EUCTR2016-002033-30-FR Belgium;Canada;Denmark;France;Hungary;Israel;Netherlands;Spain;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002033-30-ES Belgium;Canada;Denmark;France;Israel;Netherlands;Spain;Sweden;United States;
2016 Phase 3 EUCTR2016-002033-30-BE Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-005814-31-AT Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
2016 Phase 2 EUCTR2015-005078-39-DE Austria;Germany;Israel;Italy;United States;
2016 Phase 2 EUCTR2015-005078-39-AT Austria;Germany;Israel;Italy;United States;
Levodopa/carbidopa/entacapone
Novartis
2006 Phase 4 NCT00391898 Spain;
Novartis Pharma AG
2006 - EUCTR2005-001032-72-PT Czech Republic;Italy;Portugal;
Levodopa/dopa decarboxylase inhibitor
Bial - Portela C S.A.
2016 Phase 4 NCT02847442 Germany;
Liatermin
Amgen
2003 Phase 1/Phase 2 NCT00111982 United States;
North Bristol NHS Trust (NBT)
2013 Phase 2 EUCTR2013-001881-40-GB United Kingdom;
2012 Phase 2 EUCTR2011-003866-34-GB United Kingdom;
Liatermin (r-metHuGDNF)
Amgen
2003 Phase 1 NCT00115427 United States;
Lidocaine
Dept. of Clinical pharmacology and Neurology, Ehime University
2012 - JPRN-UMIN000007617 Japan;
Parkinson'
s disease and Movement Disorder Center
Light box ( Litebook company)
McGill University Health Center
2011 Phase 0 NCT01489982 Canada;
Light box (Litebook company)
McGill University Health Center
2011 Phase 0 NCT01489982 Canada;
Linaclotide
The 988th Hospitail of Joint Logistic Support Force
2021 Phase 4 ChiCTR2100043303 China;
Lingzhi (Ganoderma)
Xuanwu Hospital, Beijing
2005 Phase 2 NCT00224263 China;
Lipopolysaccharide
University of Exeter
2022 - NCT05205291 United Kingdom;
Liquigen MCT oil
National Institute of Neurological Disorders and Stroke (NINDS)
2021 Phase 1 NCT04584346 United States;
Liraglutide
Cedars-Sinai Medical Center
2017 Phase 2 NCT02953665 United States;
Lisparin
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-DE Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-CZ Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
Lisuride Hydrogenmaleate
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-DE Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-CZ Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
Lisuride TTS
NEUROBIOTEC GMBH
2007 - EUCTR2006-003732-30-IT Germany;Italy;Poland;
Lisuride TTS 10cm²
Axxonis Pharma AG
2007 - EUCTR2006-003732-30-DE Germany;Italy;Poland;
NeuroBiotec Pharma AG
2008 - EUCTR2006-003732-30-PL Germany;Italy;Poland;
Lisuride TTS 20cm²
Axxonis Pharma AG
2007 - EUCTR2006-003732-30-DE Germany;Italy;Poland;
NeuroBiotec Pharma AG
2008 - EUCTR2006-003732-30-PL Germany;Italy;Poland;
Lisuride Transdermal System
National Institute of Neurological Disorders and Stroke (NINDS)
2004 Phase 2 NCT00089622 United States;
Lithium
University at Buffalo
2019 Phase 1 NCT04273932 United States;
Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules
Beijing Friendship Hospital
2021 Phase 4 NCT04871464 China;
Lixisenatide
University Hospital, Toulouse
2018 Phase 2 NCT03439943 France;
Local Anesthesia (lidocaine hydrochloride)
Nantes University Hospital
2014 - NCT02236260 France;
Local Trade Name,
GlaxoSmithKline Research & Development Limited
2013 - EUCTR2011-002827-17-SK Estonia;Korea, Republic of;Russian Federation;Slovakia;United States;
Lovastatin
National Taiwan University Hospital
2017 Phase 2 NCT03242499 Taiwan;
Low dose AFFITOPE® PD03A + Adjuvant
Affiris AG
2014 Phase 1 NCT02267434 Austria;
Low dose levodopa
Rush University Medical Center
2018 - NCT04956939 United States;
Low-Frequency-Only Stimulation
The Cleveland Clinic
2021 Phase 1 NCT05022147 United States;
Lu 00-800
H. Lundbeck A/S
2006 Phase 4 EUCTR2005-002038-36-GB Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
Lu AE04621
H. Lundbeck A/S
2016 Phase 1 NCT02649608 United States;
Lu AF28996
H. Lundbeck A/S
2020 Phase 1 NCT04291859 Netherlands;United States;
Lu AF82422
H. Lundbeck A/S
2018 Phase 1 NCT03611569 United States;
Lubiprostone
Dokkyo Medical University
2016 - JPRN-UMIN000022023 Japan;
2016 - JPRN-UMIN000022022 Japan;
University of Arkansas
2009 - NCT00669461 United States;
Lumbar Puncture
National Institute of Neurological Disorders and Stroke (NINDS)
2017 Phase 1 NCT03104725 United States;
MANTADIX
CHU Toulouse
2007 - EUCTR2006-006684-22-FR France;
MARS
Eisai Limited
2007 Phase 3 EUCTR2007-000801-30-PL Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 Phase 3 EUCTR2007-000801-30-FR Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 Phase 3 EUCTR2007-000801-30-ES Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 Phase 3 EUCTR2006-002937-20-FR Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2007 - EUCTR2007-000801-30-LV Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 - EUCTR2007-000801-30-LT Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 - EUCTR2007-000801-30-HU Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 - EUCTR2007-000801-30-EE Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 - EUCTR2007-000801-30-CZ Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain;
2007 - EUCTR2006-002937-20-HU Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2007 - EUCTR2006-002937-20-ES Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2007 - EUCTR2006-002339-26-PT Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-002339-26-HU Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-002339-26-ES Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-002339-26-DE Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-004314-33-GB Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-004314-33-ES Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002937-20-LV Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-LT Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-EE Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002937-20-CZ Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain;
2006 - EUCTR2006-002339-26-SE Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-LT Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-GB Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-EE Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-CZ Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-BE Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002339-26-AT Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-SE Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-PT Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-LT Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-HU Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-EE Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-DE Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-CZ Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004314-33-BE Austria;Belgium;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-004314-33-AT Austria;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2004 - EUCTR2004-000361-35-CZ Czech Republic;Italy;
ME2125 (safinamide mesilate)
Meiji Seika Pharma Co., Ltd.
2015 Phase 3 JPRN-JapicCTI-153057 Japan;
2015 Phase 2-3 JPRN-JapicCTI-153056 Japan;
MEDI1341
AstraZeneca
2020 Phase 1 NCT04449484 United States;
2017 Phase 1 NCT03272165 United Kingdom;United States;
MEG
Howard Gendelman, MD
2013 Phase 1 NCT01882010 United States;
MEMANTINE HYDROCHLORIDE
H. Lundbeck A/S
2007 Phase 3 EUCTR2005-002038-36-GR Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
2006 Phase 3 EUCTR2005-002038-36-FR Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
2006 - EUCTR2005-002038-36-DE Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
2006 - EUCTR2005-002038-36-AT Austria;France;Germany;Greece;Italy;Spain;United Kingdom;
METHYLPHENIDATE HYDROCHLORIDE
University Medical Center Groningen
2010 - EUCTR2009-012643-42-NL Netherlands;
MIRAPEXIN*30CPR 0,
CASA DI CURA PRIVATA S.RAFFAELE - PISANA
2009 - EUCTR2009-015833-66-IT Italy;
MK0657
Merck Sharp & Dohme Corp.
2007 Phase 1 NCT00505843 United States;
MODOPAR
CHU de Toulouse
2010 Phase 3 EUCTR2010-018650-12-FR France;
MS Band 2
IRCCS San Camillo, Venezia, Italy
2017 - NCT03425877 Italy;
MSC
The University of Texas Health Science Center, Houston
2020 Phase 2 NCT04506073 United States;
MSK-DA01 Cell Delivery Device
BlueRock Therapeutics
2021 Phase 1 NCT04802733 Canada;United States;
Madopar
Universitätsklinik für Neurologie Innsbruck
2010 - EUCTR2010-019354-40-AT Austria;
Madopar 125 mg T, tablets
BIAL-Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-002754-24-IT Germany;Italy;Portugal;Spain;United Kingdom;
Bial - Portela & Ca, S.A.
2022 Phase 4 EUCTR2020-002754-24-DE Germany;Italy;Portugal;Spain;United Kingdom;
2021 Phase 4 EUCTR2020-002754-24-ES Germany;Italy;Portugal;Spain;United Kingdom;
Madopar 125 mg, orodispersible tablet
Pharmaceutical Technology and Biopharmacy, University of Groningen
2018 Phase 2 EUCTR2017-004006-18-NL Netherlands;
Madopar 200+
Madopar LT
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2011 - EUCTR2010-022363-35-DE Germany;
Madopar Tab. 125 or Perkin Tab. 25-
SK Chemicals Co., Ltd.
2021 Phase 4 NCT04821687 Korea, Republic of;
Madopar monotherapy
Peking University Third Hospital
2018 Phase 4 NCT04968613 China;
Madopar® 125
Bial - Portela C S.A.
2001 Phase 1 NCT02763852 Portugal;
Madopar® 125 mg T Tablets Levodopa 100 mg Benserazide 25 mg (as benserazide hydrochloride)
BIAL-Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-002754-24-IT Germany;Italy;Portugal;Spain;United Kingdom;
Madopar® 250
Bial - Portela C S.A.
2006 Phase 1 NCT03097211 Portugal;
2006 Phase 1 NCT03094156 Portugal;
Madopar® HBS
Bial - Portela C S.A.
2009 Phase 1 NCT02169466 Portugal;
Madopar® HBS 125
Bial - Portela C S.A.
2004 Phase 1 NCT03091543 Portugal;
Magnesium oxide
Dokkyo Medical University
2016 - JPRN-UMIN000022023 Japan;
2016 - JPRN-UMIN000022022 Japan;
Maltodextrin
University of Florida
2021 - NCT04829760 United States;
Mannitol
Hadassah Medical Organization
2018 Phase 2 NCT03823638 Israel;
Mantadix
CHU de Toulouse
2012 Phase 2 EUCTR2011-005201-75-FR France;
University Hospital, Toulouse
2007 Phase 4 NCT00632762 France;
Masitinib mesylate
AB Science
2015 Phase 2 EUCTR2010-024424-26-SK Bulgaria;Czech Republic;France;Germany;Hungary;Romania;Slovakia;South Africa;Spain;United States;
Massage with a spiky ball
University Medical Center Groningen
2015 Phase 2 NCT02230930 Netherlands;
Mavoglurant
NOVARTIS FARMA
2012 - EUCTR2011-004378-27-IT Austria;Canada;Germany;Hungary;Italy;Spain;United States;
Novartis Pharma Services AG
2012 - EUCTR2011-004378-27-SK Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
2012 - EUCTR2011-004378-27-HU Austria;Canada;France;Germany;Hungary;Italy;Spain;United States;
2012 - EUCTR2011-004378-27-AT Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States;
Medical Cannabis
Sheba Medical Center
2021 - NCT05106504 Israel;
Melatonin
Instituto Mexicano del Seguro Social
2021 Phase 2/Phase 3 NCT04287543 Mexico;
University College London
2015 Phase 2 EUCTR2014-002697-37-GB United Kingdom;
University College, London
2015 Phase 2 NCT02359448 United Kingdom;
Melatonin PR
Seoul National University Hospital
2016 Phase 2 NCT02789592 Korea, Republic of;
Melatonin(Circadin®)
KIMJisun
2016 Phase 4 NCT03258294 -
Kuhnil Pharmaceutical Co., Ltd.
2016 Phase 4 NCT02768077 -
Melevodopa and decarboxylase inhibitor
VERNALIS DEVELOPMENT LIMITED
2006 - EUCTR2006-004112-51-IT Italy;
Melperon
OVATION PHARMACEUTICALS INC
2007 - EUCTR2007-002874-75-IT Italy;
2007 - EUCTR2007-000307-15-IT Italy;
Melperone HCl
Lundbeck LLC
2005 Phase 2 NCT00125138 India;Italy;United States;
Memantin Orion
Regional Dementia Research Centre, Dept of Neurology
2018 Phase 4 EUCTR2017-002707-10-DK Denmark;
Memantine
Baylor College of Medicine
2006 Phase 4 NCT00646204 United States;
Department of Neurology, Juntendo University School of Medicine
2013 - JPRN-UMIN000010596 Japan;
H. Lundbeck A/S
2007 Phase 4 NCT00855686 Germany;
Helse Stavanger HF
2006 Phase 2 NCT00630500 Norway;Sweden;United Kingdom;
Johns Hopkins University
2006 - NCT00294554 United States;
Neurologisk afdeling F
2005 Phase 2 EUCTR2004-004139-74-DK Denmark;
University Hospital, Lille
2009 Phase 4 NCT01108029 France;
Wayne State University
2019 Phase 3 NCT03858270 United States;
Zealand University Hospital
2020 Phase 4 NCT04117178 Denmark;
Memantine (drug)
University of Aarhus
2005 - NCT00375778 Denmark;
Mesdopetam
Integrative Research Laboratories AB
2020 Phase 2 NCT04435431 France;Israel;Italy;Poland;Serbia;United States;
Integrative Research Laboratories Sweden AB
2021 Phase 2 EUCTR2020-002010-41-IT France;Israel;Italy;Poland;Serbia;United States;
Integrative Research Laboratories Sweden AB (IRLAB)
2020 Phase 2 EUCTR2020-002010-41-FR France;Israel;Italy;Poland;Serbia;United States;
Mesdopetam (IRL790)
Integrative Research Laboratories AB
2018 Phase 2 NCT03368170 Sweden;United Kingdom;
Mesencephalic Neuronal Precursor Cells
Bundang CHA Hospital
2013 Phase 1/Phase 2 NCT01860794 Korea, Republic of;
Mesenchymal stem cells
Hebei Newtherapy BIo-Pharma technology Co., Ltd.
2018 Phase 1 NCT03550183 China;
Mestinon
Department of Neurology, Roskilde Hospital
2012 Phase 2 EUCTR2012-000122-21-DK Denmark;
Metabolic Cofactor Supplementation
Istanbul Medipol University Hospital
2019 Phase 2 NCT04044131 Turkey;
Metformin
Institute of Clinical Pharmacology, Central South University
2012 Phase 1 study ChiCTR-TTRCC-12002751 China;
Peking Union Medical College Hospital
2020 Phase 4 ChiCTR2000029465 China;
Methylphenidate
Department of Veterans Affairs
2006 - NCT00393562 United States;
Hubert Fernandez
2016 Early Phase 1 NCT02879136 United States;
Laval University
2010 Phase 4 NCT01244269 Canada;
Oregon Health and Science University
2004 Phase 2 NCT00359723 United States;
University Hospital, Lille
2009 Phase 4 NCT00914095 France;
Methylphenidate (MPD)
University of Cincinnati
2007 Phase 4 NCT00526630 United States;
Methylprednisolone
Prevail Therapeutics
2020 Phase 1/Phase 2 NCT04127578 Israel;United States;
Mid dose ANAVEX2-73
Anavex Life Sciences Corp.
2018 Phase 2 NCT03774459 Australia;Spain;
Midazolam
Kyowa Kirin Co., Ltd.
2019 Phase 1 NCT03970798 Japan;
PharmaTher Inc.
2021 Phase 2 NCT04912115 United States;
Midodrine
Philadelphia Veterans Affairs Medical Center
2014 - NCT02365012 United States;
Vanderbilt University Medical Center
2020 Early Phase 1 NCT04620382 United States;
2016 Phase 1 NCT02897063 United States;
Minocycline
University of Rochester
2003 Phase 2 NCT00063193 United States;
Minodronic acid
Department of Orthopaedic Surgery, Niigata University Medical and Dental Hospital
2018 - JPRN-UMIN000033285 Japan;
Mirabegron
Daniel Burdick, MD
2014 Phase 4 NCT02092181 United States;
HealthPartners Institute
2015 Phase 4 NCT02536976 United States;
Seoul National University Hospital
2017 Phase 4 NCT03412513 Korea, Republic of;
Mirapex
Abbott Healthcare Products B.V.
2009 - EUCTR2008-000400-81-DE Germany;Italy;Portugal;
Boehringer Ingelheim
2005 Phase 4 NCT00144300 United States;
Rajesh Pahwa, MD
2006 Phase 3 NCT00275275 United States;
SOLVAY PHARMACEUTICALS B.V.
2009 - EUCTR2008-000400-81-IT Germany;Italy;Portugal;
Solvay Pharmaceuticals B.V.
2008 Phase 2 EUCTR2008-004943-12-SK Slovakia;
Solvay Pharmaceuticals BV
2009 - EUCTR2008-000400-81-PT Germany;Italy;Portugal;
Mirapex (pramipexole)
Institute for Neurodegenerative Disorders
2004 Phase 2 NCT00096720 United States;
Mirapex ER
Seoul National University Hospital
2011 Phase 4 NCT01515774 Korea, Republic of;
Mirapex LA
Boehringer Ingelheim
2012 - NCT01525641 Japan;
Mirapexin
NEUROBIOTEC GMBH
2007 - EUCTR2006-003732-30-IT Germany;Italy;Poland;
Mirapexin / Sifrol
Boehringer Ingelheim España S.A.
2006 Phase 4 EUCTR2005-003788-22-ES Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Mirapexin extended release various strengths
University Hospital of North Staffordshire
2013 Phase 4 EUCTR2012-000801-64-GB United Kingdom;
Mirapexin/Sifrol
Boehringer Ingelheim España S.A.
2006 Phase 4 EUCTR2005-003788-22-ES Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
MitoQ
Antipodean Pharmaceuticals, Inc.
2006 Phase 2 NCT00329056 Australia;New Zealand;
Modafinil
Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine
2015 - JPRN-UMIN000019676 Japan;
Department of Veterans Affairs
2006 - NCT00393562 United States;
University of Arkansas
2017 Early Phase 1 NCT03083132 United States;
University of Chicago
2016 Phase 2 NCT02857244 United States;
Modal
Oregon Health and Science University
2021 - NCT04468919 United States;
Regis University
2017 - NCT04223245 United States;
The Cleveland Clinic
2020 Phase 2 NCT04634331 United States;
Modiodal
Theranexus S.A.
2018 Phase 2 EUCTR2017-004475-31-HU Czech Republic;France;Germany;Hungary;United States;
2018 Phase 2 EUCTR2017-004475-31-CZ Czech Republic;France;Germany;Hungary;United States;
Modopar 125
UHToulouse
2016 Phase 2;Phase 3 EUCTR2015-001523-24-FR France;
Modopar 62,5
UHToulouse
2016 Phase 2;Phase 3 EUCTR2015-001523-24-FR France;
Monoamine oxidase B inhibitors
NEWRON PHARMACEUTICALS
2007 - EUCTR2006-005861-21-IT Italy;
2004 - EUCTR2004-000833-12-IT Italy;Spain;
Montelukast Krka
Stockholm Health Care Services
2021 Phase 2 EUCTR2020-000148-76-SE Sweden;
Motion Analysis
Howard Gendelman, MD
2013 Phase 1 NCT01882010 United States;
Moxifloxacin
Bial - Portela C S.A.
2010 Phase 1 NCT01532115 France;
Kyowa Kirin Co., Ltd.
2020 Phase 1 NCT04342273 Japan;
Sunovion
2017 Phase 2 NCT03187301 Italy;United States;
Moxifloxacin infusion
UCB Pharma
2006 Phase 1 NCT00292227 South Africa;
Muscimol
National Institute of Neurological Disorders and Stroke (NINDS)
2009 Phase 1 NCT00921128 United States;
Mémantine
Chru de Lille
2009 - EUCTR2008-008210-38-FR France;
N acetyl cysteine
Thomas Jefferson University
2020 Phase 2 NCT04459052 United States;
N-0923
National Institute of Neurological Disorders and Stroke (NINDS)
1999 Phase 2 NCT00001931 United States;
N-Acetylcysteine
National Institute of Neurological Disorders and Stroke (NINDS)
2017 Phase 1 NCT03104725 United States;
N-acetylcysteine
University of Minnesota
2011 Phase 1 NCT01427517 United States;
Weill Medical College of Cornell University
2012 Phase 1/Phase 2 NCT01470027 United States;
N-acetylcysteine capsule
University of Minnesota
2014 Phase 2 NCT02212678 United States;
N.A.
INTEC PHARMA LTD
2018 Phase 2 EUCTR2018-001209-95-IT Italy;Spain;
N04BA
SynAgile Corporation
2021 Phase 2 EUCTR2020-003372-41-IT Italy;Luxembourg;Spain;
N04BC07
CHU Rennes
2021 Phase 4 EUCTR2021-000826-89-FR France;
N04BD02
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
2011 - EUCTR2009-015161-31-DE Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
2011 - EUCTR2009-015161-31-PT Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2011 Phase 3 EUCTR2009-015161-31-GB Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015161-31-BG Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Schering-Plough Research Institute, a division of Schering Corporation
2011 - EUCTR2009-015161-31-PL Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015161-31-CZ Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-SE Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-NL Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-FI Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-AT Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
NACOM 100
IMPAX LABORATORIES, INC.
2010 - EUCTR2009-017238-39-IT France;Germany;Italy;
NACOM levodopa+cardidopa
MERCK SERONO SA
2009 - EUCTR2008-002769-30-IT Italy;
NAL
Mundipharma Research GmbH & Co. KG
2012 - EUCTR2011-002901-31-DE Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-GB Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-HU Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-CZ Czech Republic;Germany;Hungary;Spain;United Kingdom;
NBTX-001
Nobilis Therapeutics Inc.
2019 Phase 1 NCT04097080 Russian Federation;
ND0611
NeuroDerm Ltd.
2010 Phase 1 NCT01103011 Israel;
ND0612
NEURODERM LTD.
2020 Phase 3 EUCTR2018-004156-37-IT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002780-17-IT Austria;France;Italy;Netherlands;Spain;United States;
2016 Phase 2 EUCTR2015-005814-31-IT Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
2016 Phase 2 EUCTR2015-005078-39-IT Austria;Germany;Israel;Italy;United States;
NeuroDerm Ltd.
2020 Phase 3 EUCTR2018-004156-37-SK Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-SE Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-PT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-NL Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-GB Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-ES Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-BE Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004156-37-AT Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004156-37-HU Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004156-37-CZ Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002780-17-FR Austria;France;Italy;Netherlands;Spain;United States;
2018 Phase 3 EUCTR2017-002780-17-ES Austria;France;Italy;Netherlands;Spain;United States;
2018 Phase 3 EUCTR2016-002033-30-NL Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002033-30-HU Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002033-30-GB Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2015-005814-31-PL Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
2017 Phase 2 EUCTR2015-005814-31-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States;
2017 Phase 2 EUCTR2015-005814-31-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States;
2017 Phase 2 EUCTR2015-005814-31-DE Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2015-005814-31-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
2017 Phase 2 EUCTR2015-005814-31-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States;
2016 Phase 3 NCT02782481 Israel;
2016 Phase 3 EUCTR2016-002033-30-FR Belgium;Canada;Denmark;France;Hungary;Israel;Netherlands;Spain;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002033-30-ES Belgium;Canada;Denmark;France;Israel;Netherlands;Spain;Sweden;United States;
2016 Phase 3 EUCTR2016-002033-30-BE Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 2 NCT02726386 Austria;Czechia;France;Germany;Israel;Italy;Poland;Spain;United States;
2016 Phase 2 EUCTR2015-005814-31-AT Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
2016 Phase 2 EUCTR2015-005078-39-DE Austria;Germany;Israel;Italy;United States;
2016 Phase 2 EUCTR2015-005078-39-AT Austria;Germany;Israel;Italy;United States;
2015 Phase 1 NCT02604914 United Kingdom;
2012 Phase 1 NCT01486628 Israel;
ND0612 (Levodopa/Carbidopa solution)
NeuroDerm Ltd.
2015 Phase 2 NCT02577523 Austria;Israel;Italy;United States;
ND1421
Schwarz Biosciences GmbH
2006 Phase 2 EUCTR2005-004290-19-GB Austria;Germany;Spain;United Kingdom;
2006 - EUCTR2005-004290-19-DE Germany;Spain;United Kingdom;
2005 - EUCTR2005-004290-19-AT Austria;Germany;Spain;United Kingdom;
ND1587
Schwarz Biosciences GmbH
2008 - EUCTR2006-006752-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006907-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
- - EUCTR2006-006907-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006907-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
ND1589
Schwarz Biosciences GmbH
2008 - EUCTR2006-006752-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006907-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
- - EUCTR2006-006907-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006907-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
ND1590
Schwarz Biosciences GmbH
2008 - EUCTR2006-006752-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006907-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
- - EUCTR2006-006907-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006907-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
ND1702
Schwarz Biosciences GmbH
2008 - EUCTR2006-006752-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006907-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
- - EUCTR2006-006907-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006907-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
NE3107
BioVie Inc.
2021 Phase 1/Phase 2 NCT05083260 -
NERIXIA*IM EV 1F
FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE
2010 - EUCTR2010-018904-94-IT Italy;
NEUPRO 2 mg/24 h parche transdérmico
UCB Pharma SA
2011 Phase 4 EUCTR2010-021394-37-ES Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;
NEUPRO 4 mg/24 h parche transdérmico
UCB Pharma SA
2011 Phase 4 EUCTR2010-021394-37-ES Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;
NEUPRO 6 mg/24 h parche transdérmico
UCB Pharma SA
2011 Phase 4 EUCTR2010-021394-37-ES Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;
NEUPRO 8 mg/24 h parche transdérmico
UCB Pharma SA
2011 Phase 4 EUCTR2010-021394-37-ES Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;
NEUPRO*28CER 2MG/24H
FONDAZIONE SANTA LUCIA
2012 - EUCTR2012-001218-40-IT Italy;
NEUPRO*28CER 4MG/24H
FONDAZIONE SANTA LUCIA
2012 - EUCTR2012-001218-40-IT Italy;
NEUPRO*28CER 6MG/24H
FONDAZIONE SANTA LUCIA
2012 - EUCTR2012-001218-40-IT Italy;
NEUPRO*28CER 8MG/24H
FONDAZIONE SANTA LUCIA
2012 - EUCTR2012-001218-40-IT Italy;
NEUPRO*7CER 4MG/24H
FONDAZIONE SANTA LUCIA
2012 - EUCTR2012-001218-40-IT Italy;
NEUPRO*7CER 6MG/24H
FONDAZIONE SANTA LUCIA
2012 - EUCTR2012-001218-40-IT Italy;
NEUPRO*7CER 8MG/24H
FONDAZIONE SANTA LUCIA
2012 - EUCTR2012-001218-40-IT Italy;
NJ-Tube: Silicon ED Tube
AbbVie (prior sponsor, Abbott)
2011 Phase 2 NCT01479127 Japan;
NLX-112
Neurolixis SAS
2021 Phase 2 EUCTR2020-006053-22-SE Sweden;
NLY01
Neuraly, Inc.
2020 Phase 2 NCT04154072 Canada;United States;
NO
Department of Anesthesiology, Affiliated Hospital of Guizhou Medical University
2019 - ChiCTR1900024459 China;
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
2019 - ChiCTR1900026156 China;
NPC transplantation
Chinese Academy of Sciences
2017 Phase 1/Phase 2 NCT03119636 China;
NR2B NMDA Antagonist CP-101,606 (traxoprodil)
Pfizer
2005 Phase 2 NCT00163085 United States;
NS 2330
Boehringer Ingelheim
2003 Phase 2 NCT00148486 Canada;United States;
NS2330
National Institute of Neurological Disorders and Stroke (NINDS)
2000 Phase 2 NCT00006077 United States;
NT 101
Merz Pharmaceuticals GmbH
2014 Phase 3 EUCTR2012-005539-10-DE Germany;Poland;United States;
NTCELL Implantation
Living Cell Technologies
2016 Phase 2 NCT02683629 New Zealand;
NW-1015
MERCK SERONO SA
2010 - EUCTR2010-020109-34-IT Italy;Spain;
2009 Phase 3 EUCTR2008-005492-94-IT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
Merck Serono International S.A.
2008 Phase 3 EUCTR2007-002963-28-ES Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
2008 - EUCTR2007-002964-90-ES Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2007 - EUCTR2007-002964-90-NL Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2007 - EUCTR2007-002964-90-FI Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Merck Serono S.A - Geneva
2008 Phase 3 EUCTR2007-002964-90-GB Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom;
Merck Serono S.A-Geneva
2009 - EUCTR2007-002963-28-PT Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
Merck Serono S.A. - Geneva
2010 Phase 3 EUCTR2008-005492-94-BE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
2010 Phase 2 EUCTR2009-017174-20-FR Austria;France;Germany;
2010 - EUCTR2010-020109-34-ES Italy;Spain;
2010 - EUCTR2008-005492-94-NL Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
2010 - EUCTR2007-002964-90-CZ Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-005492-94-SK Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-005492-94-GB Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-005492-94-FR Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-005492-94-ES Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
2009 - EUCTR2008-005492-94-HU Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 - EUCTR2007-002964-90-FR Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-002964-90-DE Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2007 Phase 3 EUCTR2007-002964-90-SK Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom;
2007 Phase 3 EUCTR2007-002963-28-SK Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
Merck Serono S.A.-Geneva
2008 - EUCTR2007-002964-90-HU Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Merck Serono SA - Geneva
2009 Phase 3 EUCTR2008-004146-88-SK Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
2009 Phase 3 EUCTR2008-004146-88-ES Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
2009 Phase 3 EUCTR2008-001966-10-SK Austria;Estonia;Hungary;Slovakia;United Kingdom;
2009 - EUCTR2008-004146-88-PT Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
2009 - EUCTR2008-004146-88-PL Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
2009 - EUCTR2008-001966-10-HU Austria;Estonia;Hungary;United Kingdom;
2009 - EUCTR2008-001966-10-GB Austria;Estonia;Hungary;United Kingdom;
2009 - EUCTR2008-001966-10-EE Austria;Estonia;Hungary;United Kingdom;
2009 - EUCTR2008-001966-10-AT Austria;Estonia;Hungary;United Kingdom;
NEWRON PHARMACEUTICALS
2007 - EUCTR2006-005861-21-IT Italy;
2006 - EUCTR2006-005860-14-IT Italy;
2004 - EUCTR2004-000835-27-IT Italy;Spain;
2004 - EUCTR2004-000833-12-IT Italy;Spain;
Newron Pharmaceuticals
2011 - EUCTR2008-005492-94-PT Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2011 - EUCTR2008-005492-94-FI Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2011 - EUCTR2008-005492-94-CZ Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2011 - EUCTR2008-005492-94-BG Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2010 - EUCTR2008-004146-88-DE Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
2009 Phase 3 EUCTR2008-004146-88-BG Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
2009 - EUCTR2008-005492-94-EE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2009 - EUCTR2008-005492-94-AT Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2009 - EUCTR2008-004146-88-FI Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
2009 - EUCTR2008-004146-88-CZ Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
- - EUCTR2008-005492-94-DE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States;
Newron Pharmaceuticals S.P.A
2005 Phase 3 EUCTR2004-000835-27-ES Italy;Spain;
Newron Pharmaceuticals S.p.A.
2004 Phase 3 EUCTR2004-000833-12-ES Italy;Spain;
Newron Pharmaceuticals SpA
2011 Phase 3 EUCTR2007-002964-90-BE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Slovakia;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2010 - EUCTR2007-002963-28-DE Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States;
2009 - EUCTR2007-002964-90-AT Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2009 - EUCTR2007-002963-28-PL Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
2009 - EUCTR2007-002963-28-CZ Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States;
2009 - EUCTR2007-002963-28-BG Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States;
2008 - EUCTR2007-002964-90-EE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2007 - EUCTR2007-002963-28-FI Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Poland;Portugal;South Africa;Spain;United States;
NW-1015E, EMD 1195686, MSC2191632B
Merck Serono S.A. - Geneva
2011 - EUCTR2009-017174-20-AT Austria;Canada;France;Germany;South Africa;
2010 - EUCTR2009-017174-20-DE Austria;Canada;France;Germany;South Africa;
NYX-458
Aptinyx
2019 Phase 2 NCT04148391 United States;
Nabilone
Medical University Innsbruck
2018 Phase 3 NCT03773796 Austria;
2017 Phase 2 NCT03769896 Austria;
Nacom
Otto-von-Guericke University, Medical Faculty, Dpt. of Neurology
2009 - EUCTR2009-011093-15-DE Germany;
Nacom 100
Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
2010 Phase 3 EUCTR2009-017238-39-BE Belgium;France;Germany;Italy;
Novartis Pharma Services AG
2008 - EUCTR2007-003134-42-DE Germany;
Nadolol
CuraSen Therapeutics, Inc.
- Phase 2 EUCTR2020-006067-28-BE Australia;Belgium;New Zealand;United Kingdom;
Nalmefene
University Hospital, Clermont-Ferrand
2016 Phase 2 NCT02934919 France;
Naltrexone
University of Pennsylvania
2009 Phase 4 NCT01052831 United States;
Nardil
TEVA Pharmaceuticals Industries Ltd
2006 - EUCTR2006-005140-89-NL Netherlands;
Nebicapone
BIAL - Portela & Cª, SA
2006 - EUCTR2006-001793-24-PT Austria;Portugal;
2006 - EUCTR2006-001793-24-AT Austria;Portugal;
Bial - Portela C S.A.
2006 Phase 2 NCT03103399 -
2006 Phase 1 NCT03097211 Portugal;
2001 Phase 1 NCT02772627 Portugal;
Nebulizer
University of Florida
2015 Phase 1 NCT02390089 United States;
Nelotanserin
Axovant Sciences Ltd.
2016 Phase 2 NCT02871427 United States;
2016 Phase 2 NCT02708186 United States;
Neu-120
Neurim Pharmaceuticals Ltd.
2008 Phase 1/Phase 2 NCT00607451 Israel;
Neupro
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2011 - EUCTR2010-022363-35-DE Germany;
Luye Pharma Group Ltd.
2020 Phase 1 NCT04384666 United States;
2013 Phase 1 NCT02055274 United States;
Peking University Third Hospital
2021 - NCT04957420 China;
SCHWARZ PHARMA
2008 - EUCTR2006-006752-35-IT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
UCB BIOSCIENCES GMBH
2013 - EUCTR2012-002840-26-IT Austria;Bulgaria;Hungary;Italy;Russian Federation;Slovenia;Spain;Turkey;Ukraine;United States;
UCB Biosciences GmbH
2013 Phase 4 EUCTR2012-002608-42-GB Argentina;France;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-002840-26-SK Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States;
2013 - EUCTR2012-002840-26-SI Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States;
2013 - EUCTR2012-002840-26-RO Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States;
2013 - EUCTR2012-002840-26-HU Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States;
2013 - EUCTR2012-002840-26-ES Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States;
2013 - EUCTR2012-002840-26-BG Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States;
2013 - EUCTR2012-002840-26-AT Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States;
2013 - EUCTR2012-002608-42-HU Argentina;France;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-002608-42-DE Germany;Hungary;Poland;Slovakia;United Kingdom;United States;
2012 - EUCTR2012-002608-42-SK Argentina;France;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
Neupro (Reference)
Sandoz
2019 Phase 1 NCT04183634 Germany;
Neupro 2 mg/24 h transdermal patch
SCHWARZ PHARMA Deutschland GmbH
2007 - EUCTR2006-005438-19-DE Germany;
Schwarz Pharma Deutschland GmbH, UCB Group
- - EUCTR2009-014341-84-DE Germany;
Neupro 2mg/24 h transdermal patch
Schwarz Biosciences GmbH
2008 - EUCTR2006-006752-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006752-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Neupro 2mg/24h transdermal patch
Schwarz Biosciences GmbH
2007 Phase 3 EUCTR2006-006907-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
- - EUCTR2006-006907-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006907-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
UCB Pharma SA
2011 Phase 4 EUCTR2010-021394-37-SK Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
2011 Phase 4 EUCTR2010-021394-37-BE Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
2011 - EUCTR2010-021394-37-HU Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-DE Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-CZ Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-BG Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-AT Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
Neupro 4 mg/24 h transdermal patch
SCHWARZ PHARMA Deutschland GmbH
2007 - EUCTR2006-005438-19-DE Germany;
Schwarz Pharma Deutschland GmbH, UCB Group
- - EUCTR2009-014341-84-DE Germany;
Neupro 4Mg/24Hr Transdermal Patch
Luye Pharma Group Ltd.
2018 Phase 1 NCT03733561 United States;
Neupro 4mg/24 h transdermal patch
Schwarz Biosciences GmbH
2008 - EUCTR2006-006752-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006752-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Neupro 4mg/24h transdermal patch
Schwarz Biosciences GmbH
2007 Phase 3 EUCTR2006-006907-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
- - EUCTR2006-006907-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006907-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
UCB Celltech, UK - Registered Branch of UCB Pharma SA
2011 - EUCTR2011-000056-42-GB United Kingdom;
UCB Pharma SA
2011 Phase 4 EUCTR2010-021394-37-SK Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
2011 Phase 4 EUCTR2010-021394-37-BE Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
2011 - EUCTR2010-021394-37-HU Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-DE Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-CZ Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-BG Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-AT Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
Neupro 6 mg/24 h transdermal patch
SCHWARZ PHARMA Deutschland GmbH
2007 - EUCTR2006-005438-19-DE Germany;
Schwarz Pharma Deutschland GmbH, UCB Group
- - EUCTR2009-014341-84-DE Germany;
Neupro 6mg/24 h transdermal patch
Schwarz Biosciences GmbH
2008 - EUCTR2006-006752-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006752-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Neupro 6mg/24h transdermal patch
Schwarz Biosciences GmbH
2007 Phase 3 EUCTR2006-006907-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
- - EUCTR2006-006907-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006907-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
UCB Celltech, UK - Registered Branch of UCB Pharma SA
2011 - EUCTR2011-000056-42-GB United Kingdom;
UCB Pharma SA
2011 Phase 4 EUCTR2010-021394-37-SK Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
2011 Phase 4 EUCTR2010-021394-37-BE Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
2011 - EUCTR2010-021394-37-HU Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-DE Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-CZ Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-BG Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-AT Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
Neupro 8 mg/24 h transdermal patch
SCHWARZ PHARMA Deutschland GmbH
2007 - EUCTR2006-005438-19-DE Germany;
Schwarz Biosciences GmbH
2008 - EUCTR2006-006752-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006752-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Pharma Deutschland GmbH, UCB Group
- - EUCTR2009-014341-84-DE Germany;
Neupro 8mg/24h transdermal patch
Schwarz Biosciences GmbH
2007 Phase 3 EUCTR2006-006907-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
- - EUCTR2006-006907-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006907-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
UCB Celltech, UK - Registered Branch of UCB Pharma SA
2011 - EUCTR2011-000056-42-GB United Kingdom;
UCB Pharma SA
2011 Phase 4 EUCTR2010-021394-37-SK Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
2011 Phase 4 EUCTR2010-021394-37-BE Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;
2011 - EUCTR2010-021394-37-HU Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-DE Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-CZ Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-BG Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
2011 - EUCTR2010-021394-37-AT Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland;
Neupro®
UCB Pharma
2011 - NCT01330290 Germany;
Neupro® 8 mg/24 h
Luye Pharma Switzerland AG
2021 Phase 2 EUCTR2021-000867-65-DE Germany;
Neuraceq
Fundació Clínic per la Recerca Biomèdica
2016 Phase 4 EUCTR2014-001014-25-ES Spain;
Institute for Neurodegenerative Disorders
2016 Phase 2 EUCTR2015-004129-15-ES Spain;
NeuroEPO
International Center for Neurological Restoration, Cuba
2015 Phase 1/Phase 2 NCT04110678 Cuba;
Neurohormonal mechanisms
Institut National de la Santé Et de la Recherche Médicale, France
2017 - NCT03272230 France;
Neurpro
Unità Malattie Neurodegenerative, Ospedale Cardinale Giovanni Panico, Tricase
2013 - EUCTR2013-000827-15-IT Italy;
Niacin
VA Office of Research and Development
2020 - NCT03808961 United States;
2016 - NCT03462680 United States;
Niacinamide
VA Office of Research and Development
2020 - NCT03808961 United States;
Nicorette 10mg/ 16 h
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2008 - EUCTR2008-001336-13-FR France;
Nicorette 15 mg/ 16 h
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2008 - EUCTR2008-001336-13-FR France;
Nicorette 5 mg/ 16 h
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2008 - EUCTR2008-001336-13-FR France;
Nicotine
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2008 - EUCTR2008-001336-13-FR France;
Department of Clinical Pharmacology and Neurology Ehime University graduated School of Medicine
2015 - JPRN-UMIN000016664 Japan;
Neuraltus Pharmaceuticals, Inc.
2009 Phase 1/Phase 2 NCT00957918 United States;
Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)
El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
2019 Phase 2 NCT03865121 Mexico;
Nicotine gum
New York Institute of Technology
2015 - NCT02452125 United States;
Nicotine patch
University of Vermont
2010 Phase 4 NCT01216904 United States;
Nicotine transdermal patch
James BOYD MD
2012 Phase 2 NCT01560754 Germany;United States;
Nicotinell 17,5 mg/24-Stunden-Pflaster
Philipps-University Marburg
2011 Phase 2 EUCTR2010-020299-42-DE Germany;United States;
Nicotinell 35 mg/24-Stunden-Pflaster
Philipps-University Marburg
2011 Phase 2 EUCTR2010-020299-42-DE Germany;United States;
Nilotinib
Georgetown University
2014 Phase 1 NCT02281474 United States;
Nilotinib 150mg oral capsule [Tasigna]
Georgetown University
2017 Phase 2 NCT02954978 United States;
Nilotinib 300mg oral capsule [Tasigna]
Georgetown University
2017 Phase 2 NCT02954978 United States;
Nitrogen
Juntendo University School of Medicine, Neurology
2013 - JPRN-UMIN000010014 Japan;
None
The First Affiliated Hospital of University of Science and Technology of China (Southern District Phase 2)
2021 Phase 0 ChiCTR2100048680 China;
Normal Saline
Vanderbilt University
2008 Phase 2/Phase 3 NCT00608231 United States;
Normal saline
dr.dargahi
2020 Phase 2 NCT04687878 Iran, Islamic Republic of;
Northera
The Cooper Health System
2017 Phase 4 NCT03034564 United States;
Nortriptyline
Rutgers, The State University of New Jersey
2003 Phase 2 NCT00062738 United States;
University College, London
2019 Phase 3 NCT03652870 -
Nortriptyline hydrochloride
University College London Comprehensive Clinical Trials Unit
2019 Phase 3 EUCTR2018-002942-35-GB United Kingdom;
OC oral solution treatment A
Orient Pharma Co., Ltd.
2011 Phase 2 NCT01370811 United States;
OC oral solution treatment B
Orient Pharma Co., Ltd.
2011 Phase 2 NCT01370811 United States;
OC oral solution treatment C
Orient Pharma Co., Ltd.
2011 Phase 2 NCT01370811 United States;
OC oral solution treatment D
Orient Pharma Co., Ltd.
2011 Phase 2 NCT01370811 United States;
OCT - TCE
Massachusetts General Hospital
2019 - NCT04566341 United States;
ODM-101
Orion Corporation
2011 - EUCTR2010-022200-46-LV Finland;Germany;Latvia;Lithuania;
2011 - EUCTR2010-022200-46-LT Finland;Germany;Latvia;Lithuania;
2011 - EUCTR2010-022200-46-FI Finland;Germany;Latvia;Lithuania;
- - EUCTR2010-022200-46-DE Finland;Germany;Latvia;Lithuania;
ODM-101 105mg Carbidopa
Orion Corporation, Orion Pharma
2011 Phase 2 NCT01766258 -
ODM-101 65mg Carbidopa
Orion Corporation, Orion Pharma
2011 Phase 2 NCT01766258 -
ODM-104
Orion Corporation
2017 Phase 2 EUCTR2015-004507-23-HU Finland;Germany;Hungary;Latvia;
2017 Phase 2 EUCTR2015-004507-23-FI Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-LV Finland;Germany;Hungary;Latvia;
2016 Phase 2 EUCTR2015-004507-23-DE Finland;Germany;Hungary;Latvia;
OFF Dopaminergic Medication
The Cleveland Clinic
2021 Phase 1 NCT05022147 United States;
ON Dopaminergic Medication
The Cleveland Clinic
2021 Phase 1 NCT05022147 United States;
ONO-2160/CD
ONO PHARMACEUTICAL CO.,LTD.
2014 Phase 1 JPRN-JapicCTI-142702 -
2013 Phase 1 JPRN-JapicCTI-132189 -
ONO-2370
ONO PHARMACEUTICAL CO.,LTD.
2016 Phase 2 JPRN-JapicCTI-153112 Japan;
ONO-2506PO
Ono Pharmaceutical Co. Ltd
2004 Phase 2 NCT00212693 -
OPC
Bial - Portela C S.A.
2011 Phase 1 NCT02169427 Netherlands;
OSU 6162 similar to (-)-OSU 6162
Björn Holmberg
2010 Phase 1;Phase 2 EUCTR2009-016360-37-SE Sweden;
OSU6162 similar to (-)-OSU 6162
A. Carlsson Research AB
2014 Phase 2 EUCTR2013-002545-10-SE Sweden;
OTHER NERVOUS SYSTEM DRUGS
EISAI LTD UK
2007 - EUCTR2006-005714-12-IT Italy;
OXB-102
Sio Gene Therapies
2018 Phase 1/Phase 2 NCT03720418 France;United Kingdom;
OXN 10 mg / 5 mg PR
Mundipharma Research GmbH & Co. KG
2012 - EUCTR2011-002901-31-DE Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-GB Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-ES Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-HU Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-CZ Czech Republic;Germany;Hungary;Spain;United Kingdom;
OXN 20 mg / 10 mg PR
Mundipharma Research GmbH & Co. KG
2012 - EUCTR2011-002901-31-DE Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-GB Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-ES Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-HU Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-CZ Czech Republic;Germany;Hungary;Spain;United Kingdom;
OXN 5 mg/2.5 mg PR
Mundipharma Research GmbH & Co. KG
2012 - EUCTR2011-002901-31-DE Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-GB Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-ES Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-HU Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-CZ Czech Republic;Germany;Hungary;Spain;United Kingdom;
OXYCODO
Mundipharma Research GmbH & Co. KG
2011 Phase 3 EUCTR2011-002901-31-ES Czech Republic;Germany;Hungary;Spain;United Kingdom;
OXYCODONE HYDROCHLORIDE
UHToulouse
2016 Phase 2;Phase 3 EUCTR2015-001523-24-FR France;
OXYTOCIN SYNTHETIC
Abteilung für Neurologie der Medizinischen Universität Innsbruck
2019 Phase 2 EUCTR2018-002877-23-AT Austria;
Onabotulinumtoxin A Injection
University of North Carolina, Chapel Hill
2018 Phase 2 NCT03301272 United States;
OnabotulinumtoxinA
Johns Hopkins University
2018 Phase 1 NCT03069911 United States;
Ondansetron 8 mg film-coated tablets
University College London
2020 Phase 2 EUCTR2019-003962-41-GB United Kingdom;
Ondansetron hydrochloride dihydrate
University College London
2020 Phase 2 EUCTR2019-003962-41-GB United Kingdom;
Ongentys
BIAL - Portela & Ca, S.A.
2016 Phase 4 EUCTR2016-002391-27-GB Germany;United Kingdom;
2016 Phase 4 EUCTR2016-002391-27-DE Germany;United Kingdom;
BIAL – Portela & Cª, S.A.
2021 Phase 3 EUCTR2020-005011-52-FR Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
2021 Phase 3 EUCTR2020-005011-52-BE Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
BIAL-Portela & Ca, S.A.
2021 Phase 3 EUCTR2020-005011-52-IT Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom;
Bial - Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-001175-32-PT Germany;Italy;Portugal;Spain;United Kingdom;
2020 Phase 4 EUCTR2020-001175-32-GB Germany;Italy;Portugal;Spain;United Kingdom;
Bial - Portela C S.A.
2019 Phase 1 NCT03820037 United Kingdom;
2018 Phase 1 NCT04265027 United Kingdom;
SK Chemicals Co., Ltd.
2021 Phase 4 NCT04821687 Korea, Republic of;
Ongentys 50 mg capsule rigide
BIAL-Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-002754-24-IT Germany;Italy;Portugal;Spain;United Kingdom;
2020 Phase 4 EUCTR2020-001175-32-IT Germany;Italy;Portugal;Spain;United Kingdom;
Ongentys 50 mg hard capsules
BIAL-Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-002754-24-IT Germany;Italy;Portugal;Spain;United Kingdom;
Bial - Portela & Ca, S.A.
2022 Phase 4 EUCTR2020-002754-24-DE Germany;Italy;Portugal;Spain;United Kingdom;
2021 Phase 4 EUCTR2020-002754-24-ES Germany;Italy;Portugal;Spain;United Kingdom;
2021 Phase 4 EUCTR2020-001176-15-PT Germany;Portugal;
2021 Phase 4 EUCTR2020-001176-15-DE Germany;Portugal;
Opicapone
BIAL - Portela & Ca, S.A.
2011 - EUCTR2010-021860-13-DE Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
BIAL-Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-002754-24-IT Germany;Italy;Portugal;Spain;United Kingdom;
2020 Phase 4 EUCTR2020-001175-32-IT Germany;Italy;Portugal;Spain;United Kingdom;
Bial - Portela & Ca, S.A.
2020 Phase 4 EUCTR2020-001175-32-GB Germany;Italy;Portugal;Spain;United Kingdom;
Bial - Portela C S.A.
2021 Phase 4 NCT04990284 -
2021 Phase 4 NCT04986995 Portugal;
2021 Phase 4 NCT04986982 United Kingdom;
2021 Phase 3 NCT04978597 Bulgaria;
2020 - NCT03959540 United Kingdom;
Neurocrine Biosciences
2021 - NCT04787965 United States;
2018 Phase 1 NCT03496870 United States;
ONO PHARMACEUTICAL CO.,LTD.
2016 Phase 2 JPRN-JapicCTI-153112 Japan;
Rabin Medical Center
2013 Phase 3 NCT01851850 Israel;
Opicapone (OPC)
Bial - Portela C S.A.
2017 Phase 1 NCT03116295 Germany;
2014 Phase 1 NCT03116308 -
Opicapone 50 mg hard capsules
Bial - Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-001175-32-PT Germany;Italy;Portugal;Spain;United Kingdom;
Optimal drug therapy
Vanderbilt University Medical Center
2006 - NCT00282152 United States;
Optimized antiparkinsonian treatment
AbbVie
2017 Phase 3 NCT02799381 Finland;Greece;Hungary;Italy;Slovakia;Spain;United States;
Optimized oral treatment
University Hospital, Lille
2020 Phase 1/Phase 2 NCT04332276 France;
Optional pharmacogenetic assessment
Tools4Patient
2018 Phase 1/Phase 2 NCT03407378 Belgium;France;United States;
Oral Levodopa/Carbidopa
AbbVie (prior sponsor, Abbott)
2011 Phase 2 NCT01479127 Japan;
Oral escitalopram
New York University School of Medicine
2003 Phase 2/Phase 3 NCT00070941 United States;
Oral levodopa and carbidopa
NeuroDerm Ltd.
2014 Phase 1/Phase 2 NCT02096601 Israel;United States;
Orally disintegrating selegiline (Zelapar)
Parkinson's Disease and Movement Disorder Center of Boca Raton
2007 Phase 4 NCT00443872 United States;
Orfadin
Synosia Therapeutics AG
2009 - EUCTR2009-013670-41-FR Czech Republic;France;
2009 - EUCTR2009-013670-41-CZ Czech Republic;France;
Other Parkinson's Disease treatments
Merck Sharp & Dohme Corp.
2007 Phase 2 NCT00537017 Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Singapore;Spain;United States;
2006 Phase 2 NCT00406029 Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Italy;New Zealand;Peru;Singapore;South Africa;Spain;United States;
Over-encapsulated Entacapone Tablets
BIAL - Portela & Ca, S.A.
2011 Phase 3 EUCTR2010-021860-13-RO Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-SK Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-ES Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
2011 - EUCTR2010-021860-13-DE Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-CZ Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-BG Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2011 - EUCTR2010-021860-13-AT Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2010 - EUCTR2010-021860-13-PT Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;
2010 - EUCTR2010-021860-13-LV Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
2010 - EUCTR2010-021860-13-HU Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain;
Over-encapsulated Modafinil
Theranexus S.A.
2018 Phase 2 EUCTR2017-004475-31-HU Czech Republic;France;Germany;Hungary;United States;
2018 Phase 2 EUCTR2017-004475-31-CZ Czech Republic;France;Germany;Hungary;United States;
Oxaloacetate (OAA)
University of Kansas Medical Center
2012 Phase 2/Phase 3 NCT01741701 United States;
Oxybuprocaine
Utano National Hospital, National Hospital Organization
2013 - JPRN-UMIN000017695 Japan;
Oxybutynin and darifenacin
Department of Veterans Affairs
2009 - NCT00892450 United States;
Oxybutynin hydrochloride
Summit (Cambridge) Ltd.
2007 - EUCTR2007-004654-81-GB United Kingdom;
Oxycodone/Naloxone Prolonged Release tablets
Mundipharma Research GmbH & Co KG
2011 Phase 3 NCT01439100 Czech Republic;Germany;Hungary;Poland;Romania;Spain;United Kingdom;
Oxycodone/naloxone prolonged release tablets 10 mg /
Mundipharma Research GmbH & Co. KG
2012 - EUCTR2011-002901-31-DE Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-GB Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-ES Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-HU Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-CZ Czech Republic;Germany;Hungary;Spain;United Kingdom;
Oxycodone/naloxone prolonged release tablets 20 mg /
Mundipharma Research GmbH & Co. KG
2012 - EUCTR2011-002901-31-DE Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-GB Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-ES Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-HU Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-CZ Czech Republic;Germany;Hungary;Spain;United Kingdom;
Oxycodone/naloxone prolonged release tablets 5 mg /
Mundipharma Research GmbH & Co. KG
2012 - EUCTR2011-002901-31-DE Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-GB Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-ES Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-HU Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-CZ Czech Republic;Germany;Hungary;Spain;United Kingdom;
Oxycontin LP
UHToulouse
2016 Phase 2;Phase 3 EUCTR2015-001523-24-FR France;
Oxygen
Tools4Patient
2018 Phase 1/Phase 2 NCT03407378 Belgium;France;United States;
P2B001
Pharma Two B Ltd
2018 Phase 3 EUCTR2017-001420-21-ES Canada;France;Germany;Spain;United States;
2018 Phase 3 EUCTR2017-001420-21-DE Canada;France;Germany;Spain;United States;
Pharma Two B Ltd.
2018 Phase 3 NCT03329508 Canada;Germany;Spain;United States;
P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),
Pharma Two B Ltd.
2013 Phase 2/Phase 3 NCT01968460 Israel;United States;
P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),
Pharma Two B Ltd.
2013 Phase 2/Phase 3 NCT01968460 Israel;United States;
PARCOPA
UCB Pharma
2004 Phase 3 NCT00139867 United States;
PAT
NYU Langone Health
2017 - NCT03178786 United States;
PBF-509
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
2014 Phase 1 NCT02111330 Spain;
2012 Phase 1 NCT01691924 Spain;
PD patients H&Y=1.5-2 Medications OFF
Giovanni Mirabella
2020 - NCT03665493 Italy;
PD patients H&Y=1.5-2 Medications ON
Giovanni Mirabella
2020 - NCT03665493 Italy;
PD patients H&Y=3 Medications OFF
Giovanni Mirabella
2020 - NCT03665493 Italy;
PD patients H&Y=3 Medications ON
Giovanni Mirabella
2020 - NCT03665493 Italy;
PD vitamin supplementation
New York Institute of Technology
2008 - NCT01238926 United States;
PEG
The 988th Hospitail of Joint Logistic Support Force
2021 Phase 4 ChiCTR2100043303 China;
PEG tube
AbbVie
2013 Phase 3 NCT01960842 Japan;Korea, Republic of;Taiwan;
AbbVie (prior sponsor, Abbott)
2009 Phase 3 NCT00660387 New Zealand;United States;
2009 Phase 3 NCT00360568 Germany;New Zealand;United States;
2009 Phase 3 NCT00357994 Germany;United States;
2008 Phase 3 NCT00335153 Australia;Canada;Czech Republic;Finland;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States;
PET
Zionexa
2021 Phase 3 NCT04265209 -
PET/CT
Asan Medical Center
2006 Phase 3 NCT00468078 Korea, Republic of;
PF-06412562
Milton S. Hershey Medical Center
2018 Phase 1 NCT03665454 United States;
Pfizer
2014 Phase 1 NCT02006290 United States;
PF-06649751
Cerevel Therapeutics, LLC
2021 Phase 3 EUCTR2019-002952-17-DE Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2021 Phase 3 EUCTR2019-002952-17-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2021 Phase 3 EUCTR2019-002951-40-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2021 Phase 3 EUCTR2019-002949-38-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002952-17-HU Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002952-17-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002951-40-HU Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002951-40-ES Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002951-40-DE Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002951-40-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002950-22-HU Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 EUCTR2019-002949-38-PL Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002949-38-HU Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002949-38-ES Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002949-38-DE Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States;
2020 Phase 3 EUCTR2019-002949-38-CZ Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States;
Pfizer
2016 Phase 2 NCT02847650 France;Germany;Israel;United States;
2015 Phase 1 NCT02373072 Belgium;United States;
2014 Phase 1 NCT02224664 Belgium;United States;
Pfizer, Inc.
2017 Phase 2 EUCTR2016-001575-71-ES France;Germany;Israel;Spain;United States;
2016 Phase 2 EUCTR2016-001575-71-DE France;Germany;Israel;Spain;United States;
2016 Phase 2 EUCTR2015-004912-39-ES France;Germany;Japan;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-004912-39-DE France;Germany;Japan;Spain;United Kingdom;United States;
PF-06649751 -
Pfizer Inc., 235 East 42nd Street, New York, New York
2017 Phase 2 EUCTR2017-000128-81-ES Canada;France;Germany;Spain;United States;
2017 Phase 2 EUCTR2017-000128-81-DE Canada;France;Germany;Spain;United States;
PF-06649751 high dose (15 mg QD)
Pfizer
2016 Phase 2 NCT02687542 Canada;France;Germany;Japan;Spain;United States;
PF-06649751 low dose (1 mg QD)
Pfizer
2016 Phase 2 NCT02687542 Canada;France;Germany;Japan;Spain;United States;
PF-06649751 middle dose 1 (3 mg QD)
Pfizer
2016 Phase 2 NCT02687542 Canada;France;Germany;Japan;Spain;United States;
PF-06649751 middle dose 2 (7 mg QD)
Pfizer
2016 Phase 2 NCT02687542 Canada;France;Germany;Japan;Spain;United States;
PF-06669571
Pfizer
2015 Phase 1 NCT02565628 United States;
PG203
Celon Pharma S.A.
2021 Phase 2 EUCTR2020-006004-16-PL Poland;
PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj
Seoul National University Hospital
2011 Phase 4 NCT01313819 Korea, Republic of;
PR Oxycodone
University Hospital, Toulouse
2016 Phase 2/Phase 3 NCT02601586 France;
PR001
Prevail Therapeutics
2020 Phase 1/Phase 2 NCT04127578 Israel;United States;
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE
Pharma Two B Ltd
2018 Phase 3 EUCTR2017-001420-21-ES Canada;France;Germany;Spain;United States;
2018 Phase 3 EUCTR2017-001420-21-DE Canada;France;Germany;Spain;United States;
PRIM-DJ2727
The University of Texas Health Science Center, Houston
2019 Phase 1 NCT03671785 United States;
2017 Phase 1/Phase 2 NCT03026231 United States;
PROSCAR*30CPR RIV
AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI
2011 - EUCTR2011-000612-26-IT Italy;
PRX002
Prothena Biosciences Limited
2014 Phase 1 NCT02157714 United States;
2014 Phase 1 NCT02095171 United States;
PRX002, ELT2, anti-alpha-synuclein monoclonal antibody
F. HOFFMANN - LA ROCHE LTD.
2021 Phase 2 EUCTR2020-004997-23-IT Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
F. Hoffmann-La Roche Ltd
2021 Phase 2 EUCTR2020-004997-23-FR Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004997-23-AT Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000087-15-FR Austria;France;Germany;Spain;United States;
2017 Phase 2 EUCTR2017-000087-15-ES Austria;France;Germany;Spain;United States;
2017 Phase 2 EUCTR2017-000087-15-DE Austria;France;Germany;Spain;United States;
2017 Phase 2 EUCTR2017-000087-15-AT Austria;France;Germany;Spain;United States;
Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
2021 Phase 2 EUCTR2020-004997-23-ES Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
PS
Central Hospital, Nancy, France
2021 - NCT04933513 France;
PS128
Professor Lu Neurological Clinic
2020 - NCT04722211 Taiwan;
2020 - NCT04722198 Taiwan;
PT320
Peptron, Inc.
2020 Phase 2 NCT04269642 Korea, Republic of;
PXT002331
PREXTON THERAPEUTICS B.V.
2017 Phase 2 EUCTR2017-000135-14-IT Austria;France;Germany;Italy;Spain;United Kingdom;
Prexton Therapeutics
2016 Phase 1 NCT02639221 United Kingdom;
Prexton Therapeutics B.V.
2017 Phase 2 EUCTR2017-000135-14-GB Austria;Germany;Spain;United Kingdom;
2017 Phase 2 EUCTR2017-000135-14-ES Austria;Germany;Italy;Spain;United Kingdom;
2017 Phase 2 EUCTR2017-000135-14-DE Austria;Germany;Italy;Spain;United Kingdom;
2017 Phase 2 EUCTR2017-000135-14-AT Austria;Germany;Spain;United Kingdom;
PXT002331 -
Prexton Therapeutics
2018 Phase 2 NCT03331848 -
PXT002331 - dose 1
Prexton Therapeutics
2017 Phase 2 NCT03162874 Austria;France;Germany;Italy;Spain;United Kingdom;
PXT002331 - dose 2
Prexton Therapeutics
2017 Phase 2 NCT03162874 Austria;France;Germany;Italy;Spain;United Kingdom;
PYM50028
Phytopharm
2010 Phase 2 NCT01060878 Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
Phytopharm plc
2011 - EUCTR2010-018534-44-HU Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
2011 - EUCTR2010-018534-44-DE Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
2011 - EUCTR2010-018534-44-CZ Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
2010 Phase 2 EUCTR2010-018534-44-GB Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States;
PYRIDOSTIGMINE BROMIDE
Department of Neurology, Roskilde Hospital
2012 Phase 2 EUCTR2012-000122-21-DK Denmark;
Paracetamol
Bial - Portela C S.A.
2014 Phase 1 NCT02305017 -
Parapres
INSTITUT DE RECERCA HSCSP
2016 Phase 2 EUCTR2016-000679-25-ES Spain;
Parcopa
Baylor College of Medicine
2006 Phase 4 NCT00590122 United States;
UCB Pharma
2005 Phase 3 NCT00139880 United States;
Pardaprunox
Solvay Pharmaceuticals
2006 Phase 3 NCT00335166 Australia;Czech Republic;Estonia;France;Germany;India;Italy;Lithuania;Malaysia;Netherlands;Poland;Portugal;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States;
Pardoprunox
Abbott Products
2009 Phase 2 NCT00903838 Germany;Italy;Portugal;
Solvay Pharmaceuticals
2007 Phase 3 NCT00407095 Albania;Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Latvia;Lithuania;Peru;Russian Federation;Ukraine;United States;
2007 Phase 3 NCT00406588 Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Latvia;Lithuania;Peru;Russian Federation;Ukraine;United States;
2007 Phase 3 NCT00335374 Australia;Czech Republic;Estonia;France;Germany;India;Italy;Lithuania;Malaysia;Netherlands;Poland;Portugal;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States;
2007 Phase 3 NCT00332917 Argentina;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Finland;Former Serbia and Montenegro;India;Israel;Mexico;New Zealand;Peru;Romania;Russian Federation;Serbia;Slovakia;South Africa;Sweden;Ukraine;United States;
2006 Phase 3 NCT00269516 Argentina;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Finland;Former Serbia and Montenegro;India;Israel;Mexico;New Zealand;Peru;Romania;Russian Federation;Serbia;Slovakia;South Africa;Sweden;Ukraine;United States;
Pardoprunox hydrochloride
Abbott Healthcare Products B.V.
2009 - EUCTR2008-000400-81-DE Germany;Italy;Portugal;
SOLVAY PHARMACEUTICALS B.V.
2009 - EUCTR2008-000400-81-IT Germany;Italy;Portugal;
Solvay Pharmaceuticals
2009 Phase 3 EUCTR2007-001095-36-SK Hungary;Slovakia;
2008 Phase 3 EUCTR2007-001096-10-SK Hungary;Slovakia;
2008 - EUCTR2007-001096-10-HU Hungary;
2008 - EUCTR2007-001095-36-HU Hungary;
Solvay Pharmaceuticals B.V.
2008 Phase 2 EUCTR2008-004943-12-SK Slovakia;
Solvay Pharmaceuticals BV
2009 - EUCTR2008-000400-81-PT Germany;Italy;Portugal;
Paroxetine
Rutgers, The State University of New Jersey
2003 Phase 2 NCT00062738 United States;
University of Rochester
2005 Phase 3 NCT00086190 Canada;Puerto Rico;United States;
Part 1, JM-010 component Group A
Bukwang Pharmaceutical
2021 Phase 2 NCT04377945 United States;
Part 1, JM-010 component Group B
Bukwang Pharmaceutical
2021 Phase 2 NCT04377945 United States;
Part 1, JM-010 component Group C
Bukwang Pharmaceutical
2021 Phase 2 NCT04377945 United States;
Part 2, JM-010 combination Group A
Bukwang Pharmaceutical
2021 Phase 2 NCT04377945 United States;
Part 2, JM-010 combination Group B
Bukwang Pharmaceutical
2021 Phase 2 NCT04377945 United States;
Part 2, JM-010 component Group C
Bukwang Pharmaceutical
2021 Phase 2 NCT04377945 United States;
Perampanel
Eisai Inc.
2007 Phase 2 NCT00566462 United States;
2004 Phase 2 NCT01634360 -
Eisai Limited
2007 Phase 3 NCT00505622 France;
Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J)
AbbVie (prior sponsor, Abbott)
2013 Phase 3 NCT01736176 United States;
Percutaneous endoscopic gastrostomy tube
AbbVie
2017 Phase 3 NCT02799381 Finland;Greece;Hungary;Italy;Slovakia;Spain;United States;
Percutaneous endoscopic gastrostomy tube (PEG tube)
AbbVie (prior sponsor, Abbott)
2006 Phase 4 NCT00141518 Norway;Sweden;
Pergolide
Valeant Pharmaceuticals International, Inc.
2008 - NCT00624741 -
Phenlarmide Tablets
Yiling Pharmaceutical Inc.
2019 Phase 1 NCT04164121 China;
Physical exam and UPDRS part III assessment
Howard Gendelman, MD
2013 Phase 1 NCT01882010 United States;
Piclozotan
Asubio Pharmaceuticals, Inc.
2007 Phase 2 NCT00623363 Guatemala;Romania;United States;
Pilocarpine
Nagoya University
2017 - JPRN-UMIN000026128 Japan;
katsuno Masahisa
2017 Phase 2 JPRN-jRCTs041180018 Japan;
Pimavanserin
ACADIA Pharmaceuticals Inc.
2020 Phase 4 NCT04292223 United States;
2019 Phase 2 NCT04164758 United States;
2018 Phase 2 NCT03482882 United States;
VA Office of Research and Development
2022 Phase 4 NCT04373317 United States;
Pimavanserin (ACP-103)
ACADIA Pharmaceuticals Inc
2009 Phase 3 EUCTR2007-003035-22-PT Austria;Belgium;Canada;European Union;France;India;Italy;Portugal;Russian Federation;Sweden;Ukraine;United Kingdom;United States;
ACADIA Pharmaceuticals Inc.
2008 Phase 3 EUCTR2007-003035-22-GB Austria;Belgium;Canada;European Union;France;India;Italy;Portugal;Russian Federation;Sweden;Ukraine;United Kingdom;United States;
Acadia Pharmaceuticals Inc
2008 Phase 2;Phase 3 EUCTR2007-003035-22-SE Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
2008 Phase 2;Phase 3 EUCTR2007-003035-22-BE Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
Pimavanserin tartrate
ACADIA Pharmaceuticals Inc
2009 Phase 3 EUCTR2007-003035-22-PT Austria;Belgium;Canada;European Union;France;India;Italy;Portugal;Russian Federation;Sweden;Ukraine;United Kingdom;United States;
ACADIA Pharmaceuticals Inc.
2016 - NCT02762591 -
2010 Phase 3 NCT01174004 Canada;United States;
2008 Phase 3 EUCTR2007-003035-22-GB Austria;Belgium;Canada;European Union;France;India;Italy;Portugal;Russian Federation;Sweden;Ukraine;United Kingdom;United States;
Acadia Pharmaceuticals Inc
2009 Phase 2;Phase 3 EUCTR2007-003035-22-AT Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
2008 Phase 2;Phase 3 EUCTR2007-003035-22-SE Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
2008 Phase 2;Phase 3 EUCTR2007-003035-22-FR Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
2008 Phase 2;Phase 3 EUCTR2007-003035-22-BE Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
2008 - EUCTR2007-003051-36-SE Austria;Portugal;Spain;Sweden;
2008 - EUCTR2007-003051-36-PT Austria;Portugal;Spain;Sweden;
2008 - EUCTR2007-003051-36-ES Austria;Portugal;Spain;Sweden;
2008 - EUCTR2007-003051-36-BE Austria;Belgium;Portugal;Spain;Sweden;
2008 - EUCTR2007-003051-36-AT Austria;Portugal;Spain;Sweden;
2008 - EUCTR2007-002906-23-BG Bulgaria;France;United Kingdom;
2007 - EUCTR2007-002906-23-GB Bulgaria;France;United Kingdom;
2007 - EUCTR2007-002906-23-FR Bulgaria;France;United Kingdom;
Pimavanserin tartrate (ACP-103)
ACADIA Pharmaceuticals Inc.
2008 Phase 3 NCT00658567 Austria;Belgium;Italy;Poland;Portugal;Serbia;Spain;Sweden;United States;
2007 Phase 3 NCT00550238 Austria;Belgium;Canada;France;India;Italy;Poland;Portugal;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom;United States;
2007 Phase 3 NCT00477672 Bulgaria;France;India;Russian Federation;Ukraine;United Kingdom;United States;
2004 Phase 2 NCT01518309 United States;
Pioglitazone
University of Rochester
2011 Phase 2 NCT01280123 United States;
Pirepemat
Integrative Research Laboratories AB
2022 Phase 2 NCT05258071 -
Piribedil
Desitin Arzneimittel GmbH
2010 Phase 3 NCT01007864 Germany;
2009 - EUCTR2009-012419-16-DE Germany;
2008 - NCT00727727 Germany;
2008 - NCT00725478 -
Henan University of Traditional Chinese Medicine
2009 - ChiCTR-TRC-12002150 China;
Institut de Recherches Internationales Servier
2006 Phase 2 EUCTR2005-000314-12-DE Germany;Spain;
2005 Phase 2 EUCTR2005-000314-12-ES Germany;Spain;
Institut de Recherches Internationales Servier (I.R.I.S.)
2005 - EUCTR2005-002010-38-DE Germany;
Piribedil (Clarium)
Desitin Arzneimittel GmbH
2009 - NCT01519856 Germany;
Pitolisant
BIOPROJET
2010 - EUCTR2009-013886-24-SE Czech Republic;Germany;Sweden;
2010 - EUCTR2009-013886-24-DE Czech Republic;Germany;Sweden;
2009 - EUCTR2009-013886-24-CZ Czech Republic;Germany;Sweden;
2009 - EUCTR2009-013885-14-FR France;Spain;
2009 - EUCTR2009-013885-14-ES France;Spain;
Pittsburgh Compound B
Sunnybrook Health Sciences Centre
2016 - NCT02524405 Canada;
Placebo
Meiji Seika Pharma Co., Ltd.
2015 Phase 3 JPRN-JapicCTI-153057 Japan;
2015 Phase 2-3 JPRN-JapicCTI-153056 Japan;
ONO PHARMACEUTICAL CO.,LTD.
2016 Phase 2 JPRN-JapicCTI-153112 Japan;
Otsuka Pharmaceutical Co., Ltd.
2009 Phase 3 JPRN-JapicCTI-090888 -
Plantago ovata husk
Rottapharm Spain
2006 Phase 1 NCT00507715 Spain;
Posiphen
Annovis Bio Inc.
2020 Phase 1/Phase 2 NCT04524351 United States;
Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin)
Hospices Civils de Lyon
2019 - NCT03970239 France;
Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin)
Hospices Civils de Lyon
2019 - NCT03970239 France;
Pramipexol
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-DE Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-CZ Austria;Czech Republic;Germany;Italy;
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
Shanghai General Hospital
2020 Phase 0 ChiCTR2000037624 China;
Pramipexol Extended Release
Boehringer Ingelheim
2007 Phase 3 NCT00479401 Argentina;Austria;Brazil;Czech Republic;Finland;Germany;Hungary;India;Japan;Malaysia;Russian Federation;Slovakia;Taiwan;Ukraine;United States;
2007 Phase 3 NCT00466167 Austria;Czech Republic;Hungary;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom;
Pramipexol Immediate Release
Boehringer Ingelheim
2007 Phase 3 NCT00479401 Argentina;Austria;Brazil;Czech Republic;Finland;Germany;Hungary;India;Japan;Malaysia;Russian Federation;Slovakia;Taiwan;Ukraine;United States;
2007 Phase 3 NCT00466167 Austria;Czech Republic;Hungary;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom;
Pramipexole
Abbott Products
2009 Phase 2 NCT00903838 Germany;Italy;Portugal;
Boehringer Ingelheim
2011 - NCT01361009 China;
2008 Phase 3 NCT00601523 Argentina;Austria;Czech Republic;Finland;France;Germany;Hungary;India;Japan;Malaysia;Netherlands;Russian Federation;Slovakia;Taiwan;Ukraine;United States;
2008 - NCT02236728 -
2007 Phase 3 NCT00577460 Austria;Czech Republic;Hungary;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom;
2006 Phase 4 NCT00402233 United States;
2006 Phase 4 NCT00321854 Austria;Finland;France;Germany;Italy;Japan;Spain;Sweden;United Kingdom;United States;
2006 Phase 4 NCT00297778 Austria;Finland;France;Germany;Italy;Netherlands;Norway;Romania;Russian Federation;South Africa;Spain;Sweden;Ukraine;United Kingdom;
2006 Phase 4 EUCTR2005-004949-34-FI Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - NCT00349310 Austria;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2004 - NCT02248181 -
2003 Phase 3 NCT00240409 China;
2003 - NCT02248207 -
2002 - NCT02248168 -
1999 Phase 3 NCT02172573 -
1998 Phase 4 NCT02233023 -
1998 Phase 3 NCT02177357 -
1998 - NCT02248220 -
Boehringer Ingelheim AB
2006 Phase 4 EUCTR2005-004949-34-SE Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003788-22-SE Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Austria GmbH
2006 - EUCTR2005-004949-34-AT Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003788-22-AT Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim España S.A.
2006 Phase 4 EUCTR2005-003788-22-ES Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim España, S.A.
2006 - EUCTR2005-004949-34-ES Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Limited
2006 Phase 4 EUCTR2005-003788-22-GB Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Ltd
2006 Phase 4 EUCTR2005-004949-34-GB Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Pharma GmbH & Co. KG
2006 - EUCTR2005-004949-34-DE Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003788-22-DE Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Department of Neurology, Brain Hospital Affiliated to Nanjing Medical University
2019 Phase 0 ChiCTR1900021708 China;
Department of Neurology, Juntendo University
2011 - JPRN-UMIN000006521 Japan;
Geriatric Hospital of Hainan
2019 - ChiCTR1900022534 China;
Huashan Hospital
2011 - NCT01470859 China;
Institute of Clinical Pharmacology, Central South University
2012 Phase 1 study ChiCTR-TTRCC-12002751 China;
Institute of Psychology, Chinese Academy of Sciences
2018 - ChiCTR1800015331 China;
Kissei Pharmaceutical Co., Ltd.
2019 Phase 2 NCT03845387 Japan;
NEUROBIOTEC GMBH
2007 - EUCTR2006-003732-30-IT Germany;Italy;Poland;
Oregon Health and Science University
2003 Phase 1 NCT00666653 United States;
Qualissima
2008 Phase 4 NCT01048229 -
SOLVAY PHARMACEUTICALS B.V.
2009 - EUCTR2008-000400-81-IT Germany;Italy;Portugal;
2006 - EUCTR2006-000678-57-IT Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
Sandoz
2012 Phase 4 NCT01673724 Korea, Republic of;
Solvay Pharmaceuticals
2006 Phase 3 NCT00335166 Australia;Czech Republic;Estonia;France;Germany;India;Italy;Lithuania;Malaysia;Netherlands;Poland;Portugal;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States;
The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital)
2020 Phase 4 ChiCTR2000039050 China;
The Affiliated Brain Hospital of Nanjing Medical University( Nanjing Brain Hospital)
2018 - ChiCTR1800019942 China;
Vanderbilt University Medical Center
2019 Phase 1 NCT04249544 United States;
West China Hospital of Sichuan University
2020 Phase 1 ChiCTR2000035564 China;
Pramipexole 0.125 mg tablets
Boehringer Ingelheim
1998 Phase 3 NCT00274131 -
Pramipexole 0.5 mg tablets
Boehringer Ingelheim
1998 Phase 3 NCT00274131 -
Pramipexole ER
BOEHRINGER ING.
2008 - EUCTR2007-004235-37-IT Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-000074-23-IT Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
BOEHRINGER INGELHEIM
2008 Phase 3 EUCTR2007-004234-16-FR Austria;Czech Republic;Finland;France;Hungary;Netherlands;Slovakia;
2007 Phase 3 EUCTR2007-003353-90-FR France;Germany;Netherlands;
Boehringer Ingelheim
2008 - EUCTR2007-004235-37-GB Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-003353-90-NL France;Germany;Netherlands;
Boehringer Ingelheim AB
2008 - EUCTR2007-004235-37-SE Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-000074-23-SE Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim España, S.A.
2008 Phase 3 EUCTR2007-004235-37-ES Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2007-000074-23-ES Austria;Czech Republic;Hungary;Italy;Slovakia;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Finland Ky
2008 - EUCTR2007-004234-16-FI Austria;Czech Republic;Finland;France;Hungary;Netherlands;
2007 - EUCTR2007-000073-39-FI Austria;Czech Republic;Finland;Hungary;
Boehringer Ingelheim Limited
2007 - EUCTR2007-000074-23-GB Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Pharma Ges mbH
2008 Phase 3 EUCTR2007-004235-37-HU Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-004235-37-PL Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-004235-37-CZ Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-004234-16-HU Austria;Czech Republic;Finland;France;Hungary;Netherlands;
2007 Phase 3 EUCTR2007-000074-23-SK Austria;Czech Republic;Hungary;Italy;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2007-000073-39-SK Austria;Czech Republic;Finland;Germany;Hungary;Slovakia;
2007 - EUCTR2007-000074-23-HU Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-000073-39-HU Austria;Czech Republic;Finland;Hungary;
2007 - EUCTR2007-000073-39-AT Austria;Czech Republic;Finland;Hungary;
Boehringer Ingelheim Pharma GmbH & Co. KG
2007 - EUCTR2007-003353-90-DE France;Germany;Netherlands;
2007 - EUCTR2007-000074-23-AT Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-000073-39-DE Austria;Czech Republic;Finland;Germany;Hungary;
Boehringer Ingelheim RCV GmbH & Co KG
2009 - EUCTR2007-004235-37-AT Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2009 - EUCTR2007-004234-16-AT Austria;Czech Republic;Finland;France;Hungary;Netherlands;
2008 Phase 3 EUCTR2007-004235-37-SK Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom;
2008 Phase 3 EUCTR2007-004234-16-SK Austria;Czech Republic;Finland;France;Hungary;Netherlands;Slovakia;
2008 - EUCTR2007-004234-16-CZ Austria;Czech Republic;Finland;France;Hungary;Netherlands;
2007 Phase 3 EUCTR2007-000074-23-CZ Austria;Czech Republic;Hungary;Italy;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-000073-39-CZ Austria;Czech Republic;Finland;Hungary;
Boehringer Ingelheim bv
2007 - EUCTR2007-004234-16-NL Austria;Czech Republic;Finland;France;Hungary;Netherlands;
Pharma Two B Ltd.
2018 Phase 3 NCT03329508 Canada;Germany;Spain;United States;
Pramipexole Extended Release
Boehringer Ingelheim
2010 - NCT01097421 Sweden;
2007 Phase 3 NCT00558025 France;Germany;Netherlands;
2007 Phase 2/Phase 3 NCT00560508 Japan;
Pramipexole IR
Boehringer Ingelheim
2018 Phase 4 NCT03521635 China;
Pramipexole Immediate Release
Boehringer Ingelheim
2007 Phase 3 NCT00558025 France;Germany;Netherlands;
2007 Phase 2/Phase 3 NCT00560508 Japan;
Pramipexole SR
Boehringer Ingelheim
2018 Phase 4 NCT03521635 China;
Pramipexole dihydrochloride extended-release tablets
Pharma Two B Ltd
2018 Phase 3 EUCTR2017-001420-21-ES Canada;France;Germany;Spain;United States;
2018 Phase 3 EUCTR2017-001420-21-DE Canada;France;Germany;Spain;United States;
Pramipexole dihydrochloride monohydrate
Abbott Healthcare Products B.V.
2009 - EUCTR2008-000400-81-DE Germany;Italy;Portugal;
Solvay Pharmaceuticals B.V.
2008 Phase 2 EUCTR2008-004943-12-SK Slovakia;
Solvay Pharmaceuticals BV
2009 - EUCTR2008-000400-81-PT Germany;Italy;Portugal;
Pramipexole dihydrochloride monohydrate extended release
University Hospital of North Staffordshire
2013 Phase 4 EUCTR2012-000801-64-GB United Kingdom;
Pramipexole extended release tablet
Boehringer Ingelheim
2010 Phase 3 NCT01191944 China;
Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole)
First Affiliated Hospital of Zhejiang University
2020 - NCT04275492 China;
Pramipexole immediate release
Boehringer Ingelheim
2008 - NCT00651183 Austria;
Pramipexole immediate release tablet
Boehringer Ingelheim
2010 Phase 3 NCT01191944 China;
Pramipexole or ropinirole
Desitin Arzneimittel GmbH
2010 Phase 3 NCT01007864 Germany;
Prasinezumab
F. HOFFMANN - LA ROCHE LTD.
2021 Phase 2 EUCTR2020-004997-23-IT Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
F. Hoffmann-La Roche Ltd
2021 Phase 2 EUCTR2020-004997-23-FR Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004997-23-AT Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
Hoffmann-La Roche
2021 Phase 2 NCT04777331 Austria;Canada;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
2021 Phase 2 EUCTR2020-004997-23-ES Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride)
First Affiliated Hospital of Zhejiang University
2020 - NCT04275492 China;
Prednisone
Prevail Therapeutics
2020 Phase 1/Phase 2 NCT04127578 Israel;United States;
Preladenant
Merck Sharp & Dohme Corp.
2011 Phase 2 NCT01294800 Japan;
2011 Phase 1 NCT01323855 Germany;
2010 Phase 3 NCT01227265 Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States;
2010 Phase 3 NCT01215227 Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2007 Phase 2 NCT00537017 Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Singapore;Spain;United States;
2006 Phase 2 NCT00406029 Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Italy;New Zealand;Peru;Singapore;South Africa;Spain;United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
2011 - EUCTR2009-015161-31-DE Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
2011 Phase 3 EUCTR2009-013552-72-GB Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015162-57-PT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015161-31-PT Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2011 Phase 3 EUCTR2009-015162-57-GB Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-BG Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015161-31-GB Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015161-31-BG Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-013552-72-BG Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
- - EUCTR2009-013552-72-DE Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Merck Sharp & Dohme corp.
2011 Phase 3 EUCTR2009-015162-57-NL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Schering Corporation, división Schering-Plough Research
2010 Phase 3 EUCTR2009-013552-72-ES Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
Schering-Plough Research Institute, a division of Schering Corporation
2011 Phase 3 EUCTR2009-015162-57-LV Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-LT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-FI Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-ES Austria;Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2011 Phase 3 EUCTR2009-015162-57-CZ Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-013552-72-CZ Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2010-020112-11-LV Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States;
2011 - EUCTR2010-020112-11-LT Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States;
2011 - EUCTR2009-015162-57-SE Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-PL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-AT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015161-31-PL Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015161-31-CZ Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-013552-72-PL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 Phase 3 EUCTR2009-015161-31-IT Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2009-015161-31-FR Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2009-013552-72-HU Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2009-013552-72-FI Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-SE Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-NL Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-FI Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-AT Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-013552-72-SE Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-013552-72-IT Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
Schering-Plough Research Institute, division of Schering Corporation
2011 - EUCTR2009-015162-57-IT Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
Tokyo Metropolitan Institute of Gerontology
2016 - JPRN-UMIN000025638 Japan;
Preladenant 10 mg tablet
Merck Sharp & Dohme Corp.
2010 Phase 3 NCT01155479 Argentina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 Phase 3 NCT01155466 Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Preladenant 2 mg tablet
Merck Sharp & Dohme Corp.
2010 Phase 3 NCT01155479 Argentina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 Phase 3 NCT01155466 Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Preladenant 5 mg tablet
Merck Sharp & Dohme Corp.
2010 Phase 3 NCT01155479 Argentina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 Phase 3 NCT01155466 Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Premarin ®
The Parkinson Study Group
2003 Phase 2 NCT00234676 United States;
Pridia (Donepezil Hydrochloride)
The Newcastle upon Tyne Hospitals NHS Foundation Trust
2012 Phase 3 EUCTR2009-015170-35-GB United Kingdom;
Pridopidine
Prilenia
2019 Phase 2 NCT03922711 United States;
Primary Cervical Dystonia (Trihexyphenidyl)
University of Florida
2014 - NCT02046447 United States;
Primavanserin tartrate
ACADIA PHARMACEUTICALS INC.
2009 - EUCTR2007-003035-22-IT Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom;
Prior Donepezil
Eisai Inc.
2003 Phase 3 NCT01327859 United Kingdom;
Prior Donzepezil
Eisai Inc.
2003 Phase 3 NCT01327859 United Kingdom;
ProSavin
Axovant Sciences Ltd.
2011 Phase 1/Phase 2 NCT01856439 France;United Kingdom;
Oxford BioMedica
2008 Phase 1/Phase 2 NCT00627588 France;United Kingdom;
Oxford BioMedica (UK) Ltd
2010 Phase 1;Phase 2 EUCTR2007-001109-26-GB United Kingdom;
2010 - EUCTR2009-017253-35-GB United Kingdom;
Probiotic
University of British Columbia
2020 Phase 2 NCT03968133 Canada;
Probiotic Capsule
University of Malaya
2017 - NCT03377322 Malaysia;
Probiotics
Franca Marino
2021 - NCT05173701 Italy;
Probiotics with prebiotic
National University of Malaysia
2018 Phase 3 NCT04451096 Malaysia;
Prolonged release tablet
Boehringer Ingelheim Finland Ky
2007 - EUCTR2007-000073-39-FI Austria;Czech Republic;Finland;Hungary;
Boehringer Ingelheim Pharma Ges mbH
2007 Phase 3 EUCTR2007-000073-39-SK Austria;Czech Republic;Finland;Germany;Hungary;Slovakia;
2007 - EUCTR2007-000073-39-HU Austria;Czech Republic;Finland;Hungary;
2007 - EUCTR2007-000073-39-AT Austria;Czech Republic;Finland;Hungary;
Boehringer Ingelheim Pharma GmbH & Co. KG
2007 - EUCTR2007-000073-39-DE Austria;Czech Republic;Finland;Germany;Hungary;
Boehringer Ingelheim RCV GmbH & Co KG
2007 - EUCTR2007-000073-39-CZ Austria;Czech Republic;Finland;Hungary;
Prolopa®
Bial - Portela C S.A.
2008 Phase 1 NCT02169895 Canada;
Propofol
Clinica Universidad de Navarra, Universidad de Navarra
2014 Phase 4 NCT02256319 Spain;
Columbia University
2003 - NCT00615472 United States;
Department of Anesthesiology, the First Affiliated Hospital of Sun Yat-Sen University
2020 Phase 4 ChiCTR2000039697 China;
The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
2019 - ChiCTR1900021760 China;
University of Texas Southwestern Medical Center
2020 - NCT04502550 United States;
West China Hospital, Sichuan University
2016 - ChiCTR-IOR-16010168 China;
Xuanwu Hospital of CCMU
2018 - ChiCTR1800014542 China;
Propofol-Lipuro
Clínica Universidad de Navarra/Universidad de Navarra
2014 - EUCTR2014-000868-17-ES Spain;
Propranolol HCl CF 40 mg tablet
Radboud University Nijmegen
2017 Phase 3 EUCTR2016-004629-18-NL Netherlands;
Psilocybin
Maastricht University
2022 Phase 2 EUCTR2021-000041-40-NL Netherlands;
Psilocybin therapy
Joshua Woolley, MD/PhD
2021 Phase 2 NCT04932434 United States;
Psilocybine
Maastricht University
2022 Phase 2 EUCTR2021-000041-40-NL Netherlands;
Psyllium
University of Florida
2021 - NCT04829760 United States;
Pyridostigmine bromide
Christian Baumann
2012 Phase 2 NCT01993680 Switzerland;
QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD
Pfizer
2017 Phase 2 NCT03185481 United States;
QD to 15 mg QD PF-06649751
Pfizer
2017 Phase 2 NCT03185481 United States;
QD to 7 mg QD PF-06649751 (de-escalated in parent study)
Pfizer
2017 Phase 2 NCT03185481 United States;
QD to 7 mg QD PF-06649751 (if de-escalated in parent study)
Pfizer
2017 Phase 2 NCT03185481 United States;
Quetiapine
ACADIA Pharmaceuticals Inc.
2019 Phase 2 NCT04164758 United States;
National Institute on Aging (NIA)
2002 Phase 4 NCT00043849 United States;
VA Office of Research and Development
2022 Phase 4 NCT04373317 United States;
R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride
Fujimoto Pharmaceutical Corporation
2006 Phase 2 EUCTR2006-000361-11-GB United Kingdom;
R-metHuGDNF
North Bristol NHS Trust (NBT)
2013 Phase 2 EUCTR2013-001881-40-GB United Kingdom;
2012 Phase 2 EUCTR2011-003866-34-GB United Kingdom;
RAAV-GAD
Neurologix, Inc.
2011 - NCT01301573 United States;
RAS
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
2021 Phase 0 ChiCTR2100045506 China;
University of Toronto
2009 - NCT03316365 -
RASAGILINA MESILATO
Teva Pharmaceutical Industries Ltd
2009 Phase 4 EUCTR2009-011541-24-ES France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
RASAGILINE MESILATE
Dresden University of Technology
2011 - EUCTR2010-023756-82-DE Germany;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
2011 - EUCTR2009-015162-57-PT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2011 Phase 3 EUCTR2009-015162-57-GB Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-BG Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Merck Sharp & Dohme corp.
2011 Phase 3 EUCTR2009-015162-57-NL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Pharma Two B Ltd
2018 Phase 3 EUCTR2017-001420-21-ES Canada;France;Germany;Spain;United States;
2018 Phase 3 EUCTR2017-001420-21-DE Canada;France;Germany;Spain;United States;
Schering-Plough Research Institute, a division of Schering Corporation
2011 Phase 3 EUCTR2009-015162-57-LV Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-LT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-FI Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-ES Austria;Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2011 Phase 3 EUCTR2009-015162-57-CZ Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-SE Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-PL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-AT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
REQUIP 21 CPR 0,
SCHWARZ PHARMA
2004 - EUCTR2004-002609-66-IT Germany;Italy;
REQUIP*21CPR
CASA DI CURA PRIVATA S.RAFFAELE - PISANA
2009 - EUCTR2009-015833-66-IT Italy;
REQUIP*21CPR 0,
GlaxoSmithKline R D
2006 - EUCTR2005-005423-34-IT Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
REQUIP*28CPR 8MG R.P.
CASA DI CURA PRIVATA S.RAFFAELE - PISANA
2009 - EUCTR2009-015833-66-IT Italy;
REQUIP-LP
CHU de Toulouse
2009 - EUCTR2009-012529-12-FR France;
REQUIP-MODUTAB ,
GlaxoSmithKline Research & Development Limited
2013 - EUCTR2011-002827-17-EE Estonia;Korea, Republic of;Russian Federation;Slovakia;United States;
REQUIP-MODUTAB,
GlaxoSmithKline Research & Development Limited
2013 - EUCTR2011-002828-41-EE Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States;
RIV-TDS 13.3 mg/24 h
University of Bristol
2019 Phase 3 EUCTR2018-003219-23-GB United Kingdom;
RM-131
Motus Therapeutics, Inc.
2013 Phase 2 NCT01955616 United States;
RO
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2011 - EUCTR2010-022363-35-DE Germany;
RO7046015
F. HOFFMANN - LA ROCHE LTD.
2021 Phase 2 EUCTR2020-004997-23-IT Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
F. Hoffmann-La Roche Ltd
2021 Phase 2 EUCTR2020-004997-23-FR Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-004997-23-AT Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-000087-15-FR Austria;France;Germany;Spain;United States;
2017 Phase 2 EUCTR2017-000087-15-ES Austria;France;Germany;Spain;United States;
2017 Phase 2 EUCTR2017-000087-15-AT Austria;France;Germany;Spain;United States;
Hoffmann-La Roche
2017 Phase 2 NCT03100149 Austria;France;Germany;Spain;United States;
Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
2021 Phase 2 EUCTR2020-004997-23-ES Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States;
RO7046015/PRASINEZUMAB
F. Hoffmann-La Roche Ltd
2017 Phase 2 EUCTR2017-000087-15-DE Austria;France;Germany;Spain;United States;
ROP+L-Dopa
GlaxoSmithKline
2007 Phase 4 NCT00485069 Japan;
ROT-TDS 8 mg/24 h
Luye Pharma Switzerland AG
2021 Phase 2 EUCTR2021-000867-65-DE Germany;
RQ-00000010
Virginia Commonwealth University
2016 Phase 1 NCT02838797 United States;
RVG 08740
Centre for Human Drug Research
2020 Phase 2 EUCTR2020-000686-16-NL Netherlands;
RVG 55618
Radboud University Nijmegen
2017 Phase 3 EUCTR2016-004629-18-NL Netherlands;
RVT-101
Axovant Sciences Ltd.
2016 Phase 2 NCT02910102 United States;
RYAH-Medtech Inhaler
OMNI Medical Services, LLC
2018 Phase 2 NCT03944447 United States;
Raclopride
Institute of Biomedical Research and Innovation
2015 - JPRN-UMIN000016485 Japan;
Nagoya City Rehabilitation Agency
2019 - JPRN-UMIN000036952 Japan;
National Institute of Neurological Disorders and Stroke (NINDS)
2002 - NCT00032812 United States;
Tokyo Metropolitan Institute of Gerontology
2014 - JPRN-UMIN000014709 Japan;
Racol
St. Mariannna University School of Medicine
2012 - JPRN-UMIN000008057 Japan;
Radotinib HCl
Il-Yang Pharm. Co., Ltd.
2021 Phase 2 NCT04691661 France;
Ramelteon
Massachusetts General Hospital
2009 - NCT00907595 United States;
Southern California Institute for Research and Education
2007 Phase 4 NCT00462254 United States;
Rasagilin
Technische Universität Dresden
2009 - EUCTR2008-005085-30-DE Germany;
Rasagilina mesilato (12 weeks)
Universita di Verona
2018 - NCT03648671 Italy;
Rasagiline
Beijing Hospital
2018 - ChiCTR1800016949 China;
Bial - Portela C S.A.
2009 Phase 1 NCT01532141 France;
2009 Phase 1 NCT01532128 France;
Brown University
2011 Phase 4 NCT01382342 United States;
Chongqing Fortune Pharmaceutical Co., Ltd.
2011 Phase 3 NCT01736891 China;
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
2008 Phase 4 NCT00755027 Spain;
Georgetown University
2012 Phase 4 NCT01497652 United States;
H. Lundbeck A/S
2012 Phase 3 NCT01556165 China;
2012 Phase 1 NCT01652313 China;
Istanbul University
2007 Phase 4 NCT00696215 Turkey;
Lundbeck Italia S.p.A.
2010 Phase 4 NCT01055379 Italy;
Merck Sharp & Dohme Corp.
2010 Phase 3 NCT01215227 Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
Pharma Two B Ltd.
2018 Phase 3 NCT03329508 Canada;Germany;Spain;United States;
Qualissima
2008 Phase 4 NCT01048229 -
Research and Development University Hospital of North Staffordshire
2014 - EUCTR2014-000335-17-GB United Kingdom;
Schering-Plough Research Institute, a division of Schering Corporation
2010 Phase 3 EUCTR2009-015161-31-IT Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2010 - EUCTR2009-013552-72-IT Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
Schering-Plough Research Institute, division of Schering Corporation
2011 - EUCTR2009-015162-57-IT Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
St. Josef Hospital Bochum
2011 Phase 4 NCT01385735 Germany;
TAKEDA PHARMACEUTICAL COMPANY LTD.
2018 - JPRN-JapicCTI-184181 Japan;
TEVA
2005 - EUCTR2005-001416-42-IT Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
Takeda
2018 - NCT03727139 Japan;
Technische Universität Dresden
2011 Phase 4 NCT01442610 Germany;
Teva Branded Pharmaceutical Products R&D, Inc.
2012 Phase 4 NCT01723228 United States;
Teva Neuroscience, Inc.
2009 Phase 4 NCT01049984 United States;
Teva Pharmaceutical Industries
2013 Phase 1 NCT01879748 United States;
Teva Pharmaceutical Industries Ltd
2009 - EUCTR2009-011541-24-IT France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
The Parkinson's Institute
2009 Phase 4 NCT01007630 United States;
Thomas Guttuso
2014 - NCT02278588 United States;
UNIVERSITA` DEGLI STUDI DI PARMA
2009 - EUCTR2009-013004-31-IT Italy;
University of Florida
2016 Phase 2 NCT02789020 United States;
2009 Phase 4 NCT01168596 United States;
University of Zurich
2011 Phase 4 NCT01178047 Switzerland;
Rasagiline 1 mg capsule
Merck Sharp & Dohme Corp.
2010 Phase 3 NCT01155479 Argentina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 Phase 3 NCT01155466 Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Rasagiline 1mg tablet
TEVA Pharmaceuticals Industries Ltd
2006 - EUCTR2006-005140-89-NL Netherlands;
Rasagiline 2 mg tablet
TEVA Pharmaceuticals Industries Ltd
2006 - EUCTR2006-005140-89-NL Netherlands;
Rasagiline Mesylate
Teva Neuroscience, Inc.
1997 Phase 3 NCT00203060 United States;
Teva Pharmaceutical Industries
2005 Phase 3 NCT00256204 Argentina;Austria;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Romania;Spain;United Kingdom;United States;
Rasagiline mesilate
TEVA Pharmaceuticals Industries Ltd
2006 - EUCTR2006-005140-89-NL Netherlands;
Teva Pharmaceuticals Industries LtD
2005 Phase 3 EUCTR2005-001416-42-GB Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-001416-42-ES Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-PT Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-HU Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-DE Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-AT Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
Rasagiline mesylate
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
2011 - EUCTR2009-015162-57-PT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2011 Phase 3 EUCTR2009-015162-57-GB Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-BG Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Merck Sharp & Dohme corp.
2011 Phase 3 EUCTR2009-015162-57-NL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Pharma Two B Ltd
2018 Phase 3 EUCTR2017-001420-21-ES Canada;France;Germany;Spain;United States;
2018 Phase 3 EUCTR2017-001420-21-DE Canada;France;Germany;Spain;United States;
Schering-Plough Research Institute, a division of Schering Corporation
2011 Phase 3 EUCTR2009-015162-57-LV Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-LT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-FI Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-ES Austria;Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2011 Phase 3 EUCTR2009-015162-57-CZ Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-SE Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-PL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-AT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Teva Pharmaceutical Industries
2009 - NCT01032486 Canada;
2009 - NCT00936676 Argentina;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Romania;Spain;United Kingdom;United States;
2004 Phase 3 NCT00203138 United States;
2002 Phase 3 NCT00203164 United States;
2001 Phase 3 NCT00203177 Canada;United States;
2000 Phase 3 NCT00203125 United States;
Teva Pharmaceutical Industries Ltd
2009 Phase 4 EUCTR2009-011541-24-HU France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 Phase 4 EUCTR2009-011541-24-GB Argentina;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Romania;Spain;United Kingdom;United States;
2009 Phase 4 EUCTR2009-011541-24-FR France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 - EUCTR2009-011541-24-PT France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 - EUCTR2009-011541-24-NL France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 - EUCTR2009-011541-24-DE France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
Rasagiline mesylate plus Mirapex
Teva Neuroscience, Inc.
2006 Phase 4 NCT00399477 United States;
Rasagiline mesylate with Levodopa
Teva Neuroscience, Inc.
2006 Phase 4 NCT00399477 United States;
Rasagiline mesylate with Requip
Teva Neuroscience, Inc.
2006 Phase 4 NCT00399477 United States;
Rasagiline tablets
Teva Pharmaceuticals Industries LtD
2005 Phase 3 EUCTR2005-001416-42-GB Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-001416-42-ES Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-PT Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-HU Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-DE Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-AT Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
ReQuip PR
GlaxoSmithKline
2010 Phase 3 NCT01154166 China;
Recombinant human Cerebral Dopamine Neurotrophic Factor
Herantis Pharma Plc
2018 Phase 1;Phase 2 EUCTR2018-000346-19-SE Finland;Sweden;
2018 Phase 1;Phase 2 EUCTR2018-000346-19-FI Finland;Sweden;
2017 Phase 1;Phase 2 EUCTR2015-004175-73-FI Finland;
Renishaw Neuro Solutions Ltd.
2019 Phase 1;Phase 2 EUCTR2017-005170-19-FI Finland;Sweden;
2018 Phase 1;Phase 2 EUCTR2017-005170-19-SE Finland;Sweden;
Recombinant-methionyl human glial cell line-derived neurotrophic factor
National Center for Research Resources (NCRR)
2000 Phase 1 NCT00006488 United States;
Reduced Glutathione
Bastyr University
2015 Phase 2 NCT02424708 United States;
University of Washington
2014 Phase 1 NCT02324426 United States;
Regular Novolin R
HealthPartners Institute
2020 Phase 2 NCT04251585 United States;
Remifentanil
Columbia University
2003 - NCT00615472 United States;
The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
2019 - ChiCTR1900021760 China;
Remifentanyl
West China Hospital, Sichuan University
2016 - ChiCTR-IOR-16010168 China;
Reminyl
Otto-von-Guericke University, Medical Faculty, Dpt. of Neurology
2009 - EUCTR2009-011093-15-DE Germany;
Reminyl Retard
UMCG
2009 - EUCTR2008-006278-13-NL Netherlands;
Renishaw Drug Delivery System
Herantis Pharma Plc.
2018 Phase 1/Phase 2 NCT03775538 Finland;Sweden;
2017 Phase 1/Phase 2 NCT03295786 Finland;Sweden;
Repaglinide
Bial - Portela C S.A.
2009 Phase 1 NCT01536366 Portugal;
Requip
Boehringer Ingelheim
2005 Phase 4 NCT00144300 United States;
Schwarz Biosciences GmbH
2004 - EUCTR2004-002609-66-DE Germany;Italy;
Requip Modutab,
GlaxoSmithKline Research & Development Limited
2013 - EUCTR2011-002828-41-SK Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States;
Requip PR
GlaxoSmithKline
2010 Phase 3 NCT01536574 China;
Rajesh Pahwa, MD
2006 Phase 3 NCT00275275 United States;
Requip XL prolonged-release
University Hospital of North Staffordshire
2013 Phase 4 EUCTR2012-000801-64-GB United Kingdom;
Requip prolonged release
University Hospital of North Staffordshire
2013 Phase 4 EUCTR2012-000801-64-GB United Kingdom;
Requip-Modutab
GlaxoSmithKline Research & Development Limited
2007 - EUCTR2006-006209-94-DE Germany;
Resistant maltodextrin
Northwestern University
2018 Phase 2 NCT03667404 United States;
Resistant starch
Saarland University
2016 - NCT02784145 Germany;
Resistive respiratory loads
University of Florida
2017 - NCT03321019 United States;
Restex Tabletten
BIAL-Portela & Ca, SA
2009 - EUCTR2009-012897-12-RO Romania;
Rifampicin
Kyowa Kirin Co., Ltd.
2019 Phase 1 NCT04070495 Japan;
Rifampin 300mg BID + istradefylline 40mg Day 8 only
Kyowa Hakko Kirin Pharma, Inc.
2014 Phase 1 NCT02174250 United States;
Rifaximin
Mayo Clinic
2012 Phase 3 NCT01662791 United States;
Taipei Medical University Shuang Ho Hospital
2019 Phase 1/Phase 2 NCT03958708 Taiwan;
University of California, San Francisco
2019 Phase 1/Phase 2 NCT03575195 United States;
University of Cincinnati
2015 Phase 2/Phase 3 NCT02470780 United States;
Ritalin
University Medical Center Groningen
2010 - EUCTR2009-012643-42-NL Netherlands;
Rituximab
Prevail Therapeutics
2020 Phase 1/Phase 2 NCT04127578 Israel;United States;
Rivastigmin Luye Transdermal Patches - 4.6mg/24h
University of Bristol
2019 Phase 3 EUCTR2018-003219-23-GB United Kingdom;
Rivastigmine
NOVARTIS FARMA
2008 - EUCTR2007-000350-31-IT France;Italy;Spain;
Novartis Farmacéutica S.A
2008 Phase 3 EUCTR2007-000350-31-ES France;Italy;Spain;
Novartis Pharma AG
2008 - EUCTR2007-000350-31-FR France;Italy;Spain;
Research and Enterprise Department
2012 Phase 2 EUCTR2011-003053-25-GB United Kingdom;
University Hospital, Lille
2009 Phase 3 NCT00767091 France;
VU University Medical Center
2013 Phase 4 NCT01856738 Netherlands;
Rivastigmine CF
VU University Medical Center
2013 Phase 4 EUCTR2013-001722-25-NL Netherlands;
Rivastigmine Luye Transdermal Patch- 9.5mg/24h
University of Bristol
2019 Phase 3 EUCTR2018-003219-23-GB United Kingdom;
Rivastigmine Patch 9.5 cm2
University of California, San Francisco
2010 Phase 4 NCT00988117 United States;
Rivastigmine Transdermal System
University of Bristol
2020 Phase 3 NCT04226248 United Kingdom;
Rivastigmine capsule
Novartis
2008 Phase 3 NCT00623103 Argentina;Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Turkey;United Kingdom;United States;
Rivastigmine transdermal patch
Novartis
2008 Phase 3 NCT00623103 Argentina;Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Turkey;United Kingdom;United States;
University of Maryland, Baltimore
2019 Phase 4 NCT03840837 United States;
Rivastigmine transdermal system 13.3 mg/24 h
University of Bristol
2019 Phase 3 EUCTR2018-003219-23-GB United Kingdom;
Ropinirole
CHU de Toulouse
2009 - EUCTR2009-012529-12-FR France;
GlaxoSmithKline
2010 Phase 1 NCT01435915 China;
2007 Phase 2 NCT00460148 Germany;South Africa;
2003 Phase 3 NCT00381472 Belgium;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
GlaxoSmithKline Research & Development Limited
2007 - EUCTR2006-006209-94-DE Germany;
Kansai Medical University
2010 - JPRN-UMIN000003601 Japan;
Otsuka Pharmaceutical Co., Ltd.
2009 Phase 3 NCT01628926 Japan;
2009 Phase 3 JPRN-JapicCTI-090888 -
Pfizer
2001 Phase 3 NCT00036218 Argentina;Mexico;Puerto Rico;United States;
SCHWARZ PHARMA
2004 - EUCTR2004-002609-66-IT Germany;Italy;
Schwarz Biosciences GmbH
2004 - EUCTR2004-002609-66-DE Germany;Italy;
UNIVERSITA` DEGLI STUDI DI PARMA
2009 - EUCTR2009-013004-31-IT Italy;
Ropinirole (as hydrochloride)
University Hospital of North Staffordshire
2013 Phase 4 EUCTR2012-000801-64-GB United Kingdom;
Ropinirole CR 2mg tablet
GlaxoSmithKline
2013 Phase 3 NCT01929317 Japan;
Ropinirole CR 8mg tablet
GlaxoSmithKline
2013 Phase 3 NCT01929317 Japan;
Ropinirole Hydrochloride
Agarwal, Pinky, M.D.
2005 Phase 3 NCT00260793 United States;
Roxane Laboratories
2004 - NCT00674310 -
2004 - NCT00673088 -
Ropinirole IR
GlaxoSmithKline
2009 Phase 3 NCT00823836 Japan;
Ropinirole IR Tablets
GlaxoSmithKline
2006 Phase 3 EUCTR2005-005423-34-ES Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
GlaxoSmithKline Research & Development Ltd
2006 Phase 3 EUCTR2005-005423-34-GB Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-005423-34-HU Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-005423-34-DE Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-005423-34-CZ Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
Ropinirole Implant
Titan Pharmaceuticals
2017 Phase 1/Phase 2 NCT03250117 United States;
Ropinirole PR,
GlaxoSmithKline Research & Development Limited
2013 - EUCTR2011-002828-41-SK Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States;
2013 - EUCTR2011-002828-41-EE Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States;
2013 - EUCTR2011-002827-17-SK Estonia;Korea, Republic of;Russian Federation;Slovakia;United States;
2013 - EUCTR2011-002827-17-EE Estonia;Korea, Republic of;Russian Federation;Slovakia;United States;
Ropinirole PR/XR
GlaxoSmithKline
2009 Phase 3 NCT00823836 Japan;
Ropinirole PR/XR Tablets
GlaxoSmithKline
2006 Phase 3 EUCTR2005-005423-34-ES Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
GlaxoSmithKline Research & Development Ltd
2006 Phase 3 EUCTR2005-005423-34-GB Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-005423-34-HU Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-005423-34-DE Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-005423-34-CZ Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
Ropinirole PR/XR tablets
GlaxoSmithKline R D
2006 - EUCTR2005-005423-34-IT Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
Ropinirole Prolonged release
Seoul National University Hospital
2009 Phase 4 NCT00986245 Korea, Republic of;
Ropinirole XL
GlaxoSmithKline
2009 Phase 1 NCT01371682 Belgium;
Ropinirole XL (formerly CR)
GlaxoSmithKline
2004 Phase 3 NCT00632736 Belgium;Czech Republic;France;Germany;Hungary;Italy;Philippines;Poland;Spain;United Kingdom;United States;
2002 Phase 3 NCT00650104 Belgium;France;Netherlands;Norway;United States;
Ropinirole controlled-release (REQUIP CR) for RLS
GlaxoSmithKline
2003 Phase 3 NCT00363727 United States;
Ropinirole hydrochloride
GlaxoSmithKline
2006 Phase 3 EUCTR2005-005423-34-ES Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
GlaxoSmithKline Research & Development Ltd
2006 Phase 3 EUCTR2005-005423-34-GB Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-005423-34-HU Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-005423-34-DE Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2005-005423-34-CZ Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
Ropinirole hydrochloride extended-release tablet placebo
Hisamitsu Pharmaceutical Co.,Inc.
2015 Phase 3 JPRN-JapicCTI-152870 -
Ropinirole hydrochloride prolonged release
University Hospital of North Staffordshire
2013 Phase 4 EUCTR2012-000801-64-GB United Kingdom;
Ropinirole immediate release
GlaxoSmithKline
2006 Phase 3 NCT00331149 Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
Ropinirole monotherapy
GlaxoSmithKline
2012 Phase 4 NCT01485172 Estonia;Korea, Republic of;Poland;Russian Federation;Slovakia;United States;
Ropinirole oral product
Titan Pharmaceuticals
2017 Phase 1/Phase 2 NCT03250117 United States;
Ropinirole prolonged release
GlaxoSmithKline
2006 Phase 3 NCT00331149 Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
Ropinirole prolonged release/extended release(PR/XR)
GlaxoSmithKline
2007 Phase 2 NCT00434304 Japan;
Ropinirole/L-dopa
GlaxoSmithKline
2012 Phase 4 NCT01494532 Argentina;Chile;Estonia;Korea, Republic of;Poland;Russian Federation;Slovakia;United States;
Rosuvastatin
Kyowa Kirin Co., Ltd.
2019 Phase 1 NCT03970798 Japan;
Rotigotin
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2011 - EUCTR2010-022363-35-DE Germany;
Rotigotina
FONDAZIONE SANTA LUCIA
2012 - EUCTR2012-001218-40-IT Italy;
Rotigotine
Azienda Ospedaliera Cardinale G. Panico
2013 Phase 2 NCT02103465 Italy;
Department of Neurology, Changzheng Hospital, Second Military Medical University
2016 - ChiCTR-CPC-15007223 China;
Ospedale Generale Di Zona Moriggia-Pelascini
2013 - NCT02100176 Italy;
Research and Development University Hospital of North Staffordshire
2014 - EUCTR2014-000335-17-GB United Kingdom;
SCHWARZ BIOSCIENCES
2005 Phase 3 EUCTR2004-002650-59-GB United Kingdom;
SCHWARZ PHARMA
2007 - EUCTR2006-006907-35-IT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2004 - EUCTR2004-002609-66-IT Germany;Italy;
2004 - EUCTR2004-000148-26-IT Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
SCHWARZ PHARMA Deutschland GmbH
2007 - EUCTR2006-005438-19-DE Germany;
Schwarz BioSciences Inc.
2008 - EUCTR2004-000148-26-HU Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2008 - EUCTR2004-000148-26-AT Austria;Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 Phase 3 EUCTR2004-000148-26-ES Austria;Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 - EUCTR2004-000148-26-SE Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 - EUCTR2004-000148-26-FI Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 - EUCTR2004-000148-26-CZ Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
Schwarz Biosciences GmbH
2008 - EUCTR2006-006752-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006907-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-ES Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006907-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-HU Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-FI Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 - EUCTR2006-006752-35-AT Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-002641-12-GB Austria;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-002641-12-ES Austria;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-002598-21-GB Austria;United Kingdom;
2005 - EUCTR2004-002641-12-AT Austria;Italy;Spain;United Kingdom;
2004 - EUCTR2004-002609-66-DE Germany;Italy;
2004 - EUCTR2004-002598-21-AT Austria;United Kingdom;
- - EUCTR2006-006907-35-DE Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Schwarz Biosciences GmbH, UCB Group
2007 Phase 3 EUCTR2006-006907-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-006752-35-GB Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom;
Shandong Luye Pharmaceutical Co., Ltd./CMIC Co., Ltd.
2019 Phase 1 JPRN-JapicCTI-194763 Japan;
UCB BIOSCIENCES GmbH
2013 Phase 4 NCT01782222 Austria;Hungary;Poland;Slovakia;Slovenia;Spain;United States;
2012 Phase 4 NCT01744496 Germany;Hungary;Korea, Republic of;Poland;Slovakia;United States;
2012 Phase 4 NCT01711866 Korea, Republic of;Malaysia;Singapore;Taiwan;United States;
2012 Phase 3 NCT01723904 Australia;Korea, Republic of;Malaysia;Singapore;Taiwan;
UCB Korea Co., Ltd.
2012 Phase 4 NCT01523301 Korea, Republic of;
UCB Pharma
2012 Phase 3 NCT01646268 China;
2012 Phase 3 NCT01646255 China;
2012 Phase 3 NCT01536015 United States;
2011 Phase 4 NCT01300819 Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Hungary;Italy;Romania;Slovakia;Spain;Switzerland;
2007 Phase 4 NCT00594464 Germany;
2007 Phase 3 NCT00593606 -
2007 Phase 3 NCT00522379 Chile;India;Mexico;Peru;United States;
2007 Phase 3 NCT00519532 Australia;Austria;Finland;Germany;Hungary;Italy;New Zealand;Poland;South Africa;Spain;United Kingdom;United States;
2007 Phase 3 NCT00474058 Australia;Austria;Finland;Germany;Hungary;Italy;New Zealand;Poland;South Africa;Spain;United Kingdom;United States;
2006 Phase 1 NCT01964573 Korea, Republic of;
2006 Phase 1 NCT00292227 South Africa;
2005 Phase 3 NCT00505687 Austria;Germany;Israel;Italy;South Africa;Spain;United Kingdom;United States;
2004 Phase 3 NCT00501969 Australia;Austria;Croatia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;New Zealand;Norway;Poland;South Africa;Spain;Sweden;United Kingdom;
2004 Phase 3 NCT00243945 Germany;
2004 Phase 3 NCT00242008 United States;
2002 Phase 3 NCT00599196 Australia;Austria;Belgium;Croatia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;South Africa;Spain;Sweden;Switzerland;United Kingdom;
2002 Phase 3 NCT00594386 Canada;United States;
2002 Phase 3 NCT00594165 Canada;United States;
UCB Pharma SA
2012 Phase 4 NCT01519882 United Kingdom;
2011 - EUCTR2010-021394-37-IT Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;
Unità Malattie Neurodegenerative, Ospedale Cardinale Giovanni Panico, Tricase
2013 - EUCTR2013-000827-15-IT Italy;
University Hospital, Grenoble
2012 Phase 3 NCT02786667 France;
Wakayama Medical University
2018 Phase 1 JPRN-UMIN000033409 Japan;
Rotigotine (Reference product PR 2.1.1)
UCB BIOSCIENCES GmbH
2014 Phase 1 NCT02230904 Germany;
Rotigotine (Test product PR 2.3.1)
UCB BIOSCIENCES GmbH
2014 Phase 1 NCT02230904 Germany;
Rotigotine Nasal Spray
Schwarz Biosciences GmbH
2006 Phase 2 EUCTR2005-004290-19-GB Austria;Germany;Spain;United Kingdom;
2006 - EUCTR2005-004290-19-DE Germany;Spain;United Kingdom;
2005 - EUCTR2005-004290-19-AT Austria;Germany;Spain;United Kingdom;
Rotigotine TTS (Test)
Sandoz
2019 Phase 1 NCT04183634 Germany;
Rotigotine hydrochloride
Schwarz Biosciences GmbH
2006 Phase 2 EUCTR2005-004290-19-GB Austria;Germany;Spain;United Kingdom;
2006 - EUCTR2005-004290-19-DE Germany;Spain;United Kingdom;
2005 - EUCTR2005-004290-19-AT Austria;Germany;Spain;United Kingdom;
Rotigotine nasal spray
UCB Pharma
2006 Phase 2 NCT00296192 Germany;
Rotigotine transdermal patch
Johns Hopkins University
2016 Phase 4 NCT02365870 United States;
UCB Pharma
2011 Phase 1 NCT01338896 Austria;Germany;United Kingdom;
Rotigotine transdermal patch 2mg/24h(10cm2)
Schwarz Pharma Deutschland GmbH, UCB Group
- - EUCTR2009-014341-84-DE Germany;
Rotigotine transdermal patch 4mg/24h (20cm2)
Schwarz Pharma Deutschland GmbH, UCB Group
- - EUCTR2009-014341-84-DE Germany;
Rotigotine transdermal patch 6mg/24h (30cm2)
Schwarz Pharma Deutschland GmbH, UCB Group
- - EUCTR2009-014341-84-DE Germany;
Rotigotine transdermal patch 8mg/24h (40cm2)
Schwarz Pharma Deutschland GmbH, UCB Group
- - EUCTR2009-014341-84-DE Germany;
Rotigotine, extended-release microspheres
Luye Pharma Group Ltd.
2013 Phase 1 NCT04044547 -
Rytary
Impax Laboratories, LLC
2015 Phase 2 NCT02271503 United States;
S 90049
Institut de Recherches Internationales Servier (I.R.I.S.)
2005 - EUCTR2005-002010-38-DE Germany;
S 90049 - F36
Institut de Recherches Internationales Servier
2005 Phase 2 EUCTR2005-000314-12-ES Germany;Spain;
S 90049 - F38
Institut de Recherches Internationales Servier
2005 Phase 2 EUCTR2005-000314-12-ES Germany;Spain;
S.c. apomorphine
SUNOVION PHARMACEUTICALS INC
2018 Phase 3 EUCTR2016-003456-70-IT Austria;France;Germany;Italy;Spain;United Kingdom;
Sunovion Pharmaceuticals Inc.
2018 Phase 3 EUCTR2016-003456-70-ES Austria;Spain;United Kingdom;
2018 Phase 3 EUCTR2016-003456-70-DE Austria;France;Germany;Italy;Spain;United Kingdom;
2018 Phase 3 EUCTR2016-003456-70-AT Austria;France;Germany;Italy;Spain;United Kingdom;
2017 Phase 3 EUCTR2016-003456-70-GB Austria;France;Germany;Italy;Spain;United Kingdom;
S90049
Institut de Recherches Internationales Servier
2006 Phase 2 EUCTR2005-000314-12-DE Germany;Spain;
SA
HKBU School of Chinese Medicine
2017 - ChiCTR-IPR-17011987 China;
SAFINAMIDE METANSOLFONATO
OSPEDALE SANTA MARIA DELLA MISERICORDIA
2021 Phase 3 EUCTR2018-004892-11-IT Italy;
ZAMBON SPA
2019 Phase 4 EUCTR2017-002426-20-IT Austria;France;Germany;Italy;Spain;
2015 Phase 3 EUCTR2014-002600-24-IT Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
SAFINAMIDE METHANESULFONATE
ZAMBON SPA
2019 Phase 4 EUCTR2017-002426-20-IT Austria;France;Germany;Italy;Spain;
Zambon SpA
2019 Phase 4 EUCTR2017-002426-20-FR Austria;France;Spain;
2019 Phase 4 EUCTR2017-002426-20-AT Austria;Spain;
2018 Phase 4 EUCTR2017-002426-20-ES Spain;
SAGE-217
Sage Therapeutics
2016 Phase 2 NCT03000569 United States;
SAGE-718
Sage Therapeutics
2020 Phase 2 NCT04476017 United States;
SAM
Shenzhen People's Hospital
2017 - ChiCTR1800019216 China;
University of Valencia
2020 - NCT04353947 Spain;
SAM-e
New York University School of Medicine
2003 Phase 2/Phase 3 NCT00070941 United States;
SAR402671, GZ402671 or GZ/SAR402671
Genzyme Corporation
2019 Phase 2 EUCTR2016-000657-12-GR Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2016-000657-12-AT Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000657-12-PT Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000657-12-IT Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000657-12-DE Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000657-12-SE Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000657-12-ES Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
SCH 420814
Merck Sharp & Dohme Corp.
2009 Phase 1 NCT00845000 United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
2011 - EUCTR2009-015161-31-DE Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
2011 Phase 3 EUCTR2009-013552-72-GB Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015162-57-PT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015161-31-PT Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2011 Phase 3 EUCTR2009-015162-57-GB Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-BG Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015161-31-GB Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015161-31-BG Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-013552-72-BG Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
- - EUCTR2009-013552-72-DE Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Merck Sharp & Dohme corp.
2011 Phase 3 EUCTR2009-015162-57-NL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Schering Corporation, división Schering-Plough Research
2010 Phase 3 EUCTR2009-013552-72-ES Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
Schering Plough Research Institute
2007 - EUCTR2007-001717-42-FR France;Spain;
2006 - EUCTR2005-005146-39-IT Italy;
Schering-Plough Research Institute, a division of Schering Corporation
2011 Phase 3 EUCTR2009-015162-57-LV Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-LT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-FI Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-015162-57-ES Austria;Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2011 Phase 3 EUCTR2009-015162-57-CZ Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2009-013552-72-CZ Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2010-020112-11-LV Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States;
2011 - EUCTR2010-020112-11-LT Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States;
2011 - EUCTR2009-015162-57-SE Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-PL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015162-57-AT Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2009-015161-31-PL Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-015161-31-CZ Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2011 - EUCTR2009-013552-72-PL Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 Phase 3 EUCTR2009-015161-31-FR Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2009-013552-72-HU Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2009-013552-72-FI Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-SE Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-NL Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-FI Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-015161-31-AT Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
2010 - EUCTR2009-013552-72-SE Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
SCH 900800
Merck Sharp & Dohme Corp.
2013 Phase 1 NCT01500707 -
SCH420814
Schering-Plough Research Institute, a division of Schering Corporation
2010 Phase 3 EUCTR2009-015161-31-IT Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
2010 - EUCTR2009-013552-72-IT Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
Schering-Plough Research Institute, division of Schering Corporation
2011 - EUCTR2009-015162-57-IT Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;
SEP-363856
Sunovion
2016 Phase 2 NCT02969369 United States;
SER-214
Serina Therapeutics
2016 Phase 1 NCT02579473 United States;
SIFROL
Boehringer Ingelheim AB
2007 - EUCTR2007-000074-23-SE Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Limited
2007 - EUCTR2007-000074-23-GB Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Pharma Ges mbH
2007 Phase 3 EUCTR2007-000074-23-SK Austria;Czech Republic;Hungary;Italy;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-000074-23-HU Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Pharma GmbH & Co. KG
2007 - EUCTR2007-000074-23-AT Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim RCV GmbH & Co KG
2007 Phase 3 EUCTR2007-000074-23-CZ Austria;Czech Republic;Hungary;Italy;Spain;Sweden;United Kingdom;
SINEMET
EISAI LTD UK
2007 - EUCTR2006-005714-12-IT Italy;
Institute for Neurodegenerative Disorders
2005 - EUCTR2004-001485-41-ES Spain;United Kingdom;
SINEMET - 100 MG + 25 MG COMPRESSE 50 COMPRESSE DIVISIBILI
INTEC PHARMA LTD
2018 Phase 2 EUCTR2018-001209-95-IT Italy;Spain;
SINEMET 10-100
Intec Pharma, Ltd.
2016 Phase 3 EUCTR2015-003512-20-SK Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-HU Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-ES Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
SINEMET 100 mg + 25 mg compresse
BIAL-Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-002754-24-IT Germany;Italy;Portugal;Spain;United Kingdom;
SynAgile Corporation
2014 Phase 2 EUCTR2014-002295-87-IT Italy;
SINEMET 100 mg + 25 mg tablets
BIAL-Portela & Ca, S.A.
2021 Phase 4 EUCTR2020-002754-24-IT Germany;Italy;Portugal;Spain;United Kingdom;
Bial - Portela & Ca, S.A.
2022 Phase 4 EUCTR2020-002754-24-DE Germany;Italy;Portugal;Spain;United Kingdom;
2021 Phase 4 EUCTR2020-002754-24-ES Germany;Italy;Portugal;Spain;United Kingdom;
SINEMET 125
Centre for Human Drug Research
2020 Phase 2 EUCTR2020-000686-16-NL Netherlands;
SINEMET 25-100
INTEC PHARMA LTD
2016 Phase 3 EUCTR2015-003512-20-IT Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Intec Pharma, Ltd.
2016 Phase 3 EUCTR2015-003512-20-SK Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-PL Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-HU Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-GB Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003512-20-ES Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
SINEMET 25/100
BIAL-Portela & Ca, SA
2009 - EUCTR2009-012897-12-RO Romania;
Bial - Portela & Cª, S.A.
2008 - EUCTR2008-003869-72-PT Portugal;
SINEMET CR
Novartis Pharma AG
2006 - EUCTR2005-001032-72-CZ Czech Republic;Italy;Portugal;
SINEMET Plus
NEURODERM LTD.
2018 Phase 3 EUCTR2017-002780-17-IT Austria;France;Italy;Netherlands;Spain;United States;
NeuroDerm Ltd.
2018 Phase 3 EUCTR2017-002780-17-FR Austria;France;Italy;Netherlands;Spain;United States;
2018 Phase 3 EUCTR2017-002780-17-ES Austria;France;Italy;Netherlands;Spain;United States;
SINEMET*50CPR 100MG+
VERNALIS DEVELOPMENT LIMITED
2006 - EUCTR2006-004112-51-IT Italy;
SINEMET® Plus 25 mg/100 mg Tablets
Civitas Therapeutics, Inc.
2012 - EUCTR2012-000181-37-GB Israel;Serbia;United Kingdom;
SINEMET®-Plus Tablets
Impax Laboratories, Inc.
2010 - EUCTR2009-014688-37-PL France;Germany;Poland;Spain;
2009 Phase 3 EUCTR2009-014688-37-FR France;Germany;Poland;Spain;
2009 - EUCTR2009-014688-37-DE France;Germany;Poland;Spain;
SIRIO*30CPR EFF 25MG+
VERNALIS DEVELOPMENT LIMITED
2006 - EUCTR2006-004112-51-IT Italy;
SK&F101468
GlaxoSmithKline Research & Development Limited
2013 - EUCTR2011-002828-41-SK Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States;
2013 - EUCTR2011-002828-41-EE Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States;
2013 - EUCTR2011-002827-17-SK Estonia;Korea, Republic of;Russian Federation;Slovakia;United States;
2013 - EUCTR2011-002827-17-EE Estonia;Korea, Republic of;Russian Federation;Slovakia;United States;
2007 - EUCTR2006-006209-94-DE Germany;
SKF-101468A
GlaxoSmithKline R D
2006 - EUCTR2005-005423-34-IT Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
SLV308
SOLVAY PHARMACEUTICALS B.V.
2009 - EUCTR2008-000400-81-IT Germany;Italy;Portugal;
Solvay Pharmaceuticals
2009 Phase 3 EUCTR2007-001095-36-SK Hungary;Slovakia;
2008 Phase 3 EUCTR2007-001096-10-SK Hungary;Slovakia;
2008 - EUCTR2007-001096-10-HU Hungary;
2008 - EUCTR2007-001095-36-HU Hungary;
2005 Phase 3 NCT00134251 Bulgaria;Former Serbia and Montenegro;Malta;Serbia;
SLV308 (mono) hydro
Solvay pharmaceuticals
2006 Phase 3 EUCTR2006-000678-57-GB Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
SLV308 (mono) hydrochlo
Solvay Pharmaceuticals
2006 Phase 3 EUCTR2006-000858-45-SK Finland;Slovakia;Sweden;
SLV308 (mono) hydrochlori
Solvay Pharmaceuticals
2006 - EUCTR2006-000859-18-CZ Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
Solvay pharmaceuticals
2007 - EUCTR2006-000859-18-PT Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
2007 - EUCTR2006-000859-18-NL Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
2007 - EUCTR2006-000678-57-CZ Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
2006 - EUCTR2006-000859-18-LT Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
2006 - EUCTR2006-000859-18-EE Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
2006 - EUCTR2006-000678-57-NL Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
2006 - EUCTR2006-000678-57-LT Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
2006 - EUCTR2006-000678-57-EE Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
2006 - EUCTR2006-000678-57-DE Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
Solvay pharmaceuticals B.V.
2006 - EUCTR2006-000678-57-PT Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
SLV308 (mono) hydrochloride
Solvay Pharmaceuticals
2007 - EUCTR2006-000858-45-SE Finland;Sweden;
2006 Phase 3 EUCTR2006-000858-45-SK Finland;Slovakia;Sweden;
2006 - EUCTR2006-000859-18-CZ Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
2006 - EUCTR2006-000858-45-FI Finland;Sweden;
2006 - EUCTR2005-006033-32-SK Finland;Slovakia;Sweden;
2006 - EUCTR2005-006033-32-SE Finland;Slovakia;Sweden;
2006 - EUCTR2005-006033-32-FI Finland;Slovakia;Sweden;
2005 - EUCTR2005-002432-10-MT Malta;
Solvay pharmaceuticals
2007 Phase 3 EUCTR2006-000678-57-FR Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
2007 - EUCTR2006-000859-18-PT Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
2007 - EUCTR2006-000859-18-NL Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
2007 - EUCTR2006-000859-18-DE Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
2007 - EUCTR2006-000678-57-CZ Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
2006 Phase 3 EUCTR2006-000678-57-GB Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
2006 - EUCTR2006-000859-18-LT Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
2006 - EUCTR2006-000859-18-EE Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal;
2006 - EUCTR2006-000678-57-NL Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
2006 - EUCTR2006-000678-57-LT Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
2006 - EUCTR2006-000678-57-EE Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
2006 - EUCTR2006-000678-57-DE Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
Solvay pharmaceuticals B.V.
2006 - EUCTR2006-000678-57-PT Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
SLV308 (mono)hydrochloride
SOLVAY PHARMACEUTICALS B.V.
2006 - EUCTR2006-000678-57-IT Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
SLV308 hydrochloride
Abbott Healthcare Products B.V.
2009 - EUCTR2008-000400-81-DE Germany;Italy;Portugal;
Solvay Pharmaceuticals B.V.
2008 Phase 2 EUCTR2008-004943-12-SK Slovakia;
Solvay Pharmaceuticals BV
2009 - EUCTR2008-000400-81-PT Germany;Italy;Portugal;
SLV308(mono)hydrochloride
Solvay Pharmaceuticals
2007 - EUCTR2006-005183-91-LV Latvia;Lithuania;
2007 - EUCTR2006-005183-91-LT Latvia;Lithuania;
2007 - EUCTR2006-005182-20-LV Latvia;Lithuania;
2007 - EUCTR2006-005182-20-LT Latvia;Lithuania;
SND 919 CL2 Y
BOEHRINGER INGELHEIM
2008 Phase 3 EUCTR2007-004234-16-FR Austria;Czech Republic;Finland;France;Hungary;Netherlands;Slovakia;
2007 Phase 3 EUCTR2007-003353-90-FR France;Germany;Netherlands;
Boehringer Ingelheim
2008 - EUCTR2007-004235-37-GB Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-003353-90-NL France;Germany;Netherlands;
2006 Phase 4 EUCTR2005-004949-34-FI Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim AB
2008 - EUCTR2007-004235-37-SE Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2006 Phase 4 EUCTR2005-004949-34-SE Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003788-22-SE Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Austria GmbH
2006 - EUCTR2005-004949-34-AT Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003788-22-AT Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim España S.A.
2006 Phase 4 EUCTR2005-003788-22-ES Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim España, S.A.
2008 Phase 3 EUCTR2007-004235-37-ES Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004949-34-ES Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Finland Ky
2008 - EUCTR2007-004234-16-FI Austria;Czech Republic;Finland;France;Hungary;Netherlands;
2007 - EUCTR2007-000073-39-FI Austria;Czech Republic;Finland;Hungary;
Boehringer Ingelheim Limited
2006 Phase 4 EUCTR2005-003788-22-GB Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Ltd
2006 Phase 4 EUCTR2005-004949-34-GB Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Pharma Ges mbH
2008 Phase 3 EUCTR2007-004235-37-HU Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-004235-37-PL Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-004235-37-CZ Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-004234-16-HU Austria;Czech Republic;Finland;France;Hungary;Netherlands;
2007 Phase 3 EUCTR2007-000073-39-SK Austria;Czech Republic;Finland;Germany;Hungary;Slovakia;
2007 - EUCTR2007-000073-39-HU Austria;Czech Republic;Finland;Hungary;
2007 - EUCTR2007-000073-39-AT Austria;Czech Republic;Finland;Hungary;
Boehringer Ingelheim Pharma GmbH & Co. KG
2007 - EUCTR2007-003353-90-DE France;Germany;Netherlands;
2007 - EUCTR2007-000073-39-DE Austria;Czech Republic;Finland;Germany;Hungary;
2006 - EUCTR2005-004949-34-DE Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003788-22-DE Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim RCV GmbH & Co KG
2009 - EUCTR2007-004235-37-AT Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2009 - EUCTR2007-004234-16-AT Austria;Czech Republic;Finland;France;Hungary;Netherlands;
2008 Phase 3 EUCTR2007-004235-37-SK Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom;
2008 Phase 3 EUCTR2007-004234-16-SK Austria;Czech Republic;Finland;France;Hungary;Netherlands;Slovakia;
2008 - EUCTR2007-004234-16-CZ Austria;Czech Republic;Finland;France;Hungary;Netherlands;
2007 - EUCTR2007-000073-39-CZ Austria;Czech Republic;Finland;Hungary;
Boehringer Ingelheim bv
2007 - EUCTR2007-004234-16-NL Austria;Czech Republic;Finland;France;Hungary;Netherlands;
SND 919 CL2Y
BOEHRINGER ING.
2008 - EUCTR2007-004235-37-IT Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-000074-23-IT Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim AB
2007 - EUCTR2007-000074-23-SE Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim España, S.A.
2007 Phase 3 EUCTR2007-000074-23-ES Austria;Czech Republic;Hungary;Italy;Slovakia;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Limited
2007 - EUCTR2007-000074-23-GB Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Pharma Ges mbH
2007 Phase 3 EUCTR2007-000074-23-SK Austria;Czech Republic;Hungary;Italy;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-000074-23-HU Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Pharma GmbH & Co. KG
2007 - EUCTR2007-000074-23-AT Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim RCV GmbH & Co KG
2007 Phase 3 EUCTR2007-000074-23-CZ Austria;Czech Republic;Hungary;Italy;Spain;Sweden;United Kingdom;
SNN0031
NeuroNova AB
2009 - EUCTR2007-007853-30-SE Sweden;
Newron Sweden AB
2013 Phase 1 NCT01829867 Sweden;
2009 Phase 1/Phase 2 NCT00866502 Sweden;
SOLIGEN
Institute for Neurodegenerative Disorders
2005 - EUCTR2004-001485-41-ES Spain;United Kingdom;
SPECT
Zionexa
2021 Phase 3 NCT04265209 -
SPECT imaging
Tel-Aviv Sourasky Medical Center
2013 Phase 2 NCT01931488 Israel;
SPM 926
SCHWARZ PHARMA
2004 - EUCTR2004-002609-66-IT Germany;Italy;
SPM 962
Otsuka Pharmaceutical Co., Ltd.
2009 Phase 3 NCT01631825 Japan;
2009 Phase 3 NCT01628926 Japan;
2009 Phase 3 JPRN-JapicCTI-090888 -
2008 Phase 2/Phase 3 NCT01628965 Japan;
2007 Phase 2/Phase 3 NCT00537485 Japan;
2006 Phase 2 NCT01631812 Japan;
2006 Phase 2 NCT01628848 Japan;
2005 Phase 2 NCT01634243 Japan;
SCHWARZ BIOSCIENCES
2005 Phase 3 EUCTR2004-002650-59-GB United Kingdom;
SCHWARZ PHARMA
2004 - EUCTR2004-002609-66-IT Germany;Italy;
Schwarz BioSciences Inc.
2008 - EUCTR2004-000148-26-HU Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2008 - EUCTR2004-000148-26-AT Austria;Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 Phase 3 EUCTR2004-000148-26-ES Austria;Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 - EUCTR2004-000148-26-SE Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 - EUCTR2004-000148-26-FI Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
2004 - EUCTR2004-000148-26-CZ Czech Republic;Finland;Hungary;Italy;Spain;Sweden;
Schwarz Biosciences GmbH
2005 Phase 3 EUCTR2004-002641-12-GB Austria;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-002641-12-ES Austria;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-002598-21-GB Austria;United Kingdom;
2005 - EUCTR2004-002641-12-AT Austria;Italy;Spain;United Kingdom;
2004 - EUCTR2004-002598-21-AT Austria;United Kingdom;
UCB Pharma
2004 Phase 3 NCT00244387 Germany;
2004 Phase 3 NCT00243971 Germany;
SPM962
Schwarz Biosciences GmbH
2004 - EUCTR2004-002609-66-DE Germany;Italy;
Unità Malattie Neurodegenerative, Ospedale Cardinale Giovanni Panico, Tricase
2013 - EUCTR2013-000827-15-IT Italy;
SQJZ herbal mixtures
Dongzhimen Hospital, Beijing
2015 Phase 2 NCT02616120 China;
SR57667B
Sanofi
2004 Phase 2 NCT00220272 Canada;Finland;France;Netherlands;Spain;Switzerland;United Kingdom;
2003 Phase 2 NCT00228150 Austria;Canada;Denmark;France;Germany;Morocco;Netherlands;Portugal;South Africa;Spain;Sweden;Tunisia;United Kingdom;
STALEVO*100CPR 100/25/
AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
2010 - EUCTR2010-019396-29-IT Italy;
STALEVO*100CPR 50/12,5/
AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
2010 - EUCTR2010-019396-29-IT Italy;
SYN115
BIOTIE THERAPIES INC.
2015 Phase 3 EUCTR2014-005630-60-IT Austria;Canada;Czech Republic;Germany;Italy;Spain;United States;
Biotie Therapies Inc.
2015 Phase 3 EUCTR2014-005630-60-ES Austria;Canada;Czech Republic;European Union;Germany;Spain;United States;
Biotie Therapies Inc. (a wholly owned subsidiary of Acorda Therapeutics Inc.)
2015 Phase 3 EUCTR2014-005630-60-CZ Austria;Canada;Czech Republic;European Union;Germany;Spain;United States;
Biotie Therapies Inc.(a wholly owned subsidiary of Acorda Therapeutics Inc.)
2016 Phase 3 EUCTR2014-005630-60-AT Austria;Canada;Czech Republic;European Union;Germany;Spain;United States;
2015 Phase 3 EUCTR2014-005630-60-DE Austria;Canada;Czech Republic;European Union;Germany;Spain;United States;
SYN115 Tablets,
Biotie Therapies Inc.
2012 - EUCTR2011-005054-59-RO Argentina;Canada;Chile;Romania;Ukraine;United States;
SYN120
Biotie Therapies Inc.
2014 Phase 2 NCT02258152 United States;
Safety observation
Amgen
2005 - NCT00148369 Canada;United Kingdom;United States;
Safinamida
Merck Serono S.A. - Geneva
2010 - EUCTR2010-020109-34-ES Italy;Spain;
Safinamide
Alain Kaelin
2019 Phase 4 NCT03968744 Switzerland;
IRCCS San Raffaele
2018 Phase 4 NCT03843944 Italy;
MERCK SERONO INTERNATIONAL SA
2008 Phase 3 EUCTR2007-002963-28-IT Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
MERCK SERONO SA
2009 Phase 3 EUCTR2008-004146-88-IT Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
2009 - EUCTR2008-002769-30-IT Italy;
Merck Serono International S.A.
2008 Phase 3 EUCTR2007-002963-28-ES Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
2008 - EUCTR2007-002964-90-ES Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2007 - EUCTR2007-002964-90-NL Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2007 - EUCTR2007-002964-90-FI Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Merck Serono S.A - Geneva
2008 Phase 3 EUCTR2007-002964-90-GB Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom;
Merck Serono S.A-Geneva
2009 - EUCTR2007-002963-28-PT Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
Merck Serono S.A. - Geneva
2011 - EUCTR2009-017174-20-AT Austria;Canada;France;Germany;South Africa;
2010 Phase 3 EUCTR2008-005492-94-BE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
2010 Phase 2 EUCTR2009-017174-20-FR Austria;France;Germany;
2010 - EUCTR2009-017174-20-DE Austria;Canada;France;Germany;South Africa;
2010 - EUCTR2008-005492-94-NL Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
2010 - EUCTR2007-002964-90-CZ Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-005492-94-SK Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-005492-94-GB Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-005492-94-FR Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-005492-94-ES Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
2009 - EUCTR2008-005492-94-HU Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 - EUCTR2007-002964-90-FR Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-002964-90-DE Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
2007 Phase 3 EUCTR2007-002964-90-SK Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom;
2007 Phase 3 EUCTR2007-002963-28-SK Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
Merck Serono S.A.-Geneva
2008 - EUCTR2007-002964-90-HU Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom;
Merck Serono SA - Geneva
2009 Phase 3 EUCTR2008-004146-88-SK Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
2009 Phase 3 EUCTR2008-004146-88-ES Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain;
2009 Phase 3 EUCTR2008-001966-10-SK Austria;Estonia;Hungary;Slovakia;United Kingdom;
2009 - EUCTR2008-004146-88-PT Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
2009 - EUCTR2008-004146-88-PL Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
2009 - EUCTR2008-001966-10-HU Austria;Estonia;Hungary;United Kingdom;
2009 - EUCTR2008-001966-10-GB Austria;Estonia;Hungary;United Kingdom;
2009 - EUCTR2008-001966-10-EE Austria;Estonia;Hungary;United Kingdom;
2009 - EUCTR2008-001966-10-AT Austria;Estonia;Hungary;United Kingdom;
NEWRON PHARMACEUTICALS
2007 - EUCTR2006-005861-21-IT Italy;
2006 - EUCTR2006-005860-14-IT Italy;
2004 - EUCTR2004-000835-27-IT Italy;Spain;
2004 - EUCTR2004-000833-12-IT Italy;Spain;
Newron
2011 Phase 2 NCT01264861 United States;
2010 Phase 2 NCT01211587 Spain;United States;
2010 Phase 2 NCT01113320 Austria;Canada;France;Germany;South Africa;
2009 Phase 3 NCT00865579 Romania;
2007 Phase 3 NCT01286935 -
2007 Phase 3 NCT01187966 -
2005 Phase 3 NCT00642889 -
2004 Phase 3 NCT00643045 -
Newron Pharmaceuticals
2011 - EUCTR2008-005492-94-PT Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2011 - EUCTR2008-005492-94-FI Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2011 - EUCTR2008-005492-94-CZ Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2011 - EUCTR2008-005492-94-BG Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2010 - EUCTR2008-004146-88-DE Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
2009 Phase 3 EUCTR2008-004146-88-BG Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
2009 - EUCTR2008-005492-94-EE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2009 - EUCTR2008-005492-94-AT Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2009 - EUCTR2008-004146-88-FI Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
2009 - EUCTR2008-004146-88-CZ Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
- - EUCTR2008-005492-94-DE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States;
Newron Pharmaceuticals S.P.A
2005 Phase 3 EUCTR2004-000835-27-ES Italy;Spain;
Newron Pharmaceuticals S.p.A.
2004 Phase 3 EUCTR2004-000833-12-ES Italy;Spain;
Newron Pharmaceuticals SpA
2011 Phase 3 EUCTR2007-002964-90-BE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Slovakia;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2010 - EUCTR2007-002963-28-DE Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States;
2009 - EUCTR2007-002964-90-AT Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2009 - EUCTR2007-002963-28-PL Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain;
2009 - EUCTR2007-002963-28-CZ Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States;
2009 - EUCTR2007-002963-28-BG Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States;
2008 - EUCTR2007-002964-90-EE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
2007 - EUCTR2007-002963-28-FI Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Poland;Portugal;South Africa;Spain;United States;
Zambon SpA
2019 Phase 3 NCT03881371 China;
Safinamide (as add-on therapy)
Newron
2007 Phase 3 NCT00605683 Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Israel;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States;
Safinamide + Levodopa
Newron
2009 Phase 1/Phase 2 NCT01026428 Italy;
Safinamide Methanesulfonate
Zambon SpA
2019 Phase 4 NCT03841604 Austria;France;Germany;Italy;Spain;
2019 Phase 3 NCT03987750 -
Safinamide metansolfonato (12 weeks)
Universita di Verona
2018 - NCT03648671 Italy;
Safinamide methansulfonate
Zambon SpA
2019 Phase 4 EUCTR2017-002426-20-FR Austria;France;Spain;
2019 Phase 4 EUCTR2017-002426-20-AT Austria;Spain;
2018 Phase 4 EUCTR2017-002426-20-ES Spain;
Safinamide, MAO-B inhibitor
Newron
2009 Phase 3 NCT01028586 Switzerland;
Safinimide 50-100 mg/day
Newron
2009 Phase 3 NCT00627640 Australia;Austria;Belgium;Canada;Estonia;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Slovakia;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States;
Sage leaf
Newcastle Upon tyne Hospitals NHS Foundation Trust
2007 - EUCTR2007-002899-34-GB United Kingdom;
Saline
NeuroDerm Ltd.
2011 Phase 1/Phase 2 NCT01229332 Israel;
Yale University
2012 Phase 2 NCT02419313 United States;
Saline Intranasal Delivery
Bastyr University
2012 Phase 1 NCT01398748 United States;
Saracatinib
King's College London
2019 Early Phase 1 NCT03661125 United Kingdom;
Sarcosine Capsule
China Medical University Hospital
2010 - NCT01785628 Taiwan;
Sargramostim
Howard Gendelman, MD
2013 Phase 1 NCT01882010 United States;
University of Nebraska
2019 Phase 1 NCT03790670 United States;
Sarizotan
EMD Serono
2004 Phase 3 NCT00105508 United States;
Sarizotan HC1
EMD Serono
2004 Phase 3 NCT00105521 United States;
Sarizotan HCl
EMD Serono
2002 Phase 2 NCT00314288 Belgium;Bulgaria;Canada;France;Germany;Hungary;Portugal;Romania;South Africa;United Kingdom;United States;
Sarizotan Hydrochloride
MERCK KGaA
2004 Phase 3 EUCTR2004-001594-25-ES Austria;Finland;Spain;
Sarizotan hydrochloride
MERCK S.P.A.
2004 - EUCTR2004-001593-10-IT Italy;United Kingdom;
Merck KGaA
2005 Phase 3 EUCTR2005-000444-84-GB Austria;Finland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000444-84-ES Austria;Finland;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000444-84-FI Finland;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000444-84-AT Austria;Finland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-001594-25-AT Austria;Finland;Spain;
2004 - EUCTR2004-001594-25-FI Finland;Spain;
Sedation with IV propofol
Hadassah Medical Organization
2006 - NCT00355927 Israel;
Selegiline
Department of Neurology, Juntendo Koshigaya Hospital
2012 - JPRN-UMIN000008477 Japan;
FP Pharmaceutical Corp.
2012 Phase 2 JPRN-JapicCTI-122000 -
- Phase 3 JPRN-JapicCTI-121954 -
- Phase 2 JPRN-JapicCTI-101020 -
Institute of Psychology, Chinese Academy of Sciences
2018 - ChiCTR1800015331 China;
Ito Hidefumi
2016 Phase 2 JPRN-jRCTs051180098 Japan;
Longhua Hospital Shanghai University of Traditional Chinese Medicine
2018 - ChiCTR1800018017 China;
2018 - ChiCTR1800017949 China;
Osaka Redcross HospitalWakayama Prefectural Medical College
2016 Phase 2 JPRN-UMIN000022533 Japan;
Research and Development University Hospital of North Staffordshire
2014 - EUCTR2014-000335-17-GB United Kingdom;
Second Affiliated Hospital of Soochow University
2020 Phase 4 NCT04870372 China;
The Second Affiliated Hospital of Soochow University
2020 Phase 4 ChiCTR2100045946 China;
Union Medical College Affiliated Hospital of Tongji Medical College, Huazhong University of science and technology
2020 Phase 0 ChiCTR2000037828 China;
University of South Florida
2014 Phase 4 NCT02225548 United States;
Selegiline HCl 5 PCH
TEVA Pharmaceuticals Industries Ltd
2006 - EUCTR2006-005140-89-NL Netherlands;
Semaglutide
Oslo University Hospital
2019 Phase 2 NCT03659682 -
Semi continuous intra-oral administration of LD/CD
IRCCS San Raffaele
2015 Phase 2 NCT02763137 Italy;
Senfrol monotherapy
Peking University Third Hospital
2018 Phase 4 NCT04968613 China;
Seroquel
King’s College London & King’s College Hospital
2005 Phase 4 EUCTR2004-002608-13-GB United Kingdom;
Sertraline
National Cheng-Kung University Hospital
2015 Phase 1/Phase 2 NCT02917122 -
Zhejiang University
2011 - NCT01437189 China;
Sevoflurane
The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
2019 - ChiCTR1900026956 China;
Sham Surgery
Ceregene
2006 Phase 2 NCT00400634 United States;
Sangamo Therapeutics
2009 Phase 1/Phase 2 NCT00985517 United States;
Sham compression
Vanderbilt University Medical Center
2020 Early Phase 1 NCT04620382 United States;
Sham tDCS
National Cheng-Kung University Hospital
2015 Phase 1/Phase 2 NCT02917122 -
Sham tPCS
Western University, Canada
2019 - NCT04054960 Canada;
Sifol
Boehringer Ingelheim AB
2006 - EUCTR2005-003788-22-SE Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Austria GmbH
2006 - EUCTR2005-003788-22-AT Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim España S.A.
2006 Phase 4 EUCTR2005-003788-22-ES Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Limited
2006 Phase 4 EUCTR2005-003788-22-GB Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Sifrol
BOEHRINGER ING.
2007 - EUCTR2007-000074-23-IT Austria;Hungary;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim
2007 - EUCTR2007-003353-90-NL France;Germany;Netherlands;
2006 Phase 4 EUCTR2005-004949-34-FI Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim AB
2006 Phase 4 EUCTR2005-004949-34-SE Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003788-22-SE Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Austria GmbH
2006 - EUCTR2005-004949-34-AT Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003788-22-AT Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Limited
2006 Phase 4 EUCTR2005-003788-22-GB Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Ltd
2006 Phase 4 EUCTR2005-004949-34-GB Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Boehringer Ingelheim Pharma GmbH & Co. KG
2007 - EUCTR2007-003353-90-DE France;Germany;Netherlands;
2006 - EUCTR2005-003788-22-DE Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Sifrol 0,088
Axxonis Pharma AG
2007 - EUCTR2006-003732-30-DE Germany;Italy;Poland;
NeuroBiotec Pharma AG
2008 - EUCTR2006-003732-30-PL Germany;Italy;Poland;
Sifrol 0,18
Axxonis Pharma AG
2007 - EUCTR2006-003732-30-DE Germany;Italy;Poland;
NeuroBiotec Pharma AG
2008 - EUCTR2006-003732-30-PL Germany;Italy;Poland;
Sifrol 0,35
Axxonis Pharma AG
2007 - EUCTR2006-003732-30-DE Germany;Italy;Poland;
NeuroBiotec Pharma AG
2008 - EUCTR2006-003732-30-PL Germany;Italy;Poland;
Sifrol 0,7
Axxonis Pharma AG
2007 - EUCTR2006-003732-30-DE Germany;Italy;Poland;
NeuroBiotec Pharma AG
2008 - EUCTR2006-003732-30-PL Germany;Italy;Poland;
Sifrol, 0,35 mg Tablette
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
Sifrol, 0,70 mg Tablette
Axxonis Pharma GmbH
2006 - EUCTR2005-001006-12-AT Austria;Czech Republic;Germany;Italy;
Sifrol, Mirapexin
Boehringer Ingelheim España, S.A.
2006 - EUCTR2005-004949-34-ES Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom;
Sifrol®
Boehringer Ingelheim
2002 - NCT02231255 -
2000 - NCT02231294 -
Sildenafil
Bispebjerg Hospital
2003 Phase 4 NCT01941732 Denmark;
Loma Linda University
2002 Phase 2 NCT02162979 United States;
Silodosin
Juntendo University School of Medicine
2012 - JPRN-UMIN000008138 Japan;
Simvastatin
Plymouth Hospitals NHS Trust
2015 Phase 3 EUCTR2015-000148-40-GB United Kingdom;
University Hospital Plymouth NHS Trust
2016 Phase 2 NCT02787590 United Kingdom;
Simvastatine
CHU de Bordeaux
2009 - EUCTR2009-011736-35-FR France;
Sinemet
Acorda Therapeutics
2019 Phase 1 NCT03887884 United States;
DR. REDDY’S LABORATORIES LIMITED
2017 Phase 2 EUCTR2017-000262-30-IT Italy;
Institut de Recerca del Hospital de la Santa Creu i Sant Pau
2007 - EUCTR2006-002408-32-ES Spain;
Institute for Neurodegenerative Disorders
2005 - EUCTR2004-001485-41-GB Spain;United Kingdom;
2005 - EUCTR2004-001485-41-AT Austria;Spain;United Kingdom;
NOVARTIS FARMA
2005 - EUCTR2005-001032-72-IT Czech Republic;Italy;Portugal;
2004 - EUCTR2004-000185-12-IT Finland;Italy;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA
2005 - EUCTR2004-005234-39-FI Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-FI Finland;Italy;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA, Finland
2005 Phase 4 EUCTR2004-005234-39-GB Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA, 02200 Espoo, Finland
2008 - EUCTR2004-005234-39-DE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2007 Phase 3 EUCTR2004-000185-12-GB Austria;Finland;Italy;Sweden;United Kingdom;
2006 - EUCTR2004-005234-39-LV Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2006 - EUCTR2004-005234-39-LT Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 Phase 4 EUCTR2004-005234-39-IE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-005234-39-SE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-005234-39-DK Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-SE Finland;Italy;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-AT Austria;Finland;Italy;Sweden;United Kingdom;
UMCG
2009 - EUCTR2008-006278-13-NL Netherlands;
Sinemet (carbidopa/levodopa)
Acorda Therapeutics
2012 Phase 2 NCT01617135 Israel;Serbia;United Kingdom;
Sinemet (comparator)
XenoPort, Inc.
2010 Phase 2 NCT01171313 United States;
Sinemet (levodopa/carbidopa)
Orion Corporation, Orion Pharma
2009 Phase 1 NCT01070628 Finland;
Sinemet 200mg/
Orion Corporation, Orion Pharma
2008 Phase 2 NCT00562198 Finland;
Sinemet 25-100 Oral Tablet
XenoPort, Inc.
2009 Phase 1/Phase 2 NCT00914602 United States;
Sinemet 25/100
Bial - Portela C S.A.
2001 Phase 1 NCT02763839 Portugal;
Sinemet CR
CombinatoRx, Inc
2008 - EUCTR2007-005033-11-DE Germany;
Huashan Hospital
2011 - NCT01470859 China;
McGill University Health Centre/Research Institute of the McGill University Health Centre
2017 Phase 4 NCT03111485 Canada;
Sinemet CR 25Mg-100Mg Extended-Release Tablet
Intec Pharma Ltd.
2018 Phase 2 NCT03576638 -
Sinemet IR
Depomed
2012 Phase 2 NCT01515410 United States;
Sinemet Plus
Institut de Recerca del Hospital de la Santa Creu i Sant Pau
2015 Phase 4 EUCTR2015-002631-17-ES Spain;
Sinemet plus (levodopa/carbidopa)
NOVARTIS FARMACEUTICA, S.A
2006 - EUCTR2006-000680-28-ES Spain;
Sinemet-Plus Tablets
Impax Laboratories, Inc.
2009 - EUCTR2009-014688-37-ES France;Germany;Poland;Spain;
Sinemet®
Acorda Therapeutics
2016 Phase 1 NCT02812394 United States;
Bial - Portela C S.A.
2005 Phase 2 NCT02834507 -
2005 Phase 1 NCT02774564 Portugal;
Civitas Therapeutics, Inc.
2012 - EUCTR2012-000181-37-GB Israel;Serbia;United Kingdom;
Intec Pharma Ltd.
2016 Phase 3 NCT02605434 Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States;
Orion Corporation Orion Pharma
2007 - EUCTR2007-002496-14-FI Finland;
Sinemet® 100/
Bial - Portela C S.A.
2009 Phase 1 NCT01533077 Canada;
Sinemet® 100/25
Bial - Portela C S.A.
2008 Phase 1 NCT02169479 Canada;
2004 Phase 1 NCT03091868 Portugal;
Sinemet® CR
CombinatoRx, Inc
2008 - EUCTR2007-005033-11-DE Germany;
Sinemet® CR 100/25
Bial - Portela C S.A.
2008 Phase 1 NCT02169453 Canada;
Sinemet® controlled release (Carbidopa/levodopa)
Bristol-Myers Squibb
2007 - NCT00460954 Canada;
Sinemet®25-100
Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
2007 - EUCTR2006-000577-29-DE Germany;United States;
Sirolimus
Prevail Therapeutics
2020 Phase 1/Phase 2 NCT04127578 Israel;United States;
Sitagliptin
Peking Union Medical College Hospital
2020 Phase 4 ChiCTR2000029465 China;
Sodium chloride
Shanghai Tongji Hospital, Tongji University
2017 - ChiCTR-INR-17012013 China;
Sodium oxybate
Baylor College of Medicine
2004 - NCT00641186 -
Sodium phosphate enema, oral rifaximin and polyethylene glycol
Torre Médica Santé
2018 Phase 1 NCT04730245 Mexico;
Solifenacin
VA Office of Research and Development
2018 Phase 3 NCT03149809 United States;
Solifenacin Succinate (VESIcare)
University of South Florida
2007 Phase 4 NCT00584090 United States;
Solifenacin succinate (VESIcare)
University of South Florida
2010 Phase 4 NCT01018264 United States;
Solu-Cortef, powder for solution for injection, 100mg, and 'Act-O-Vial'
University Medical Center Groningen
2015 Phase 2 EUCTR2014-000657-36-NL Netherlands;
Solution de chlorhydrate de dopamine anaérobie
InBrain Pharma SAS
2020 Phase 1;Phase 2 EUCTR2020-000155-12-FR France;
Soluzione di levodopa/carbidopa
NEURODERM LTD.
2016 Phase 2 EUCTR2015-005814-31-IT Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States;
2016 Phase 2 EUCTR2015-005078-39-IT Austria;Germany;Israel;Italy;United States;
Sorbitol
Istanbul Medipol University Hospital
2019 Phase 2 NCT04044131 Turkey;
Soy protein
Chulalongkorn University
2011 Phase 4 NCT01662414 Thailand;
Spheramine (BAY86-5280)
Bayer
2003 Phase 2 NCT00206687 Austria;France;Germany;Spain;United States;
2000 Phase 2 NCT00761436 United States;
Spiropent
CuraSen Therapeutics, Inc.
2020 Phase 2 EUCTR2020-003796-17-GB United Kingdom;
- Phase 2 EUCTR2020-006067-28-BE Australia;Belgium;New Zealand;United Kingdom;
SpotOn balance glasses
SpotOn Therapeutics Ltd.
2018 - NCT03942172 Israel;
Stalevo
Molecular NeuroImaging
2004 Phase 2 NCT00200447 -
NOVARTIS FARMA
2005 - EUCTR2005-001032-72-IT Czech Republic;Italy;Portugal;
2004 - EUCTR2004-000185-12-IT Finland;Italy;Sweden;United Kingdom;
Novartis Pharma AG
2006 - EUCTR2005-001032-72-PT Czech Republic;Italy;Portugal;
Orion Corporation Orion Pharma
2006 Phase 4 EUCTR2006-001755-36-GB Germany;Sweden;United Kingdom;
- - EUCTR2006-001755-36-DE Germany;Sweden;United Kingdom;
Orion Corporation Orion Pharma, FI-02200 Espoo, Finland
2006 - EUCTR2006-001755-36-SE Germany;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA
2005 - EUCTR2004-005234-39-FI Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-FI Finland;Italy;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA, Finland
2005 Phase 4 EUCTR2004-005234-39-GB Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
Orion Corporation, ORION PHARMA, 02200 Espoo, Finland
2008 - EUCTR2004-005234-39-DE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2007 Phase 3 EUCTR2004-000185-12-GB Austria;Finland;Italy;Sweden;United Kingdom;
2006 - EUCTR2004-005234-39-LV Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2006 - EUCTR2004-005234-39-LT Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 Phase 4 EUCTR2004-005234-39-IE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-005234-39-SE Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-005234-39-DK Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-SE Finland;Italy;Sweden;United Kingdom;
2004 - EUCTR2004-000185-12-AT Austria;Finland;Italy;Sweden;United Kingdom;
Orion Corporation, Orion Pharma
2016 Phase 2 NCT02764125 Finland;Germany;Hungary;Latvia;
2011 Phase 2 NCT01766258 -
2006 Phase 4 NCT00462007 Germany;Sweden;United Kingdom;
Second Affiliated Hospital, School of Medicine, Zhejiang University
2022 Phase 4 NCT04952194 -
Stalevo (levodopa/ carbidopa/ entacapone)
Orion Corporation, Orion Pharma
2009 Phase 1 NCT01070628 Finland;
Stalevo (levodopa/carbidopa/entacapona)
NOVARTIS FARMACEUTICA, S.A
2006 - EUCTR2006-000680-28-ES Spain;
Stalevo (levodopa/carbidopa/entacapone)
Orion Corporation, Orion Pharma
2005 Phase 4 NCT00125567 Denmark;Finland;Germany;Ireland;Sweden;United Kingdom;
Stalevo 100
NOVARTIS FARMACEUTICA, S.A
2006 - EUCTR2006-000680-28-ES Spain;
Stalevo 100 mg/ 25 mg/ 200 mg Filmtabletten
Novartis Pharma Services AG
2008 - EUCTR2007-003134-42-DE Germany;
Stalevo 100 mg/25 mg /
Novartis Pharma AG
2006 - EUCTR2005-001032-72-CZ Czech Republic;Italy;Portugal;
Stalevo 100/25/
Orion Corporation
2011 - EUCTR2010-022915-21-SE Finland;Sweden;
2011 - EUCTR2010-022915-21-FI Finland;Sweden;
Stalevo 150
Institut de Recerca del Hospital de la Santa Creu i Sant Pau
2007 - EUCTR2006-002408-32-ES Spain;
NOVARTIS FARMACEUTICA, S.A
2006 - EUCTR2006-000680-28-ES Spain;
Stalevo 150/37.5/
Orion Corporation
2011 - EUCTR2010-022915-21-SE Finland;Sweden;
2011 - EUCTR2010-022915-21-FI Finland;Sweden;
Stalevo®
Asan Medical Center
2015 - NCT02452606 Korea, Republic of;
Orion Corporation Orion Pharma
2007 - EUCTR2007-002496-14-FI Finland;
Standard LD/CD
IRCCS San Raffaele
2015 Phase 2 NCT02763137 Italy;
Static, dynamic and functional balance exercises with dual task
Istanbul University-Cerrahpasa
2019 - NCT03939559 -
Stilnoct
Aston University
2018 Phase 2 EUCTR2017-004297-34-GB United Kingdom;
Stimulator OFF
Maastricht University Medical Center
2015 - NCT02632279 Netherlands;
Stimulator ON
Maastricht University Medical Center
2015 - NCT02632279 Netherlands;
Strattera
Oregon Health and Science University
2011 Phase 4 NCT01340885 United States;
Study Drug
Pfizer
2010 - NCT01270711 -
Subcutaneous apomorphine
Sunovion
2018 Phase 3 NCT03391882 Austria;France;Germany;Italy;Spain;United Kingdom;
Subcutaneous hydrocortisone
University Medical Center Groningen
2015 Phase 2 NCT02230930 Netherlands;
Subjects will undergo the 123-I IBVM imaging visit
Institute for Neurodegenerative Disorders
2007 Phase 0 NCT00556764 United States;
Sugar Pill
New York Institute of Technology
2014 Phase 0 NCT02259049 United States;
Oregon Health and Science University
2009 - NCT00794313 United States;
Sugar pill
Henry Ford Health System
2015 Phase 2 NCT02066571 United States;
Rush University Medical Center
2011 Phase 2 NCT01351168 United States;
2010 Phase 2 NCT01341080 United States;
Sulforaphane
Central South University
2021 Phase 2 NCT05084365 -
Sumanirole
Pfizer
2003 Phase 3 NCT00058838 Argentina;Australia;Austria;Belgium;Colombia;France;Germany;Greece;Italy;Mexico;Peru;Puerto Rico;Spain;United States;
2001 Phase 3 NCT00036218 Argentina;Mexico;Puerto Rico;United States;
2000 Phase 3 NCT00036205 Argentina;Colombia;Puerto Rico;United States;
Supressi. T-Diet plus Range
Vegenat, S.A.
2010 - NCT01192529 Spain;
Suvorexant
Burdick, Daniel, M.D.
2016 Phase 4 NCT02729714 United States;
Synthetic Oxytocin
Abteilung für Neurologie der Medizinischen Universität Innsbruck
2019 Phase 2 EUCTR2018-002877-23-AT Austria;
Syntocinon 40 IU/ml nasal spray
Abteilung für Neurologie der Medizinischen Universität Innsbruck
2019 Phase 2 EUCTR2018-002877-23-AT Austria;
TACROLIMUS TABLETS
Kyoto University Hospital
2018 Phase 3 JPRN-JMA-IIA00385 Japan;
TAK-071
Takeda
2020 Phase 2 NCT04334317 United States;
TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)
Novartis
2002 Phase 1/Phase 2 NCT00407212 Brazil;Canada;France;Germany;Italy;Netherlands;Portugal;United Kingdom;United States;
TD-9855
THERAVANCE BIOPHARMA ANTIBIOTICS, INC.
2019 Phase 3 EUCTR2018-003289-15-IT Austria;Bulgaria;Canada;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Theravance Biopharma
2016 Phase 2 NCT02705755 United States;
Theravance Biopharma Ireland Limited
2020 Phase 3 EUCTR2018-003941-41-PT Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-003941-41-AT Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-003289-15-PT Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-003289-15-DE Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-PL Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-IT Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-HU Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-GB Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-ES Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-EE Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003941-41-BG Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-PL Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-HU Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-GB Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-ES Austria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-EE Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-DK Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-BG Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-003289-15-AT Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
TECHNETIUM (99MTC) EXAMETAZIME
IDIBAPS
2016 Phase 2 EUCTR2015-004238-85-ES Spain;
THN02
Theranexus S.A.
2018 Phase 2 EUCTR2017-004475-31-HU Czech Republic;France;Germany;Hungary;United States;
2018 Phase 2 EUCTR2017-004475-31-CZ Czech Republic;France;Germany;Hungary;United States;
THN102 Dosage A
Theranexus
2018 Phase 2 NCT03624920 Czechia;France;Germany;Hungary;United States;
THN102 Dosage B
Theranexus
2018 Phase 2 NCT03624920 Czechia;France;Germany;Hungary;United States;
THN102 Dosage C
Theranexus
2018 Phase 2 NCT03624920 Czechia;France;Germany;Hungary;United States;
TO
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2010 - EUCTR2009-017416-33-DE Germany;
TOZ
Biotie Therapies
2017 Phase 3 EUCTR2016-003961-25-HU Australia;Canada;Czech Republic;European Union;Germany;Hungary;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003961-25-GB Australia;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003961-25-ES Australia;Canada;Czech Republic;European Union;Germany;Hungary;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003961-25-DE Australia;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003961-25-CZ Australia;Canada;Czech Republic;European Union;Germany;Hungary;Spain;United Kingdom;United States;
TRIGEL
LobSor Pharmaceuticals AB
2015 Phase 1 NCT02448914 Sweden;
TULOBUTEROL HYDROCHLORIDE
CuraSen Therapeutics, Inc.
2020 Phase 2 EUCTR2020-003796-17-GB United Kingdom;
TVP-1012
TEVA
2005 - EUCTR2005-001416-42-IT Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
TEVA Pharmaceuticals Industries Ltd
2006 - EUCTR2006-005140-89-NL Netherlands;
Takeda
2015 Phase 3 NCT02337764 Japan;
2015 Phase 3 NCT02337751 Japan;
2015 Phase 3 NCT02337725 Japan;
2015 Phase 2/Phase 3 NCT02337738 Japan;
Teva Pharmaceuticals Industries LtD
2005 Phase 3 EUCTR2005-001416-42-GB Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-001416-42-ES Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-PT Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-HU Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-DE Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2005 - EUCTR2005-001416-42-AT Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
TVP-1012 (1 mg/day) with levodopa
TAKEDA PHARMACEUTICAL COMPANY LTD.
2015 Phase 3 JPRN-JapicCTI-152762 -
Tadalafil
University of South Florida
2014 Phase 4 NCT02225548 United States;
Talampanel
National Institute of Neurological Disorders and Stroke (NINDS)
2005 Phase 2 NCT00108667 United States;
Teva Pharmaceutical Industries
2006 Phase 1/Phase 2 NCT00036296 Canada;United States;
Talineuren
InnoMedica Schweiz AG
2021 Phase 1 NCT04976127 Switzerland;
Targinact 10 mg/5 mg prolonged-release tablets
Mundipharma Research GmbH & Co. KG
2012 - EUCTR2011-002901-31-DE Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-GB Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-ES Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-HU Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-CZ Czech Republic;Germany;Hungary;Spain;United Kingdom;
Targinact 20 mg/10 mg prolonged-release tablets
Mundipharma Research GmbH & Co. KG
2012 - EUCTR2011-002901-31-DE Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-GB Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-ES Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-HU Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-CZ Czech Republic;Germany;Hungary;Spain;United Kingdom;
Targinact 5 mg/2.5 mg prolonged-release tablets
Mundipharma Research GmbH & Co. KG
2012 - EUCTR2011-002901-31-DE Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-GB Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 Phase 3 EUCTR2011-002901-31-ES Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-HU Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2011-002901-31-CZ Czech Republic;Germany;Hungary;Spain;United Kingdom;
Tasmar
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2010 - EUCTR2009-017416-33-DE Germany;
Dept of Neuroscience, Uppsala University
2008 - EUCTR2008-003581-26-SE Sweden;
Tavapadon
Cerevel Therapeutics, LLC
2021 Phase 3 NCT04760769 Australia;Czechia;France;Germany;Italy;Poland;Spain;United States;
2020 Phase 3 NCT04542499 Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States;
2020 Phase 3 NCT04223193 Australia;France;Germany;Hungary;Italy;Poland;Serbia;Spain;Ukraine;United States;
2019 Phase 3 NCT04201093 Australia;Bulgaria;Canada;Czechia;France;Germany;Israel;Italy;Poland;Spain;Ukraine;United States;
Terazosin
Cedars-Sinai Medical Center
2020 Phase 2 NCT04386317 United States;
Jordan Schultz
2019 Phase 1/Phase 2 NCT03905811 United States;
Terazosin therapy
Cedars-Sinai Medical Center
2021 Phase 2 NCT05109364 -
Tigan®
Ipsen
2007 Phase 4 NCT00489255 United States;
Tissue samplings
Michael J. Fox Foundation for Parkinson's Research
2015 - NCT02572713 Canada;United States;
Tocovid Suprabio (HOV-12020)
National Neuroscience Institute
2021 Phase 2 NCT04491383 Singapore;
Tolcapon
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
2010 - EUCTR2009-017416-33-DE Germany;
Tolcapone
Dept of Neuroscience, Uppsala University
2008 - EUCTR2008-003581-26-SE Sweden;
Uppsala University
2008 Phase 4 NCT00906828 Sweden;
Tolubuterol Hydrochloride
CuraSen Therapeutics, Inc.
2020 Phase 2 EUCTR2020-003796-17-GB United Kingdom;
Topiramate
Oregon Health and Science University
2009 - NCT00794313 United States;
Rush University Medical Center
2013 Phase 2 NCT01789047 United States;
Topiramate (drug)
University Health Network, Toronto
2004 Phase 2 NCT00296959 Canada;
Tozadenant
Biotie Therapies Inc.
2017 Phase 3 NCT03051607 Canada;United Kingdom;United States;
2015 Phase 3 NCT02453386 Austria;Canada;Czech Republic;Czechia;Germany;Italy;Spain;United States;
2012 - EUCTR2011-005054-59-RO Argentina;Canada;Chile;Romania;Ukraine;United States;
2008 Phase 2 NCT00605553 United States;
Tozadenant (SYN115) 120 mg BID
Biotie Therapies Inc.
2011 Phase 2/Phase 3 NCT01283594 Argentina;Canada;Chile;Romania;Ukraine;United States;
Tozadenant (SYN115) 180 mg BID
Biotie Therapies Inc.
2011 Phase 2/Phase 3 NCT01283594 Argentina;Canada;Chile;Romania;Ukraine;United States;
Tozadenant (SYN115) 240 mg BID
Biotie Therapies Inc.
2011 Phase 2/Phase 3 NCT01283594 Argentina;Canada;Chile;Romania;Ukraine;United States;
Tozadenant (SYN115) 60 mg BID
Biotie Therapies Inc.
2011 Phase 2/Phase 3 NCT01283594 Argentina;Canada;Chile;Romania;Ukraine;United States;
Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant)
Fudan University
2008 Phase 2/Phase 3 NCT00629161 China;
Transdermal flumazenil (Added 4/2020)
Nicolaas Bohnen, MD, PhD
2018 Phase 1/Phase 2 NCT03440112 United States;
Transdermal nicotine
Assistance Publique - Hôpitaux de Paris
2009 Phase 2 NCT00873392 France;
Trimethobenzamide
US WorldMeds LLC
2012 Phase 4 NCT01770145 United States;
Trimethobenzamide Hydrochloride
Pfizer
2015 Phase 1 NCT02373072 Belgium;United States;
Trivastal
Institut de Recherches Internationales Servier (I.R.I.S.)
2005 - EUCTR2005-002010-38-DE Germany;
Tryptophan (TRP) depletion
Maastricht University Medical Center
2015 - NCT02632279 Netherlands;
Tyramine
Teva Pharmaceutical Industries
2000 Phase 3 NCT00203125 United States;
Tyrosine
New York Institute of Technology
2012 Phase 1/Phase 2 NCT01676103 United States;
UB-312
United Neuroscience Ltd.
2019 Phase 1 NCT04075318 Netherlands;
UCB0022
UCB Biopharma SRL
2021 Phase 1 NCT04867642 United Kingdom;
UCB0599
UCB Biopharma S.P.R.L.
2019 Phase 1 NCT04875962 United States;
UCB Biopharma SRL
2021 Phase 2 EUCTR2020-003265-19-PL Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003265-19-NL Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003265-19-IT Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003265-19-FR Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003265-19-ES Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003265-19-DE Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 NCT04658186 Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
UCB7853
UCB Biopharma SRL
2020 Phase 1 NCT04651153 Netherlands;United Kingdom;
Ubiquinol
Weill Medical College of Cornell University
2012 Phase 2 NCT03061513 -
Umbilical cord blood therapy
MinYoung Kim, M.D.
2014 - NCT02236065 Korea, Republic of;
Urate
Ehime University Graduate School of Medicine
2016 Phase 2 JPRN-UMIN000020527 Japan;
Nagai Masahiro
2016 Phase 2 JPRN-jRCTs061180060 Japan;
Ursodeoxycholic acid
Sheffield Teaching Hospitals NHS Foundation Trust
2018 Phase 2 EUCTR2018-001887-46-GB United Kingdom;
University of Minnesota
2020 Phase 1 NCT02967250 United States;
Ursonorm
Sheffield Teaching Hospitals NHS Foundation Trust
2018 Phase 2 NCT03840005 United Kingdom;
2018 Phase 2 EUCTR2018-001887-46-GB United Kingdom;
Usual dopaminergic per os treatment
Rennes University Hospital
2009 Phase 3 NCT01039090 France;
V1512 and Entacapone
Vernalis (R&D) Ltd
2006 Phase 1/Phase 2 NCT00491998 Italy;
V81444
Vernalis (R&D) Ltd
2012 Phase 1 NCT02764892 -
2011 Phase 1 NCT01634568 United Kingdom;
VARENICLINE TARTRATE
VU University Medical Center
2012 Phase 3 EUCTR2012-001530-34-NL Netherlands;
VIUSID/ALZER
Catalysis SL
2009 Phase 3 NCT01016470 Cuba;
VR040
Vectura Group plc
2006 Phase 2 EUCTR2006-005509-79-GB United Kingdom;
2006 Phase 2 EUCTR2006-004582-33-GB United Kingdom;
2005 Phase 2 EUCTR2005-005120-13-GB United Kingdom;
Vectura Limited
2009 - EUCTR2008-004447-11-GB Germany;Italy;United Kingdom;
- - EUCTR2008-004447-11-DE Germany;Italy;United Kingdom;
VR040/Aspirair® inhaler
South Glasgow University Hospitals NHS Trust
2007 Phase 2 NCT01693081 Serbia;United Kingdom;
VY-AADC01
Neurocrine Biosciences
2017 Phase 1 NCT03065192 United States;
2013 Phase 1 NCT01973543 United States;
VY-AADC02
Neurocrine Biosciences
2018 Phase 2 NCT03562494 United States;
Valerian
National Center for Complementary and Integrative Health (NCCIH)
2000 Phase 2 NCT00070928 United States;
Valiloxybate
XWPharma
2021 Phase 2 NCT05056194 -
Varenicline
Rush University Medical Center
2010 Phase 2 NCT01341080 United States;
University of Michigan
2017 Phase 2 NCT04403399 United States;
2015 Phase 2 NCT02933372 -
VU University Medical Center
2013 Phase 4 NCT02473562 Netherlands;
Variation of behaviors of Parkinson's disease
Centre Hospitalier Universitaire, Amiens
2018 Phase 3 NCT03146130 France;
Vehicle
Neuraly, Inc.
2020 Phase 2 NCT04154072 Canada;United States;
Venglustat GZ/SAR402671
Genzyme, a Sanofi Company
2016 Phase 2 NCT02906020 Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
Venglustat malate
Genzyme Corporation
2018 Phase 2 EUCTR2016-000657-12-AT Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000657-12-PT Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000657-12-DE Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000657-12-SE Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
Venlafaxine
The Third Affiliated Hospital of Beijing University of Traditional Chinese Medicine
2014 Phase 2 study ChiCTR-TRC-14005143 China;
University of Rochester
2005 Phase 3 NCT00086190 Canada;Puerto Rico;United States;
ViNeuro
Hospital Authority, Hong Kong
2005 - NCT00517842 China;
Vitamin B12 Supplementation
Emory University
2006 Phase 2/Phase 3 NCT00208611 United States;
Vitamin D3
Jikei University School of Medicine
2009 - JPRN-UMIN000001841 Japan;
Memorial Medical Center
2009 Phase 2 NCT00907972 United States;
VA Office of Research and Development
2011 Phase 2 NCT01119131 United States;
Vitamin D3 - high dose
Emory University
2007 Phase 4 NCT00571285 United States;
Vortioxetine
IRCCS San Raffaele
2020 Phase 4 NCT04301492 Italy;
WD-1603
Hong Kong WD Pharmaceutical Co., Limited
2020 Phase 1 NCT04553978 -
WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS
Hong Kong WD Pharmaceutical Co., Limited
2020 Phase 1 NCT04513340 India;
WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
Hong Kong WD Pharmaceutical Co., Limited
2020 Phase 1 NCT04591535 India;
WD-1603 Carbidopa-Levodopa Extended-Release Tablets
Shanghai WD Pharmaceutical Co., Ltd.
2021 Phase 2 NCT05036473 China;
2021 Phase 1 NCT05128175 India;
WIN-1001X
Medi Help Line
2020 Phase 2 NCT04220762 Korea, Republic of;
Warfarin
Bial - Portela C S.A.
2014 Phase 1 NCT02305030 -
2009 Phase 1 NCT02169440 Portugal;
Water
Department of Neurology, Juntendo University School of Medicine
2010 - JPRN-UMIN000007497 Japan;
Federal University of Health Science of Porto Alegre
2021 - NCT04863118 -
Juntendo University Koshigaya Hospital
2015 - JPRN-UMIN000019090 Japan;
Juntendo University School of Medicine, Neurology
2013 - JPRN-UMIN000010014 Japan;
Kaida Wang
2019 Phase 0 ChiCTR1900025894 China;
Nagoya graduate school of medicine university
2015 - JPRN-UMIN000019654 Japan;
Weancare-domus
Milko Zanini
2021 - NCT04983290 Italy;
Whey protein
Chulalongkorn University
2011 Phase 4 NCT01662414 Thailand;
White chocolate ( cocoa)
Technische Universität Dresden
2013 - NCT02275884 Germany;
Wuling Powder
Beijing Hospital
2017 Phase 4 NCT03195231 -
XADAGO (safinamide)
Supernus Pharmaceuticals, Inc.
2017 - NCT03944785 United States;
XADAGO - 100 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE
OSPEDALE SANTA MARIA DELLA MISERICORDIA
2021 Phase 3 EUCTR2018-004892-11-IT Italy;
XADAGO - 50 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE
OSPEDALE SANTA MARIA DELLA MISERICORDIA
2021 Phase 3 EUCTR2018-004892-11-IT Italy;
XC130-A10H
Xoc Pharmaceuticals
2019 Phase 1 NCT04043338 United States;
XP21279
XenoPort, Inc.
2009 Phase 1/Phase 2 NCT00914602 United States;
XP21279 and carbidopa (experimental)
XenoPort, Inc.
2010 Phase 2 NCT01171313 United States;
Xadago
Institut de Recerca Hospital de la Santa Creu i Sant Pau
2017 Phase 4 EUCTR2017-003254-17-ES Spain;
ZAMBON SPA
2019 Phase 4 EUCTR2017-002426-20-IT Austria;France;Germany;Italy;Spain;
2015 Phase 3 EUCTR2014-002600-24-IT Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
Zambon S.P.A.
2015 Phase 3 EUCTR2014-002600-24-SE Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2015 Phase 3 EUCTR2014-002600-24-GB Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2015 Phase 3 EUCTR2014-002600-24-ES Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2015 Phase 3 EUCTR2014-002600-24-AT Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
Zambon SpA
2019 Phase 4 EUCTR2017-002426-20-FR Austria;France;Spain;
2019 Phase 4 EUCTR2017-002426-20-AT Austria;Spain;
2018 Phase 4 EUCTR2017-002426-20-ES Spain;
Xeomin
Merz Pharmaceuticals GmbH
2014 Phase 3 EUCTR2012-005539-10-DE Germany;Poland;United States;
Xiaoyao Pill
Xuanwu Hospital, Beijing
2008 Phase 2 NCT01416818 China;
Yohimbine HCl
Nathaniel M. Robbins
2021 Early Phase 1 NCT04346394 United States;
Zelapar
Baylor College of Medicine
2007 Phase 4 NCT00640159 United States;
Zoledronic Acid 5Mg/Bag 100Ml Inj
California Pacific Medical Center Research Institute
2019 Phase 4 NCT03924414 United States;
Zoledronic acid
Department of Orthopaedic Surgery, Niigata University Medical and Dental Hospital
2018 - JPRN-UMIN000033285 Japan;
Zolmitriptan
Contera Pharma
2020 Phase 2 EUCTR2017-003415-19-IT France;Germany;Italy;Spain;
2018 Phase 2 EUCTR2017-003415-19-ES France;Germany;Spain;
Zolpidem
Aston University
2018 Phase 2 NCT03621046 United Kingdom;
Zolpidem Tartrate
Aston University
2018 Phase 2 EUCTR2017-004297-34-GB United Kingdom;
Zolpidem first dose
Rush University Medical Center
2011 Phase 2 NCT01351168 United States;
Zolpidem second dose
Rush University Medical Center
2011 Phase 2 NCT01351168 United States;
Zonegran
The Cooper Health System
2016 Phase 4 NCT03034538 United States;
Zonisamide
Dainippon Sumitomo Pharma Co., Ltd.
2010 Phase 3 JPRN-JapicCTI-101198 -
Department of Neurology, University of Yamanashi
2013 - JPRN-UMIN000010371 Japan;
Hamamatsu University School of Medicine
2015 - JPRN-UMIN000019524 Japan;
Hiroshi Kataoka
2021 Phase 2-3 JPRN-jRCTs051200160 Japan;
Ito Hidefumi
2016 Phase 2 JPRN-jRCTs051180098 Japan;
Katsuno Masahisa
2021 Phase 2 JPRN-jRCTs041190126 Japan;
Mazandaran University of Medical Sciences
2013 Phase 2/Phase 3 NCT01766128 -
Medical Corporation Abe Neurology Clinic
2016 - JPRN-UMIN000024859 Japan;
Osaka Redcross HospitalWakayama Prefectural Medical College
2016 Phase 2 JPRN-UMIN000022533 Japan;
Ouchi Yasuomi
2015 - JPRN-jRCTs041180070 Japan;
Zonisamide Capsules
Ain Shams University
2020 - NCT04182399 Egypt;
[11C]-PIB
Vanderbilt University Medical Center
2020 Early Phase 1 NCT04768101 United States;
[11C]PXT012253
H. Lundbeck A/S
2019 Early Phase 1 NCT03826134 Sweden;
[123I] 5-IA
Institute for Neurodegenerative Disorders
2006 Phase 2 NCT00397696 United States;
[123I] IBVM and SPECT imaging
Institute for Neurodegenerative Disorders
2007 Phase 0 NCT00556764 United States;
[123I] mZINT injection and serial dynamic SPECT imaging
Institute for Neurodegenerative Disorders
2007 Phase 1 NCT00427674 United States;
[123I]-IBVM
Institute for Neurodegenerative Disorders
2007 Phase 2 NCT00480701 United States;
[123I]-IBZM imaging
Molecular NeuroImaging
2004 Phase 2 NCT00200447 -
[123I]B-CIT
Institute for Neurodegenerative Disorders
2006 Phase 2 NCT00273351 United States;
[123I]B-CIT SPECT imaging
Institute for Neurodegenerative Disorders
2000 Phase 2 NCT00134784 -
[123I]CLINDE
Institute for Neurodegenerative Disorders
2008 Phase 1 NCT00612872 United States;
[123I]MNI-420
Institute for Neurodegenerative Disorders
2009 Phase 1 NCT00970229 United States;
[123I]beta CIT
Institute for Neurodegenerative Disorders
2003 Phase 2 NCT00129675 United States;
[123I]beta CIT and SPECT imaging
Institute for Neurodegenerative Disorders
2001 Phase 2 NCT00117819 United States;
[123I]beta-CIT
Institute for Neurodegenerative Disorders
2006 Phase 2 NCT00387075 United States;
2006 Phase 2 NCT00315250 United States;
[123I]beta-CIT and SPECT imaging
Institute for Neurodegenerative Disorders
2006 Phase 2 NCT00387075 United States;
2004 Phase 2 NCT00096720 United States;
1992 Phase 2 NCT00132626 -
[123I]ß CIT
Institute for Neurodegenerative Disorders
2003 Phase 2 NCT00129675 United States;
[123I]ß CIT and SPECT imaging
Institute for Neurodegenerative Disorders
2001 Phase 2 NCT00117819 United States;
[123I]ß-CIT
Institute for Neurodegenerative Disorders
2006 Phase 2 NCT00387075 United States;
2006 Phase 2 NCT00315250 United States;
[123I]ß-CIT and SPECT imaging
Institute for Neurodegenerative Disorders
2006 Phase 2 NCT00387075 United States;
2004 Phase 2 NCT00096720 United States;
1992 Phase 2 NCT00132626 -
[14C]-BIA 9-1067
Bial - Portela C S.A.
2017 Phase 1 NCT03119194 United Kingdom;
[18F] CFPyPB
Institute for Neurodegenerative Disorders
2011 Phase 1 NCT01461109 United States;
[18F] LBT-999 PET
University Hospital, Tours
2015 Early Phase 1 NCT02393027 France;
[18F] PBR06
Institute for Neurodegenerative Disorders
2009 Phase 1 NCT01028209 United States;
[18F] PI-2620
Michael J. Fox Foundation for Parkinson's Research
2021 Phase 2 NCT04906590 United States;
[18F]-FEPPA
Institute for Neurodegenerative Disorders
2009 Phase 1 NCT00970333 United States;
[18F]DPA-714 PET scan
Nantes University Hospital
2018 Phase 2 NCT03230526 France;
[18F]FDOPA
Daniel Claassen
2020 Phase 1 NCT04246437 United States;
[18F]FDOPA PET/CT
University of Saskatchewan
2016 - NCT02538315 Canada;
[18F]FPEB
Institute for Neurodegenerative Disorders
2009 Phase 1 NCT00870974 United States;
[18F]MK-9470
Institute for Neurodegenerative Disorders
2011 Phase 1 NCT01462708 United States;
[18F]MNI-1126
Invicro
2018 Phase 1 NCT03587649 United States;
[18F]MNI-444
Invicro
2021 Phase 1 NCT05009199 United States;
[18F]MPPF
Institute for Neurodegenerative Disorders
2011 Phase 1 NCT01461083 United States;
[18F]NOS
University of Pennsylvania
2019 Early Phase 1 NCT04062526 United States;
[18F]P17-059
Five Eleven Pharma, Inc.
2021 Phase 1 NCT03903549 United States;
[18F]PI-2620
Asan Medical Center
2018 Early Phase 1 NCT03510572 Korea, Republic of;
[18F]T807 ([18F]MNI-777)
Molecular NeuroImaging
2014 Phase 1 NCT02103894 United States;
[18F]UCB-2897
Invicro
2022 Phase 1 NCT05274568 United States;
[21CFR640.30] Plasma from 18 - 25 year old volunteer donors
The Neurology Center
2018 Phase 4 NCT04202757 United States;
[F-18] Fluorodopa Positron Emission Tomography
Andrew Newberg
2022 Phase 2 NCT05103618 United States;
Thomas Jefferson University
2020 Phase 2 NCT04459052 United States;
saline
Beijing Tiantan Hospital
2022 - NCT05197439 China;
sodium chloride (normal saline)
Asubio Pharmaceuticals, Inc.
2007 Phase 2 NCT00623363 Guatemala;Romania;United States;